{"docstore/metadata": {"e8367158-985b-429e-a5c8-e8ab2e069226": {"doc_hash": "16d228939cf2b20568dc7b1fa8b3d1c0d225dcc8e2d386ec145d7f30c9b6cd79"}, "fbc7b43c-64d6-4628-8f48-f6bdd57f9126": {"doc_hash": "1fd7d9c4e8414e2669b03383acaf00b05ea5097d4b9e795186395f5da62fbdde"}, "e8c6d2a2-0adb-4cf9-ae00-3cc3d3748f38": {"doc_hash": "a67d44e47ad1038d319830ce7bd3d2073ebee5c955c133e85bb8bb4902d3ac7c"}, "179fea6b-a621-4ca2-bc32-2f58591dc0a3": {"doc_hash": "939c56679a3e0fdd635df0125c52be6a808c37743e56892bc829aafb8db31170"}, "828116ce-92d6-4423-96f3-0627d28d4fa6": {"doc_hash": "277c8755cd1d11cc284d7b6b15424040ec8dd7af0a6e908eff3600a060ab68b5"}, "60ca1e0c-4a43-4c6d-b606-ba4f3c37a057": {"doc_hash": "9292bddbaa57c972b3660186c90c4bd4dc734172bde21e97d8c2d27adb7e4954"}, "ec61d254-153e-4310-926b-f98d96d2ac84": {"doc_hash": "48b349e05feb98d7088222e53b38daac759c68d343acf563916f3d34655435d6"}, "e6885415-de4d-40e1-a0a2-095ddde91d24": {"doc_hash": "3a5d37b8d0aba4aeb7dcef536016f0070ac6ad313e85178219445d87b8dffe80"}, "0b416d6f-9590-4f69-95ce-4b9373c5b1be": {"doc_hash": "d655031db2b0665ed9883a21a8b3eeebe2c833be68d4aeadd32612810d4bb7a7"}, "cfbc779e-1774-4513-8728-83aa3e098f80": {"doc_hash": "22a5caa0c2cc3e482c20d0089203c1a40ee5b8f00e0c07af40596aad6971fb33"}, "4d7bdc16-de54-452a-835d-765c70565c00": {"doc_hash": "3e64fd9705f966c670ffcd62930685a2fc534fa11489bdcee1e1c2f3b51e1f20"}, "d909c016-22b6-4f23-bfa8-ca12ca21c02f": {"doc_hash": "d57012c1e8e1a4be4c6483c6267ad87866d66af5cdf04b57770d1b320157f7ce"}, "d80c027b-d513-4b32-bc73-dd8fcf4d152f": {"doc_hash": "45a4e2ce12ef397153306616abbc7b333fe8a8c9bdfee7df6699b637a5aab3a1"}, "39facf3d-c35f-4301-8e54-c92941485bb6": {"doc_hash": "29cfe463d6044fd1a4ad6d2836f397ced737c9f6bbc1bcee856c8e9f1e68fb2b"}, "52ba0a41-116e-4925-b6dd-035394193eba": {"doc_hash": "ce82f8ef1594e1b1c875118a8496de6dc0c61f02b44116ba5597a54fb5f76707"}, "33e9d596-74a3-4bd5-bdca-245e5237612e": {"doc_hash": "ddb42a5a9f78c2ceb1b5ff8ef5869da505d42df94f3ca60be340ca2d7527ff6f"}, "c3d89a56-4b22-43e5-8c22-e710f1fdff3f": {"doc_hash": "cc28839bd03e052e25660baa8bdce9008bb6f369e66fc4879064436305f3a237"}, "8c68f38c-d94a-4ba3-a644-6ffc84869e2f": {"doc_hash": "abd4a083bf5acf17b03fcc6a742f6a904906e4c3dd5cbb9e8995ebb6366e76df"}, "b2b1dd3d-5ec3-4335-a5eb-bbabbabceb8a": {"doc_hash": "b852b4d9317d8affd0dc216c4a38fe67073679021cccea3601750d9bd64e9147"}, "62affe7e-6ea2-4c56-babc-22aaa7e11d8f": {"doc_hash": "68b02fcf23631e58c3314aedb0c10dd2015ef3617883d35769d15b88bd5baf6d"}, "c0b6ecab-08db-4692-933c-8af2a53e82e9": {"doc_hash": "a4aeff5f25fc8363171cc7c6f8648b36fb89f93232ce2e75efc414bb5ee1d664"}, "c6c9d8b2-2236-4692-8975-0343a2614cf3": {"doc_hash": "0334156b7d0610b4619b902573b072c4ca4f7824ade68d9cdbb7a3e080048b3b"}, "d89b1f18-9ad1-4ab1-8e8c-9b3913387db7": {"doc_hash": "32c4591b02f3b488c76873199a8a67d934f29a68d3388034ab07167844e99950"}, "98f038f5-6726-480f-abf4-c950e88e7a8b": {"doc_hash": "d3e2c6a158b1be70ae7420509a9fa848b1d65238a35ef625672b2777e162478f"}, "9ccbc34e-dd32-411e-88ea-a70ab8c24cf9": {"doc_hash": "78e52fbc1c95481a4f58c1b02b82fa3e89b989a35d4878b0695d1f9108835449"}, "95b22f20-a73a-4e2e-b16c-294e8539016a": {"doc_hash": "66275a84cda03a6d789e4468d16108ea035a7aefa288d810a8129350524fa919"}, "36910835-2005-4969-a81c-7d9e3943368e": {"doc_hash": "f68e9bf008ccbf1997585b0285296ec1e4ec311e4f8ed7bcaa0696a04a911f0d"}, "07c5de27-f8a8-4550-8aad-b9b941d9f002": {"doc_hash": "b43a61b4cb30f88df7aa6948285f27a0510d6e6b4f3a452994922812ba3252e1"}, "8cb669f5-65e6-49d2-8778-066c0becf55d": {"doc_hash": "72da08ba58f3b5aa18073fe4a9dcbe7e5f941cf834d48d1f80ff9ff12381618f"}, "e3e4d821-4c75-4461-aa00-8c4540288cdf": {"doc_hash": "36696a27ec51b33f1fa89342cf62294aacf50c70127f6da569269fd3bebdca95"}, "fad20180-fd1e-4982-b95e-9f6797450289": {"doc_hash": "b7928573e93cc353afc3fd4018a632b6582d2c78741daf8b5f525ee4010109e6"}, "39b1baff-bd7a-4f97-881e-0efa18ec67de": {"doc_hash": "4f09124cc93ffa21f3b80bc922c064e147d15d0883cf1bf2623f621c2cc8d4c0"}, "3303ff81-498c-471b-9453-c65f30d41ce2": {"doc_hash": "146a8109ddcc04b1d4f8bd6397e07b143ebaf38356cbc1c5cdc4642732c7832a"}, "750ecb05-ce93-4c55-b516-5dee9433b779": {"doc_hash": "969b0fabe95d9d0833694e1ce1aefb23bb8ee85f3bf21c605f6b8c2d38a5cfd3"}, "2a96318f-77c2-48c3-833f-cd4bad0f1fca": {"doc_hash": "96b925ad652c6506ea80e21538dccbbccc5a56e99db8c6bc88337e47797e078d"}, "7f46c743-42a4-4295-984f-c07a2c5453a1": {"doc_hash": "67a7ab5eb53ab8fc35c0de13e7f1093a8f2af989fcfdf3ece94a33c8d929c925"}, "f756ad64-f0d3-4093-b9ef-8499b3cf1904": {"doc_hash": "5e342b8b1c83bb85610b63e037f39994465bda7a4c05643f02895a13937722f0"}, "f69d1a74-5d69-4f94-807a-cefb2c59c1f9": {"doc_hash": "6feff49a12a47759ce2bb651f53d823b7a91269c164f4d7f1b8e6f97395f318b"}, "1d95806f-bb56-4341-a077-d50b281119f3": {"doc_hash": "fd3ae78462d686a09024edd45213701a2be717362e797a20fbed49457a5881a9"}, "575eaf74-47b0-47d0-8d55-0bea36c35712": {"doc_hash": "7d03b98c36436ed8962e3ea7bb65eceb15b52b4c9a8e14604b7ac2055390cb27"}, "e4ee745d-241c-4117-94d0-f29138fb9121": {"doc_hash": "684fe31337ca4ca10bd5e59912a79290bab35c089bfb8fc8dc3719b6239acfa8"}, "f826b24e-a8f1-4488-a76d-d87018b9107e": {"doc_hash": "b2d9ebad5c11f5b465af34d94d337cbf83353aa75d832cc2b0d41dc9e96b31bc"}, "c460400d-e882-48d3-b8e0-d254fd17abd8": {"doc_hash": "a94d6103232d063670fc5e8b56979731f585dc868eb9b2ba8a83e8ea356d5153"}, "b5714203-bd3b-4d38-81e3-f958daee6998": {"doc_hash": "93ceecf766479675b0cd68f98fcf662a0c8a86d3bb13325d3f42aafc8522d43c"}, "02b6a1d8-b496-4ac9-ab89-d339d0f7f743": {"doc_hash": "3444e7f1652242f11f93012db09c1fb3a43bef181ecccff55982c9eef05ecb54"}, "f2557d05-79aa-4670-b627-97d3e7d55973": {"doc_hash": "0c0e828c5c4421eef258e493c968d8e7679af9d8d3d68a3d750030f1ac7fed79"}, "cff20283-f30e-44d8-8d99-aa3a6662fb19": {"doc_hash": "52a2767cce9c4cb48db5dc16711ee54aeee09ac7c72521a2f0eed4d8da8d0d4e"}, "4ebec4af-53d0-48f9-9c9f-6ccce56aad51": {"doc_hash": "8b60eaf59762a2e20215bdd28b0e9dde9e19846c7da50bd533e92be3af50e056"}, "46711fc8-6987-43ef-bdca-0be10f58dc73": {"doc_hash": "24d6c5669e981209a3b68892a6effa071738dca3924202262dc993ef25c1f9ee"}, "be5bce79-eb27-4d8a-95bc-7b0f3aadb33c": {"doc_hash": "16d228939cf2b20568dc7b1fa8b3d1c0d225dcc8e2d386ec145d7f30c9b6cd79", "ref_doc_id": "e8367158-985b-429e-a5c8-e8ab2e069226"}, "77f477f9-acc8-4d5b-86e1-52d88b3d883c": {"doc_hash": "9d927bd7fd9d236cb7747813417395e2388fd89857c14aee28b56ad68d35a4d9", "ref_doc_id": "fbc7b43c-64d6-4628-8f48-f6bdd57f9126"}, "a5613f3c-bd79-4559-b9d7-5fa741e489c6": {"doc_hash": "70b3673ebc5ed5866345790ad0a914120669f03c47fc108b0bc116adc0cc09c8", "ref_doc_id": "fbc7b43c-64d6-4628-8f48-f6bdd57f9126"}, "440cea16-129a-48ab-b1dc-0eb994e05aa9": {"doc_hash": "62b3c7cc56330ec3bc30bb55971206d33178432ba90c1ec1bfadd509401c6106", "ref_doc_id": "e8c6d2a2-0adb-4cf9-ae00-3cc3d3748f38"}, "e367707b-7065-418b-8892-9d462cf4e40d": {"doc_hash": "279eb2fc9587a9fb011bc3e8ccde76a778375b2dda0a7f28cebb69857af85e03", "ref_doc_id": "e8c6d2a2-0adb-4cf9-ae00-3cc3d3748f38"}, "b80d98ae-8507-4a50-9f3a-454b781f73f1": {"doc_hash": "ccd5ccb5c00bd2761a2d9bdc44c04518e59434f6def42507154388435954c39d", "ref_doc_id": "179fea6b-a621-4ca2-bc32-2f58591dc0a3"}, "fa999e05-7f52-4821-8c6c-18dbb9eda2d1": {"doc_hash": "23de03e2bfce2706e2d7621e8359782027ed85a771c97239fd43a82525c8ffe2", "ref_doc_id": "179fea6b-a621-4ca2-bc32-2f58591dc0a3"}, "8d32498e-a8d9-4e72-854f-494352eedbd5": {"doc_hash": "762a34403e736146042df3b5ed4eb9aee366fb8c6d977341e1f8ecdc7f754a8b", "ref_doc_id": "179fea6b-a621-4ca2-bc32-2f58591dc0a3"}, "7d886c06-e2b7-4dbf-9d6b-722f83cefdd3": {"doc_hash": "277c8755cd1d11cc284d7b6b15424040ec8dd7af0a6e908eff3600a060ab68b5", "ref_doc_id": "828116ce-92d6-4423-96f3-0627d28d4fa6"}, "407595dc-9fd0-4d16-b81a-ba9505f8c735": {"doc_hash": "9292bddbaa57c972b3660186c90c4bd4dc734172bde21e97d8c2d27adb7e4954", "ref_doc_id": "60ca1e0c-4a43-4c6d-b606-ba4f3c37a057"}, "34ab9799-60bd-46a0-94f4-8f583fe96cbf": {"doc_hash": "282090a511657f916dd54a47355035dc552ebfe9e7a061b523c650854bc02290", "ref_doc_id": "ec61d254-153e-4310-926b-f98d96d2ac84"}, "a7f11ea8-7379-40e0-8847-b466446f8cfb": {"doc_hash": "f5b64ef14bdaf115b03cb272ebf65f523e26c65c538e96ffa5f698d2b5f0a615", "ref_doc_id": "ec61d254-153e-4310-926b-f98d96d2ac84"}, "5ff4b21a-ed02-4e7d-91ac-81e8f68f886f": {"doc_hash": "3a5d37b8d0aba4aeb7dcef536016f0070ac6ad313e85178219445d87b8dffe80", "ref_doc_id": "e6885415-de4d-40e1-a0a2-095ddde91d24"}, "5120c0d5-2ab3-41e6-a192-a42056abbd7d": {"doc_hash": "e4e0b4228688b877aa3ff592ededcc3488286e24fb755eea6a5c29f693d5aee2", "ref_doc_id": "0b416d6f-9590-4f69-95ce-4b9373c5b1be"}, "8ed60e2c-2ed2-414c-8b80-85e6fd60e891": {"doc_hash": "1506f9241cfa903925ee1ad1d99c0879dca5834b86b6a27d5794fc59c8f12db4", "ref_doc_id": "0b416d6f-9590-4f69-95ce-4b9373c5b1be"}, "08203a68-55a7-4557-8fd1-3c11d7243920": {"doc_hash": "75fa1d3a51c8c0f68718b805a0cd94691f2c0284c5e3367a66ca5fa48d33b76d", "ref_doc_id": "0b416d6f-9590-4f69-95ce-4b9373c5b1be"}, "79d1e961-1570-40df-b300-d1740e97f430": {"doc_hash": "22a5caa0c2cc3e482c20d0089203c1a40ee5b8f00e0c07af40596aad6971fb33", "ref_doc_id": "cfbc779e-1774-4513-8728-83aa3e098f80"}, "aabdd5a0-f667-444c-a944-43473cf1af7c": {"doc_hash": "af505611e56e1b7c1fac7522b201f09c4f10b12ed5d05dd4a3aeb56282e8aae2", "ref_doc_id": "4d7bdc16-de54-452a-835d-765c70565c00"}, "208768f7-5921-49bc-9786-d158f4c33ff3": {"doc_hash": "fa565a77ddbe409bcd4a9e321f67a661db93b88bfadf306967077bf568ae545b", "ref_doc_id": "4d7bdc16-de54-452a-835d-765c70565c00"}, "2c655528-e28f-4472-9ca8-d4bcbcc584eb": {"doc_hash": "d5ed7c6f8885fc45bfc72c242591e25c8716583f931f8797deb6bb73b8698e96", "ref_doc_id": "4d7bdc16-de54-452a-835d-765c70565c00"}, "24b7101e-cbc4-404d-9837-5f38cf5197d5": {"doc_hash": "d57012c1e8e1a4be4c6483c6267ad87866d66af5cdf04b57770d1b320157f7ce", "ref_doc_id": "d909c016-22b6-4f23-bfa8-ca12ca21c02f"}, "6e75b99d-7f6b-4be8-a8b0-af2689c142ff": {"doc_hash": "45a4e2ce12ef397153306616abbc7b333fe8a8c9bdfee7df6699b637a5aab3a1", "ref_doc_id": "d80c027b-d513-4b32-bc73-dd8fcf4d152f"}, "3a3a8fb4-509a-42ac-a18f-dbe63b54a782": {"doc_hash": "c3f1caa5c8a92972ff95c626b34c8c17da8fb6bcc22bcc7d29a09bbb62f917a8", "ref_doc_id": "39facf3d-c35f-4301-8e54-c92941485bb6"}, "79413c02-507c-40db-ad28-2abfa2733d6e": {"doc_hash": "a757c57bfbbeba1d695a26d1069288429f6312060f2704c765750664013b765d", "ref_doc_id": "39facf3d-c35f-4301-8e54-c92941485bb6"}, "9a0c095a-1054-4c85-b40e-3aff2286fc5b": {"doc_hash": "670af14dca58c00f6f465eb130ac08614484834c71eca655b824c5520ac75da0", "ref_doc_id": "52ba0a41-116e-4925-b6dd-035394193eba"}, "fe81a5fd-0f01-44c3-9470-8edfc9347ac1": {"doc_hash": "a28ad913d28d8c8bf33b5f30d7221b4da9cb85261398a528ff7c72719987cc03", "ref_doc_id": "52ba0a41-116e-4925-b6dd-035394193eba"}, "939d8416-be1a-4862-bf53-f8586b920a77": {"doc_hash": "07b5f79bda5e7039ac900a049afeac3759b97a4875a5ea62379e00da7c9ea64e", "ref_doc_id": "52ba0a41-116e-4925-b6dd-035394193eba"}, "bb265177-6182-451b-adab-d5bc91004bdb": {"doc_hash": "0a32c20b7dbf4842361102752bcd1be5bfd60ac3645122aca2b5f0673c4a898e", "ref_doc_id": "33e9d596-74a3-4bd5-bdca-245e5237612e"}, "bc2b06be-8e87-4274-b56f-24d0156bc624": {"doc_hash": "a969fefa6789dacdce8d19e973bb8628428d96869512c03cba797f5924e8ccbc", "ref_doc_id": "33e9d596-74a3-4bd5-bdca-245e5237612e"}, "89591778-7fdb-4196-8712-a5aaf4ff8377": {"doc_hash": "e67d5f3c5316eb06b049f7195ec15a60e6322dcd629581d01ce3dc1789380eb0", "ref_doc_id": "c3d89a56-4b22-43e5-8c22-e710f1fdff3f"}, "4067330b-497b-404d-a51d-1459e38829d8": {"doc_hash": "03b2d0efd3b6686a6639a160a2c020afb4ad971ed12ca5b913b4d1e930d9421b", "ref_doc_id": "c3d89a56-4b22-43e5-8c22-e710f1fdff3f"}, "c9c92c30-a621-4840-a1fb-6c0a6e6ca7ca": {"doc_hash": "521a7b5e8e8e6f9c293c213c3f81d01ca524b03c372cd24b62bbea1919ed9c09", "ref_doc_id": "c3d89a56-4b22-43e5-8c22-e710f1fdff3f"}, "0ff980a9-ea75-4c8e-83da-35234a8307d4": {"doc_hash": "40023a84e05129a5c943d4a60234885035a1c7d227ed416eaa60682702df70d9", "ref_doc_id": "c3d89a56-4b22-43e5-8c22-e710f1fdff3f"}, "f4529daf-160a-4783-9e6a-d483b23c65c6": {"doc_hash": "f944e3d45baeccaac3ff321f560e2c95b5f8eebda532ece94eaf28f83fbbc9f6", "ref_doc_id": "8c68f38c-d94a-4ba3-a644-6ffc84869e2f"}, "241fa311-b5ff-4f54-b854-9b6655690f3b": {"doc_hash": "766cc4aa9305e3a8db6ff135ba5af31e4e251c9c01c4ddde2f54e0f3ac16127e", "ref_doc_id": "8c68f38c-d94a-4ba3-a644-6ffc84869e2f"}, "540ed3df-e85b-4a29-8cae-53ec560c99bf": {"doc_hash": "4448b224786af3637ab41803cfbcd40cd5e07074510daa03775342bb5c796431", "ref_doc_id": "8c68f38c-d94a-4ba3-a644-6ffc84869e2f"}, "4d1deb53-b2c9-4676-8c7c-90555d41b910": {"doc_hash": "2872aa339813d888bc2af666e5e39962d5c27ce5c954f87a072746cac035a89c", "ref_doc_id": "8c68f38c-d94a-4ba3-a644-6ffc84869e2f"}, "108948e1-c9b3-4ecb-b438-4cad50941c4a": {"doc_hash": "238fa0275e03ba1708c4b670fd9a5e90970967f69b855b3815023de37876cf85", "ref_doc_id": "b2b1dd3d-5ec3-4335-a5eb-bbabbabceb8a"}, "0b7832d7-8d9e-433f-bd1b-31eb3aacc380": {"doc_hash": "75fef78dfe89ad55bd107d077d5db98b1ed879ac30a1375a60c784cf14667ab8", "ref_doc_id": "b2b1dd3d-5ec3-4335-a5eb-bbabbabceb8a"}, "18828972-2bba-4fb8-afd3-e1a2a4cdddca": {"doc_hash": "f05336720f9bdc734299a36b9e31c3edfe9934caef770ff4a3c89f9f367c8692", "ref_doc_id": "b2b1dd3d-5ec3-4335-a5eb-bbabbabceb8a"}, "e9c34073-59d5-4c24-bea4-c343710eb374": {"doc_hash": "5f11f9351eeae037ca3f82ca8a36ba6e456a778e12e862ce2049d0a2e65d3ea1", "ref_doc_id": "b2b1dd3d-5ec3-4335-a5eb-bbabbabceb8a"}, "3ab5b55f-aa72-4335-855e-a916f109c160": {"doc_hash": "68b02fcf23631e58c3314aedb0c10dd2015ef3617883d35769d15b88bd5baf6d", "ref_doc_id": "62affe7e-6ea2-4c56-babc-22aaa7e11d8f"}, "6e77fdf8-83f9-41dd-9750-5c71a7b177f4": {"doc_hash": "a4aeff5f25fc8363171cc7c6f8648b36fb89f93232ce2e75efc414bb5ee1d664", "ref_doc_id": "c0b6ecab-08db-4692-933c-8af2a53e82e9"}, "dee44469-9b53-4909-a7b5-ba501654f9ce": {"doc_hash": "0334156b7d0610b4619b902573b072c4ca4f7824ade68d9cdbb7a3e080048b3b", "ref_doc_id": "c6c9d8b2-2236-4692-8975-0343a2614cf3"}, "8a5fbe2f-2c32-40f3-bfc3-9c955425261a": {"doc_hash": "72e0ea66b147dc76861cb400014f6efefee871cd42cac60d683879da409acb56", "ref_doc_id": "d89b1f18-9ad1-4ab1-8e8c-9b3913387db7"}, "9d8199a8-124d-4097-9388-79e046b848d8": {"doc_hash": "da67f81eac592ce096f5904d17b88eeede548f5d76ce28e09a2b44dc5b102811", "ref_doc_id": "d89b1f18-9ad1-4ab1-8e8c-9b3913387db7"}, "19f9ba9e-0a35-41f5-af09-823ca29c720e": {"doc_hash": "ef36b730609e136e61b44905cc42316def0c4a2fa4477b7d6fb36ae86cfa1cf3", "ref_doc_id": "98f038f5-6726-480f-abf4-c950e88e7a8b"}, "be9e326d-47e8-436d-a198-8b9bf4f96b79": {"doc_hash": "776b0eb69b80fb61b7a2d1f1fefbfc3350dace395c07809cbea2da231b7af12d", "ref_doc_id": "98f038f5-6726-480f-abf4-c950e88e7a8b"}, "359c8fc0-a342-467f-8ab1-faf2afa24070": {"doc_hash": "fe198801302bcb429440bd2906b73f1c5b0c6d29cc955a8d6e2ab6a5f13cc78f", "ref_doc_id": "9ccbc34e-dd32-411e-88ea-a70ab8c24cf9"}, "dcffa9f3-fbcb-4f28-8724-1558f033a9e6": {"doc_hash": "00f602c8cacc7c8e783ea9c05313a25b26e556f7da8aa26ff275d29c8566031e", "ref_doc_id": "9ccbc34e-dd32-411e-88ea-a70ab8c24cf9"}, "56802194-142b-4fbd-bfc8-5d8c73906620": {"doc_hash": "a3c4d3ad216808ced68d60188e735ae5eea0c608b397bdb1d47250e633fd1ad3", "ref_doc_id": "95b22f20-a73a-4e2e-b16c-294e8539016a"}, "d7db29cb-aeb7-40b1-90fd-ff036b9d22e6": {"doc_hash": "9cee11c9b540b0842149c28bb50475de887922b7e3154a9b55ec8d8fe928d87a", "ref_doc_id": "95b22f20-a73a-4e2e-b16c-294e8539016a"}, "28ae66e6-1c10-4582-83b5-daee0fe3c450": {"doc_hash": "5c2e6fccdf45984973d56eda8f397a7bd420d89aeba67a3dde84f6ae13b0fdf8", "ref_doc_id": "36910835-2005-4969-a81c-7d9e3943368e"}, "835a638d-1256-4e5d-87ee-d9dada6163dd": {"doc_hash": "d5b38d0621d715aa3e2420a3f7d1b676705178b175eb6d3c6f967ca0992e8011", "ref_doc_id": "36910835-2005-4969-a81c-7d9e3943368e"}, "f56e5171-9c4b-4b16-b1cd-3e6b7cbfa092": {"doc_hash": "b1023e85c3feeee1b7f8fd2cc2da8749106ca9b4e77081597054f8ec26aba6b6", "ref_doc_id": "07c5de27-f8a8-4550-8aad-b9b941d9f002"}, "33a7f957-e8dd-4888-a937-84d2680792b1": {"doc_hash": "73ef9d132817a5c639c76a54342ffc0ccea7e2ba044ad5415b85ec5fde1e8b46", "ref_doc_id": "07c5de27-f8a8-4550-8aad-b9b941d9f002"}, "64223be2-293b-4c35-8f1b-eb12fc178bed": {"doc_hash": "5c7719918196faaf5b982dc014f1d64ddb2349dacbb0d94a45a002f1d6032c3e", "ref_doc_id": "8cb669f5-65e6-49d2-8778-066c0becf55d"}, "6a9f58b3-c71e-4352-94d4-151f16b8a630": {"doc_hash": "99e3f2f4be658982774dc7eb9666a7d6a8822ce8036760b96c8d61c1fde751ab", "ref_doc_id": "8cb669f5-65e6-49d2-8778-066c0becf55d"}, "5117bc10-bc5f-4d7b-bd02-58e517f2da48": {"doc_hash": "8a9e6f8b3c54b9e527770e2dd3e29fb9740751220667da5b05365a74ad6987e3", "ref_doc_id": "e3e4d821-4c75-4461-aa00-8c4540288cdf"}, "7d7e58c2-790c-4cff-a9a8-caeefe9662a1": {"doc_hash": "0700c1d42514372f6108150fe7c5b94e83117596c97229d2e8f8a33325f9a551", "ref_doc_id": "e3e4d821-4c75-4461-aa00-8c4540288cdf"}, "e779041b-5988-4813-b94e-0d12a91b5cc9": {"doc_hash": "a71d623805710a16e8730968866dd1c3bbcf36a8c7ea9791c1a9ad1dd4cb7061", "ref_doc_id": "fad20180-fd1e-4982-b95e-9f6797450289"}, "14007e47-4b81-4439-b2ab-b1dd8fda12c5": {"doc_hash": "64856653b6e13885f81c15aa0ca43731d9a7b0e6d4d62bd8a524ae5aaedaee41", "ref_doc_id": "fad20180-fd1e-4982-b95e-9f6797450289"}, "3445ce62-8f52-4027-b311-6f6b3a1eb30e": {"doc_hash": "51a07cb70e22982415e9cfc165d996006a4a603e76bfe8874eb532428c67aec9", "ref_doc_id": "39b1baff-bd7a-4f97-881e-0efa18ec67de"}, "39177dbc-01da-4022-8155-dbfd35a56c6b": {"doc_hash": "6daf58966a6674b9657d313bf14d94f9afee9f0ae3bbd780a624ed321b987ff5", "ref_doc_id": "39b1baff-bd7a-4f97-881e-0efa18ec67de"}, "1f72a469-7c1a-4904-93f9-ee7c7409d029": {"doc_hash": "12ca31ce566162302cc3505c4d572a2b244972a129a2250293fb228bbec040db", "ref_doc_id": "3303ff81-498c-471b-9453-c65f30d41ce2"}, "bbedaa9b-af8a-42c0-90ad-c5d00173dc63": {"doc_hash": "574c85740f1d690fcfb2ee71b7c802177af75578cf04116b96e602a9e3442c74", "ref_doc_id": "3303ff81-498c-471b-9453-c65f30d41ce2"}, "19722332-929f-4b1a-8e55-f227cf4e8002": {"doc_hash": "921854c317d4ef7307eb7179ab7e3bf5e5368c75d900c8538bb0ed322d348b12", "ref_doc_id": "750ecb05-ce93-4c55-b516-5dee9433b779"}, "ead72480-90e7-4caf-8d2d-4bf4726ce808": {"doc_hash": "3eb49aa67b3e7a8be6de6619108ceaec6a3338c192c607c95b3a30490c669fbb", "ref_doc_id": "750ecb05-ce93-4c55-b516-5dee9433b779"}, "e86e60e1-6417-4169-9a8a-51afea16bb97": {"doc_hash": "96b925ad652c6506ea80e21538dccbbccc5a56e99db8c6bc88337e47797e078d", "ref_doc_id": "2a96318f-77c2-48c3-833f-cd4bad0f1fca"}, "9dc2dc99-b10b-4f4f-8313-fe8423bf82c0": {"doc_hash": "12b69c302de56a54ba9235eaef7ea9edcb980d601fc8942f5330237cb745a5b8", "ref_doc_id": "7f46c743-42a4-4295-984f-c07a2c5453a1"}, "cfe40769-c5ea-46cd-b8f7-7e8993559d3d": {"doc_hash": "9b534c62c3ad19a9b9425406ef0ac0095af54a8365fda9c3d7031866b7f0d017", "ref_doc_id": "7f46c743-42a4-4295-984f-c07a2c5453a1"}, "fdcd1b76-d431-4094-a5c2-3e11c8e1a2e8": {"doc_hash": "5e342b8b1c83bb85610b63e037f39994465bda7a4c05643f02895a13937722f0", "ref_doc_id": "f756ad64-f0d3-4093-b9ef-8499b3cf1904"}, "b44cdc30-f355-4d61-8285-2c60c232d0cc": {"doc_hash": "bea7920f89138122b51e24db63a8d851b7576bd000c639cff48acb24ff4c3c01", "ref_doc_id": "f69d1a74-5d69-4f94-807a-cefb2c59c1f9"}, "05429d5f-26ba-4e97-9e5f-16dec6dcac91": {"doc_hash": "d81647fe070f4469149df126b67d96c7c4e2182fdd8e88702d8c39114b67051b", "ref_doc_id": "f69d1a74-5d69-4f94-807a-cefb2c59c1f9"}, "ef3b6c2b-647e-4ac2-8ec6-85397b35cd0c": {"doc_hash": "fd3ae78462d686a09024edd45213701a2be717362e797a20fbed49457a5881a9", "ref_doc_id": "1d95806f-bb56-4341-a077-d50b281119f3"}, "2ae3427e-259b-4ad6-acfb-23368ccb295e": {"doc_hash": "4e7f6c699eee779ac4f24352714653ba7e064d9d2e8a094ae74977f13af4c28d", "ref_doc_id": "575eaf74-47b0-47d0-8d55-0bea36c35712"}, "72c760c5-0411-4bc1-8611-779a563049dc": {"doc_hash": "4b41a0509f9ece3595c8b6ba5d62d4ad1f5956eb63c74d6e5ceac3b67881cf59", "ref_doc_id": "575eaf74-47b0-47d0-8d55-0bea36c35712"}, "bedc3d7a-801e-4c30-a72c-6db929a0a8ce": {"doc_hash": "3005463214d42ab546b2163c9e48d7fff1d2720c82895be43495f791db78a821", "ref_doc_id": "575eaf74-47b0-47d0-8d55-0bea36c35712"}, "f9f18101-8be1-477f-8308-578eeee46688": {"doc_hash": "a962d0e1010f4539910ce70d55edb0fc4fa85a998eb0931c9182a23c62a5da26", "ref_doc_id": "e4ee745d-241c-4117-94d0-f29138fb9121"}, "fe21853b-2bfe-407b-af49-d68ff1dd0e56": {"doc_hash": "2880b481a748b3d3b513fe0735539d589b8782ba5287773efc9baad764c0e9f7", "ref_doc_id": "e4ee745d-241c-4117-94d0-f29138fb9121"}, "678d3b30-b33d-4992-b394-2c9c3e55eccb": {"doc_hash": "3e078ec48f94883d023ca719cf2b0dee0a7f111818e09b4d95278a7998de7808", "ref_doc_id": "e4ee745d-241c-4117-94d0-f29138fb9121"}, "e1f7ca74-2bf2-4004-8640-3c996aba31fc": {"doc_hash": "269dcfb45eaa2366d8df6c5f762580d90f7e833f096259a0b2dbbd0f08d646f3", "ref_doc_id": "f826b24e-a8f1-4488-a76d-d87018b9107e"}, "e0f5ddbf-3206-4b92-a60b-2cf534a23db3": {"doc_hash": "7af1193fb46911facde681e5a80c51ce2d3cdf20fe320e7f773fed5d2660a499", "ref_doc_id": "f826b24e-a8f1-4488-a76d-d87018b9107e"}, "bf0a70bc-64a5-4675-abd4-20e0738f3175": {"doc_hash": "80d08fab29c0a2b05f6022e6dbf967cbf23fc58ac002cbec6484c172fd4b0422", "ref_doc_id": "f826b24e-a8f1-4488-a76d-d87018b9107e"}, "0c861258-b0c4-488c-9bb4-60d1bb865dd6": {"doc_hash": "07e884785258c2022f69056ac75955fdaa48a17afda0acbcaddc0b899198d2d9", "ref_doc_id": "c460400d-e882-48d3-b8e0-d254fd17abd8"}, "8f90d074-930c-4ffd-b1f2-56a48b194329": {"doc_hash": "840de22278a1406d83b425884f4eb019dd81058fa88664a957b1a1c957f5f4a4", "ref_doc_id": "c460400d-e882-48d3-b8e0-d254fd17abd8"}, "5bcc1590-3bbd-4f58-9769-bd1308b18a3c": {"doc_hash": "e95e34e82dd9b11671cc6474df80e142586d50a2359100d4750568d9ca6e99f8", "ref_doc_id": "b5714203-bd3b-4d38-81e3-f958daee6998"}, "effccb3f-b112-4274-9896-e7ae58f09586": {"doc_hash": "7db3b583646d9b025437e49d24284582031cdd3a71fadc353df45ab6dc758f6b", "ref_doc_id": "b5714203-bd3b-4d38-81e3-f958daee6998"}, "f02f8199-8c9a-4151-8165-f7bd02754e86": {"doc_hash": "6056c9544d70394381f5eeec98736784664d083085e899905e3550c4bfc9a0bf", "ref_doc_id": "02b6a1d8-b496-4ac9-ab89-d339d0f7f743"}, "1455d3f0-9b2a-4285-8698-7aee6f5183f3": {"doc_hash": "f762312f68f0dbee5ef60dc6bc1f9ed13d11dde618b8ed63a093835129db3c10", "ref_doc_id": "02b6a1d8-b496-4ac9-ab89-d339d0f7f743"}, "6a348906-ec20-44fc-a355-cdba0a470d7d": {"doc_hash": "7eae0c01dfb39e39e34d1df76a58e5077f7c6e19ceec1ce42804668f8eceb7bb", "ref_doc_id": "f2557d05-79aa-4670-b627-97d3e7d55973"}, "c919b4d9-d475-4a60-acf9-8e8de0353489": {"doc_hash": "54f3ee8c3906e2571474aaf2ef66afc26ed7e9d46c586ec88d2dffae68f82e1e", "ref_doc_id": "f2557d05-79aa-4670-b627-97d3e7d55973"}, "4443bd53-5015-40bc-97a3-e5abcdf72531": {"doc_hash": "4db1ee933dbd0b23eee1838ee59166a634ab7f9c0618f5f55b6f72896bdbb7b4", "ref_doc_id": "f2557d05-79aa-4670-b627-97d3e7d55973"}, "4d0d5aac-8548-46c8-867e-a408192887b4": {"doc_hash": "fb5e45dba57ec13b5d09054d8db33898ea7c675a93d75517fc2297617d697aab", "ref_doc_id": "cff20283-f30e-44d8-8d99-aa3a6662fb19"}, "daceba57-bd3c-46d0-9ff9-e76352e88a4c": {"doc_hash": "3f873c7a1e1c7d85ca5d2cba8802ffb7b0506150709e210aa282c2ef189b5471", "ref_doc_id": "cff20283-f30e-44d8-8d99-aa3a6662fb19"}, "5cec4ed2-bed3-47e2-9fb2-f63345acbcfd": {"doc_hash": "da4fbc71b9d5667a925ce50482f6ed3a13aadfc47e6f171b9c7fbd6f76d4929e", "ref_doc_id": "cff20283-f30e-44d8-8d99-aa3a6662fb19"}, "88759eb9-e1c6-4b40-8258-0a003c283fd9": {"doc_hash": "f0c622d81960f301d8eb10d0e8dc37da97327960bdeb63f85c7a40e73025b30f", "ref_doc_id": "cff20283-f30e-44d8-8d99-aa3a6662fb19"}, "1655e39f-e135-48be-83f8-1e60b712ef87": {"doc_hash": "94b0498330840da454ff7f8cdb55103489fa586161d81fabd0239265d7eb0185", "ref_doc_id": "4ebec4af-53d0-48f9-9c9f-6ccce56aad51"}, "884f0274-61fe-4505-9d80-bc4328a0edfd": {"doc_hash": "fb369cc67ff5f31e012eb4657f40f06ce5bb7e24c727133a327d5f13592e6f61", "ref_doc_id": "4ebec4af-53d0-48f9-9c9f-6ccce56aad51"}, "86e1fe65-887c-45bd-a7ab-e9f4093f1c0c": {"doc_hash": "ad63144cce5e2423e4d5290b6285fb413f0f2c4de9a4cd76dbc81e4cfb8db44d", "ref_doc_id": "4ebec4af-53d0-48f9-9c9f-6ccce56aad51"}, "07f3087e-050e-4d26-a071-7b65c556750a": {"doc_hash": "0e45e2c55a04186e59fd2586e9523247ba40c9694f1c3810c13f16cacdf43e13", "ref_doc_id": "4ebec4af-53d0-48f9-9c9f-6ccce56aad51"}, "e445081a-5dd1-4611-88c7-005ef0543d58": {"doc_hash": "24d6c5669e981209a3b68892a6effa071738dca3924202262dc993ef25c1f9ee", "ref_doc_id": "46711fc8-6987-43ef-bdca-0be10f58dc73"}}, "docstore/data": {"be5bce79-eb27-4d8a-95bc-7b0f3aadb33c": {"__data__": {"id_": "be5bce79-eb27-4d8a-95bc-7b0f3aadb33c", "embedding": null, "metadata": {"page_label": "812", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e8367158-985b-429e-a5c8-e8ab2e069226", "node_type": "4", "metadata": {"page_label": "812", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "16d228939cf2b20568dc7b1fa8b3d1c0d225dcc8e2d386ec145d7f30c9b6cd79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77f477f9-acc8-4d5b-86e1-52d88b3d883c", "node_type": "1", "metadata": {}, "hash": "0ffd558698d15c041a4336b57efc48917cdb4684546dd6b5e64ae5e8a4bd75c4", "class_name": "RelatedNodeInfo"}}, "text": "Resource\nThe Immune Landscape of Cancer\nGraphical Abstract\nHighlights\ndSix identi\ufb01ed immune subtypes span cancer tissue types and\nmolecular subtypes\ndImmune subtypes differ by somatic aberrations,microenvironment, and survival\ndMultiple control modalities of molecular networks affecttumor-immune interactions\ndThese analyses serve as a resource for exploring\nimmunogenicity across cancer typesAuthors\nVe\u00b4steinn Thorsson, David L. Gibbs,\nScott D. Brown, ..., Mary L. Disis,Benjamin G. Vincent, Ilya Shmulevich\nCorrespondence\nvesteinn.thorsson@systemsbiology.org\n(V.T.),benjamin.vincent@unchealth.unc.edu\n(B.G.V.),\nilya.shmulevich@systemsbiology.org (I.S.)\nIn Brief\nThorsson et al. present immunogenomics\nanalyses of more than 10,000 tumors,identifying six immune subtypes thatencompass multiple cancer types and arehypothesized to de\ufb01ne immune responsepatterns impacting prognosis. This workprovides a resource for understandingtumor-immune interactions, withimplications for identifying ways toadvance research on immunotherapy.\nThorsson et al., 2018, Immunity 48, 812\u2013830\nApril 17, 2018 \u00aa2018 The Authors. Published by Elsevier Inc.\nhttps://doi.org/10.1016/j.immuni.2018.03.023\niAn update to this article is included at the end", "start_char_idx": 0, "end_char_idx": 1229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77f477f9-acc8-4d5b-86e1-52d88b3d883c": {"__data__": {"id_": "77f477f9-acc8-4d5b-86e1-52d88b3d883c", "embedding": null, "metadata": {"page_label": "813", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fbc7b43c-64d6-4628-8f48-f6bdd57f9126", "node_type": "4", "metadata": {"page_label": "813", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "1fd7d9c4e8414e2669b03383acaf00b05ea5097d4b9e795186395f5da62fbdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be5bce79-eb27-4d8a-95bc-7b0f3aadb33c", "node_type": "1", "metadata": {"page_label": "812", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "16d228939cf2b20568dc7b1fa8b3d1c0d225dcc8e2d386ec145d7f30c9b6cd79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5613f3c-bd79-4559-b9d7-5fa741e489c6", "node_type": "1", "metadata": {}, "hash": "c22e92700406b62581ae5e3d01ad01c10e47d00a8f7d99afa428b581f707dc31", "class_name": "RelatedNodeInfo"}}, "text": "Immunity\nResource\nThe Immune Landscape of Cancer\nVe\u00b4steinn Thorsson,1,37,*David L. Gibbs,1,36Scott D. Brown,2Denise Wolf,3Dante S. Bortone,4Tai-Hsien Ou Yang,5\nEduard Porta-Pardo,6,7Galen F. Gao,8Christopher L. Plaisier,1,9James A. Eddy,10Elad Ziv,11Aedin C. Culhane,12\nEvan O. Paull,13I.K. Ashok Sivakumar,14Andrew J. Gentles,15Raunaq Malhotra,16Farshad Farshidfar,17\nAntonio Colaprico,18Joel S. Parker,4Lisle E. Mose,4Nam Sy Vo,19Jianfang Liu,20Yuexin Liu,19Janet Rader,21\nVarsha Dhankani,1Sheila M. Reynolds,1Reanne Bowlby,2Andrea Califano,13Andrew D. Cherniack,8\nDimitris Anastassiou,5Davide Bedognetti,22Younes Mokrab,22Aaron M. Newman,35Arvind Rao,19Ken Chen,19\nAlexander Krasnitz,23Hai Hu,20Tathiane M. Malta,24,25Houtan Noushmehr,24,25Chandra Sekhar Pedamallu,26\n(Author list continued on next page)\nSUMMARY\nWe performed an extensive immunogenomic anal-\nysis of more than 10,000 tumors comprising 33diverse cancer types by utilizing data compiled by\nTCGA. Across cancer types, we identi\ufb01ed six im-\nmune subtypes\u2014wound healing, IFN- gdominant,\nin\ufb02ammatory, lymphocyte depleted, immunologi-cally quiet, and TGF- bdominant\u2014characterized by\ndifferences in macrophage or lymphocyte signa-tures, Th1:Th2 cell ratio, extent of intratumoral het-erogeneity, aneuploidy, extent of neoantigen load,overall cell proliferation, expression of immunomod-\nulatory genes, and prognosis. Speci\ufb01c driver\nmutations correlated with lower ( CTNNB1 ,NRAS ,\norIDH1 ) or higher ( BRAF ,TP53 ,o rCASP8 ) leukocyte\nlevels across all cancers. Multiple control modalitiesof the intracellular and extracellular networks (tran-scription, microRNAs, copy number, and epigenetic\nprocesses) were involved in tumor-immune cell inter-actions, both across and within immune subtypes.Our immunogenomics pipeline to characterize theseheterogeneous tumors and the resulting data are\nintended to serve as a resource for future targeted\nstudies to further advance the \ufb01eld.\nINTRODUCTION\nThe Cancer Genome Atlas (TCGA) has profoundly illuminated the\ngenomic landscape of human malignancy.", "start_char_idx": 0, "end_char_idx": 2053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5613f3c-bd79-4559-b9d7-5fa741e489c6": {"__data__": {"id_": "a5613f3c-bd79-4559-b9d7-5fa741e489c6", "embedding": null, "metadata": {"page_label": "813", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fbc7b43c-64d6-4628-8f48-f6bdd57f9126", "node_type": "4", "metadata": {"page_label": "813", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "1fd7d9c4e8414e2669b03383acaf00b05ea5097d4b9e795186395f5da62fbdde", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77f477f9-acc8-4d5b-86e1-52d88b3d883c", "node_type": "1", "metadata": {"page_label": "813", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "9d927bd7fd9d236cb7747813417395e2388fd89857c14aee28b56ad68d35a4d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "440cea16-129a-48ab-b1dc-0eb994e05aa9", "node_type": "1", "metadata": {}, "hash": "c71e631a3f58e5eaf049a9cabc4746b2a4bc2958135b83c5d7289419280ea53a", "class_name": "RelatedNodeInfo"}}, "text": "Speci\ufb01c driver\nmutations correlated with lower ( CTNNB1 ,NRAS ,\norIDH1 ) or higher ( BRAF ,TP53 ,o rCASP8 ) leukocyte\nlevels across all cancers. Multiple control modalitiesof the intracellular and extracellular networks (tran-scription, microRNAs, copy number, and epigenetic\nprocesses) were involved in tumor-immune cell inter-actions, both across and within immune subtypes.Our immunogenomics pipeline to characterize theseheterogeneous tumors and the resulting data are\nintended to serve as a resource for future targeted\nstudies to further advance the \ufb01eld.\nINTRODUCTION\nThe Cancer Genome Atlas (TCGA) has profoundly illuminated the\ngenomic landscape of human malignancy. Genomic and tran-\nscriptomic data derived from bulk tumor samples have been\nused to study the tumor microenvironment (TME), and measuresof immune in\ufb01ltration de\ufb01ne molecular subtypes of ovarian,\nmelanoma, and pancreatic cancer ( Bailey et al., 2016; The Can-\ncer Genome Atlas Network, 2015; The Cancer Genome Atlas1Institute for Systems Biology, 401 Terry Ave N, Seattle, WA 98109, USA\n2Canada\u2019s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC V5Z 4S6, Canada\n3University of California, San Francisco, Box 0808, 2340 Sutter Street, S433, San Francisco, CA 94115, USA\n4Lineberger Comprehensive Cancer Center, Curriculum in Bioinformatics and Computational Biology, University of North Carolina, 125\nMason Farm Road, Chapel Hill, NC 27599-7295, USA\n5Department of Systems Biology and Department of Electrical Engineering, Columbia University, New York, NY 10027, USA\n6Barcelona Supercomputing Centre, c/Jordi Girona, 29, 08034 Barcelona, Spain\n7SBP Medical Discovery Institute, La Jolla, CA 92037, USA\n8The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA\n9School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ 85281, USA\n10Sage Bionetworks, 2901 Third Ave, Suite 330, Seattle, WA 98121, USA\n11Department of Medicine, Institute for Human Genetics, Helen Diller Family Comprehensive Cancer Center, University of California, San\nFrancisco, 1450 3rd St, San Francisco, CA 94143, USA\n12Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA\n13Irving Cancer Research Center, Room 913,1130 St. Nicholas Avenue, New York, NY 10032, USA\n14Department of Computer Science, Institute for Computational Medicine; Johns Hopkins University, Baltimore, MD 21218, USA\n15Departments of Medicine and Biomedical Data Science, Stanford University, Stanford, CA 94305, USA\n16Seven Bridges Genomics, Cambridge, MA 02142, USA\n17Department of Oncology, University of Calgary, Calgary, AB T2N 4N1, Canada\n18Universite libre de Bruxelles (ULB), Computer Science Department, Faculty of Sciences, Boulevard du Triomphe - CP212, 1050 Bruxelles,\nBelgium\n19Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA\n20Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA 15963, USA\n21Medical College of Wisconsin, 9200 Wisconsin Avenue, Milwaukee, WI 53226 USA\n22Division of Translational Medicine, Research Branch, Sidra Medical and Research Center, PO Box 26999, Doha, Qatar\n23Simons Center for Quantitative Biology, Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724, USA\n(Af\ufb01liations continued on next page)\n812 Immunity 48, 812\u2013830, April 17, 2018 \u00aa2018 The Authors. Published by Elsevier Inc.\nThis is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).", "start_char_idx": 1378, "end_char_idx": 5036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "440cea16-129a-48ab-b1dc-0eb994e05aa9": {"__data__": {"id_": "440cea16-129a-48ab-b1dc-0eb994e05aa9", "embedding": null, "metadata": {"page_label": "814", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e8c6d2a2-0adb-4cf9-ae00-3cc3d3748f38", "node_type": "4", "metadata": {"page_label": "814", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "a67d44e47ad1038d319830ce7bd3d2073ebee5c955c133e85bb8bb4902d3ac7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5613f3c-bd79-4559-b9d7-5fa741e489c6", "node_type": "1", "metadata": {"page_label": "813", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "70b3673ebc5ed5866345790ad0a914120669f03c47fc108b0bc116adc0cc09c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e367707b-7065-418b-8892-9d462cf4e40d", "node_type": "1", "metadata": {}, "hash": "d33a477f20722d9caefca7bdf0f8a0b742b17f01c049f7e53392d493043e3289", "class_name": "RelatedNodeInfo"}}, "text": "Research Network, 2011 ) and immune gene expression in other\ntumors varies by molecular subtype ( Iglesia et al., 2016 ). Charac-\nterization of the immune microenvironment using gene expres-sion signatures, T cell receptor (TCR), and B cell receptor\n(BCR) repertoire, and analyses to identify neo-antigenic immune\ntargets provide a wealth of information in many cancer types andhave prognostic value ( Bindea et al., 2013; Brown et al., 2014,\n2015; Charoentong et al., 2017; Gentles et al., 2015; Iglesia\net al., 2016; Li et al., 2016; Porta-Pardo and Godzik, 2016;Rooney et al., 2015 ).\nContemporaneous with the work of TCGA, cancer immuno-\ntherapy has revolutionized cancer care. Antibodies againstCTLA-4, PD-1, and PD-L1 are effective in treating a variety of\nmalignancies. However, the biology of the immune microenvi-\nronment driving these responses is incompletely understood(Hugo et al., 2016; McGranahan et al., 2016 ) but is critical to\nthe design of immunotherapy treatment strategies.\nWe integrated major immunogenomics methods to charac-\nterize the immune tumor microenvironment (TME) across 33 can-cers analyzed by TCGA, applying methods for the assessment of\ntotal lymphocytic in\ufb01ltrate (from genomic and H&E image data),\nimmune cell fractions from deconvolution analysis of mRNA-seq data, immune gene expression signatures, neoantigen pre-\ndiction, TCR and BCR repertoire inference, viral RNA expression,\nand somatic DNA alterations ( Table S1 ). Transcriptional regulato-\nry networks and extracellular communication networks that may\ngovern the TME were found, as were possible germline determi-\nnants of TME features, and prognostic models were developed.\nThrough this approach, we identi\ufb01ed and characterized six\nimmune subtypes spanning multiple tumor types, with potential\ntherapeutic and prognostic implications for cancer manage-\nment. All data and results are provided in Supplemental Tables ,\nat the NCI Genomic Data Commons (GDC, https://portal.gdc.\ncancer.gov ), and though the Cancer Research Institute iAtlas\nportal for interactive exploration and visualization ( http://www.cri-iatlas.org ), and are intended to serve as a resource for future\nstudies in the \ufb01eld of immunogenomics.\nRESULTS\nAnalytic Pipeline\nTo characterize the immune response to cancer in all TCGA\ntumor samples, identify common immune subtypes, and eval-\nuate whether tumor-extrinsic features can predict outcomes,we analyzed the TME across the landscape of all TCGA tumor\nsamples. First, source datasets from all 33 TCGA cancer types\nand six molecular platforms (mRNA, microRNA, and exomesequencing; DNA methylation-, copy number-, and reverse-\nphase protein arrays) were harmonized by the PanCanAtlas\nconsortium for uniform quality control, batch effect correction,normalization, mutation calling, and curation of survival data ( Ell-\nrott et al., 2018; Liu et al., 2018 ). We then performed a series of\nanalyses, which we summarize here and describe in detail in\nthe ensuing manuscript sections as noted within parentheses.We \ufb01rst compiled published tumor immune expression signa-\ntures and scored these across all non-hematologic TCGA cancer\ntypes. Meta-analysis of subsequent cluster analysis identi\ufb01edcharacteristic immunooncologic gene signatures, which were\nthen used to cluster TCGA tumor types into six groups, or\nsubtypes (described in Immune Subtypes in Cancer ). Leukocyte\nproportion and cell type were then de\ufb01ned from DNA\nmethylation, mRNA, and image analysis (see Composition of\nthe Tumor Immune In\ufb01ltrate ). Survival modeling was performed\nto assess how immune subtypes associate with patient prog-nosis (see Prognostic Associations of Tumor Immune Response\nMeasures ).", "start_char_idx": 0, "end_char_idx": 3684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e367707b-7065-418b-8892-9d462cf4e40d": {"__data__": {"id_": "e367707b-7065-418b-8892-9d462cf4e40d", "embedding": null, "metadata": {"page_label": "814", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e8c6d2a2-0adb-4cf9-ae00-3cc3d3748f38", "node_type": "4", "metadata": {"page_label": "814", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "a67d44e47ad1038d319830ce7bd3d2073ebee5c955c133e85bb8bb4902d3ac7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "440cea16-129a-48ab-b1dc-0eb994e05aa9", "node_type": "1", "metadata": {"page_label": "814", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "62b3c7cc56330ec3bc30bb55971206d33178432ba90c1ec1bfadd509401c6106", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b80d98ae-8507-4a50-9f3a-454b781f73f1", "node_type": "1", "metadata": {}, "hash": "af768bc631a823c6cbd05df871c5eaa81ac1dbc3302b82338751adaf585fc04c", "class_name": "RelatedNodeInfo"}}, "text": "We then performed a series of\nanalyses, which we summarize here and describe in detail in\nthe ensuing manuscript sections as noted within parentheses.We \ufb01rst compiled published tumor immune expression signa-\ntures and scored these across all non-hematologic TCGA cancer\ntypes. Meta-analysis of subsequent cluster analysis identi\ufb01edcharacteristic immunooncologic gene signatures, which were\nthen used to cluster TCGA tumor types into six groups, or\nsubtypes (described in Immune Subtypes in Cancer ). Leukocyte\nproportion and cell type were then de\ufb01ned from DNA\nmethylation, mRNA, and image analysis (see Composition of\nthe Tumor Immune In\ufb01ltrate ). Survival modeling was performed\nto assess how immune subtypes associate with patient prog-nosis (see Prognostic Associations of Tumor Immune Response\nMeasures ). Neoantigen prediction and viral RNA expression (see\nSurvey of Immunogenicity ), TCR and BCR repertoire inference\n(see The Adaptive Immune Receptor Repertoire in Cancer ),\nand immunomodulator (IM) expression and regulation (see\nRegulation of Immunomodulators ) were characterized in theSusan Bullman,26Akinyemi I. Ojesina,27Andrew Lamb,10Wanding Zhou,28Hui Shen,28Toni K. Choueiri,26\nJohn N. Weinstein,19Justin Guinney,10Joel Saltz,29Robert A. Holt,2Charles S. Rabkin,30The Cancer Genome Atlas\nResearch Network, Alexander J. Lazar,31Jonathan S. Serody,32Elizabeth G. Demicco,33,36Mary L. Disis,34,36\nBenjamin G. Vincent,4,*and Ilya Shmulevich1,*\n24Department of Neurosurgery, Henry Ford Hospital, Detroit, MI 48202, USA\n25Department of Genetics, Ribeirao Preto Medical School, University of Sa \u02dco Paulo, Sa \u02dco Paulo, Brazil\n26Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA\n27University of Alabama at Birmingham, Birmingham, AL 35294, USA\n28Center for Epigenetics, Van Andel Research Institute, Grand Rapids, MI 49503, USA\n29Department of Biomedical Informatics, Stony Brook Medicine, 100 Nicolls Rd, Stony Brook, NY 11794, USA\n30Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Dr., Bethesda, MD 20892, USA\n31Departments of Pathology, Genomics Medicine and Translational Molecular Pathology, The University of Texas MD Anderson Cancer\nCenter, 1515 Holcombe Blvd-Unit 85, Houston, TX 77030, USA\n32Department of Medicine and Microbiology and Lineberger Comprehensive Cancer Center, 125 Mason Farm Road, Chapel Hill, NC\n27599-7295, USA\n33Mount Sinai Hospital, Department of Pathology and Laboratory Medicine, 600 University Ave., Toronto, ON M5G 1X5, Canada\n34UW Medicine Cancer Vaccine Institute, 850 Republican Street, Brotman Building, 2nd Floor, Room 221, Box 358050, University of\nWashington, Seattle, WA 98109-4714, USA\n35Institute for Stem Cell Biology and Regenerative Medicine and Department of Biomedical Data Science, Stanford University, Stanford, CA\n94305, USA\n36These authors contributed equally\n37Lead Author\n*Correspondence: vesteinn.thorsson@systemsbiology.org (V.T.), benjamin.vincent@unchealth.unc.edu (B.G.V.), ilya.shmulevich@\nsystemsbiology.org (I.S.)\nhttps://doi.org/10.1016/j.immuni.2018.03.023\nImmunity 48, 812\u2013830, April 17, 2018 813", "start_char_idx": 2874, "end_char_idx": 6021, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b80d98ae-8507-4a50-9f3a-454b781f73f1": {"__data__": {"id_": "b80d98ae-8507-4a50-9f3a-454b781f73f1", "embedding": null, "metadata": {"page_label": "815", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "179fea6b-a621-4ca2-bc32-2f58591dc0a3", "node_type": "4", "metadata": {"page_label": "815", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "939c56679a3e0fdd635df0125c52be6a808c37743e56892bc829aafb8db31170", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e367707b-7065-418b-8892-9d462cf4e40d", "node_type": "1", "metadata": {"page_label": "814", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "279eb2fc9587a9fb011bc3e8ccde76a778375b2dda0a7f28cebb69857af85e03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa999e05-7f52-4821-8c6c-18dbb9eda2d1", "node_type": "1", "metadata": {}, "hash": "195fe447845fe0037654c4f48f101b8e7bec1a7d529ae29130a40c90086f0297", "class_name": "RelatedNodeInfo"}}, "text": "context of TCGA tumor types, TCGA-de\ufb01ned molecular\nsubtypes, and these six immune subtypes, so as to assess the\nrelationship between factors affecting immunogenicity and\nimmune in\ufb01ltrate. In order to assess the degree to whichspeci\ufb01c underlying somatic alterations (pathways, copy-number\nalterations, and driver mutations) may drive the composition of\nthe TME, we identi\ufb01ed which alterations correlate with modi\ufb01edimmune in\ufb01ltrate (see Immune Response Correlates of Somatic\nVariation ). We likewise asked whether gender and ancestry\npredispose individuals to particular tumor immune responses\n(see Immune Response Correlates of Demographic and Germ-\nline Variation ). Finally, we sought to identify the underlying intra-\ncellular regulatory networks governing the immune response to\ntumors, as well as the extracellular communication networksinvolved in establishing the particular immune milieu of the\nTME (see Networks Modulating Tumoral Immune Response ).\nImmune Subtypes in Cancer\nTo characterize intratumoral immune states, we scored 160 im-\nmune expression signatures and used cluster analysis to identifymodules of immune signature sets ( Figure 1 A, top). Five immune\nexpression signatures\u2014macrophages/monocytes ( Beck et al.,\n2009 ), overall lymphocyte in\ufb01ltration (dominated by T and B cells)\n(Calabro et al., 2009 ), TGF- bresponse ( Teschendorff et al., 2010 ),\nIFN-gresponse ( Wolf et al., 2014 ), and wound healing ( Chang\net al., 2004 )\u2014which robustly reproduced co-clustering of these\nimmune signature sets, were selected to perform cluster analysis\nof all 30 non-hematologic cancer types ( Figures 1 A middle, and\nS1A). The six resulting clusters \u2018\u2018Immune Subtypes,\u2019\u2019 C1\u2013C6\n(with 2,416, 2,591, 2,397, 1,157, 385, and 180 cases, respectively)were characterized by a distinct distribution of scores over the \ufb01ve\nrepresentative signatures ( Figure 1 A, bottom) and showed\ndistinct immune signatures based on the dominant sample char-acteristics of their tumor samples ( Figures 1 B and 1C). Immune\nsubtypes spanned anatomical location and tumor type, while in-\ndividual tumor types and TCGA subtypes ( Figures 1 D and S1B\u2013\nS1D) varied substantially in their proportion of immune subtypes.\nC1 (wound healing) had elevated expression of angiogenic\ngenes, a high proliferation rate ( Figure 1 C), and a Th2 cell bias\nto the adaptive immune in\ufb01ltrate. Colorectal cancer (COAD[colon adenocarcinoma], READ [rectum adenocarcinoma]) and\nlung squamous cell carcinoma (LUSC) were rich in C1, as were\nbreast invasive carcinoma (BRCA) luminal A ( Figures S1 C and\nS1D), head and neck squamous cell carcinoma (HNSC) classical,\nand the chromosomally unstable (CIN) gastrointestinal subtype.\nC2 (IFN- gdominant) had the highest M1/M2 macrophage po-\nlarization ( Figure S2 A, mean ratio = 0.52, p < 10\n/C0149, Wilcoxon\ntest relative to next-highest), a strong CD8 signal and, together\nwith C6, the greatest TCR diversity. C2 also showed a high pro-liferation rate, which may override an evolving type I immune\nresponse, and was comprised of highly mutated BRCA, gastric,\novarian (OV), HNSC, and cervical tumors (CESC).\nC3 (in\ufb02ammatory) was de\ufb01ned by elevated Th17 and Th1\ngenes ( Figure 1 C, both p < 10\n/C023), low to moderate tumor cell\nproliferation, and, along with C5, lower levels of aneuploidy\nand overall somatic copy number alterations than the othersubtypes.", "start_char_idx": 0, "end_char_idx": 3366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa999e05-7f52-4821-8c6c-18dbb9eda2d1": {"__data__": {"id_": "fa999e05-7f52-4821-8c6c-18dbb9eda2d1", "embedding": null, "metadata": {"page_label": "815", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "179fea6b-a621-4ca2-bc32-2f58591dc0a3", "node_type": "4", "metadata": {"page_label": "815", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "939c56679a3e0fdd635df0125c52be6a808c37743e56892bc829aafb8db31170", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b80d98ae-8507-4a50-9f3a-454b781f73f1", "node_type": "1", "metadata": {"page_label": "815", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "ccd5ccb5c00bd2761a2d9bdc44c04518e59434f6def42507154388435954c39d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d32498e-a8d9-4e72-854f-494352eedbd5", "node_type": "1", "metadata": {}, "hash": "a4e4ef508766fcf2cc77fee3f7052dbecc3056cde68889f55cf5567cfa64b1d9", "class_name": "RelatedNodeInfo"}}, "text": "C2 also showed a high pro-liferation rate, which may override an evolving type I immune\nresponse, and was comprised of highly mutated BRCA, gastric,\novarian (OV), HNSC, and cervical tumors (CESC).\nC3 (in\ufb02ammatory) was de\ufb01ned by elevated Th17 and Th1\ngenes ( Figure 1 C, both p < 10\n/C023), low to moderate tumor cell\nproliferation, and, along with C5, lower levels of aneuploidy\nand overall somatic copy number alterations than the othersubtypes. C3 was enriched in most kidney, prostate adenocarci-\nnoma (PRAD), pancreatic adenocarcinoma (PAAD), and papillary\nthyroid carcinomas (THCA).C4 (lymphocyte depleted) was enriched in particular subtypes\nof adrenocortical carcinoma (ACC), pheochromocytoma and\nparaganglioma (PCPG), liver hepatocellular carcinoma (LIHC),\nand gliomas, and displayed a more prominent macrophagesignature ( Figure 2 A), with Th1 suppressed and a high M2\nresponse ( Figure S2 A).\nC5 (immunologically quiet), consisted mostly of brain lower-\ngrade gliomas (LGG) ( Figures 1 D and S1B), exhibited the lowest\nlymphocyte (p < 10\n/C017) and highest macrophage (p < 10/C07)\nresponses ( Figure 2 A), dominated by M2 macrophages ( Fig-\nure S2 A). Glioma subtypes ( Ceccarelli et al., 2016 ) CpG island\nmethylator phenotype-high (CIMP-H), the 1p/19q codeletion sub-\ntype and pilocytic astrocytoma-like (PA-like) were prevalent in C5,\nwith remaining subtypes enriched in C4. IDHmutations were en-\nriched in C5 over C4 (80% of IDH mutations, p < 2 310/C016,\nFisher\u2019s exact test), suggesting an association of IDHmutations\nwith favorable immune composition. Indeed, IDHmutations asso-\nciate with TME composition ( Venteicher et al., 2017 ) and decrease\nleukocyte chemotaxis, leading to fewer tumor-associated im-\nmune cells and better outcome ( Amankulor et al., 2017 ).\nFinally, C6 (TGF- bdominant), which was a small group of\nmixed tumors not dominant in any one TCGA subtype, displayed\nthe highest TGF- bsignature (p < 10/C034) and a high lymphocytic\nin\ufb01ltrate with an even distribution of type I and type II T cells.\nThese six categories represent features of the TME that largely\ncut across traditional cancer classi\ufb01cations to create groupings\nand suggest certain treatment approaches may be independentof histologic type. For a complete list of the TCGA cancer type\nabbreviations, please see https://gdc.cancer.gov/resources-\ntcga-users/tcga-code-tables/tcga-study-abbreviations .\nComposition of the Tumor Immune In\ufb01ltrate\nLeukocyte fraction (LF) varied substantially across immunesubtypes ( Figure 1 C) and tumor types ( Figure 2 B). Tumors within\nthe top third LF included cancers most responsive to immune\ncheckpoint inhibitors, such as lung adenocarcinoma (LUAD),LUSC, cutaneous melanoma (SKCM), HNSC, and kidney renal\nclear cell carcinoma (KIRC), and in particular, the LUSC.secre-\ntory, LUAD.6, bladder urothelial carcinoma (BLCA.4), kidney renalpapillary cell carcinoma (KIRP.C2a), and HNSCC mesenchymalsubtypes. Uveal melanoma (UVM) and ACC had very low LF. Gli-\noma subtypes displayed a greater range in LF than other tumors,\nwhich may re\ufb02ect the presence or absence of microglia.\nThe leukocyte proportion of tumor stromal fraction, r, varied\nacross tumor types and immune subtypes ( Figures 2 C and\nS2B), ranging from >90% in SKCM to <10% in stroma-rich\ntumors such as PAAD, PRAD, and LGG. Some tumors, e.g.,\nBRCA, showed variation within annotated or immune subtypes.", "start_char_idx": 2920, "end_char_idx": 6316, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d32498e-a8d9-4e72-854f-494352eedbd5": {"__data__": {"id_": "8d32498e-a8d9-4e72-854f-494352eedbd5", "embedding": null, "metadata": {"page_label": "815", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "179fea6b-a621-4ca2-bc32-2f58591dc0a3", "node_type": "4", "metadata": {"page_label": "815", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "939c56679a3e0fdd635df0125c52be6a808c37743e56892bc829aafb8db31170", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa999e05-7f52-4821-8c6c-18dbb9eda2d1", "node_type": "1", "metadata": {"page_label": "815", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "23de03e2bfce2706e2d7621e8359782027ed85a771c97239fd43a82525c8ffe2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d886c06-e2b7-4dbf-9d6b-722f83cefdd3", "node_type": "1", "metadata": {}, "hash": "dd9ddd4e881216de368f1f3f0ae56920c1939f2d4d4c5ca45689bcd5dcfcc284", "class_name": "RelatedNodeInfo"}}, "text": "Uveal melanoma (UVM) and ACC had very low LF. Gli-\noma subtypes displayed a greater range in LF than other tumors,\nwhich may re\ufb02ect the presence or absence of microglia.\nThe leukocyte proportion of tumor stromal fraction, r, varied\nacross tumor types and immune subtypes ( Figures 2 C and\nS2B), ranging from >90% in SKCM to <10% in stroma-rich\ntumors such as PAAD, PRAD, and LGG. Some tumors, e.g.,\nBRCA, showed variation within annotated or immune subtypes.\nIn BRCA, C1 has the lowest r(r\nC1= 0.44) while rC2= 0.61 was\n37% higher (p < 0.001) ( Figure S2 B), and there were likewise\ndifferences between luminal A and basal BRCA ( rLumA= 0.45\nandrBasal= 0.67 [p < 0.001]). For LGG, rC5= 0.28 (p < 0.001),\nwhereas rC3= 0.48 and rC4= 0.50 (p < 0.001) ( Figure S2 B),\nand in READ, rCIN= 0.40 and rMSI= 0.78 (p < 0.001).\nThe spatial fraction of tumor regions with tumor-in\ufb01ltrating\nlymphocytes (TILs), estimated by analysis of digitized TCGAH&E-stained slides ( Saltz et al., 2018 ), varied by immune sub-\ntype, with C2 the highest (p < 10\n/C016,Figure 2 D). Image estimates\ncorrelated modestly with molecular estimates of lymphocyte\n814 Immunity 48, 812\u2013830, April 17, 2018", "start_char_idx": 5858, "end_char_idx": 7027, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d886c06-e2b7-4dbf-9d6b-722f83cefdd3": {"__data__": {"id_": "7d886c06-e2b7-4dbf-9d6b-722f83cefdd3", "embedding": null, "metadata": {"page_label": "816", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "828116ce-92d6-4423-96f3-0627d28d4fa6", "node_type": "4", "metadata": {"page_label": "816", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "277c8755cd1d11cc284d7b6b15424040ec8dd7af0a6e908eff3600a060ab68b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d32498e-a8d9-4e72-854f-494352eedbd5", "node_type": "1", "metadata": {"page_label": "815", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "762a34403e736146042df3b5ed4eb9aee366fb8c6d977341e1f8ecdc7f754a8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "407595dc-9fd0-4d16-b81a-ba9505f8c735", "node_type": "1", "metadata": {}, "hash": "4ba781b61788f25a9ffc65594c09f4c7ae4353f999a7adbea2df964968ea7fb1", "class_name": "RelatedNodeInfo"}}, "text": "AB\nC\nD\nFigure 1. Immune Subtypes in Cancer\n(A) Expression signature modules and identi\ufb01cation of immune subtypes. Top: Consensus clustering of the pairwise correlation of cancer immune gene\nexpression signature scores (rows and columns). Five modules of shared associations are indicated by boxes. Middle: Representative gene expressio n\nsignatures from each module (columns), which robustly reproduced module clustering, were used to cluster TGCA tumor samples (rows), resulting in si x immune\nsubtypes C1\u2013C6 (colored circles). Bottom: Distributions of signature scores within the six subtypes (rows), with dashed line indicating the median .\n(B) Key characteristics of immune subtypes.(C) Values of key immune characteristics by immune subtype.(D) Distribution of immune subtypes within TCGA tumors. The proportion of samples belonging to each immune subtype is shown, with colors as in (A). Bar width\nre\ufb02ects the number of tumor samples.See also Figure S1 andTable S1 .\nImmunity 48, 812\u2013830, April 17, 2018 815", "start_char_idx": 0, "end_char_idx": 1013, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "407595dc-9fd0-4d16-b81a-ba9505f8c735": {"__data__": {"id_": "407595dc-9fd0-4d16-b81a-ba9505f8c735", "embedding": null, "metadata": {"page_label": "817", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "60ca1e0c-4a43-4c6d-b606-ba4f3c37a057", "node_type": "4", "metadata": {"page_label": "817", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "9292bddbaa57c972b3660186c90c4bd4dc734172bde21e97d8c2d27adb7e4954", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d886c06-e2b7-4dbf-9d6b-722f83cefdd3", "node_type": "1", "metadata": {"page_label": "816", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "277c8755cd1d11cc284d7b6b15424040ec8dd7af0a6e908eff3600a060ab68b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34ab9799-60bd-46a0-94f4-8f583fe96cbf", "node_type": "1", "metadata": {}, "hash": "c39fc8de7409eaa3f76b990fc4ac152edcd42dfce95a417546915a9df58f9c60", "class_name": "RelatedNodeInfo"}}, "text": "proportion ( Figures S2 C and S2D), in part because the molecular\nestimate is more similar to cell count, while spatial TIL is a\nfraction of the area. The relative similarity of the estimates of lym-phocytic content between two radically different methodologiesreinforces the robustness of individual methods.\nPrognostic Associations of Tumor Immune Response\nMeasures\nImmune subtypes associated with overall survival (OS) and\nprogression-free interval (PFI) ( Figures 3 A and S3A). C3 hadthe best prognosis (OS HR 0.628, p = 2.34 310\n/C08relative to\nC1, adjusted for tumor type), while C2 and C1 had less favorable\noutcomes despite having a substantial immune component. Themore mixed-signature subtypes, C4 and C6, had the least favor-able outcome. Functional orientation of the TME for tumor and\nimmune subtypes was measured using the concordance index\n(CI) ( Pencina and D\u2019Agostino, 2004 ) and found to have\ncontext-dependent prognostic impact ( Figures 3 B, 3C and\nS3B). Higher lymphocyte signature associated with improved\noutcome in C1 and C2. An increased value of any of the \ufb01ve0.00.20.40.6spatial fraction of lymphocyte regions\nC1 C2 C3 C4 C5 C60.000.250.500.751.00\nUVM\nACC\nUCS\nKICH\nLGG\nPCPG\nPRAD\nTHCA\nOV\nCHOL\nREAD\nUCEC\nGBM\nSARC\nLIHC\nCOAD\nKIRP\nBRCA\nBLCA\nESCA\nCESC\nKIRC\nMESO\nSKCM\nSTAD\nTGCT\nHNSC\nPAAD\nLUAD\nLUSCLeukocyte FractionLeukocyte Fraction in TCGA Tumors\nPRAD SKCM\n0.00 0.25 0.50 0.75 1.00 0.00 0.25 0.50 0.75 1.000.000.250.500.751.00\nStromal FractionLeukocyte FractionLeukocyte vs Stromal FractionLymphocytes Macrophage Dendritic Cells Mast Neutrophils Eosinophils0.6\n0.4\n0.2\n0.0Mean  Fraction with Standard ErrorC1 C2 C3 C4 C5 C6A\nB\nC D\nFigure 2. Composition of the Tumor Immune In\ufb01ltrate\n(A) The proportion of major classes of immune cells (from CIBERSORT) within the leukocyte compartment for different immune subtypes. Error bars show the\nstandard error of the mean.(B) Leukocyte fraction (LF) within TCGA tumor types, ordered by median.(C) LF (y axis) versus non-tumor stromal cellular fraction in the TME (x axes) for two representative TCGA tumor types: PRAD, (low LF relative to stroma l content)\nand SKCM (high leukocyte fraction in the stroma). Dots represent individual tumor samples.(D) The spatial fraction of lymphocyte regions in tissue was estimated using machine learning on digital pathology H&E images (see also Saltz et al., 2018 ).\n816 Immunity 48, 812\u2013830, April 17, 2018", "start_char_idx": 0, "end_char_idx": 2408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34ab9799-60bd-46a0-94f4-8f583fe96cbf": {"__data__": {"id_": "34ab9799-60bd-46a0-94f4-8f583fe96cbf", "embedding": null, "metadata": {"page_label": "818", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ec61d254-153e-4310-926b-f98d96d2ac84", "node_type": "4", "metadata": {"page_label": "818", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "48b349e05feb98d7088222e53b38daac759c68d343acf563916f3d34655435d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "407595dc-9fd0-4d16-b81a-ba9505f8c735", "node_type": "1", "metadata": {"page_label": "817", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "9292bddbaa57c972b3660186c90c4bd4dc734172bde21e97d8c2d27adb7e4954", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7f11ea8-7379-40e0-8847-b466446f8cfb", "node_type": "1", "metadata": {}, "hash": "f457ee8a844689b025b18c14294b3e3c0123ea142f45962a0304b44eda19b538", "class_name": "RelatedNodeInfo"}}, "text": "signatures led to worse outcome in C3 ( Figure 3 B), perhaps re-\n\ufb02ecting a balanced immune response. While increased Th17\ncells generally led to improved OS, Th1 associated with worseOS across most immune subtypes, and Th2 orientation had\nmixed effects ( Figure 3 C). Tumor types displayed two behaviors\nrelative to immune orientation ( Figures 3 B, OS; S3B, PFI). In the\n\ufb01rst group including SKCM and CESC, activation of immune\npathways was generally associated with better outcome, while\nin the other, the opposite was seen. The relative abundance ofindividual immune cell types had complex associations that\ndiffered between tumor types ( Figures S3 C and S3D). These an-\nalyses extend beyond mere determination of lymphocyte pres-ence to suggest testable properties that correlate with patientoutcome in different tumor types and immune contexts.\nWe obtained and validated a survival model using elastic-net\nCox proportional hazards (CoxPH) modeling with cross-valida-tion. Low- and high-score tumors displayed signi\ufb01cant survival\ndifferences in the validation set ( Figure 3 D), with good prediction\naccuracy ( Figure 3 E). Incorporating immune features intoAB\nCD\nEFFigure 3. Immune Response and Prognostics\n(A) Overall survival (OS) by immune subtype.\n(B) Concordance index (CI) for \ufb01ve characteristicimmune expression signature scores ( Figure 1 A) in\nrelation to OS, for immune subtypes and TCGA tu-mor types. Red denotes higher and blue lower risk,with an increase in the signature score.(C) CI for T helper cell scores in relation to OS withinimmune subtypes.(D) Risk strati\ufb01cation from elastic net modeling ofimmune features. Tumor samples were divided intodiscovery and validation sets, and an elastic netmodel was optimized on the discovery set usingimmune gene signatures, TCR/BCR richness, andneoantigen counts. Kaplan-Meier plot shows thehigh (red) and low (blue) risk groups from this model\nas applied to the validation set, p < 0.0001 ( G-rho\nfamily of tests, Harrington and Fleming).(E) Prediction versus outcome from elastic net modelin validation set data (from D). Top: Patient outcomesfor each sample (black, survival; red, death) plottedwith vertical jitter, along the sample\u2019s model pre-diction (x axis). Middle: Fractional density of theoutcomes plotted against their model predictions.Con\ufb01dence intervals were generated by boot-strapping with replacement. Bottom: LOESS \ufb01t ofthe actual outcomes against the model predictions;narrow con\ufb01dence bands con\ufb01rm good predictionaccuracy.(F) CoxPH models of stage and tumor type (\u2018\u2018Tissue\u2019\u2019)with (full model) or without (reduced model) thevalidation set predictions of the elastic net modelwere compared; the full model signi\ufb01cantly out-performed the reduced model in all comparisons\n(p < 0.001; false discovery rate (FDR) BH-corrected).\nSee also Figure S3 .\nCox models \ufb01t with tumor type, stage, and\ntumor type + stage ( Figure 3 F) improved\npredictive accuracy, highlighting the impor-\ntance of the immune TME in determiningsurvival. Lymphocyte expression signature,high number of unique TCR clonotypes, cy-\ntokines made by activated Th1 and Th17 cells, and M1 macro-\nphages most strongly associated with improved OS ( Figure S3 E),\nwhile wound healing, macrophage regulation, and TGF- bassoci-\nated with worse OS, recapitulating survival associations in im-\nmune subtypes. Within tumor types, the prognostic implicationsof immune subtypes seen in univariate analyses were largely\nmaintained, with C3 correlating with better OS in six tumor types\nand C4 with poor OS in three cancer types ( Figure S3 F).\nImmune Response Correlates of Somatic Variation\nThe immune in\ufb01ltrate was related to measures of DNA damage,including copy number variation (CNV) burden (both in terms ofnumber of segments and fraction of genome alterations),\naneuploidy, loss of heterozygosity (LOH), homologous recombi-\nnation de\ufb01ciency (HRD), and intratumor heterogeneity (ITH) ( Fig-\nure 4 A).", "start_char_idx": 0, "end_char_idx": 3937, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7f11ea8-7379-40e0-8847-b466446f8cfb": {"__data__": {"id_": "a7f11ea8-7379-40e0-8847-b466446f8cfb", "embedding": null, "metadata": {"page_label": "818", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ec61d254-153e-4310-926b-f98d96d2ac84", "node_type": "4", "metadata": {"page_label": "818", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "48b349e05feb98d7088222e53b38daac759c68d343acf563916f3d34655435d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34ab9799-60bd-46a0-94f4-8f583fe96cbf", "node_type": "1", "metadata": {"page_label": "818", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "282090a511657f916dd54a47355035dc552ebfe9e7a061b523c650854bc02290", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ff4b21a-ed02-4e7d-91ac-81e8f68f886f", "node_type": "1", "metadata": {}, "hash": "1a238a3453422ac6e7b842da34657af0646c8adc8f6f63a80a9ffecfcc846082", "class_name": "RelatedNodeInfo"}}, "text": "Within tumor types, the prognostic implicationsof immune subtypes seen in univariate analyses were largely\nmaintained, with C3 correlating with better OS in six tumor types\nand C4 with poor OS in three cancer types ( Figure S3 F).\nImmune Response Correlates of Somatic Variation\nThe immune in\ufb01ltrate was related to measures of DNA damage,including copy number variation (CNV) burden (both in terms ofnumber of segments and fraction of genome alterations),\naneuploidy, loss of heterozygosity (LOH), homologous recombi-\nnation de\ufb01ciency (HRD), and intratumor heterogeneity (ITH) ( Fig-\nure 4 A). LF correlated negatively with CNV segment burden, with\nstrongest correlation in C6 and C2, and positively with\naneuploidy, LOH, HRD, and mutation load, particularly in C3.These results suggest a differential effect of multiple smaller,\nImmunity 48, 812\u2013830, April 17, 2018 817", "start_char_idx": 3344, "end_char_idx": 4214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ff4b21a-ed02-4e7d-91ac-81e8f68f886f": {"__data__": {"id_": "5ff4b21a-ed02-4e7d-91ac-81e8f68f886f", "embedding": null, "metadata": {"page_label": "819", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e6885415-de4d-40e1-a0a2-095ddde91d24", "node_type": "4", "metadata": {"page_label": "819", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "3a5d37b8d0aba4aeb7dcef536016f0070ac6ad313e85178219445d87b8dffe80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7f11ea8-7379-40e0-8847-b466446f8cfb", "node_type": "1", "metadata": {"page_label": "818", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "f5b64ef14bdaf115b03cb272ebf65f523e26c65c538e96ffa5f698d2b5f0a615", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5120c0d5-2ab3-41e6-a192-a42056abbd7d", "node_type": "1", "metadata": {}, "hash": "e3a066e564c5f2dc523a4d60dfa8868fc3bd255b3e5db1dac9a6c63949d6aee5", "class_name": "RelatedNodeInfo"}}, "text": "AB\nC\nD\nE\nFigure 4. Immune Response and Genome State\n(A) Correlation of DNA damage measures (rows) with LF. From left to right: all TCGA tumors; averaged over tumor type; grouped by immune subtype.\n(B) LF association with copy number (CN) alterations. Left: Differences between observed and expected mean LF in tumors with ampli\ufb01cations, by genom ic\nregion. Signi\ufb01cant (FDR < 0.01) differences in mean LF are marked with black caps on the pro\ufb01les. Right: Same, for deletions.\n(legend continued on next page)\n818 Immunity 48, 812\u2013830, April 17, 2018", "start_char_idx": 0, "end_char_idx": 547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5120c0d5-2ab3-41e6-a192-a42056abbd7d": {"__data__": {"id_": "5120c0d5-2ab3-41e6-a192-a42056abbd7d", "embedding": null, "metadata": {"page_label": "820", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0b416d6f-9590-4f69-95ce-4b9373c5b1be", "node_type": "4", "metadata": {"page_label": "820", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "d655031db2b0665ed9883a21a8b3eeebe2c833be68d4aeadd32612810d4bb7a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ff4b21a-ed02-4e7d-91ac-81e8f68f886f", "node_type": "1", "metadata": {"page_label": "819", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "3a5d37b8d0aba4aeb7dcef536016f0070ac6ad313e85178219445d87b8dffe80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ed60e2c-2ed2-414c-8b80-85e6fd60e891", "node_type": "1", "metadata": {}, "hash": "680546e759438d50727d0a64630e9a20a1bcf75a23f615229500fc0d75f3ce77", "class_name": "RelatedNodeInfo"}}, "text": "focal copy number events versus larger events on immune in\ufb01l-\ntration in certain immune subtypes.\nSpeci\ufb01c SCNAs affected LF and immune composition ( Figures\n4B and S4A). Chromosome 1p (including TNFRS9 andVTCN1 )\nampli\ufb01cation associated with higher LF, while its deletion did\nthe opposite. 19q deletion (including TGFB1 ) also correlated\nwith lower LF, consistent with the role of TGF- bin immune cell\nrecruitment ( Bierie and Moses, 2010 ). Ampli\ufb01cation of chr2,\n20q, and 22q (including CTLA4 ,CD40 , and ADORA2 , respec-\ntively), and deletions of 5q, 9p, and chr19 (including IL13 and\nIL4,IFNA1 and IFNA2 , and ICAM1 , respectively) associated\nwith changes in macrophage polarity ( Figure S4 A). IL-13 in\ufb02u-\nences macrophage polarization ( Mantovani et al., 2005 ),\nimplying a possible basis for our observation that IL-13 deletionsassociated with altered M0 macrophage fractions.\nIncreased ITH associates with worse clinical outcomes\nor lower ef\ufb01cacy of IM therapy in a number of cancer types(McGranahan et al., 2016; Morris et al., 2016 ). ITH correlated\n(Spearman, Benjamini-Hochberg [BH]-adjusted p < 0.05) with\ntotal LF in nine tumor types (LUAD, BRCA, KIRC, HNSC, GBM\n[glioblastoma multiforme], OV, BLCA, SKCM, and READ; datanot shown) and with individual relative immune cell fractions in\nmany tumor types ( Figure S4 B). ITH was highest in C1 and\nC2 (p < 10\n/C0229relative to all others) and lowest in C3 (p = 3 3\n10/C05,Figure 1 C), possibly supporting the link between lower\nITH and improved survival.\nWe correlated mutations in 299 cancer driver genes with im-\nmune subtypes and found 33 signi\ufb01cant associations ( q< 0.1)\n(Figure 4 C,Table S2 ). C1 was enriched in mutations in driver\ngenes, such as TP53 ,PIK3CA ,PTEN ,o rKRAS . C2 was enriched\nin many of these genes, as well as HLA-A and Band CASP8 ,\nwhich could be immune-evading mechanisms ( Rooney et al.,\n2015 ). C3 was enriched in BRAF ,CDH1 , and PBRM1 mutations,\na \ufb01nding of note since patients with PBRM1 mutations respond\nparticularly well to IM therapy ( Miao et al., 2018 ). C4 was enriched\ninCTNNB1 ,EGFR , and IDH1 mutations. C5 was enriched in\nIDH1 ,ATRX , and CIC, consistent with its predominance of LGG\nsamples. C6 was only enriched in KRAS G12 mutations. Muta-\ntions in 23 driver genes associated with increased LF either in\nspeci\ufb01c tumor types or across them, including TP53 ,HLA-B ,\nBRAF ,PTEN ,NF1,APC , and CASP8 . Twelve other events were\nassociated with lower LF, including the IDH1 R132H mutation,\nGATA3 ,KRAS ,NRAS ,CTNNB1 , and NOTCH1 (Figure 4 D).\nSince driver mutations in the same pathway had opposing\ncorrelations with LF (e.g., BRAF ,KRAS ,NRAS ), we considered\nthe overall effect of somatic alterations (mutations and SCNAs)\non eight oncogenic signaling pathways. PI3K, NOTCH, and\nRTK/RAS pathway disruptions showed variable, tumor type-\nspeci\ufb01c effects on immune factors, while TGF- bpathway disrup-tions more consistently associated with lower LF (most promi-\nnently in C2 and C6; Figure S4 C), higher eosinophils (C2), and\nincreased macrophages. However, in C3, TGF- bpathway\ndisruption associated with higher LF and M1 macrophagesand lower memory B cells, helper T cells, and M0 macrophages.\nThus, TGF- bpathway disruption has context-dependent effects\non LF but may promote increased macrophages, particularlyM1.", "start_char_idx": 0, "end_char_idx": 3316, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ed60e2c-2ed2-414c-8b80-85e6fd60e891": {"__data__": {"id_": "8ed60e2c-2ed2-414c-8b80-85e6fd60e891", "embedding": null, "metadata": {"page_label": "820", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0b416d6f-9590-4f69-95ce-4b9373c5b1be", "node_type": "4", "metadata": {"page_label": "820", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "d655031db2b0665ed9883a21a8b3eeebe2c833be68d4aeadd32612810d4bb7a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5120c0d5-2ab3-41e6-a192-a42056abbd7d", "node_type": "1", "metadata": {"page_label": "820", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "e4e0b4228688b877aa3ff592ededcc3488286e24fb755eea6a5c29f693d5aee2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08203a68-55a7-4557-8fd1-3c11d7243920", "node_type": "1", "metadata": {}, "hash": "a8366f9171251394e783ac15ba631ac730fcb6b7eb706b194c8198c4fc45661b", "class_name": "RelatedNodeInfo"}}, "text": "PI3K, NOTCH, and\nRTK/RAS pathway disruptions showed variable, tumor type-\nspeci\ufb01c effects on immune factors, while TGF- bpathway disrup-tions more consistently associated with lower LF (most promi-\nnently in C2 and C6; Figure S4 C), higher eosinophils (C2), and\nincreased macrophages. However, in C3, TGF- bpathway\ndisruption associated with higher LF and M1 macrophagesand lower memory B cells, helper T cells, and M0 macrophages.\nThus, TGF- bpathway disruption has context-dependent effects\non LF but may promote increased macrophages, particularlyM1. Higher M1/M2 ratio, in turn, may reiterate the local pro-in\ufb02ammatory state in these patients.\nImmune Response Correlates of Demographic and\nGermline Variation\nImmune cell content and expression of PD-L1 varied by gender\nand genetic ancestry ( Figures 4 E and S4D).PD-L1 expression\nwas greater (p < 0.05, Kruskal-Wallis test, unadjusted) in women\nthan in men in HNSC, KIRC, LUAD, THCA, and KIRP ( Figure S4 E),\nwhile mesothelioma (MESO) showed an opposite trend. PD-L1\nexpression was lower in individuals of predicted African ancestry(overall p = 5 310\n/C06). This association was consistent across\nmost cancer types and was signi\ufb01cant (p < 0.05, unadjusted) in\nBRCA, COAD, HNSC ( Figure S4 F), and THCA. No single cis-\neQTL signi\ufb01cantly correlated with PD-L1 expression, although\nthe SNP rs822337, approximately 1 kb upstream of CD274\ntranscription start, correlated weakly (p = 0.074; 1.3 310/C04un-\nadjusted; Figure S4 G). Lymphocyte fractions tended to be lower\nin people of Asian ancestry, particularly in UCEC (uterine corpus\nendometrial carcinoma) and BLCA ( Figure S4 H). The signi\ufb01-\ncance of these demographic associations remains unclear but\nprovides hypotheses for the ef\ufb01cacy of checkpoint inhibitor\ntherapy based on genetic ancestry.\nSurvey of Immunogenicity\nPeptides predicted to bind with MHC proteins (pMHCs) and\ninduce antitumor adaptive immunity were identi\ufb01ed from SNVand indel mutations. The number of pMHCs (neoantigen load)\nvaried between immune subtypes ( Figure 1 C), correlated posi-\ntively with LF in most immune subtypes ( Figure S4 I), and trended\npositive in most TCGA tumor subtypes, with some negative cor-\nrelation seen among GI subtypes, and differential trending seen\namong individual LUAD, LUSC, OV, and KIRP subtypes ( Fig-\nure S4 J). Neoantigen load also associated with higher content\nof CD8 T cells, M1 macrophages, and CD4 memory T cells,\nand lower Treg, mast, dendritic, and memory B cells in multipletumor types ( Figure S4 K).\nMost SNV-derived peptides which bind to MHC were each\nfound in the context of a single MHC allele (89.9%). Single\nmutations generate 99.8% of unique pMHCs while 0.2% resultfrom distinct mutations in different genetic loci yielding identical\npeptides ( Figure 5 A). The most frequently observed pMHCs\n(C) Enrichment and depletion of mutations in driver genes and oncogenic mutations (OM) within immune subtypes, displayed as fold enrichment. Signi\ufb01 cance\nwas evaluated by the Cochran-Mantel-Haenszel c2test, to account for cancer type (white, no signi\ufb01cant association).\n(D) Volcano plot showing driver genes and OMs associated with changes in LF, across all tumors (\u2018\u2018Pancan\u2019\u2019) and within speci\ufb01c tumor types as indicate d. x axis:\nMultivariate correlation with LF (B-factor), taking into account tumor type and number of missense mutations. Values > 0 represent positive correla tion with LF and\nvice versa; y axis: /C0log10( p). Signi\ufb01cant events (FDR < 0.1; p < 0.003) are in orange, others in gray.", "start_char_idx": 2763, "end_char_idx": 6288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08203a68-55a7-4557-8fd1-3c11d7243920": {"__data__": {"id_": "08203a68-55a7-4557-8fd1-3c11d7243920", "embedding": null, "metadata": {"page_label": "820", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0b416d6f-9590-4f69-95ce-4b9373c5b1be", "node_type": "4", "metadata": {"page_label": "820", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "d655031db2b0665ed9883a21a8b3eeebe2c833be68d4aeadd32612810d4bb7a7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ed60e2c-2ed2-414c-8b80-85e6fd60e891", "node_type": "1", "metadata": {"page_label": "820", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "1506f9241cfa903925ee1ad1d99c0879dca5834b86b6a27d5794fc59c8f12db4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79d1e961-1570-40df-b300-d1740e97f430", "node_type": "1", "metadata": {}, "hash": "84aea2b48445ebe29098d5c19a05b7698e5821ca81ae63548135c1dd3e6d5ca3", "class_name": "RelatedNodeInfo"}}, "text": "Signi\ufb01 cance\nwas evaluated by the Cochran-Mantel-Haenszel c2test, to account for cancer type (white, no signi\ufb01cant association).\n(D) Volcano plot showing driver genes and OMs associated with changes in LF, across all tumors (\u2018\u2018Pancan\u2019\u2019) and within speci\ufb01c tumor types as indicate d. x axis:\nMultivariate correlation with LF (B-factor), taking into account tumor type and number of missense mutations. Values > 0 represent positive correla tion with LF and\nvice versa; y axis: /C0log10( p). Signi\ufb01cant events (FDR < 0.1; p < 0.003) are in orange, others in gray.\n(E) Left: Degree of association between gender for eight selected immune characteristics (rows) within TCGA tumor types (columns). Blue denotes a hi gher value\nin women than in men, and red the opposite. Right: Degree of association between the immune characteristics and the \ufb01rst principal component of geneti c\nancestry in TCGA participants (PC1), re\ufb02ecting degree of African ancestry. Blue re\ufb02ects lower values in individuals of African descent.See also Figure S4 andTable S2 .\nImmunity 48, 812\u2013830, April 17, 2018 819", "start_char_idx": 5727, "end_char_idx": 6810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79d1e961-1570-40df-b300-d1740e97f430": {"__data__": {"id_": "79d1e961-1570-40df-b300-d1740e97f430", "embedding": null, "metadata": {"page_label": "821", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cfbc779e-1774-4513-8728-83aa3e098f80", "node_type": "4", "metadata": {"page_label": "821", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "22a5caa0c2cc3e482c20d0089203c1a40ee5b8f00e0c07af40596aad6971fb33", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08203a68-55a7-4557-8fd1-3c11d7243920", "node_type": "1", "metadata": {"page_label": "820", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "75fa1d3a51c8c0f68718b805a0cd94691f2c0284c5e3367a66ca5fa48d33b76d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aabdd5a0-f667-444c-a944-43473cf1af7c", "node_type": "1", "metadata": {}, "hash": "03b01a4b89ded3bb5fbb43e1de10b8a315ec9e1c9ce00111a843516cdd9e53ee", "class_name": "RelatedNodeInfo"}}, "text": "A B\nCD\nE\nFigure 5. The Tumor-Immune Interface\n(A) Distribution of the number of pMHCs associated with number of mutations; the 4 pMHCs derived from > 40 mutations are labeled.\n(B) Numbers of tumors expressing shared pMHCs. The known cancer genes from which the most frequent pMHCs in the population are derived are indicated.(C) BCR (top) and TCR (bottom) diversity measured by Shannon entropy and species richness, logarithmically transformed, and expressed as Z-scores, for\nimmune subtypes.(D and E) Co-occurrence of CDR3a-CDR3b (D) and pMHC-CDR3 pairs (E) as a surrogate marker for shared T cell responses. Pairs found in at least two samplesand meeting statistical signi\ufb01cance are plotted, with jitter. x and y axes indicate how exclusive the pair members are: pairs in the top right typicall y co-occur,\nwhereas along the axes each member is more often found separately. Size of the circle indicates how many samples that pair was found in.See also Figure S5 andTables S3 ,S4, and S5.\n820 Immunity 48, 812\u2013830, April 17, 2018", "start_char_idx": 0, "end_char_idx": 1030, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aabdd5a0-f667-444c-a944-43473cf1af7c": {"__data__": {"id_": "aabdd5a0-f667-444c-a944-43473cf1af7c", "embedding": null, "metadata": {"page_label": "822", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4d7bdc16-de54-452a-835d-765c70565c00", "node_type": "4", "metadata": {"page_label": "822", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "3e64fd9705f966c670ffcd62930685a2fc534fa11489bdcee1e1c2f3b51e1f20", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79d1e961-1570-40df-b300-d1740e97f430", "node_type": "1", "metadata": {"page_label": "821", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "22a5caa0c2cc3e482c20d0089203c1a40ee5b8f00e0c07af40596aad6971fb33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "208768f7-5921-49bc-9786-d158f4c33ff3", "node_type": "1", "metadata": {}, "hash": "e0c0ade2a301b4213f08dd65d0a9c86ea4299cbac78a9cfb4bef4270e2903b7b", "class_name": "RelatedNodeInfo"}}, "text": "were from recurrently mutated genes ( BRAF ,IDH1 ,KRAS , and\nPIKC3A for SNVs, TP53 andRNF43 for indels) ( Figure 5 B,Tables\nS3andS4). In BRCA and LIHC, worse PFI was associated with\nhigher neoantigen load, while BLCA and UCEC showed theopposite effect ( Figure S5 A). For most tumors, however, there\nwere no clear associations between predicted pMHC count\nand survival. Within immune subtypes ( Figure S5 B), higher neo-\nantigen load was associated with improved PFI in C1 and C2 andworse PFI in C3, C4, and C5. These results suggest that\nneoantigen load provides more prognostic information within im-\nmune subtypes than based on tissue of origin, emphasizing theimportance of overall immune signaling in responding to tumor\nneoantigens.\nCancer testis antigens (CTA) overall expression, and that of in-\ndividual CTAs, varied by immune subtype with C5 having the\nhighest (p < 10\n/C013) and C3 the lowest (p = 10/C04) expression\nvalues ( Figure 1 C).CEP55 ,TTK, and PBK were broadly ex-\npressed across immune subtypes, with enrichment in C1 andC2. C5 demonstrated high expression of multiple CTAs, illus-\ntrating that CTA expression alone is insuf\ufb01cient to elicit an\nintratumoral immune response.\nWe found human papilloma virus (HPV) in 6.2% of cases,\nmainly in CESC, GBM, HNSC, and KIRC, whereas hepatitis B\nvirus (HBV) and Epstein-Barr virus (EBV) were mainly found inLIHC and STAD (stomach adenocarcinoma), respectively. In a\nregression model of all tumors, high load of each virus type asso-\nciated with immune features ( Figure S5 C, cancer-type adjusted).\nHigh EBV content associated strongly with high CTLA4 and\nCD274 expression and low B cell signatures. High HPV levels\nassociated with increased proliferation and Th2 cells but lowmacrophage content. In contrast, high HBV levels associatedwith Th17 signal and gdT cell content. These \ufb01ndings highlight\nthe diverse effect of different viruses on the immune response\nin different cancer types.\nOur \ufb01ndings suggest that pMHC burden and viral content\nimpact immune cell composition, while CTAs have inconsistent\neffects on the immune response. Moreover, the effect ofpMHC load on prognosis is disease speci\ufb01c and in\ufb02uenced by\nimmune subtype.\nThe Adaptive Immune Receptor Repertoire in Cancer\nAntigen-speci\ufb01c TCR and BCR repertoires are critical for recog-\nnition of pathogens and malignant cells and may re\ufb02ect a robustanti-tumor response comprising a large number of antigen-\nspeci\ufb01c adaptive immune cells that have undergone clonal\nexpansion and effector differentiation.\nWe evaluated TCR aandband immunoglobulin heavy and\nlight chain repertoires from RNA-seq. Mean TCR diversity values\ndiffered by immune subtype, with the highest diversity in C6 andC2 (p < 10\n/C0183, Wilcoxon, relative to all other subtypes; Figure 5 C)\nand by tumor type ( Figure S5 D, lower panel). We saw recurrent\nTCR sequences across multiple samples ( Figure S5 E,Table\nS5), suggesting a common, but not necessarily cancer-related,\nantigen (the top recurrent TCRs include known mucosal associ-\nated invariant T cell sequences). We assessed co-occurrence of\ncomplementarity determining region 3 (CDR3) aandbchains, in\norder to determine the frequency of patients with identical TCRs\n(a surrogate marker for shared T cell responses). We identi\ufb01ed\n2,812 a-bpairs present in at least 2 tumors (p %0.05, Fisher\u2019sexact test with Bonferroni correction; Figure 5 D and Table S5 ).\nLikewise, testing for co-occurrence of speci\ufb01c SNV pMHC-\nCDR3 pairs across all patients identi\ufb01ed 206 pMHC-CDR3 a\npairs and 196 pMHC-CDR3 bpairs ( Figure 5 E,Table S5 ). Thus,\na minority of these patients appear to share T cell responses,\npossibly mediated by public antigens.", "start_char_idx": 0, "end_char_idx": 3682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "208768f7-5921-49bc-9786-d158f4c33ff3": {"__data__": {"id_": "208768f7-5921-49bc-9786-d158f4c33ff3", "embedding": null, "metadata": {"page_label": "822", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4d7bdc16-de54-452a-835d-765c70565c00", "node_type": "4", "metadata": {"page_label": "822", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "3e64fd9705f966c670ffcd62930685a2fc534fa11489bdcee1e1c2f3b51e1f20", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aabdd5a0-f667-444c-a944-43473cf1af7c", "node_type": "1", "metadata": {"page_label": "822", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "af505611e56e1b7c1fac7522b201f09c4f10b12ed5d05dd4a3aeb56282e8aae2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c655528-e28f-4472-9ca8-d4bcbcc584eb", "node_type": "1", "metadata": {}, "hash": "44122e622d7730f05732cd5a8b2c0d629d013473184c75645656248c1a37cf24", "class_name": "RelatedNodeInfo"}}, "text": "We assessed co-occurrence of\ncomplementarity determining region 3 (CDR3) aandbchains, in\norder to determine the frequency of patients with identical TCRs\n(a surrogate marker for shared T cell responses). We identi\ufb01ed\n2,812 a-bpairs present in at least 2 tumors (p %0.05, Fisher\u2019sexact test with Bonferroni correction; Figure 5 D and Table S5 ).\nLikewise, testing for co-occurrence of speci\ufb01c SNV pMHC-\nCDR3 pairs across all patients identi\ufb01ed 206 pMHC-CDR3 a\npairs and 196 pMHC-CDR3 bpairs ( Figure 5 E,Table S5 ). Thus,\na minority of these patients appear to share T cell responses,\npossibly mediated by public antigens. That said, there is rela-\ntively little pMHC and TCR sharing among tumors, highlightingthe large degree of diversity in TILs.\nHigher TCR diversity only correlated with improved PFI in a\nfew tumor types (BLCA, COAD, LIHC, and UCEC) ( Figure S5 F).\nTherefore, it may be more important for the immune system tomount a robust response against only a few antigens, than a\ndiverse response against many different antigens.\nThe pattern of immunoglobulin heavy chain diversity was\nsimilar to that of TCR diversity ( Figures 5 C and S5D), with tumors\nshowing signi\ufb01cant variance in IgH repertoire diversity, suggest-\ning differential B cell recruitment and/or clonal expansion withinthe tumor types.\nRegulation of Immunomodulators\nIMs are critical for cancer immunotherapy with numerous IM ag-\nonists and antagonists being evaluated in clinical oncology ( Tang\net al., 2018 ). To advance this research, understanding of their\nexpression and modes of control in different states of the TME\nis needed. We examined IM gene expression, SCNAs, andexpression control via epigenetic and miRNA mechanisms.\nGene expression of IMs ( Table S6 ,Figure 6 A) varied across im-\nmune subtypes, and IM expression largely segregated tumors byimmune subtypes ( Figure S6 A), perhaps indicative of their role in\nshaping the TME. Genes with the greatest differences between\nsubtypes ( Figures 6 B and S6B) included CXCL10 (BH-adjusted\np<1 0\n/C05), most highly expressed in C2 (consistent with its known\ninterferon inducibility) and EDNRB (BH-adjusted p < 10/C05), most\nhighly expressed in the immunologically quiet C5. DNA methyl-\nation of many IM genes, e.g., CD40 (Figure 6 C),IL10, and\nIDO1 , inversely correlated with gene expression, suggesting\nepigenetic silencing. 294 miRNAs were implicated as possible\nregulators of IM gene expression; among these, several associ-ated with IMs in multiple subtypes ( Figure S6 C) including\nimmune inhibitors ( EDNRB ,PD-L1 , and VEGFA ) and activators\n(CD28 andTNFRSF9 ). The immune activator BTN3A1 was one\nof the most commonly co-regulated IMs from the SYGNAL-PanImmune network (below). Negative correlations between\nmiR-17 and BTN3A1 ,PDCD1LG2 , and CD274 may relate to\nthe role of this miRNA in maturation and activation of cells intoeffector or memory subsets ( Liang et al., 2015 ).\nCopy-number alterations affected multiple IMs and varied\nacross immune subtypes. C1 and C2 showed both frequentampli\ufb01cation and deletion of IM genes, consistent with their\ngreater genomic instability, while subtypes C3 and C5 generally\nshowed fewer alterations in IM genes. In particular, IMs SLAMF7 ,\nSELP ,TNFSF4 (OX40L ),IL10, and CD40 were ampli\ufb01ed less\nfrequently in C5 relative to all samples, while TGFB1 ,KIR2DL1 ,\nandKIR2DL3 deletions were enriched in C5 ( Figure 6 D), consis-\ntent with our observation of lower immune in\ufb01ltration with TGFB1\ndeletion ( Figure S4 A).CD40 was most frequently ampli\ufb01ed in C1\n(Figure 6 D) (Fisher\u2019s exact p < 10\n/C010for all comparisons\nmentioned).", "start_char_idx": 3061, "end_char_idx": 6673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c655528-e28f-4472-9ca8-d4bcbcc584eb": {"__data__": {"id_": "2c655528-e28f-4472-9ca8-d4bcbcc584eb", "embedding": null, "metadata": {"page_label": "822", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4d7bdc16-de54-452a-835d-765c70565c00", "node_type": "4", "metadata": {"page_label": "822", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "3e64fd9705f966c670ffcd62930685a2fc534fa11489bdcee1e1c2f3b51e1f20", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "208768f7-5921-49bc-9786-d158f4c33ff3", "node_type": "1", "metadata": {"page_label": "822", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "fa565a77ddbe409bcd4a9e321f67a661db93b88bfadf306967077bf568ae545b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24b7101e-cbc4-404d-9837-5f38cf5197d5", "node_type": "1", "metadata": {}, "hash": "3453ee8a37c16a682b6c1a67fd453e01d3abf1075e4f9c716d5c4a279d56e2af", "class_name": "RelatedNodeInfo"}}, "text": "C1 and C2 showed both frequentampli\ufb01cation and deletion of IM genes, consistent with their\ngreater genomic instability, while subtypes C3 and C5 generally\nshowed fewer alterations in IM genes. In particular, IMs SLAMF7 ,\nSELP ,TNFSF4 (OX40L ),IL10, and CD40 were ampli\ufb01ed less\nfrequently in C5 relative to all samples, while TGFB1 ,KIR2DL1 ,\nandKIR2DL3 deletions were enriched in C5 ( Figure 6 D), consis-\ntent with our observation of lower immune in\ufb01ltration with TGFB1\ndeletion ( Figure S4 A).CD40 was most frequently ampli\ufb01ed in C1\n(Figure 6 D) (Fisher\u2019s exact p < 10\n/C010for all comparisons\nmentioned). Overall, these marked differences in IM copy\nImmunity 48, 812\u2013830, April 17, 2018 821", "start_char_idx": 6066, "end_char_idx": 6759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24b7101e-cbc4-404d-9837-5f38cf5197d5": {"__data__": {"id_": "24b7101e-cbc4-404d-9837-5f38cf5197d5", "embedding": null, "metadata": {"page_label": "823", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d909c016-22b6-4f23-bfa8-ca12ca21c02f", "node_type": "4", "metadata": {"page_label": "823", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "d57012c1e8e1a4be4c6483c6267ad87866d66af5cdf04b57770d1b320157f7ce", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c655528-e28f-4472-9ca8-d4bcbcc584eb", "node_type": "1", "metadata": {"page_label": "822", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "d5ed7c6f8885fc45bfc72c242591e25c8716583f931f8797deb6bb73b8698e96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e75b99d-7f6b-4be8-a8b0-af2689c142ff", "node_type": "1", "metadata": {}, "hash": "9478fd95afc9816e7b5668e01acbfa2b973b4080fe7ce28082686d3194370b6e", "class_name": "RelatedNodeInfo"}}, "text": "Immune Checkpoint mRNA\nExpressionExpression \nvs. MethylationAmplifcation\nFrequencyDeletion \nFrequencyInhibitory\nN/A\nStimulatory\n02468Med. log10(x)\n0.40.20.00.2Spearman\n0.20.00.2Costimulator\nCoinhibitor\nLigand\nReceptor\nCell adhesion\nAntigen \npresentation\nOtherICOSLGCD28CD80\nCD276C10orf54BTN3A1BTN3A2SLAMF7VTCN1CD274PDCD1LG2\nIL13IL2IL4IFNA1IFNA2IL12AIL1AIFNGIL10CD40LGCD70VEGFATGFB1CX3CL1VEGFBCCL5CXCL10CXCL9IL1BTNFSF4TNFTNFSF9\nHAVCR2TLR4ADORA2ACD40EDNRBTNFRSF14KIR2DL1KIR2DL3BTLAICOSTNFRSF9LAG3CD27TNFRSF4IL2RACTLA4PDCD1TIGITTNFRSF18\nSELPICAM1ITGB2\nHLADP A1HLA DPB1HLA DRB1HLA DRAHLA CHLA AHLA BHLA DQB2HLA DQA2MICBMICAHLA DQB1HLA DQA1HLA DRB5\nENTPD1HMGB1ARG1PRF1GZMAIDO1Affymetrix 450k probe cg25239996\nmethylation level, betamRNA normalized CD40, Subtype C3\n0.00.20.40.60.81.0\n0.00.20.40.60.81.0Fraction of Samples with CNACD40\nKIR2DL3Deep Del\nShallow Del No Alteration\nShallow Amp\nDeep Amp\nAll\nCXCL10EDNRBSubtypeA B\nC\nD0369\n0369log10(x)123456123456123456123456\n0.30.20.10.00.1\n2\n000100020003000\n0.00 0.25 0.50 0.75Count\n10203040\nFigure 6. Regulation of Immunomodulators\n(A) From left to right: mRNA expression (median normalized expression levels); expression versus methylation (gene expression correlation with DN A-methylation\nbeta-value); ampli\ufb01cation frequency (the difference between the fraction of samples in which an IM is ampli\ufb01ed in a particular subtype and the ampli\ufb01 cation\nfraction in all samples); and the deletion frequency (as ampli\ufb01cations) for 75 IM genes by immune subtype.(B) Distribution of log-transformed expression levels for IM genes with largest differences across subtypes (by Kruskal-Wallis test).(C)CD40 expression is inversely correlated to methylation levels (Affymetrix 450K probe cg25239996, 125 bases upstream of CD40 TSS) in C3. Each point\nrepresents a tumor sample, and color indicates point density.(D) Proportion of samples in each immune subtype with copy number alterations in CD40 (top) and KIR2DL3 (bottom). The \u2018\u2018All\u2019\u2019 column shows the overall\nproportion (8,461 tumors).See also Figure S6 andTable S6 .\n822 Immunity 48, 812\u2013830, April 17, 2018", "start_char_idx": 0, "end_char_idx": 2090, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e75b99d-7f6b-4be8-a8b0-af2689c142ff": {"__data__": {"id_": "6e75b99d-7f6b-4be8-a8b0-af2689c142ff", "embedding": null, "metadata": {"page_label": "824", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d80c027b-d513-4b32-bc73-dd8fcf4d152f", "node_type": "4", "metadata": {"page_label": "824", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "45a4e2ce12ef397153306616abbc7b333fe8a8c9bdfee7df6699b637a5aab3a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24b7101e-cbc4-404d-9837-5f38cf5197d5", "node_type": "1", "metadata": {"page_label": "823", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "d57012c1e8e1a4be4c6483c6267ad87866d66af5cdf04b57770d1b320157f7ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a3a8fb4-509a-42ac-a18f-dbe63b54a782", "node_type": "1", "metadata": {}, "hash": "4b413e200d791404014aad71cd25c9dd2cdb6d6df5641e5e99a3510bbd744df1", "class_name": "RelatedNodeInfo"}}, "text": "AD\nB\nC\nE\nFigure 7. Predicted Networks Modulating the Immune Response to Tumors\nTME estimates and tumor cell characteristics were combined with available data on possible physical, signaling, and regulatory interactions to pre dict cellular\nand molecular interactions involved in tumoral immune responses.\n(legend continued on next page)\nImmunity 48, 812\u2013830, April 17, 2018 823", "start_char_idx": 0, "end_char_idx": 377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a3a8fb4-509a-42ac-a18f-dbe63b54a782": {"__data__": {"id_": "3a3a8fb4-509a-42ac-a18f-dbe63b54a782", "embedding": null, "metadata": {"page_label": "825", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "39facf3d-c35f-4301-8e54-c92941485bb6", "node_type": "4", "metadata": {"page_label": "825", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "29cfe463d6044fd1a4ad6d2836f397ced737c9f6bbc1bcee856c8e9f1e68fb2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e75b99d-7f6b-4be8-a8b0-af2689c142ff", "node_type": "1", "metadata": {"page_label": "824", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "45a4e2ce12ef397153306616abbc7b333fe8a8c9bdfee7df6699b637a5aab3a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79413c02-507c-40db-ad28-2abfa2733d6e", "node_type": "1", "metadata": {}, "hash": "6836eda568dc76ac942b5ca68bec916bd3b97acdc9b3a1689ac0ead54462e5e3", "class_name": "RelatedNodeInfo"}}, "text": "number may be re\ufb02ective of more direct modulation of the TME\nby cancer cells.\nAmong IMs under investigation for cancer therapy, expression\nofVISTA is relatively high in all tumor types and highest in\nMESO; BTLA expression is high in C4 and C5; HAVCR2\n(TIM-3 ) shows evidence of differential silencing among immune\nsubtypes; and IDO1 is ampli\ufb01ed, mostly in C1. The observed\ndifferences in regulation of IMs might have implications for ther-apeutic development and combination immune therapies, and\nthe multiple mechanisms at play in evoking them further high-\nlights their biological importance.\nNetworks Modulating Tumoral Immune Response\nThe immune response is determined by the collective statesofintracellular molecular networks in tumor, immune, and\nother stromal cells and the extracellular network encompassing\ndirect interaction among cells and communication via solubleproteins such as cytokines to mediate interactions among\nthose cells.\nBeginning with a large network of extracellular interactions\nknown from other sources, we identi\ufb01ed which of those meta speci\ufb01ed precondition for interaction, namely that both\ninteraction partners are consistently present within samples\nin an immune subtype, according to our TME estimates. Wefocused the network on IMs. Networks in C2 and C3 had\nabundant CD8 T cells, while C3, C4, and C6 were enriched\nin CD4 T cells.\nA small sub-network ( Figure 7 A), focused around IFN- g, illus-\ntrates some subtype-speci\ufb01c associations. In both C2 and C3,\nCD4 T cells, CD8 T cells, and NK cells correlated with expressionofIFNG and CCL5 , a potent chemoattractant. A second sub-\nnetwork ( Figure 7 B), centered on TGF- b, was found in the C2,\nC3, and C6 networks. Across subtypes, different cell types\nwere associated with abundant expression of TGFB1 : CD4\nT cells and mast cells in C3 and C6, macrophages in C6, neutro-\nphils and eosinophils in C2 and C6, and B cells, NK cells, andCD8 T cells in C2 and C3. The receptors known to bind TGF- b\nlikewise were subtype speci\ufb01c and may help mediate the\nTGF- b-driven in\ufb01ltrates, with TGFBR1 ,2, and 3found only in\nthe C3 and C6 networks. These results largely echo \ufb01ndingsseen in our TGF- bpathway analysis ( Figure S4 C), which exam-\nined the effects of intracellular, rather than extracellular,\nsignaling disruption on immune TME composition across im-mune subtypes. Finally, a third cytokine subnetwork illustratesvariation in T cell ligands and receptors across immune subtypes\n(Figure 7 C). CD4 and CD8 receptors fell into two groups, those\nfound in C2, C3, and C6 networks, such as PDCD1 , and those\nabsent in C3, such as IL2RA andLAG3 . Some T cell-associated\nligands were subtype speci\ufb01c, such as CD276 (C2, C6), IL1B\n(C6), and VEGFB (C4).\nThe derived extracellular networks re\ufb02ect the properties of\nimmune subtypes in terms of cellular propensities and immune\npathway activation noted earlier ( Figures 1 B, 1C, 2A, and S2\nA),\nbut also place those properties in the context of possible interac-tions in the TME that may play a role in sculpting those same\nproperties. The particular associations observed among IMs\nwithin distinct subtypes may be important for identifying direc-tions for therapy.\nWe next used two complementary approaches, master regu-\nlators (MRs) and SYGNAL, to synthesize a pan-cancer tran-scriptional regulatory network describing the interactions\nlinking genomic events to transcriptional regulators to down-\nstream target genes, and \ufb01nally to immune in\ufb01ltration and pa-tient survival. In both approaches, somatic alterations were\nused as anchors to infer regulatory relationships, in that they\ncan act as a root cause of the \u2018\u2018downstream\u2019\u2019 transcriptionalchanges mediated through transcription factors (TFs) andmiRNAs.\nThis resulted in two transcriptional networks.", "start_char_idx": 0, "end_char_idx": 3782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79413c02-507c-40db-ad28-2abfa2733d6e": {"__data__": {"id_": "79413c02-507c-40db-ad28-2abfa2733d6e", "embedding": null, "metadata": {"page_label": "825", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "39facf3d-c35f-4301-8e54-c92941485bb6", "node_type": "4", "metadata": {"page_label": "825", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "29cfe463d6044fd1a4ad6d2836f397ced737c9f6bbc1bcee856c8e9f1e68fb2b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a3a8fb4-509a-42ac-a18f-dbe63b54a782", "node_type": "1", "metadata": {"page_label": "825", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "c3f1caa5c8a92972ff95c626b34c8c17da8fb6bcc22bcc7d29a09bbb62f917a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a0c095a-1054-4c85-b40e-3aff2286fc5b", "node_type": "1", "metadata": {}, "hash": "f222a9c572ba73c740a4c5a4a02521e0bc501fc7c0031ac3205df9f40dd95c7e", "class_name": "RelatedNodeInfo"}}, "text": "The particular associations observed among IMs\nwithin distinct subtypes may be important for identifying direc-tions for therapy.\nWe next used two complementary approaches, master regu-\nlators (MRs) and SYGNAL, to synthesize a pan-cancer tran-scriptional regulatory network describing the interactions\nlinking genomic events to transcriptional regulators to down-\nstream target genes, and \ufb01nally to immune in\ufb01ltration and pa-tient survival. In both approaches, somatic alterations were\nused as anchors to infer regulatory relationships, in that they\ncan act as a root cause of the \u2018\u2018downstream\u2019\u2019 transcriptionalchanges mediated through transcription factors (TFs) andmiRNAs.\nThis resulted in two transcriptional networks. The \ufb01rst one,\nMR-PanImmune, consisted of 26 MRs that acted as hubs asso-ciated with observed gene expression and LF, connected with\n15 putative upstream driver events ( Figure 7 D). The second\n(A) Immune subtype-speci\ufb01c extracellular communication network involving IFN- g(IFNG , bottom of the diagram), whose expression is concordant with that of its\ncognate receptors IFNGR1 andIFNGR2 (bottom right and left, respectively), in C2 and C3 (yellow and green arrows, respectively; line thickness indicates strength\nof association). NK cells (left), which are known to secrete IFN- g, could be producing IFN- gin C2 and C3, as the NK cellular fraction is concordant with IFNG\nexpression in both. CXCR3 is known to be expressed on NK cells and has concordant levels, but only in C3 (green arrow). This is a subnetwork within a larger\nnetwork constructed by similarly combining annotations of known interactions between ligands, receptors, and particular immune cells types, with evidence for\nconcordance of those components.(B) TGF- bsubnetwork. Magenta: C6.\n(C) T cell subnetwork.\n(D) Master Regulator (MR)-Pan-Immune Network. The network diagram shows 26 MR \u2018\u2018hubs\u2019\u2019 (\ufb01lled orange) signi\ufb01cantly associated with 15 upstream dri ver\nevents (orange rings), along with proteins linking the two. The lineage factor VAV1 (on left) is inferred to be a MR by combining predicted protein activity with data\non gene expression, protein interactions, and somatic alterations. VAV1 activity correlates with LF (degree of correlation depicted as degree of or ange). Mutations\ninHRAS (center of network) are statistically associated with changes in LF. The HRAS and VAV1 proteins are in close proximity on a large network of known\nprotein-protein interactions (not shown), as both can lead to activation of protein MAP2K1, (as shown connecting with dotted lines). Mutations in HRAS are\nassociated (p < 0.05) with VAV1 activity, and their link through documented protein interactions implies that HRAS could directly modulate the activ ity of VAV1. In\nthe diagram, the size of MR nodes represents their ranked activity. Smaller nodes with red borders represent mutated and/or copy-number altered gene s\nstatistically associated with one or more MR and LF, with the thickness of the border representing the number of associated MRs; small gray nodes are \u2018\u2018 linker\u2019\u2019\nproteins.(E) Regulators of immune subtypes from SYGNAL-PanImmune Network. Tumor types (octagons) linked through mutations (purple chevrons) to transcript ion\nfactors (TFs, red triangles) and miRNAs (orange diamonds) that actively regulate the expression of IMs in biclusters associated with a single immune subtype\n(circles). The network describes predicted causal and mechanistic regulatory relationships linking tumor types through their somatic mutations ( yellow edges)\nwhich causally modulate the activity of TFs and/or miRNAs (purple edges), which in turn regulate genes (not shown) whose expression is associated wit ha n\nimmune subtype (red edges). For example, RB1 mutations in LIHC (5% of patients) have signi\ufb01cant evidence for causally modulating the activity of PRDM1\nwhich in turn regulates genes associated (causal model at least 3 times as likely as alternative models and p value < 0.05) with C1 and C2. Interactions f or this path\nare bolded.\n824 Immunity 48, 812\u2013830, April 17, 2018", "start_char_idx": 3061, "end_char_idx": 7131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a0c095a-1054-4c85-b40e-3aff2286fc5b": {"__data__": {"id_": "9a0c095a-1054-4c85-b40e-3aff2286fc5b", "embedding": null, "metadata": {"page_label": "826", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "52ba0a41-116e-4925-b6dd-035394193eba", "node_type": "4", "metadata": {"page_label": "826", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "ce82f8ef1594e1b1c875118a8496de6dc0c61f02b44116ba5597a54fb5f76707", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79413c02-507c-40db-ad28-2abfa2733d6e", "node_type": "1", "metadata": {"page_label": "825", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "a757c57bfbbeba1d695a26d1069288429f6312060f2704c765750664013b765d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe81a5fd-0f01-44c3-9470-8edfc9347ac1", "node_type": "1", "metadata": {}, "hash": "5fda63dc601f7fb859daa3c2580ae567c95cace364c7538540571ec8e45ff5eb", "class_name": "RelatedNodeInfo"}}, "text": "one, SYGNAL-Panimmune, comprised 171 biclusters enriched\nin IMs and associated with LF.\nSeven TFs were shared between the MR- and SYGNAL-Pan-\nImmune networks, a signi\ufb01cant overlap (p = 4.8 310/C010, Fisher\u2019s\nexact test): PRDM1 ,SPI1 ,FLI1,IRF4 ,IRF8 ,STAT4 , and\nSTAT5A . Additional MRs included the hematopoietic lineage\nspeci\ufb01c factor IKZF1 , which may re\ufb02ect variation in immune\ncell content, and known IMs, such as IFNG ,IL16,CD86 , and\nTNFRSF4 . The regulators in SYGNAL-PanImmune were inferred\nto regulate a total of 27 IM genes ( Figure S7 C). The top two most\ncommonly co-regulated IMs from SYGNAL-PanImmune,BTN3A1 andBTN3A2 , are of particular interest as they modulate\nthe activation of T cells ( Cubillos-Ruiz et al., 2010 ) and have anti-\nbody-based immunotherapies ( Benyamine et al., 2016; Legut\net al., 2015 ).\nSomatic alterations in AKAP9 ,HRAS ,KRAS ,a n d PREX2\nwere inferred to modulate the activity of IMs according toboth the MR- and SYGNAL-PanImmune, a signi\ufb01cant overlap(p = 1.6 310\n/C07, Fisher\u2019s exact test). In MR-PanImmune,\nMAML1 andHRAS had the highest number of statistical inter-\nactions with 26 MRs. This analysis identi\ufb01ed complex roles forthe RAS-signaling pathway ( Figure 7 D) speci\ufb01cally through\nconnections to lineage factor VAV1 (implicated in multiple hu-\nman cancers), potentially mediated by MAP2K1 . Similarly,\nMAML1 , hypothesized to mediate cross-talk across pathways\nin cancer ( McElhinny et al., 2008 ), was associated (p %0.05)\nwith multiple MRs, including STAT1 ,STAT4 ,CIITA ,SPI1 ,\nTNFRSF4 ,CD86 ,VAV1 ,IKZF1 ,a n d IL16.\nIn SYGNAL-PanImmune, some regulators of IMs, but not up-\nstream somatic mutations, were shared between tumor types,including STAT4 , which regulated BTN3A1 and BTN3A2 in\nboth LUSC and UCEC, secondary to implied causal mutations\nTP53 and ARHGAP35 , respectively. Conversely, causal muta-\ntions shared across tumor types may associate with differenttumor-speci\ufb01c downstream regulators. TP53 was a causal\nmutation in UCEC acting through IRF7 to regulate many of the\nsame IMs as was seen in LUSC. These differences in causal re-lationships arise because the different cell types giving rise to\neach tumor type affect oncogenic paths.\nWe identi\ufb01ed the putative regulators of immune gene expres-\nsion within immune subtypes ( Figure 7 E). In these predictions,\nC1-associated biclusters were regulated by ERG ,KLF8 ,\nMAFB ,STAT5A , and TEAD2. C1 and C2 shared regulation by\nBCL5B ,ETV7 ,IRF1 ,IRF2 ,IRF4 ,PRDM1 , and SPIB , consistent\nwith IFN- gsignaling predominance in these subtypes. C3 was\nregulated by KLF15 andmiR-141-3p . C6-associated biclusters\nwere regulated by NFKB2 . C1, C2, and C6 shared regulation\nby\nSTAT2 andSTAT4 , implying shared regulation by important\nimmune TF families, such as STAT and IRF, but also differential\nemployment of subunits and family members by the immunemilieu.\nIn SYGNAL-PanImmune, the increased expression of\nbiclusters enriched with IMs from KIRC, LGG, LUSC, andREAD was associated with worse patient survival (CoxPHBH adjusted p value %0.05).", "start_char_idx": 0, "end_char_idx": 3050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe81a5fd-0f01-44c3-9470-8edfc9347ac1": {"__data__": {"id_": "fe81a5fd-0f01-44c3-9470-8edfc9347ac1", "embedding": null, "metadata": {"page_label": "826", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "52ba0a41-116e-4925-b6dd-035394193eba", "node_type": "4", "metadata": {"page_label": "826", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "ce82f8ef1594e1b1c875118a8496de6dc0c61f02b44116ba5597a54fb5f76707", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a0c095a-1054-4c85-b40e-3aff2286fc5b", "node_type": "1", "metadata": {"page_label": "826", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "670af14dca58c00f6f465eb130ac08614484834c71eca655b824c5520ac75da0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "939d8416-be1a-4862-bf53-f8586b920a77", "node_type": "1", "metadata": {}, "hash": "76081f0602cada31f78a29982cad12cf6bee6c667c0d8e5cff4ae638e2777d66", "class_name": "RelatedNodeInfo"}}, "text": "C1 and C2 shared regulation by\nBCL5B ,ETV7 ,IRF1 ,IRF2 ,IRF4 ,PRDM1 , and SPIB , consistent\nwith IFN- gsignaling predominance in these subtypes. C3 was\nregulated by KLF15 andmiR-141-3p . C6-associated biclusters\nwere regulated by NFKB2 . C1, C2, and C6 shared regulation\nby\nSTAT2 andSTAT4 , implying shared regulation by important\nimmune TF families, such as STAT and IRF, but also differential\nemployment of subunits and family members by the immunemilieu.\nIn SYGNAL-PanImmune, the increased expression of\nbiclusters enriched with IMs from KIRC, LGG, LUSC, andREAD was associated with worse patient survival (CoxPHBH adjusted p value %0.05). Conversely, the increased\nexpression of biclusters enriched with IMs from SKCM, con-\ntaining CCL5 ,CXCL9 ,CXCL10 ,HAVCR2 ,PRF1 , and MHC\nclass II genes, were associated with improved patient survival\n(BH-adjusted p %0.05).DISCUSSION\nWe report an extensive evaluation of immunogenomic features in\nmore than 10,000 tumors from 33 cancer types. Data and resultsare available as Supplemental Tables , at NCI GDC, and interac-\ntively at the CRI iAtlas portal, which is being con\ufb01gured to accept\nnew immunogenomics datasets and feature calculations as theycome available, including those derived from immunotherapyclinical trials, to develop as a \u2018\u2018living resource\u2019\u2019 for the immunoge-\nnomics community. Meta-analysis of consensus expression\nclustering revealed immune subtypes spanning multiple tumortypes and characterized by a dominance of either macrophage\nor lymphocyte signatures, T-helper phenotype, extent of intratu-\nmoral heterogeneity, and proliferative activity. All tumor sampleswere assessed for immune content by multiple methods. These\ninclude the estimation of immune cell fractions from deconvolu-\ntion of gene expression and DNA methylation data, prediction ofneoantigen-MHC pairs from mutations and HLA-typing, andevaluation of BCR and TCR repertoire from RNA-sequencing\ndata. Immune content was compared among immune and\ncancer subtypes, and somatic alterations were identi\ufb01ed thatcorrelate with changes in the TME. Finally, predictions were\nmade of regulatory networks that could in\ufb02uence the TME, and\nintracellular communication networks in the TME, based onintegrating known interactions and observed associations. Im-\nmunogenomic features were predictive of outcome, with OS\nand PFI differing between immune subtypes both within andacross cancer types.\nC4 and C6 subtypes conferred the worst prognosis on their\nconstituent tumors and displayed composite signatures re\ufb02ect-ing a macrophage dominated, low lymphocytic in\ufb01ltrate, withhigh M2 macrophage content, consistent with an immunosup-\npressed TME for which a poor outcome would be expected. In\ncontrast, tumors included in the two subtypes displaying atype I immune response, C2 and C3, had the most favorable\nprognosis, consistent with studies suggesting a dominant\ntype I immune response is needed for cancer control ( Galon\net al., 2013 ). In addition, C3 demonstrated the most pro-\nnounced Th17 signature, in agreement with a recent systematic\nreview suggesting that Th17 expression is generally associatedwith improved cancer survival ( Punt et al., 2015 ). C2 was IFN- g\ndominant and showed a less favorable survival despite having\nthe highest lymphocytic in\ufb01ltrate, a CD8 T cell-associated\nsignature, and highest M1 content, suggesting a robust anti-tu-mor immune response. One explanation for this discrepancy is\nthe aggressiveness of both the tumor types and speci\ufb01c cases\nwithin C2 relative to C3. C2 showed the highest proliferationsignature and ITH while C3 was the lowest in both those cate-\ngories. It may be that the immune response simply could not\ncontrol the rapid growth of tumors comprising C2. A secondhypothesis is that tumors in C2 are those that have already\nbeen remodeled by the existing robust type I in\ufb01ltrate and\nhave escaped immune recognition.", "start_char_idx": 2408, "end_char_idx": 6297, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "939d8416-be1a-4862-bf53-f8586b920a77": {"__data__": {"id_": "939d8416-be1a-4862-bf53-f8586b920a77", "embedding": null, "metadata": {"page_label": "826", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "52ba0a41-116e-4925-b6dd-035394193eba", "node_type": "4", "metadata": {"page_label": "826", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "ce82f8ef1594e1b1c875118a8496de6dc0c61f02b44116ba5597a54fb5f76707", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe81a5fd-0f01-44c3-9470-8edfc9347ac1", "node_type": "1", "metadata": {"page_label": "826", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "a28ad913d28d8c8bf33b5f30d7221b4da9cb85261398a528ff7c72719987cc03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb265177-6182-451b-adab-d5bc91004bdb", "node_type": "1", "metadata": {}, "hash": "ae2c95b24bd9aaa2d32c6a3d82ac1e464404c4a4b78f13068395a2eacdf457f7", "class_name": "RelatedNodeInfo"}}, "text": "C2 was IFN- g\ndominant and showed a less favorable survival despite having\nthe highest lymphocytic in\ufb01ltrate, a CD8 T cell-associated\nsignature, and highest M1 content, suggesting a robust anti-tu-mor immune response. One explanation for this discrepancy is\nthe aggressiveness of both the tumor types and speci\ufb01c cases\nwithin C2 relative to C3. C2 showed the highest proliferationsignature and ITH while C3 was the lowest in both those cate-\ngories. It may be that the immune response simply could not\ncontrol the rapid growth of tumors comprising C2. A secondhypothesis is that tumors in C2 are those that have already\nbeen remodeled by the existing robust type I in\ufb01ltrate and\nhave escaped immune recognition. While signatures biasedtoward interferon-mediated viral sensing and antigen presenta-tion genes were often associated with higher survival, interferon\nsignatures without increased antigen presentation showed an\nopposite association. Loss of genes associated with antigenprocessing and presentation is often found in tumors that\nhave been immune edited. In contrast to the potential immune\nImmunity 48, 812\u2013830, April 17, 2018 825", "start_char_idx": 5586, "end_char_idx": 6727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb265177-6182-451b-adab-d5bc91004bdb": {"__data__": {"id_": "bb265177-6182-451b-adab-d5bc91004bdb", "embedding": null, "metadata": {"page_label": "827", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "33e9d596-74a3-4bd5-bdca-245e5237612e", "node_type": "4", "metadata": {"page_label": "827", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "ddb42a5a9f78c2ceb1b5ff8ef5869da505d42df94f3ca60be340ca2d7527ff6f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "939d8416-be1a-4862-bf53-f8586b920a77", "node_type": "1", "metadata": {"page_label": "826", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "07b5f79bda5e7039ac900a049afeac3759b97a4875a5ea62379e00da7c9ea64e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc2b06be-8e87-4274-b56f-24d0156bc624", "node_type": "1", "metadata": {}, "hash": "ab09ad4a5634afd5d1c3c4fd50db60c50aadac849b70d502484bed9991934a67", "class_name": "RelatedNodeInfo"}}, "text": "editing of C2, C3 may represent immunologic control of dis-\nease, that is, immune equilibrium.\nPossible impact of somatic alterations on immune response\nwas seen. For example, KRAS mutations were enriched in C1\nand but infrequent in C5, suggesting that mutations in driver\noncogenes alter pathways that affect immune cells. Driver muta-\ntions such as TP53 , by inducing genomic instability, may alter the\nimmune landscape via the generation of neoantigens. Our \ufb01nd-ings con\ufb01rmed previous work showing that mutations in BRAF\n(Ilieva et al., 2014 ) enhance the immune in\ufb01ltrate while those in\nIDH1 diminish it ( Amankulor et al., 2017 ). Further work is needed\nto determine the functional aspects of these associations.\nTumor-speci\ufb01c neoantigens are thought to be key targets of\nanti-tumor immunity and are associated with improved OS andresponse to immune checkpoint inhibition in multiple tumor\ntypes ( Brown et al., 2014 ). We found OS correlated with pMHC\nnumber in only a limited number of tumors, with no clear associ-ation in most tumors, including several responsive to immunecheckpoint inhibitor therapy. There are some caveats to this\n\ufb01nding. The current predictors are highly sensitive but poorly\nspeci\ufb01c for neoantigen identi\ufb01cation, and our approach did notinclude neoantigens from introns or spliced variants. Moreover,\nit is not possible to fully determine the ability to process and\npresent an epitope or the speci\ufb01c T cell repertoire in each tumor,which impacts the ability to generate a neoantigen response. It is\nalso possible that the role of neoantigens may vary with tumor\ntype, as supported by our per-tumor results.\nIntegrative methods predicted tumor-intrinsic and tumor-\nextrinsic regulation in, of, and by the TME and yielded informa-\ntion on speci\ufb01c modes of intracellular and extracellular control,the latter re\ufb02ecting the network of cellular communicationamong immune cells in the TME. The resulting network was\nrich in structure, with mast cells, neutrophils, CD4 T cells, NK\ncells, B cells, eosinophils, macrophages, and CD8 T cells\ufb01guring prominently. The cellular communication network high-\nlighted the role of key receptor and ligands such as TGFB1 ,\nCXCL10 , and CXCR3 and receptor-ligand pairs, such as the\nCCL5-CCR5 axis, and illustrated how immune cell interactions\nmay differ depending on the immune system context, mani-\nfested in the immune subtype.\nPredicted intracellular networks implied that seven immune-\nrelated TFs (including interferon and STAT-family transcription\nfactors) may play an active role in transcriptional events related\nto leukocyte in\ufb01ltration, and that mutations in six genes(including Ras-family proteins) may in\ufb02uence immune in\ufb01ltra-\ntion. Across tumor types, the TFs and miRNAs regulating the\nexpression of IMs tended to be shared, while somaticmutations modulating those regulatory factors tended to differ.\nThis suggests that therapies targeting regulatory factors up-\nstream of IMs should be considered and that they may havea broader impact across tumor types than therapies focusing\non somatic mutations. Of note, in these approaches, it is not\nalways possible to fully ascertain whether some particularinteraction acts in the tumor, immune, or stromal cell compart-ments, but this could be improved on by incorporating\nadditional cell-type-speci\ufb01c knowledge. Shared elements of\nintra- and extracellular network models should also beexplored, with particular regard to the IMs and cytokines\nin both.There are important caveats to using TCGA data. First, sur-\nvival event rates and follow-up durations differ across the tu-\nmor types. Second, for most tumor types, samples with less\nthan 60% tumor cell nuclei by pathologist review wereexcluded from study, thus potentially removing the most im-\nmune-in\ufb01ltrated tumors from analysis. The degree to which\nthis biases the results, relative to the general population ofcancer patients, is dif\ufb01cult to ascertain. Our analyses werealso limited by restriction to data from genome-wide molecular\nassays, in the absence of targeted classical cellular immu-\nnology assays for con\ufb01rming cell phenotype distribution, asthose types of data have not been collected from TCGA\npatients.", "start_char_idx": 0, "end_char_idx": 4192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc2b06be-8e87-4274-b56f-24d0156bc624": {"__data__": {"id_": "bc2b06be-8e87-4274-b56f-24d0156bc624", "embedding": null, "metadata": {"page_label": "827", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "33e9d596-74a3-4bd5-bdca-245e5237612e", "node_type": "4", "metadata": {"page_label": "827", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "ddb42a5a9f78c2ceb1b5ff8ef5869da505d42df94f3ca60be340ca2d7527ff6f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb265177-6182-451b-adab-d5bc91004bdb", "node_type": "1", "metadata": {"page_label": "827", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "0a32c20b7dbf4842361102752bcd1be5bfd60ac3645122aca2b5f0673c4a898e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89591778-7fdb-4196-8712-a5aaf4ff8377", "node_type": "1", "metadata": {}, "hash": "2237b4f3cdfc548bb202f0d71aa2a57132e6378bb078e4cb13ff435630582c7a", "class_name": "RelatedNodeInfo"}}, "text": "Shared elements of\nintra- and extracellular network models should also beexplored, with particular regard to the IMs and cytokines\nin both.There are important caveats to using TCGA data. First, sur-\nvival event rates and follow-up durations differ across the tu-\nmor types. Second, for most tumor types, samples with less\nthan 60% tumor cell nuclei by pathologist review wereexcluded from study, thus potentially removing the most im-\nmune-in\ufb01ltrated tumors from analysis. The degree to which\nthis biases the results, relative to the general population ofcancer patients, is dif\ufb01cult to ascertain. Our analyses werealso limited by restriction to data from genome-wide molecular\nassays, in the absence of targeted classical cellular immu-\nnology assays for con\ufb01rming cell phenotype distribution, asthose types of data have not been collected from TCGA\npatients.\nIn summary, six stable and reproducible immune subtypes\nwere found to encompass nearly all human malignancies.\nThese subtypes were associated with prognosis, genetic, and\nimmune modulatory alterations that may shape the speci\ufb01ctypes of immune environments we have observed. With ourincreasing understanding that the tumor immune environment\nplays an important role in prognosis as well as response to\ntherapy, the de\ufb01nition of the immune subtype of a tumor mayplay a critical role in the predicting disease outcome as\nopposed to relying solely on features speci\ufb01c to individual can-\ncer types.\nSTAR+METHODS\nDetailed methods are provided in the online version of this paper\nand include the following:\ndKEY RESOURCES TABLE\ndCONTACT FOR REAGENT AND RESOURCE SHARING\ndEXPERIMENTAL MODEL AND SUBJECT DETAILS\nBHuman Subjects\nBSample Inclusion Criteria\ndMETHOD DETAILS\nBClinical and Molecular Data\nBImmune Subtype Identi\ufb01cation\nBLeukocyte and Stromal Fractions\nBImmune Cellular Fraction Estimates\nBPrognostic Correlations of Immune Phenotypes\nBCopy Number and DNA Damage Scores\nBGenomic Correlations with Immune Phenotypes\nBGenetic Ancestry\nBIdenti\ufb01cation of Neoantigens\nBGenomic Viral Content Analysis\nBT- and B- Cell Receptor Analysis\nBImmunomodulator Identi\ufb01cation and Analysis\nBThe Cell-to-Cell Communication Network\nBMaster Regulators of Immune Genes\nBSYstems Genetics Network AnaLysis\ndQUANTIFICATION AND STATISTICAL ANALYSIS\ndSOFTWARE AND DATA AVAILABILITY\nSUPPLEMENTAL INFORMATION\nSupplemental Information includes seven \ufb01gures and six tables and can be\nfound with this article online at https://doi.org/10.1016/j.immuni.2018.03.023 .\n826 Immunity 48, 812\u2013830, April 17, 2018", "start_char_idx": 3332, "end_char_idx": 5869, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89591778-7fdb-4196-8712-a5aaf4ff8377": {"__data__": {"id_": "89591778-7fdb-4196-8712-a5aaf4ff8377", "embedding": null, "metadata": {"page_label": "828", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c3d89a56-4b22-43e5-8c22-e710f1fdff3f", "node_type": "4", "metadata": {"page_label": "828", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "cc28839bd03e052e25660baa8bdce9008bb6f369e66fc4879064436305f3a237", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc2b06be-8e87-4274-b56f-24d0156bc624", "node_type": "1", "metadata": {"page_label": "827", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "a969fefa6789dacdce8d19e973bb8628428d96869512c03cba797f5924e8ccbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4067330b-497b-404d-a51d-1459e38829d8", "node_type": "1", "metadata": {}, "hash": "9ad28e2fe808a9b0470e0221b793d7bd8c431f5d82414cd9edeeb2392ef8c46d", "class_name": "RelatedNodeInfo"}}, "text": "ACKNOWLEDGMENTS\nWe are grateful to all the patients and families who contributed to this study.\nWe also thank the Of\ufb01ce of Cancer Genomics at the NCI for organizationaland logistical support of this study. The high-throughput analyses in this studywere performed on the Institute for Systems Biology-Cancer Genomics Cloud(ISB-CGC) under contract number HHSN261201400007C and on the SevenBridges Cancer Genomics Cloud under contract HHSN261201400008C,with federal funds from the National Cancer Institute, NIH, Departmentof Health and Human Services. Funding from the Cancer Research\nInstitute is gratefully acknowledged, as is support from NCI through U54\nHG003273, U54 HG003067, U54 HG003079, U24 CA143799, U24CA143835, U24 CA143840, U24 CA143843, U24 CA143845, U24 CA143848,U24 CA143858, U24 CA143866, U24 CA143867, U24 CA143882, U24CA143883, U24 CA144025, and P30 CA016672. The study was supportedby W81XWH-12-2-0050, HU0001-16-2-0004 from the US Department ofDefense through the Henry M. Jackson Foundation for the Advancement ofMilitary Medicine. We thank Peter Hammerman and Yasin S xenbabao /C21glu for\ncontributions in early phases of this work.\nAUTHOR CONTRIBUTIONS\nAnalysis, Computation, and Software: V.T., D.L.G., S.D.B., D.W., D.S.B.,\nT.O.Y., E.P.-P., G.F.G., C.L.P., J.A.E., E.Z., A.C.C., E.O.P., I.K.A.S., A.J.G.,A.M.N., R.M., F.F., A. Colaprico, J.S.P., L.E.M., N.S.V., J.L., Y.L., V.D.,S.M.R., R.B., A.D.C., D.B., Y.M., A.R., A.K., H.H., T.M.M., H.N., C.S.P., S.B.,A.I.O., A.L., W.Z., J.G., J.S., B.G.V. Supervision: J.R., A. Califano, D.A., K.C.,H.S., T.K.C., J.N.W., J.G., R.A.H., B.G.V., I.S. Writing: V.T., D.L.G., S.D.B.,D.W., D.S.B., T.O.Y., E.P.-P., G.F.G., C.L.P., E.Z., A.C.C., E.O.P., I.K.A.S.,A.J.G., R.M., F.F., A. Colaprico, N.S.V., H.H., T.M.M., H.N., J.S., C.S.R.,A.J.L., J.S.S., E.G.D., M.L.D., B.G.V., I.S.\nDECLARATION OF INTERESTS\nMichael Seiler, Peter G. Smith, Ping Zhu, Silvia Buonamici, and Lihua Yu are\nemployees of H3 Biomedicine, Inc. Parts of this work are the subject of a pat-ent application: WO2017040526 titled \u2018\u2018Splice variants associated withneomorphic sf3b1 mutants.\u2019\u2019 Shouyoung Peng, Anant A. Agrawal, James Pal-acino, and Teng Teng are employees of H3 Biomedicine, Inc. Andrew D. Cher-niack, Ashton C. Berger, and Galen F. Gao receive research support from\nBayer Pharmaceuticals. Gordon B. Mills serves on the External Scienti\ufb01c Re-\nview Board of Astrazeneca. Anil Sood is on the Scienti\ufb01c Advisory Board forKiyatec and is a shareholder in BioPath. Jonathan S. Serody receives fundingfrom Merck, Inc. Kyle R. Covington is an employee of Castle Biosciences, Inc.Preethi H. Gunaratne is founder, CSO, and shareholder of NextmiRNA Thera-peutics. Christina Yau is a part-time employee/consultant at NantOmics. FranzX. Schaub is an employee and shareholder of SEngine Precision Medicine, Inc.Carla Grandori is an employee, founder, and shareholder of SEngine PrecisionMedicine, Inc. Robert N. Eisenman is a member of the Scienti\ufb01c AdvisoryBoards and shareholder of Shenogen Pharma and Kronos Bio.", "start_char_idx": 0, "end_char_idx": 3043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4067330b-497b-404d-a51d-1459e38829d8": {"__data__": {"id_": "4067330b-497b-404d-a51d-1459e38829d8", "embedding": null, "metadata": {"page_label": "828", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c3d89a56-4b22-43e5-8c22-e710f1fdff3f", "node_type": "4", "metadata": {"page_label": "828", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "cc28839bd03e052e25660baa8bdce9008bb6f369e66fc4879064436305f3a237", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89591778-7fdb-4196-8712-a5aaf4ff8377", "node_type": "1", "metadata": {"page_label": "828", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "e67d5f3c5316eb06b049f7195ec15a60e6322dcd629581d01ce3dc1789380eb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9c92c30-a621-4840-a1fb-6c0a6e6ca7ca", "node_type": "1", "metadata": {}, "hash": "17b60c90c16837ea4b8e6276971d917f981e3886d944b72a7b3f0939223fb72c", "class_name": "RelatedNodeInfo"}}, "text": "Gordon B. Mills serves on the External Scienti\ufb01c Re-\nview Board of Astrazeneca. Anil Sood is on the Scienti\ufb01c Advisory Board forKiyatec and is a shareholder in BioPath. Jonathan S. Serody receives fundingfrom Merck, Inc. Kyle R. Covington is an employee of Castle Biosciences, Inc.Preethi H. Gunaratne is founder, CSO, and shareholder of NextmiRNA Thera-peutics. Christina Yau is a part-time employee/consultant at NantOmics. FranzX. Schaub is an employee and shareholder of SEngine Precision Medicine, Inc.Carla Grandori is an employee, founder, and shareholder of SEngine PrecisionMedicine, Inc. Robert N. Eisenman is a member of the Scienti\ufb01c AdvisoryBoards and shareholder of Shenogen Pharma and Kronos Bio. Daniel J. Wei-senberger is a consultant for Zymo Research Corporation. Joshua M. Stuart isthe founder of Five3 Genomics and shareholder of NantOmics. Marc T.Goodman receives research support from Merck, Inc. Andrew J. Gentles isa consultant for Cibermed. Charles M. Perou is an equity stock holder, consul-tant, and Board of Directors member of BioClassi\ufb01er and GeneCentric Diag-nostics and is also listed as an inventor on patent applications on the BreastPAM50 and Lung Cancer Subtyping assays. Matthew Meyerson receivesresearch support from Bayer Pharmaceuticals; is an equity holder in, consul-\ntant for, and Scienti\ufb01c Advisory Board chair for OrigiMed; and is an inventor of\na patent for EGFR mutation diagnosis in lung cancer, licensed to LabCorp.Eduard Porta-Pardo is an inventor of a patent for domainXplorer. Han Liangis a shareholder and scienti\ufb01c advisor of Precision Scienti\ufb01c and Eagle Nebula.Da Yang is an inventor on a pending patent application describing the use ofantisense oligonucleotides against speci\ufb01c lncRNA sequence as diagnosticand therapeutic tools. Yonghong Xiao was an employee and shareholder ofTESARO, Inc. Bin Feng is an employee and shareholder of TESARO, Inc.Carter Van Waes received research funding for the study of IAP inhibitorASTX660 through a Cooperative Agreement between NIDCD, NIH, and AstexPharmaceuticals. Raunaq Malhotra is an employee and shareholder of Seven\nBridges, Inc. Peter W. Laird serves on the Scienti\ufb01c Advisory Board forAnchorDx. Joel Tepper is a consultant at EMD Serono. Kenneth Wang serveson the Advisory Board for Boston Scienti\ufb01c, Microtech, and Olympus. AndreaCalifano is a founder, shareholder, and advisory board member of Darwin-Health, Inc. and a shareholder and advisory board member of Tempus, Inc.Toni K. Choueiri serves as needed on advisory boards for Bristol-MyersSquibb, Merck, and Roche. Lawrence Kwong receives research supportfrom Array BioPharma. Sharon E. Plon is a member of the Scienti\ufb01c AdvisoryBoard for Baylor Genetics Laboratory. Beth Y. Karlan serves on the Advisory\nBoard of Invitae.\nReceived: July 21, 2017\nRevised: January 23, 2018Accepted: March 21, 2018Published: April 5, 2018; corrected online: August 7, 2019\nREFERENCES\nAgarwal, V., Bell, G.W., Nam, J.W., and Bartel, D.P. (2015). Predicting effective\nmicroRNA target sites in mammalian mRNAs. eLife 4,https://doi.org/10.7554/\neLife.05005 .\nAlvarez, M.J., Shen, Y., Giorgi, F.M., Lachmann, A., Ding, B.B., Ye, B.H., and\nCalifano, A. (2016). Functional characterization of somatic mutations in cancerusing network-based inference of protein activity. Nat. Genet. 48, 838\u2013847 .\nAmankulor, N.M., Kim, Y., Arora, S., Kargl, J., Szulzewsky, F., Hanke, M.,\nMargineantu, D.H., Rao, A., Bolouri, H., Delrow, J., et al. (2017).", "start_char_idx": 2332, "end_char_idx": 5807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9c92c30-a621-4840-a1fb-6c0a6e6ca7ca": {"__data__": {"id_": "c9c92c30-a621-4840-a1fb-6c0a6e6ca7ca", "embedding": null, "metadata": {"page_label": "828", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c3d89a56-4b22-43e5-8c22-e710f1fdff3f", "node_type": "4", "metadata": {"page_label": "828", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "cc28839bd03e052e25660baa8bdce9008bb6f369e66fc4879064436305f3a237", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4067330b-497b-404d-a51d-1459e38829d8", "node_type": "1", "metadata": {"page_label": "828", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "03b2d0efd3b6686a6639a160a2c020afb4ad971ed12ca5b913b4d1e930d9421b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ff980a9-ea75-4c8e-83da-35234a8307d4", "node_type": "1", "metadata": {}, "hash": "0f6a4acf34457a9ad0ce17b88437e2d12487d4441e13f60bb1e6771aafa0462b", "class_name": "RelatedNodeInfo"}}, "text": "(2015). Predicting effective\nmicroRNA target sites in mammalian mRNAs. eLife 4,https://doi.org/10.7554/\neLife.05005 .\nAlvarez, M.J., Shen, Y., Giorgi, F.M., Lachmann, A., Ding, B.B., Ye, B.H., and\nCalifano, A. (2016). Functional characterization of somatic mutations in cancerusing network-based inference of protein activity. Nat. Genet. 48, 838\u2013847 .\nAmankulor, N.M., Kim, Y., Arora, S., Kargl, J., Szulzewsky, F., Hanke, M.,\nMargineantu, D.H., Rao, A., Bolouri, H., Delrow, J., et al. (2017). MutantIDH1 regulates the tumor-associated immune system in gliomas. GenesDev. 31, 774\u2013786 .\nAten, J.E., Fuller, T.F., Lusis, A.J., and Horvath, S. (2008). Using genetic\nmarkers to orient the edges in quantitative trait networks: the NEO software.BMC Syst. Biol. 2,3 4.\nBailey, T.L., Boden, M., Buske, F.A., Frith, M., Grant, C.E., Clementi, L., Ren,\nJ., Li, W.W., and Noble, W.S. (2009). MEME SUITE: tools for motif discoveryand searching. Nucleic Acids Res. 37, W202-208 .\nBailey, P., Chang, D.K., Nones, K., Johns, A.L., Patch, A.M., Gingras, M.C.,\nMiller, D.K., Christ, A.N., Bruxner, T.J., Quinn, M.C., et al. (2016). Genomic an-alyses identify molecular subtypes of pancreatic cancer. Nature 531, 47\u201352 .\nBarbie, D.A., Tamayo, P., Boehm, J.S., Kim, S.Y., Moody, S.E., Dunn, I.F.,\nSchinzel, A.C., Sandy, P., Meylan, E., Scholl, C., et al. (2009). SystematicRNA interference reveals that oncogenic KRAS-driven cancers requireTBK1. Nature 462, 108\u2013112 .\nBeck, A.H., Espinosa, I., Edris, B., Li, R., Montgomery, K., Zhu, S., Varma, S.,\nMarinelli, R.J., van de Rijn, M., and West, R.B. (2009). The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin. Cancer Res.15, 778\u2013787 .\nBedognetti, D., Hendrickx, W., Ceccarelli, M., Miller, L.D., and Seliger, B.\n(2016). Disentangling the relationship between tumor genetic programs andimmune responsiveness. Curr. Opin. Immunol. 39, 150\u2013158 .\nBenyamine, A., Le Roy, A., Mamessier, E., Gertner-Dardenne, J., Castanier,\nC., Orlanducci, F., Pouyet, L., Goubard, A., Collette, Y., Vey, N., et al. (2016).BTN3A molecules considerably improve Vgamma9Vdelta2T cells-basedimmunotherapy in acute myeloid leukemia. OncoImmunology 5, e1146843 .\nBierie, B., and Moses, H.L. (2010). Transforming growth factor beta (TGF-beta)\nand in\ufb02ammation in cancer. Cytokine Growth Factor Rev. 21, 49\u201359 .\nBindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf,\nA.C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013).Spatiotemporal dynamics of intratumoral immune cells reveal the immunelandscape in human cancer. Immunity 39, 782\u2013795 .", "start_char_idx": 5312, "end_char_idx": 7933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ff980a9-ea75-4c8e-83da-35234a8307d4": {"__data__": {"id_": "0ff980a9-ea75-4c8e-83da-35234a8307d4", "embedding": null, "metadata": {"page_label": "828", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c3d89a56-4b22-43e5-8c22-e710f1fdff3f", "node_type": "4", "metadata": {"page_label": "828", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "cc28839bd03e052e25660baa8bdce9008bb6f369e66fc4879064436305f3a237", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9c92c30-a621-4840-a1fb-6c0a6e6ca7ca", "node_type": "1", "metadata": {"page_label": "828", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "521a7b5e8e8e6f9c293c213c3f81d01ca524b03c372cd24b62bbea1919ed9c09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4529daf-160a-4783-9e6a-d483b23c65c6", "node_type": "1", "metadata": {}, "hash": "4ef225e8d5063fe08345b17a1e4c1426ae610022c5f3e2754797e7216c373079", "class_name": "RelatedNodeInfo"}}, "text": "(2016).BTN3A molecules considerably improve Vgamma9Vdelta2T cells-basedimmunotherapy in acute myeloid leukemia. OncoImmunology 5, e1146843 .\nBierie, B., and Moses, H.L. (2010). Transforming growth factor beta (TGF-beta)\nand in\ufb02ammation in cancer. Cytokine Growth Factor Rev. 21, 49\u201359 .\nBindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf,\nA.C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013).Spatiotemporal dynamics of intratumoral immune cells reveal the immunelandscape in human cancer. Immunity 39, 782\u2013795 .\nBolotin, D.A., Shugay, M., Mamedov, I.Z., Putintseva, E.V., Turchaninova,\nM.A., Zvyagin, I.V., Britanova, O.V., and Chudakov, D.M. (2013). MiTCR: soft-ware for T-cell receptor sequencing data analysis. Nat. Methods 10, 813\u2013814 .\nBray, N.L., Pimentel, H., Melsted, P., and Pachter, L. (2016). Near-optimal\nprobabilistic RNA-seq quanti\ufb01cation. Nat. Biotechnol. 34, 525\u2013527 .\nImmunity 48, 812\u2013830, April 17, 2018 827", "start_char_idx": 7374, "end_char_idx": 8347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4529daf-160a-4783-9e6a-d483b23c65c6": {"__data__": {"id_": "f4529daf-160a-4783-9e6a-d483b23c65c6", "embedding": null, "metadata": {"page_label": "829", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8c68f38c-d94a-4ba3-a644-6ffc84869e2f", "node_type": "4", "metadata": {"page_label": "829", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "abd4a083bf5acf17b03fcc6a742f6a904906e4c3dd5cbb9e8995ebb6366e76df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ff980a9-ea75-4c8e-83da-35234a8307d4", "node_type": "1", "metadata": {"page_label": "828", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "40023a84e05129a5c943d4a60234885035a1c7d227ed416eaa60682702df70d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "241fa311-b5ff-4f54-b854-9b6655690f3b", "node_type": "1", "metadata": {}, "hash": "c60ad202fce670579d8dba9d66a9b194dd65eab6aad5da0af3e296c2d92cf697", "class_name": "RelatedNodeInfo"}}, "text": "Brown, S.D., Warren, R.L., Gibb, E.A., Martin, S.D., Spinelli, J.J., Nelson, B.H.,\nand Holt, R.A. (2014). Neo-antigens predicted by tumor genome meta-analysiscorrelate with increased patient survival. Genome Res. 24, 743\u2013750 .\nBrown, S.D., Raeburn, L.A., and Holt, R.A. (2015). Pro\ufb01ling tissue-resident\nT cell repertoires by RNA sequencing. Genome Med. 7, 125 .\nCalabro, A., Beissbarth, T., Kuner, R., Stojanov, M., Benner, A., Asslaber, M.,\nPloner, F., Zatloukal, K., Samonigg, H., Poustka, A., et al. (2009). Effects of in\ufb01l-trating lymphocytes and estrogen receptor on gene expression and prognosisin breast cancer. Breast Cancer Res. Treat. 116, 69\u201377 .\nCarter, S.L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird,\nP.W., Onofrio, R.C., Winckler, W., Weir, B.A., et al. (2012). Absolute quanti\ufb01ca-tion of somatic DNA alterations in human cancer. Nat. Biotechnol. 30,\n413\u2013421 .\nCeccarelli, M., Barthel, F.P., Malta, T.M., Sabedot, T.S., Salama, S.R., Murray,\nB.A., Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S.M., et al. (2016).Molecular pro\ufb01ling reveals biologically discrete subsets and pathways of pro-gression in diffuse glioma. Cell 164, 550\u2013563 .\nChang, H.Y., Sneddon, J.B., Alizadeh, A.A., Sood, R., West, R.B.,\nMontgomery, K., Chi, J.T., van de Rijn, M., Botstein, D., and Brown, P.O.(2004). Gene expression signature of \ufb01broblast serum response predicts hu-man cancer progression: similarities between tumors and wounds. PLoSBiol. 2,E 7.\nCharoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder,\nD., Hackl, H., and Trajanoski, Z. (2017). Pan-cancer immunogenomic analysesreveal genotype-immunophenotype pelationships and predictors of responseto checkpoint blockade. Cell Rep. 18, 248\u2013262 .\nChen, J.C., Alvarez, M.J., Talos, F., Dhruv, H., Rieckhof, G.E., Iyer, A., Diefes,\nK.L., Aldape, K., Berens, M., Shen, M.M., et al. (2014). Identi\ufb01cation of causalgenetic drivers of human disease through systems-level analysis of regulatorynetworks. Cell 159, 402\u2013414 .\nCheng, W.Y., Ou Yang, T.H., and Anastassiou, D. (2013a). Biomolecular events\nin cancer revealed by attractor metagenes. PLoS Comput. Biol. 9, e1002920 .\nCheng, W.Y., Ou Yang, T.H., and Anastassiou, D. (2013b). Development of a\nprognostic model for breast cancer survival in an open challenge environment.Sci. Transl. Med. 5, 181ra150 .\nChu, J., Sadeghi, S., Raymond, A., Jackman, S.D., Nip, K.M., Mar, R.,\nMohamadi, H., Butter\ufb01eld, Y.S., Robertson, A.G., and Birol, I. (2014).\nBioBloom tools: fast, accurate and memory-ef\ufb01cient host species sequencescreening using bloom \ufb01lters. Bioinformatics 30, 3402\u20133404 .\nColaprico, A., Silva, T.C., Olsen, C., Garofano, L., Cava, C., Garolini, D.,\nSabedot, T.S., Malta, T.M., Pagnotta, S.M., Castiglioni, I., et al.", "start_char_idx": 0, "end_char_idx": 2776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "241fa311-b5ff-4f54-b854-9b6655690f3b": {"__data__": {"id_": "241fa311-b5ff-4f54-b854-9b6655690f3b", "embedding": null, "metadata": {"page_label": "829", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8c68f38c-d94a-4ba3-a644-6ffc84869e2f", "node_type": "4", "metadata": {"page_label": "829", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "abd4a083bf5acf17b03fcc6a742f6a904906e4c3dd5cbb9e8995ebb6366e76df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4529daf-160a-4783-9e6a-d483b23c65c6", "node_type": "1", "metadata": {"page_label": "829", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "f944e3d45baeccaac3ff321f560e2c95b5f8eebda532ece94eaf28f83fbbc9f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "540ed3df-e85b-4a29-8cae-53ec560c99bf", "node_type": "1", "metadata": {}, "hash": "93ed1eb22e6978207e50030890cdbedd78d66b0b39ff9cfdc6849ce24763dfe6", "class_name": "RelatedNodeInfo"}}, "text": "Development of a\nprognostic model for breast cancer survival in an open challenge environment.Sci. Transl. Med. 5, 181ra150 .\nChu, J., Sadeghi, S., Raymond, A., Jackman, S.D., Nip, K.M., Mar, R.,\nMohamadi, H., Butter\ufb01eld, Y.S., Robertson, A.G., and Birol, I. (2014).\nBioBloom tools: fast, accurate and memory-ef\ufb01cient host species sequencescreening using bloom \ufb01lters. Bioinformatics 30, 3402\u20133404 .\nColaprico, A., Silva, T.C., Olsen, C., Garofano, L., Cava, C., Garolini, D.,\nSabedot, T.S., Malta, T.M., Pagnotta, S.M., Castiglioni, I., et al. (2016).TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGAdata. Nucleic Acids Res. 44, e71 .\nCubillos-Ruiz, J.R., Martinez, D., Scarlett, U.K., Rutkowski, M.R., Nesbeth,\nY.C., Camposeco-Jacobs, A.L., and Conejo-Garcia, J.R. (2010). CD277 is anegative co-stimulatory molecule universally expressed by ovarian cancermicroenvironmental cells. Oncotarget 1, 329\u2013338 .\nDobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut,\nP., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seqaligner. Bioinformatics 29, 15\u201321 .\nDrake, J.M., Paull, E.O., Graham, N.A., Lee, J.K., Smith, B.A., Titz, B.,\nStoyanova, T., Faltermeier, C.M., Uzunangelov, V., Carlin, D.E., et al. (2016).Phosphoproteome integration reveals patient-speci\ufb01c networks in prostatecancer. Cell 166, 1041\u20131054 .\nEllrott, K., Bailey, M.H., Saksena, G., Covington, K.R., Kandoth, C., Stewart,\nC., Hess, J., Ma, S., McLellan, M., So\ufb01a, H.J., et al. (2018). Scalable open sci-ence approach for mutation calling of tumor exomes using multiple genomicpipelines. Cell Syst. 6,https://doi.org/10.1016/j.cels.2018.03.002 .\nFriedman, J., Hastie, T., and Tibshirani, R. (2010). Regularization paths for\ngeneralized linear models via coordinate descent. J. Stat. Softw. 33, 1\u201322 .\nGalon, J., Angell, H.K., Bedognetti, D., and Marincola, F.M. (2013). The contin-\nuum of cancer immunosurveillance: prognostic, predictive, and mechanisticsignatures. Immunity 39, 11\u201326 .Gentles, A.J., Newman, A.M., Liu, C.L., Bratman, S.V., Feng, W., Kim, D., Nair,\nV.S., Xu, Y., Khuong, A., Hoang, C.D., et al. (2015). The prognostic landscapeof genes and in\ufb01ltrating immune cells across human cancers. Nat. Med. 21,\n938\u2013945 .\nGodec, J., Tan, Y., Liberzon, A., Tamayo, P., Bhattacharya, S., Butte, A.J.,\nMesirov, J.P., and Haining, W.N. (2016). Compendium of immune signatures\nidenti\ufb01es conserved and species-speci\ufb01c biology in response to in\ufb02ammation.\nImmunity 44, 194\u2013206 .\nGusenleitner, D., Howe, E.A., Bentink, S., Quackenbush, J., and Culhane, A.C.\n(2012). iBBiG: iterative binary bi-clustering of gene sets. Bioinformatics 28,\n2484\u20132492 .\nHanahan, D., and Weinberg, R.A.", "start_char_idx": 2232, "end_char_idx": 4948, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "540ed3df-e85b-4a29-8cae-53ec560c99bf": {"__data__": {"id_": "540ed3df-e85b-4a29-8cae-53ec560c99bf", "embedding": null, "metadata": {"page_label": "829", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8c68f38c-d94a-4ba3-a644-6ffc84869e2f", "node_type": "4", "metadata": {"page_label": "829", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "abd4a083bf5acf17b03fcc6a742f6a904906e4c3dd5cbb9e8995ebb6366e76df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "241fa311-b5ff-4f54-b854-9b6655690f3b", "node_type": "1", "metadata": {"page_label": "829", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "766cc4aa9305e3a8db6ff135ba5af31e4e251c9c01c4ddde2f54e0f3ac16127e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d1deb53-b2c9-4676-8c7c-90555d41b910", "node_type": "1", "metadata": {}, "hash": "152aac8bb32915c8d9db94fb442c015ded05b6d3a61aec809fd4578e37c49ccd", "class_name": "RelatedNodeInfo"}}, "text": "Nat. Med. 21,\n938\u2013945 .\nGodec, J., Tan, Y., Liberzon, A., Tamayo, P., Bhattacharya, S., Butte, A.J.,\nMesirov, J.P., and Haining, W.N. (2016). Compendium of immune signatures\nidenti\ufb01es conserved and species-speci\ufb01c biology in response to in\ufb02ammation.\nImmunity 44, 194\u2013206 .\nGusenleitner, D., Howe, E.A., Bentink, S., Quackenbush, J., and Culhane, A.C.\n(2012). iBBiG: iterative binary bi-clustering of gene sets. Bioinformatics 28,\n2484\u20132492 .\nHanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next gener-\nation. Cell 144, 646\u2013674 .\nH\u20acanzelmann, S., Castelo, R., and Guinney, J. (2013). GSVA: gene set variation\nanalysis for microarray and RNA-seq data. BMC Bioinformatics 14,7.\nHarrow, J., Frankish, A., Gonzalez, J.M., Tapanari, E., Diekhans, M.,\nKokocinski, F., Aken, B.L., Barrell, D., Zadissa, A., Searle, S., et al. (2012).GENCODE: the reference human genome annotation for The ENCODEProject. Genome Res. 22, 1760\u20131774 .\nHendrickx, W., Simeone, I., Anjum, S., Mokrab, Y., Bertucci, F., Finetti, P.,\nCurigliano, G., Seliger, B., Cerulo, L., Tomei, S., et al. (2017). Identi\ufb01cation ofgenetic determinants of breast cancer immune phenotypes by integrativegenome-scale analysis. OncoImmunology 6, e1253654 .\nHornik, K. (2005). A CLUE for CLUster ensembles. J. Stat. Softw. 14, 1\u201325 .\nHugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S.,\nBerent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016). Genomicand transcriptomic features of response to anti-PD-1 therapy in metastaticmelanoma. Cell 165, 35\u201344 .\nHundal, J., Carreno, B.M., Petti, A.A., Linette, G.P., Grif\ufb01th, O.L., Mardis, E.R.,\nand Grif\ufb01th, M. (2016). pVAC-Seq: A genome-guided in silico approach toidentifying tumor neoantigens. Genome Med. 8,1 1.\nIglesia, M.D., Parker, J.S., Hoadley, K.A., Serody, J.S., Perou, C.M., and\nVincent, B.G. (2016). Genomic analysis of immune cell in\ufb01ltrates across 11 tu-\nmor types. J. Natl. Cancer Inst. 108,https://doi.org/10.1093/jnci/djw144 .\nIlieva, K.M., Correa, I., Josephs, D.H., Karagiannis, P., Egbuniwe, I.U.,\nCafferkey, M.J., Spicer, J.F., Harries, M., Nestle, F.O., Lacy, K.E., et al.(2014). Effects of BRAF mutations and BRAF inhibition on immune responsesto melanoma. Mol. Cancer Ther. 13, 2769\u20132783 .\nKertesz, M., Iovino, N., Unnerstall, U., Gaul, U., and Segal, E. (2007). The role of\nsite accessibility in microRNA target recognition. Nat. Genet. 39, 1278\u20131284 .\nKhurana, E., Fu, Y., Chen, J., and Gerstein, M. (2013). Interpretation of\ngenomic variants using a uni\ufb01ed biological network approach. PLoSComput. Biol. 9, e1002886 .", "start_char_idx": 4475, "end_char_idx": 7065, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d1deb53-b2c9-4676-8c7c-90555d41b910": {"__data__": {"id_": "4d1deb53-b2c9-4676-8c7c-90555d41b910", "embedding": null, "metadata": {"page_label": "829", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8c68f38c-d94a-4ba3-a644-6ffc84869e2f", "node_type": "4", "metadata": {"page_label": "829", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "abd4a083bf5acf17b03fcc6a742f6a904906e4c3dd5cbb9e8995ebb6366e76df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "540ed3df-e85b-4a29-8cae-53ec560c99bf", "node_type": "1", "metadata": {"page_label": "829", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "4448b224786af3637ab41803cfbcd40cd5e07074510daa03775342bb5c796431", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "108948e1-c9b3-4ecb-b438-4cad50941c4a", "node_type": "1", "metadata": {}, "hash": "fbf1f86f74c267d4f5e13728e3c42d2d64676d73b6ced63f9651df7f40e07725", "class_name": "RelatedNodeInfo"}}, "text": "Effects of BRAF mutations and BRAF inhibition on immune responsesto melanoma. Mol. Cancer Ther. 13, 2769\u20132783 .\nKertesz, M., Iovino, N., Unnerstall, U., Gaul, U., and Segal, E. (2007). The role of\nsite accessibility in microRNA target recognition. Nat. Genet. 39, 1278\u20131284 .\nKhurana, E., Fu, Y., Chen, J., and Gerstein, M. (2013). Interpretation of\ngenomic variants using a uni\ufb01ed biological network approach. PLoSComput. Biol. 9, e1002886 .\nKnijnenburg, T., Wang, L., Zimmermann, M., Chambwe, N., Gao, G.,\nCherniack, A., Fan, H., Shen, H., Way, G., Greene, C., et al. (2018). Genomicand molecular landscape of DNA damage repair de\ufb01ciency across TheCancer Genome Atlas. Cell Rep. 23,https://doi.org/10.1016/j.celrep.2018.\n03.076 .\nLangfelder, P., and Horvath, S. (2007). Eigengene networks for studying the re-\nlationships between co-expression modules. BMC Syst. Biol. 1,5 4.\nLangfelder, P., and Horvath, S. (2008). WGCNA: an R package for weighted\ncorrelation network analysis. BMC Bioinformatics 9, 559 .\nLefranc, M.P., Giudicelli, V., Ginestoux, C., Jabado-Michaloud, J., Folch, G.,\nBellahcene, F., Wu, Y., Gemrot, E., Brochet, X., Lane, J., et al. (2009). IMGT,the international ImMunoGeneTics information system. Nucleic Acids Res.37, D1006\u2013D1012 .\nLegut, M., Cole, D.K., and Sewell, A.K. (2015). The promise of gammadelta\nT cells and the gammadelta T cell receptor for cancer immunotherapy. Cell.Mol. Immunol. 12, 656\u2013668 .\nLi, B., and Dewey, C.N. (2011). RSEM: accurate transcript quanti\ufb01cation from\nRNA-Seq data with or without a reference genome. BMC Bioinformatics12, 323 .\nLi, H., and Durbin, R. (2009). Fast and accurate short read alignment with\nBurrows-Wheeler transform. Bioinformatics\n25, 1754\u20131760 .\n828 Immunity 48, 812\u2013830, April 17, 2018", "start_char_idx": 6623, "end_char_idx": 8382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "108948e1-c9b3-4ecb-b438-4cad50941c4a": {"__data__": {"id_": "108948e1-c9b3-4ecb-b438-4cad50941c4a", "embedding": null, "metadata": {"page_label": "830", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b2b1dd3d-5ec3-4335-a5eb-bbabbabceb8a", "node_type": "4", "metadata": {"page_label": "830", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "b852b4d9317d8affd0dc216c4a38fe67073679021cccea3601750d9bd64e9147", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d1deb53-b2c9-4676-8c7c-90555d41b910", "node_type": "1", "metadata": {"page_label": "829", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "2872aa339813d888bc2af666e5e39962d5c27ce5c954f87a072746cac035a89c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b7832d7-8d9e-433f-bd1b-31eb3aacc380", "node_type": "1", "metadata": {}, "hash": "9f8a35fe5a499f0e8bf820211a5ae61aec69ed39de727a76903c9d08c8ef718d", "class_name": "RelatedNodeInfo"}}, "text": "Li, M.X., Yeung, J.M., Cherny, S.S., and Sham, P.C. (2012). Evaluating the\neffective numbers of independent tests and signi\ufb01cant p-value thresholds incommercial genotyping arrays and public imputation reference datasets.Hum. Genet. 131, 747\u2013756 .\nLi, B., Severson, E., Pignon, J.C., Zhao, H., Li, T., Novak, J., Jiang, P., Shen, H.,\nAster, J.C., Rodig, S., et al. (2016). Comprehensive analyses of tumor immu-nity: implications for cancer immunotherapy. Genome Biol. 17, 174 .\nLiang, Y., Pan, H.F., and Ye, D.Q. (2015). microRNAs function in CD8+T cell\nbiology. J. Leukoc. Biol. 97, 487\u2013497 .\nLiu, J., Lichtenberg, T., Hoadley, K.A., Poisson, L.M., Lazar, A.J., Cherniack,\nA.D., Kovatich, A.J., Benz, C.C., Levine, D.A., Lee, A.V., et al. (2018). An\nIntegrated TCGA Pan-Cancer Clinical Data Resource to drive high quality sur-vival outcome analytics. Cell 173,https://doi.org/10.1016/j.cell.2018.02.052 .\nMantovani, A., Sica, A., and Locati, M. (2005). Macrophage polarization comes\nof age. Immunity 23, 344\u2013346 .\nMargolin, A.A., Nemenman, I., Basso, K., Wiggins, C., Stolovitzky, G., Dalla\nFavera, R., and Califano, A. (2006). ARACNE: an algorithm for the reconstruc-\ntion of gene regulatory networks in a mammalian cellular context. BMCBioinformatics 7(Suppl 1 ), S7.\nMcCarthy, S., Das, S., Kretzschmar, W., Delaneau, O., Wood, A.R., Teumer,\nA., Kang, H.M., Fuchsberger, C., Danecek, P., Sharp, K., et al. (2016). A refer-ence panel of 64,976 haplotypes for genotype imputation. Nat. Genet. 48,\n1279\u20131283 .\nMcElhinny, A.S., Li, J.L., and Wu, L. (2008). Mastermind-like transcriptional co-\nactivators: emerging roles in regulating cross talk among multiple signalingpathways. Oncogene 27, 5138\u20135147 .\nMcGranahan, N., Furness, A.J., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini,\nS.K., Jamal-Hanjani, M., Wilson, G.A., Birkbak, N.J., Hiley, C.T., et al. (2016).Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immunecheckpoint blockade. Science 351, 1463\u20131469 .\nMcLaren, W., Gil, L., Hunt, S.E., Riat, H.S., Ritchie, G.R., Thormann, A., Flicek,\nP., and Cunningham, F. (2016). The Ensembl Variant Effect Predictor. GenomeBiol. 17, 122 .\nMermel, C.H., Schumacher, S.E., Hill, B., Meyerson, M.L., Beroukhim, R., and\nGetz, G. (2011). GISTIC2.0 facilitates sensitive and con\ufb01dent localization of thetargets of focal somatic copy-number alteration in human cancers. GenomeBiol. 12, R41 .\nMiao, D., Margolis, C.A., Gao, W., Voss, M.H., Li, W., Martini, D.J., Norton, C.,\nBosse, D., Wankowicz, S.M., Cullen, D., et al. (2018). Genomic correlates ofresponse to immune checkpoint therapies in clear cell renal cell carcinoma.Science 359, 801\u2013806 .\nMorris, L.G., Riaz, N., Desrichard, A., Senbabaoglu, Y., Hakimi, A.A., Makarov,\nV., Reis-Filho, J.S., and Chan, T.A.", "start_char_idx": 0, "end_char_idx": 2774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b7832d7-8d9e-433f-bd1b-31eb3aacc380": {"__data__": {"id_": "0b7832d7-8d9e-433f-bd1b-31eb3aacc380", "embedding": null, "metadata": {"page_label": "830", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b2b1dd3d-5ec3-4335-a5eb-bbabbabceb8a", "node_type": "4", "metadata": {"page_label": "830", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "b852b4d9317d8affd0dc216c4a38fe67073679021cccea3601750d9bd64e9147", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "108948e1-c9b3-4ecb-b438-4cad50941c4a", "node_type": "1", "metadata": {"page_label": "830", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "238fa0275e03ba1708c4b670fd9a5e90970967f69b855b3815023de37876cf85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18828972-2bba-4fb8-afd3-e1a2a4cdddca", "node_type": "1", "metadata": {}, "hash": "21493ce3d010e0e3bf9a67f38845660af6718cdc2230be3b56cfa37bd7a41a89", "class_name": "RelatedNodeInfo"}}, "text": "(2011). GISTIC2.0 facilitates sensitive and con\ufb01dent localization of thetargets of focal somatic copy-number alteration in human cancers. GenomeBiol. 12, R41 .\nMiao, D., Margolis, C.A., Gao, W., Voss, M.H., Li, W., Martini, D.J., Norton, C.,\nBosse, D., Wankowicz, S.M., Cullen, D., et al. (2018). Genomic correlates ofresponse to immune checkpoint therapies in clear cell renal cell carcinoma.Science 359, 801\u2013806 .\nMorris, L.G., Riaz, N., Desrichard, A., Senbabaoglu, Y., Hakimi, A.A., Makarov,\nV., Reis-Filho, J.S., and Chan, T.A. (2016). Pan-cancer analysis of intratumorheterogeneity as a prognostic determinant of survival. Oncotarget 7,\n10051\u201310063 .\nMose, L.E., Selitsky, S.R., Bixby, L.M., Marron, D.L., Iglesia, M.D., Serody,\nJ.S., Perou, C.M., Vincent, B.G., and Parker, J.S. (2016). Assembly-basedinference of B-cell receptor repertoires from short read RNA sequencingdata with V\u2019DJer. Bioinformatics 32, 3729\u20133734 .\nNewman, A.M., Liu, C.L., Green, M.R., Gentles, A.J., Feng, W., Xu, Y., Hoang,\nC.D., Diehn, M., and Alizadeh, A.A. (2015). Robust enumeration of cell subsetsfrom tissue expression pro\ufb01les. Nat. Methods 12, 453\u2013457 .\nNielsen, M., and Andreatta, M. (2016). NetMHCpan-3.0; improved prediction\nof binding to MHC class I molecules integrating information from multiple re-ceptor and peptide length datasets. Genome Med. 8,3 3.\nPaull, E.O., Carlin, D.E., Niepel, M., Sorger, P.K., Haussler, D., and Stuart, J.M.\n(2013). Discovering causal pathways linking genomic events to transcriptionalstates using Tied Diffusion Through Interacting Events (TieDIE). Bioinformatics\n29, 2757\u20132764 .\nPavesi, G., and Pesole, G. (2006). Using Weeder for the discovery of\nconserved transcription factor binding sites. Curr Protoc BioinformaticsChapter 2 . Unit 2 11 .Pencina, M.J., and D\u2019Agostino, R.B. (2004). Overall C as a measure of discrim-\nination in survival analysis: model speci\ufb01c population value and con\ufb01dence in-terval estimation. Stat. Med. 23, 2109\u20132123 .\nPlaisier, C.L., Horvath, S., Huertas-Vazquez, A., Cruz-Bautista, I., Herrera,\nM.F., Tusie-Luna, T., Aguilar-Salinas, C., and Pajukanta, P. (2009). A systemsgenetics approach implicates USF1, FADS3, and other causal candidategenes for familial combined hyperlipidemia. PLoS Genet. 5, e1000642 .\nPlaisier, C.L., Pan, M., and Baliga, N.S. (2012). A miRNA-regulatory network\nexplains how dysregulated miRNAs perturb oncogenic processes acrossdiverse cancers. Genome Res. 22, 2302\u20132314 .\nPlaisier, C.L., O\u2019Brien, S., Bernard, B., Reynolds, S., Simon, Z., Toledo, C.M.,\nDing, Y., Reiss, D.J., Paddison, P.J., and Baliga, N.S. (2016). Causal mecha-nistic regulatory network for glioblastoma deciphered using systems geneticsnetwork analysis. Cell Syst. 3, 172\u2013186 .\nPorta-Pardo, E., and Godzik, A. (2016). Mutation drivers of immunological re-\nsponses to cancer. Cancer Immunol. Res. 4, 789\u2013798 .", "start_char_idx": 2242, "end_char_idx": 5104, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18828972-2bba-4fb8-afd3-e1a2a4cdddca": {"__data__": {"id_": "18828972-2bba-4fb8-afd3-e1a2a4cdddca", "embedding": null, "metadata": {"page_label": "830", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b2b1dd3d-5ec3-4335-a5eb-bbabbabceb8a", "node_type": "4", "metadata": {"page_label": "830", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "b852b4d9317d8affd0dc216c4a38fe67073679021cccea3601750d9bd64e9147", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b7832d7-8d9e-433f-bd1b-31eb3aacc380", "node_type": "1", "metadata": {"page_label": "830", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "75fef78dfe89ad55bd107d077d5db98b1ed879ac30a1375a60c784cf14667ab8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9c34073-59d5-4c24-bea4-c343710eb374", "node_type": "1", "metadata": {}, "hash": "476770dc79c236be95563f741b5b3f82ab9630ef576d5614723cface3d5f2937", "class_name": "RelatedNodeInfo"}}, "text": "(2012). A miRNA-regulatory network\nexplains how dysregulated miRNAs perturb oncogenic processes acrossdiverse cancers. Genome Res. 22, 2302\u20132314 .\nPlaisier, C.L., O\u2019Brien, S., Bernard, B., Reynolds, S., Simon, Z., Toledo, C.M.,\nDing, Y., Reiss, D.J., Paddison, P.J., and Baliga, N.S. (2016). Causal mecha-nistic regulatory network for glioblastoma deciphered using systems geneticsnetwork analysis. Cell Syst. 3, 172\u2013186 .\nPorta-Pardo, E., and Godzik, A. (2016). Mutation drivers of immunological re-\nsponses to cancer. Cancer Immunol. Res. 4, 789\u2013798 .\nPrice, A.L., Patterson, N.J., Plenge, R.M., Weinblatt, M.E., Shadick, N.A., and\nReich, D. (2006). Principal components analysis corrects for strati\ufb01cation ingenome-wide association studies. Nat. Genet. 38, 904\u2013909 .\nPunt, S., Langenhoff, J.M., Putter, H., Fleuren, G.J., Gorter, A., and Jordanova,\nE.S. (2015). The correlations between IL-17 vs. Th17 cells and cancer patientsurvival: a systematic review. OncoImmunology 4, e984547 .\nRamilowski, J.A., Goldberg, T., Harshbarger, J., Kloppmann, E., Lizio, M.,\nSatagopam, V.P., Itoh, M., Kawaji, H., Carninci, P., Rost, B., et al. (2015). Adraft network of ligand-receptor-mediated multicellular signalling in human.Nat. Commun. 6, 7866 .\nReiss, D.J., Plaisier, C.L., Wu, W.J., and Baliga, N.S. (2015). cMonkey2:\nAutomated, systematic, integrated detection of co-regulated gene modulesfor any organism. Nucleic Acids Res. 43, e87 .\nRooney, M.S., Shukla, S.A., Wu, C.J., Getz, G., and Hacohen, N. (2015).\nMolecular and genetic properties of tumors associated with local immunecytolytic activity. Cell 160, 48\u201361 .\nSaltz, J.H., Gupta, R., Hou, L., Kurc, T., Singh, P., Nguyen, V., Samaras, D.,\nShroyer, K.R., Zhao, T., Batiste, R., et al. (2018). Spatial organization andmolecular correlation of tumor in\ufb01ltrating lymphocytes using deep learningon pathology images. Cell Rep. 23,https://doi.org/10.1016/j.celrep.2018.\n03.086 .\nSanchez-Vega, F., Mina, M., Armenia, J., Chatila, W.K., Luna, A., La, K.,\nDimitriadoy, S., Liu, D.L., Kantheti, H.S., Sagha\ufb01nia, S., et al. (2018).Oncogenic signaling pathways in The Cancer Genome Atlas. Cell 173.\nScrucca, L., Fop, M., Murphy, T.B., and Raftery, A.E. (2016). mclust 5: clus-\ntering, classi\ufb01cation and density estimation using Gaussian \ufb01nite mixturemodels. R J. 8, 289\u2013317 .\nSenbabaoglu, Y., Gejman, R.S., Winer, A.G., Liu, M., Van Allen, E.M., de\nVelasco, G., Miao, D., Ostrovnaya, I., Drill, E., Luna, A., et al. (2016). Tumor im-mune microenvironment characterization in clear cell renal cell carcinoma\nidenti\ufb01es prognostic and immunotherapeutically relevant messenger RNA sig-\nnatures. Genome Biol. 17, 231 .\nShukla, S.A., Rooney, M.S., Rajasagi, M., Tiao, G., Dixon, P.M., Lawrence,\nM.S., Stevens, J., Lane, W.J., Dellagatta, J.L., Steelman, S., et al.", "start_char_idx": 4551, "end_char_idx": 7351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9c34073-59d5-4c24-bea4-c343710eb374": {"__data__": {"id_": "e9c34073-59d5-4c24-bea4-c343710eb374", "embedding": null, "metadata": {"page_label": "830", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b2b1dd3d-5ec3-4335-a5eb-bbabbabceb8a", "node_type": "4", "metadata": {"page_label": "830", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "b852b4d9317d8affd0dc216c4a38fe67073679021cccea3601750d9bd64e9147", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18828972-2bba-4fb8-afd3-e1a2a4cdddca", "node_type": "1", "metadata": {"page_label": "830", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "f05336720f9bdc734299a36b9e31c3edfe9934caef770ff4a3c89f9f367c8692", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ab5b55f-aa72-4335-855e-a916f109c160", "node_type": "1", "metadata": {}, "hash": "0d8f6bda271560de26211af8a831ba7ab46e7101570534a2db639ffdc65b2c3f", "class_name": "RelatedNodeInfo"}}, "text": "R J. 8, 289\u2013317 .\nSenbabaoglu, Y., Gejman, R.S., Winer, A.G., Liu, M., Van Allen, E.M., de\nVelasco, G., Miao, D., Ostrovnaya, I., Drill, E., Luna, A., et al. (2016). Tumor im-mune microenvironment characterization in clear cell renal cell carcinoma\nidenti\ufb01es prognostic and immunotherapeutically relevant messenger RNA sig-\nnatures. Genome Biol. 17, 231 .\nShukla, S.A., Rooney, M.S., Rajasagi, M., Tiao, G., Dixon, P.M., Lawrence,\nM.S., Stevens, J., Lane, W.J., Dellagatta, J.L., Steelman, S., et al. (2015).Comprehensive analysis of cancer-associated somatic mutations in class IHLA genes. Nat. Biotechnol. 33, 1152\u20131158 .\nSilva, T.C., Colaprico, A., Olsen, C., D\u2019Angelo, F., Bontempi, G., Ceccarelli, M.,\nand Noushmehr, H. (2016). TCGA Work\ufb02ow: Analyze cancer genomics andepigenomics data using Bioconductor packages. F1000Res. 5, 1542 .\nSiragusa, E., Weese, D., and Reinert, K. (2013). Fast and accurate read map-\nping with approximate seeds and multiple backtracking. Nucleic Acids Res.\n41, e78 .\nSubramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L.,\nGillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., andMesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-basedapproach for interpreting genome-wide expression pro\ufb01les. Proc. Natl.Acad. Sci. USA 102, 15545\u201315550 .\nImmunity 48, 812\u2013830, April 17, 2018 829", "start_char_idx": 6851, "end_char_idx": 8211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ab5b55f-aa72-4335-855e-a916f109c160": {"__data__": {"id_": "3ab5b55f-aa72-4335-855e-a916f109c160", "embedding": null, "metadata": {"page_label": "831", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "62affe7e-6ea2-4c56-babc-22aaa7e11d8f", "node_type": "4", "metadata": {"page_label": "831", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "68b02fcf23631e58c3314aedb0c10dd2015ef3617883d35769d15b88bd5baf6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9c34073-59d5-4c24-bea4-c343710eb374", "node_type": "1", "metadata": {"page_label": "830", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "5f11f9351eeae037ca3f82ca8a36ba6e456a778e12e862ce2049d0a2e65d3ea1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e77fdf8-83f9-41dd-9750-5c71a7b177f4", "node_type": "1", "metadata": {}, "hash": "3bb34c9cef1aa8b3843ab4fe78d16047e77d6b3d50bb2b34e631218251a16c95", "class_name": "RelatedNodeInfo"}}, "text": "Szolek, A., Schubert, B., Mohr, C., Sturm, M., Feldhahn, M., and Kohlbacher, O.\n(2014). OptiType: precision HLA typing from next-generation sequencing data.Bioinformatics 30, 3310\u20133316 .\nTang, J., Shalabi, A., and Hubbard-Lucey, V.M. (2018). Comprehensive anal-\nysis of the clinical immuno-oncology landscape. Ann. Oncol. 29, 84\u201391 .\nTatlow, P.J., and Piccolo, S.R. (2016). A cloud-based work\ufb02ow to quantify\ntranscript-expression levels in public cancer compendia. Sci. Rep. 6, 39259 .\nTaylor, A.M., Shih, J., Ha, G., Gao, G.F., Zhang, X., Berger, A.C., Schumacher,\nS.E., Wang, C., Hu, H., Liu, J., et al. (2018). Genomic and functional ap-proaches to understanding cancer aneuploidy. Cancer Cell 33,https://doi.\norg/10.1016/j.ccell.2018.03.007 .\nTeschendorff, A.E., Gomez, S., Arenas, A., El-Ashry, D., Schmidt, M.,\nGehrmann, M., and Caldas, C. (2010). Improved prognostic classi\ufb01cation ofbreast cancer de\ufb01ned by antagonistic activation patterns of immune responsepathway modules. BMC Cancer 10,6 0 4 .\nThe Cancer Genome Atlas Network (2015). Genomic classi\ufb01cation of\ncutaneous melanoma. Cell 161, 1681\u20131696 .\nThe Cancer Genome Atlas Research Network (2011). Integrated genomic an-\nalyses of ovarian carcinoma. Nature 474, 609\u2013615 .Tibshirani, R., and Walther, G. (2005). Cluster validation by prediction strength.\nJ. Comput. Graph. Stat. 14, 511\u2013528 .\nVenteicher, A.S., Tirosh, I., Hebert, C., Yizhak, K., Neftel, C., Filbin, M.G.,\nHovestadt, V., Escalante, L.E., Shaw, M.L., Rodman, C., et al. (2017).Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomasby single-cell RNA-seq. Science 355,https://doi.org/10.1126/science.\naai8478 .\nWingender, E., Schoeps, T., and Donitz, J. (2013). TFClass: an expandable hi-\nerarchical classi\ufb01cation of human transcription factors. Nucleic Acids Res. 41,\nD165\u2013D170 .\nWolf, D.M., Lenburg, M.E., Yau, C., Boudreau, A., and van \u2019t Veer, L.J. (2014).\nGene co-expression modules as clinically relevant hallmarks of breast cancerdiversity. PLoS ONE 9, e88309 .\nZack, T.I., Schumacher, S.E., Carter, S.L., Cherniack, A.D., Saksena, G.,\nTabak, B., Lawrence, M.S., Zhsng, C.Z., Wala, J., Mermel, C.H., et al.(2013). Pan-cancer patterns of somatic copy number alteration. Nat. Genet.45, 1134\u20131140 .\nZhang, Q.C., Petrey, D., Deng, L., Qiang, L., Shi, Y., Thu, C.A., Bisikirska, B.,\nLefebvre, C., Accili, D., Hunter, T., et al. (2012). Structure-based predictionof protein-protein interactions on a genome-wide scale. Nature 490, 556\u2013560 .\n830 Immunity 48, 812\u2013830, April 17, 2018", "start_char_idx": 0, "end_char_idx": 2527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e77fdf8-83f9-41dd-9750-5c71a7b177f4": {"__data__": {"id_": "6e77fdf8-83f9-41dd-9750-5c71a7b177f4", "embedding": null, "metadata": {"page_label": "832", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c0b6ecab-08db-4692-933c-8af2a53e82e9", "node_type": "4", "metadata": {"page_label": "832", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "a4aeff5f25fc8363171cc7c6f8648b36fb89f93232ce2e75efc414bb5ee1d664", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ab5b55f-aa72-4335-855e-a916f109c160", "node_type": "1", "metadata": {"page_label": "831", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "68b02fcf23631e58c3314aedb0c10dd2015ef3617883d35769d15b88bd5baf6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dee44469-9b53-4909-a7b5-ba501654f9ce", "node_type": "1", "metadata": {}, "hash": "933b61602b2850c7cae164f5407bbcf0ece913ea3fbb7c8d16edc55dbbf26f42", "class_name": "RelatedNodeInfo"}}, "text": "STAR+METHODS\nKEY RESOURCES TABLE\nREAGENT or RESOURCE SOURCE IDENTIFIER\nBiological SamplesPrimary tumor samples Multiple tissue source sites, processed\nthrough the Biospecimen Core ResourceSeeExperimental Model and Subject Details\nDeposited Data\nRaw and processed clinical, array,\nand sequence dataNCI Genomic Data Commons https://portal.gdc.cancer.gov/\nDigital Pathology Images NCI Genomic Data Commons Cancer\nDigital Slide Archivehttps://portal.gdc.cancer.gov/ http://cancer.\ndigitalslidearchive.net/\nTCGA molecular subtypes TCGA publications, Colaprico et al., 2016 ,\nand this paperhttp://bioconductor.org/packages/release/bioc/\nhtml/TCGAbiolinks.html\nGenecode GTF Harrow et al., 2012 RRID:SCR_014966 https://www.\ngencodegenes.org\nHaplotype Reference Consortium McCarthy et al., 2016 http://www.haplotype-reference-consortium.org/\nPrePPI 1.2.0 database Zhang et al., 2012 https://bhapp.c2b2.columbia.edu/PrePPI/\nPITA Kertesz et al., 2007 https://omictools.com/pita-tool\nFANTOM5 Ramilowski et al., 2015 http://fantom.gsc.riken.jp/5/suppl/Ramilowski_\net_al_2015/\nmiRDB database n/a http://www.mirdb.org\nSoftware and Algorithms\nABSOLUTE Carter et al., 2012 RRID:SCR_005198; http://www.broadinstitute.\norg/cancer/cga/absolute\nARACNE Margolin et al., 2006 RRID:SCR_002180; http://califano.c2b2.columbia.\nedu/software/\nBioBloom Tools 2.0.12 Chu et al., 2014 http://www.bcgsc.ca/platform/bioinfo/software/\nbiobloomtools\nBioconductor n/a RRID:SCR_006442; http://www.bioconductor.org/\nBwa v0.7.12 Li and Durbin, 2009 RRID:SCR_010910; http://bio-bwa.\nsourceforge.net/\nCBC linear programming solver n/a https://projects.coin-or.org/Cbc\nCIBERSORT Newman et al., 2015 https://cibersort.stanford.edu/\ncMonkey2 Reiss et al., 2015 https://github.com/baliga-lab/cmonkey2\nClue (CLUster Ensembles) Hornik, 2005 https://cran.r-project.org/web/packages/clue/\nindex.html\nDIGGIT Chen et al., 2014 . www.bioconductor.org/packages/release/bioc/\nhtml/diggit.html\ndomainXplorer Porta-Pardo and Godzik, 2016 https://github.com/eduardporta/domainXplorer\nEIGENSOFT Price et al., 2006 RRID:SCR_004965; https://reich.hms.harvard.\nedu/software\nFIRM Plaisier et al., 2012 PMID:22845231\nGISTIC 2.0 Mermel et al., 2011 RRID:SCR_000151; http://www.mmnt.net/db/0/0/\nftp-genome.wi.mit.edu/distribution/GISTIC2.0\nglmnet Friedman et al., 2010 RRID: SCR_015505; https://cran.r-project.org/\nweb/packages/glmnet/index.html\nGLPK (gnu linear programming kit) n/a https://www.gnu.org/software/glpk/\nGSVA H\u20acanzelmann et al., 2013 https://bioconductor.org/packages/release/bioc/\nhtml/GSVA.html\niBBiG Gusenleitner et al., 2012 RRID: SCR_012882;\nhttp://www.bioconductor.\norg/packages/release/bioc/html/iBBiG.html\n(Continued on next page )\nImmunity 48, 812\u2013830.e1\u2013e14, April 17, 2018 e1", "start_char_idx": 0, "end_char_idx": 2736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dee44469-9b53-4909-a7b5-ba501654f9ce": {"__data__": {"id_": "dee44469-9b53-4909-a7b5-ba501654f9ce", "embedding": null, "metadata": {"page_label": "833", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c6c9d8b2-2236-4692-8975-0343a2614cf3", "node_type": "4", "metadata": {"page_label": "833", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "0334156b7d0610b4619b902573b072c4ca4f7824ade68d9cdbb7a3e080048b3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e77fdf8-83f9-41dd-9750-5c71a7b177f4", "node_type": "1", "metadata": {"page_label": "832", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "a4aeff5f25fc8363171cc7c6f8648b36fb89f93232ce2e75efc414bb5ee1d664", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a5fbe2f-2c32-40f3-bfc3-9c955425261a", "node_type": "1", "metadata": {}, "hash": "4ff1edb9e3ed9c16413d5af69ba4f499fe9f0b4b4d0615b3acf2da3bc9de3012", "class_name": "RelatedNodeInfo"}}, "text": "CONTACT FOR REAGENT AND RESOURCE SHARING\nFurther information and requests for resources should be directed to and will be ful\ufb01lled by the Lead Contact, Vesteinn Thorsson\n(Vesteinn.Thorsson@systemsbiology.org ).\nEXPERIMENTAL MODEL AND SUBJECT DETAILS\nHuman Subjects\nA total of 11,180 participants were included in this study. This study contained both males and females, with inclusions of genders\ndependent on tumor types. There were 5,621 females, 5,138 males and 321 with missing information about gender. TCGA\u2019s goal was\nto characterize adult human tumors; therefore, the vast majority of participants were over the age of 18. However, 20 participantsunder the age of 18 had tissue submitted prior to clinical data. Age was missing for 188 participants. The range of ages was\n10\u201390 (maximum set to 90 for protection of human subjects) with a median age of diagnosis of 60 years of age. Institutional reviewContinued\nREAGENT or RESOURCE SOURCE IDENTIFIER\nISAR ( in silico admixture removal) Zack et al., 2013 PMID:24071852\nKallisto Bray et al., 2016 https://pachterlab.github.io/kallisto/\nmclust Scrucca et al., 2016 https://cran.r-project.org/web/packages/mclust/\nindex.html\nMEME Bailey et al., 2009 RRID:SCR_001783; http://meme-suite.org/\nMiTCR v1.0.3 Bolotin et al., 2013 RRID: SCR_004989; https://github.com/\nmilaboratory/mitcr/releases/download/1.0.3/mitcr-1.0.3.jar\nMSigDB Subramanian et al., 2005 http://software.broadinstitute.org/gsea/msigdb\nNetMHCpan v3.0 Nielsen and Andreatta, 2016 http://www.cbs.dtu.dk/cgi-bin/nph-sw_request?\nnetMHCpan\nNEO Aten et al., 2008 https://labs.genetics.ucla.edu/horvath/aten/NEO/\nOptiType v1.2 Szolek et al., 2014 https://github.com/FRED-2/OptiType\nPicard n/a RRID:SCR_006525; http://broadinstitute.github.io/\npicard/\nPolysolver n/a https://github.com/researchapps/polysolver\npVAC-seq (Personalized Variant\nAntigens by Cancer sequencing)Hundal et al., 2016 https://github.com/grif\ufb01thlab/pVACtools\nRSEM v1.2.21 Li and Dewey, 2011 RRID:SCR_013027; http://deweylab.biostat.wisc.\nedu/rsem/\nssGSEA Barbie et al., 2009 http://software.broadinstitute.org/cancer/\nsoftware/genepattern/modules/docs/ssGSEAProjection/4\nSTAR v2.4.2a Dobin et al., 2013 RRID: SCR_015899; https://github.com/\nalexdobin/STAR\nSYGNAL Plaisier et al., 2016 PMID:27426982\nTieDIE Paull et al., 2013 https://github.com/epaull/TieDIE\nVDJer Tool Mose et al., 2016 https://github.com/mozack/vdjer\nVEP (Ensembl Variant Effect\nPredictor) v87McLaren et al., 2016 RRID: SCR_007931; http://useast.ensembl.org/\ninfo/docs/tools/vep/index.html\nVIPER Alvarez et al., 2016 https://www.bioconductor.org/packages/release/\nbioc/html/viper.html\nWEEDER Pavesi and Pesole, 2006 https://omictools.com/weeder-tool\nWGCNA Langfelder and Horvath, 2008 RRID: SCR_003302; https://labs.genetics.ucla.\nedu/horvath/CoexpressionNetwork/\nYara Aligner v0.9.9 Siragusa et al., 2013 https://github.com/seqan/seqan/tree/master/\napps/yara\nOther\niAtlas This paper http://www.cri-iatlas.org\ne2Immunity 48, 812\u2013830.e1\u2013e14, April 17, 2018", "start_char_idx": 0, "end_char_idx": 3004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a5fbe2f-2c32-40f3-bfc3-9c955425261a": {"__data__": {"id_": "8a5fbe2f-2c32-40f3-bfc3-9c955425261a", "embedding": null, "metadata": {"page_label": "834", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d89b1f18-9ad1-4ab1-8e8c-9b3913387db7", "node_type": "4", "metadata": {"page_label": "834", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "32c4591b02f3b488c76873199a8a67d934f29a68d3388034ab07167844e99950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dee44469-9b53-4909-a7b5-ba501654f9ce", "node_type": "1", "metadata": {"page_label": "833", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "0334156b7d0610b4619b902573b072c4ca4f7824ade68d9cdbb7a3e080048b3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d8199a8-124d-4097-9388-79e046b848d8", "node_type": "1", "metadata": {}, "hash": "0fbb29db2ccd9eedb28fb34a4296a2043544908f49d14e5e50d605cbc9fa6ab5", "class_name": "RelatedNodeInfo"}}, "text": "boards at each tissue source site reviewed protocols and consent documentation and approved submission of cases to TCGA.\nDetailed clinical, pathologic and molecular characterization of these participants, as well as inclusion criteria and quality control\nprocedures have been previously published for each of the individual TGCA cancer types.\nSample Inclusion Criteria\nSurgical resection of biopsy biospecimens were collected from patients that had not received prior treatment for their disease (abla-\ntion, chemotherapy, or radiotherapy). Cases were staged according to the American Joint Committee on Cancer (AJCC). Each frozenprimary tumor specimen had a companion normal tissue specimen (blood or blood components, including DNA extracted at thetissue source site). Adjacent tissue was submitted for some cases. Specimens were shipped overnight using a cryoport that main-\ntained an average temperature of less than /C0180\n/C14C.\nPathology quality control was performed on each tumor and normal tissue (if available) specimen from either a frozen section slide\nprepared by the TCGA Biospecimen Core Resource (BCR) or from a frozen section slide prepared by the Tissue Source Site (TSS).\nHematoxylin and eosin (H&E) stained sections from each sample were subjected to independent pathology review to con\ufb01rm that the\ntumor specimen was histologically consistent with the submitted diagnosis; as required, tumor reclassi\ufb01cation and/or exclusion wasperformed by expert pathology review. Pathology review also con\ufb01rmed that the adjacent non-neoplastic \u2018\u2018normal\u2019\u2019 tissue specimen\ncontained no tumor cells. For cases of LIHC, adjacent tissue with cirrhotic changes was not acceptable as a germline control, but was\ncharacterized if accompanied by DNA from a patient-matched blood specimen. The percent tumor nuclei, percent necrosis, andother pathology annotations were also assessed. Tumor samples with R60% tumor nuclei and %20% necrosis were submitted\nfor nucleic acid extraction.\nMETHOD DETAILSClinical and Molecular Data\nThe standardized, normalized, batch corrected and platform-corrected data matrices and mutation data generated by thePanCancer Atlas consortium, available at the publication page ( https://gdc.cancer.gov/about-data/publications/pancanatlas ),\nwere used in this study. Gene expression, protein, and miRNA expression, DNA methylation, copy number variation, and gene mu-\ntations were obtained for this study for 11,080 participants. TCGA aliquot barcodes \ufb02agged as \u2018\u2018do not use\u2019\u2019 or excluded by pathologyreview by the PanCancer Atlas Consortium, and annotated according to the Merged Sample Quality Annotation \ufb01le were removed\nfrom the study. For somatic mutations FILTER values were required to be one of PASS, wga, or native_wga_mix, and only protein\ncoding mutations retained (Variant_Classi\ufb01cation one of Frame_Shift_Del, Frame_Shift_Ins,In_Frame_Del,In_Frame_Ins,Missense_Mutation, Nonsense_Mutation,Nonstop_Mutation,Splice_Site, and Translation_Start_Site). Mutations calls were required to bemade by two or more mutations callers (NCALLERS > 1). Where both normal tissue and blood was available as reference, the blood\nreference sample was used. The values of OS, OS.time, PFI, and PFI.time were used as obtained from ( Liu et al., 2018 ).\nImmune-related tumor sample characteristics and selected base data values such as demographic information, survival data and\nexpression of key immumodulators for the 11,080 participants were collected into a per participant summary matrix ( Table S1 ). For\nthe molecular data matrices above, a single representative aliquot was selected per participant for cases where more than one\naliquot was available, as follows. When data on more than one tumor sample was available, a choice of primary tumor samplewas favored, and in remaining cases metastatic were selected over \u2018\u2018additional metastatic.\u2019\u2019 For gene expression, a handful of cases\nwere not resolved by these rules and the following aliquots were adopted TCGA-23-1023: TCGA-23-1023-01A-02R-1564-13;\nTCGA-06-0156-01:TCGA-06-0156-01A-02R-1849-01; TCGA-06-0211-01:TCGA-06-0211-01B-01R-1849-01; TCGA-21-1076-01:TCGA-21-1076-01A-01R-0692-07 based on BCR annotations.", "start_char_idx": 0, "end_char_idx": 4186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d8199a8-124d-4097-9388-79e046b848d8": {"__data__": {"id_": "9d8199a8-124d-4097-9388-79e046b848d8", "embedding": null, "metadata": {"page_label": "834", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d89b1f18-9ad1-4ab1-8e8c-9b3913387db7", "node_type": "4", "metadata": {"page_label": "834", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "32c4591b02f3b488c76873199a8a67d934f29a68d3388034ab07167844e99950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a5fbe2f-2c32-40f3-bfc3-9c955425261a", "node_type": "1", "metadata": {"page_label": "834", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "72e0ea66b147dc76861cb400014f6efefee871cd42cac60d683879da409acb56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19f9ba9e-0a35-41f5-af09-823ca29c720e", "node_type": "1", "metadata": {}, "hash": "13efeabec393442581e3b1597e1aa5beb27f37db40918043844f2e5914dc9281", "class_name": "RelatedNodeInfo"}}, "text": "When data on more than one tumor sample was available, a choice of primary tumor samplewas favored, and in remaining cases metastatic were selected over \u2018\u2018additional metastatic.\u2019\u2019 For gene expression, a handful of cases\nwere not resolved by these rules and the following aliquots were adopted TCGA-23-1023: TCGA-23-1023-01A-02R-1564-13;\nTCGA-06-0156-01:TCGA-06-0156-01A-02R-1849-01; TCGA-06-0211-01:TCGA-06-0211-01B-01R-1849-01; TCGA-21-1076-01:TCGA-21-1076-01A-01R-0692-07 based on BCR annotations. Each primary data \ufb01le was loaded into a Google BigQuery table onthe ISB Cancer Genomics Cloud, annotated with uniform TCGA barcode information, permitting integration of heterogeneous\nsources into a single matrix through cloud queries.\nContributors: Vesteinn Thorsson, David L. Gibbs,Tai-Hsien Ou Yang, Dante Bortone, Katherine Hoadley\nTCGA Molecular Subtypes\nPreviously published TCGA molecular subtypes from multiple tumor types were collected and compiled into a single matrix. A total of\n7,734 TCGA samples were annotated with with molecular subtypes based on TCGA Research Network tumor-speci\ufb01c publicationsfor the following tumor types: ACC, AML, BLCA, BRCA, LGG/GBM, Pan-GI (ESCA/STAD/COAD/READ), HNSC, KICH, KIRC, KIRP,\nLIHC, LUAD, LUSC, OVCA, PCPG, PRAD, SKCM, THCA, UCEC, and UCS, with publication sources detailed on http://\nbioinformaticsfmrp.github.io/TCGAbiolinks/subtypes.html . The uni\ufb01ed patient-centric matrix contains a comprehensive collection\nof the subtypes by molecular platform. Each column contains subtype assignments of a particular molecular platform (e.g.,\nmRNA, DNA methylation, protein). We selected the most prominent subtype classi\ufb01cation of a particular tumor type based on the\ncorresponding paper recommendation and stored this information in column named \u2018\u2018Subtype_Selected.\u2019\u2019The subtype collectionmatrix and the bibliography associated with them are available within TCGAbiolinks on R/Bioconductor ( http://bioconductor.org/\npackages/release/bioc/html/TCGAbiolinks.html )(Colaprico et al., 2016 ) and using the TCGAbiolinksGUI ( Silva et al., 2016 ). The func-\ntion \u2018\u2018PanCancerAtlas_subtypes()\u2019\u2019 provides full access to the curated matrix used for this study. The \u2018\u2018Subtype_Selected\u2019\u2019 column\nwas used for molecular subtypes in this study.\nContributors: Tathiane Malta, Houtan Noushmehr, Antonio Colaprico.\nImmunity 48, 812\u2013830.e1\u2013e14, April 17, 2018 e3", "start_char_idx": 3687, "end_char_idx": 6076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19f9ba9e-0a35-41f5-af09-823ca29c720e": {"__data__": {"id_": "19f9ba9e-0a35-41f5-af09-823ca29c720e", "embedding": null, "metadata": {"page_label": "835", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "98f038f5-6726-480f-abf4-c950e88e7a8b", "node_type": "4", "metadata": {"page_label": "835", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "d3e2c6a158b1be70ae7420509a9fa848b1d65238a35ef625672b2777e162478f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d8199a8-124d-4097-9388-79e046b848d8", "node_type": "1", "metadata": {"page_label": "834", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "da67f81eac592ce096f5904d17b88eeede548f5d76ce28e09a2b44dc5b102811", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be9e326d-47e8-436d-a198-8b9bf4f96b79", "node_type": "1", "metadata": {}, "hash": "3d79084e70fc1aac13be1280ad0b3a6a5d8a331ac60c5dfce0592014ecc96374", "class_name": "RelatedNodeInfo"}}, "text": "Immune Subtype Identi\ufb01cation\nImmune Signature Compilation\nWe undertook an extensive literature search and assembled a collection of 160 immune expression signatures utilizing diverse\nresources which were considered to be reliable and comprehensive, based on the opinions of immuno-oncologist experts in thegroup. Of these signatures, 83 were derived in the context of studies of the immune response in cancer and the remaining 77\nare of general validity for immunity. The 83 signatures that are known to be associated with immune activity in tumor tissue consisted\nof 68 gene sets collected from earlier studies ( Wolf et al., 2014 ), 9 co-expression signatures derived from computational analysis of all\nTCGA gene expression datasets (immune metagene attractors), ( Cheng et al., 2013a, 2013b ), 3 signatures representing the func-\ntional orientation of the immune contexture (or Immunologic Constant of Rejection, ICR) ( Bedognetti et al., 2016; Galon et al.,\n2013; Hendrickx et al., 2017 ), and 3 signatures from a recent study characterizing the immune microenvironment of clear cell renal\ncell carcinoma ( Senbabaoglu et al., 2016 ). The 77 more general signatures comprised scores of 45 signatures representing individual\ncell types from two sources (20 from ( Gentles et al., 2015 ) and 25 from ( Bindea et al., 2013 )) and 32 scores encompassing the\ndominant modes of scores derived from the ImmuneSigDB ( Godec et al., 2016; Subramanian et al., 2005 ) (Collection C7 of MSigDB,\nBroad Institute). The modes were determined as the \ufb01rst 32 principal components of 1888 Immune C7 human gene sets, and wereused as the full set was intractably large and complex. Gene sets from Bindea et al. (2013) ,Senbabaoglu et al. (2016) , and the\nMSigDB C7 collection were scored using single-sample gene set enrichment (ssGSEA) analysis ( Barbie et al., 2009 ), as implemented\nin the GSVA R package ( H\u20acanzelmann et al., 2013 ). All other signatures were scored using methods found in the associated citations.\nImmune Signature Cluster ModelingAll available TCGA tumor samples (n = 9126) were scored for each of the 160 identi\ufb01ed gene expression signatures. Prior to model-\nbased clustering, we began by identifying a limited set of distinct and representative gene signatures to use for the model-based\nclustering analysis based on consensus clustering of all available gene signature scores over all available samples. Initial data explo-ration using all 160 gene sets implied that including the 77 more general immune signatures did not affect the identi\ufb01ed signature\nclusters, and we performed the \ufb01nal analysis with the 83 signatures derived in the cancer immune response context. Representative\nclusters were identi\ufb01ed as follows: two independent analysts used weighted gene correlation network analysis (WGCNA) to produceclusters of signatures ( Langfelder and Horvath, 2008 ). First, using gene set scores (ssGSEA) ( Barbie et al., 2009 ) over all samples,\nSpearman correlations were computed between signatures creating a correlation matrix. Then, the correlation matrix was scaled\nby taking each element to a speci\ufb01ed power and clustered using the WGCNA R package. Various WGCNA parameters wereexplored, but good results were found with TOMType = \u2019\u2019signed,\u2019\u2019 power = 18, pamStage = F, minModuleSize = 3. Each identi\ufb01ed\nmodule contained an \u2018eigen-signature\u2019 which is used to identify possible \u2018\u2018most representative\u2019\u2019 gene expression signatures from\nthose contained in the cluster module by computing a distance from each signature to the \u2018eigen-signature\u2019. Signatures having shortdistances to the eigen-signature would be considered to be more representative of the signature-module.Representative Gene Signature Identi\ufb01cation\nResults from the 2 independent WGCNA analyses yielded 9 potential signatures considered representative of identi\ufb01ed module\neigen-signatures. We then evaluated each of the potential representative signatures using the strategy put forth in \u2018\u2018cluster validationby predictive strength\u2019\u2019 ( Tibshirani and Walther, 2005 ). This strategy involves building cluster-models using random subsets of\nsamples, and making cluster predictions on the remaining unclustered samples. The predicted cluster labels are compared\nacross models built from random sample subsets.", "start_char_idx": 0, "end_char_idx": 4285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be9e326d-47e8-436d-a198-8b9bf4f96b79": {"__data__": {"id_": "be9e326d-47e8-436d-a198-8b9bf4f96b79", "embedding": null, "metadata": {"page_label": "835", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "98f038f5-6726-480f-abf4-c950e88e7a8b", "node_type": "4", "metadata": {"page_label": "835", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "d3e2c6a158b1be70ae7420509a9fa848b1d65238a35ef625672b2777e162478f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19f9ba9e-0a35-41f5-af09-823ca29c720e", "node_type": "1", "metadata": {"page_label": "835", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "ef36b730609e136e61b44905cc42316def0c4a2fa4477b7d6fb36ae86cfa1cf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "359c8fc0-a342-467f-8ab1-faf2afa24070", "node_type": "1", "metadata": {}, "hash": "951baccaa68af05d2979c259c6680615105288b00a8697f19a11ce0cf938f8f9", "class_name": "RelatedNodeInfo"}}, "text": "Signatures having shortdistances to the eigen-signature would be considered to be more representative of the signature-module.Representative Gene Signature Identi\ufb01cation\nResults from the 2 independent WGCNA analyses yielded 9 potential signatures considered representative of identi\ufb01ed module\neigen-signatures. We then evaluated each of the potential representative signatures using the strategy put forth in \u2018\u2018cluster validationby predictive strength\u2019\u2019 ( Tibshirani and Walther, 2005 ). This strategy involves building cluster-models using random subsets of\nsamples, and making cluster predictions on the remaining unclustered samples. The predicted cluster labels are compared\nacross models built from random sample subsets. For sets of features that produce strong clustering models, the labels will beconsistent.\nTo do this work, model based clustering, performed with the mclust R package ( Scrucca et al., 2016 ), which uses \ufb01nite normal\nmixture modeling, was in part selected as it can readily handle the large set of scores from the Pancancer Atlas (9,129 samples).This approach identi\ufb01ed 3 of the potential signatures as lacking robustness and they were excluded from further analysis.\nFinally, the actual genes contained in each of the potential signatures were examined by an expert in the immuno-oncology \ufb01eld for\nvalidity (Nora Disis), and one of two highly similar IFN signatures was excluded for redundancy. This left \ufb01ve \ufb01nal representative gene\nsignatures, each standing in for one of \ufb01ve signature-similarity modules ( Figure 1 A, top). The \ufb01ve identi\ufb01ed representative signatures\nare: \u2018\u2018CSF1_response\u2019\u2019 for activation of macrophages/monocytes ( Beck et al., 2009 ) (referred to throughout text and \ufb01gures as\n\u2018\u2018Macrophage,\u2019\u2019 \u2018\u2018LIexpression_score\u2019\u2019 representing overall lymphocyte in\ufb01ltration, and dominated by B and T cell signatures\n(Calabro et al., 2009 ) (referred to throughout text and \ufb01gures as \u2018\u2018Lymphocyte\u2019\u2019), TGF- bresponse \u2018\u2018TGFB_score_21050467\u2019\u2019\n(Teschendorff et al., 2010 )(\u2018\u2018 TGF- b\u2019\u2019 in text and \ufb01gures), \u2018\u2018Module3_IFN_score\u2019\u2019 representing IFN- gresponse ( Wolf et al.,\n2014 )(\u2018\u2018IFN- g\u2019\u2019 in text and \ufb01gures), and wound healing \u2018\u2018CHANG_CORE_SERUM_RESPONSE_UP\u2019\u2019( Chang et al., 2004 ) (\u2018\u2018Wound\nhealing\u2019\u2019 in text and \ufb01gures).\nUsing the \ufb01nal \ufb01ve signatures to cluster TCGA tumor samples, the number of clusters, K, was determined using scores that were\nmedian centered and scaled by median-absolute-deviation (MAD). Possible values for K (the number of clusters) ranged from 2 to 32.\nThen, 21 random subsets, each representing 50% of 9,129 TCGA aliquots, (from 9,126 participants) were selected and mclustmodels were \ufb01t to each subset, resulting in 21 clustering models. In each model, the parameter Kwas selected that maximized\nthe Bayesian Information Criterion (BIC), and an average Kwas computed. Maximal BIC was found to occur with a six cluster\nsolution, thus 6 clusters were used for the remainder of analyses.\nAn ensemble approach was used to improve predictability and increase robustness. To produce the \ufb01nal clustering, 256 sub-\nsamples were taken (each representing a random 50% of 9,129 samples), and a model was \ufb01t to each sub-sample, setting K=6 .\nThen, the \u2018\u2018GV1\u2019\u2019 method in the R package \u2018clue\u2019 (CLUster Ensembles) was used to call the consensus clusters ( Hornik, 2005 ).\ne4Immunity 48, 812\u2013830.e1\u2013e14, April 17, 2018", "start_char_idx": 3559, "end_char_idx": 6921, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "359c8fc0-a342-467f-8ab1-faf2afa24070": {"__data__": {"id_": "359c8fc0-a342-467f-8ab1-faf2afa24070", "embedding": null, "metadata": {"page_label": "836", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9ccbc34e-dd32-411e-88ea-a70ab8c24cf9", "node_type": "4", "metadata": {"page_label": "836", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "78e52fbc1c95481a4f58c1b02b82fa3e89b989a35d4878b0695d1f9108835449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be9e326d-47e8-436d-a198-8b9bf4f96b79", "node_type": "1", "metadata": {"page_label": "835", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "776b0eb69b80fb61b7a2d1f1fefbfc3350dace395c07809cbea2da231b7af12d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcffa9f3-fbcb-4f28-8724-1558f033a9e6", "node_type": "1", "metadata": {}, "hash": "7af2fcc03ad7132463e0cae251b195043e26127aaf602c2cea1fd6d5a89c7109", "class_name": "RelatedNodeInfo"}}, "text": "This method takes the list of 256 clusterings, each containing a subset of the samples, and produces a consensus cluster by\nminimizing an objective function. The entire process was performed twice to ensure reproducibility.\nContributors: David L. Gibbs, Denise Wolf, Vesteinn Thorsson, Benjamin Vincent, Ilya Shmulevich\nValidation of Model-based ClusteringTo determine the robustness of model-based clustering, we performed an analysis in which the samples were partitioned into training\nand test sets in varying proportions that ranged from 0.5% to 30%. The training set was used to build the ensemble model, which in\nturn is used to predict cluster labels on the test set (the held-out samples). The clustering of the training and test sets was comparedto results from the full model using all samples. 20 repetitions were performed. Cluster purity (CP, not to be confused with tumorpurity) and Normalized mutual information (NMI) were used to evaluate the training and test results. Cluster-purity describes the frac-\ntion of the most common label within a cluster. So, if 9/10 members of a cluster (from the reported clustering) share a label, then the\npurity is 90%. Second, the NMI describes the mutual information between our new clusters and reported clusters, normalizing byaverage entropy which puts it on a scale of zero to one. Considering both the test set and training set, when the proportion of samples\nremoved was less than 16%, the NMI averaged greater than 0.9, which indicates an excellent level of similarity to the full model. When\n32% of samples were removed, the NMI was 0.81 and 0.82 respectively, still indicating very good concordance. In both above cases(training and test) when 16% of samples were held-out, cluster purity (CP) levels were greater than 95%. Overall, there is very good\nNMI and CP scores found when removing even up to 32% of samples (2,921samples held out).\nOf note, using cluster purity (CP), the training set maintained levels above 89% even when 32% of the samples were missing. The\nexception being C6, which is noisy and had a purity level of 72% when 32% of samples were removed. The test set prediction resultsshowed slightly better CP, with 32% missing samples, purity levels for all subtypes were greater than 90%, the exception being\nC6 which had purity 71%. In addition, we explored the extent to which clustering results vary when different, but correlated, signa-\ntures are used. In clustering, the results (the cluster labels assigned to samples) are always dependent on the inputs, or in this case,the signatures. It is often the case that by using different signatures, the clustering structure will change. The question we aim to\nanswer with this is: if one uses related signatures, how different is the clustering structure? In each iteration, either one or two\nsignatures was randomly selected from the 5 main signatures. The selected signature was then replaced with a signature(s) thatwas sampled with probability proportional to the correlation structure (as seen in the heatmap of gene set signatures). After the\nreplacement of a signature (one or two), the complete ensemble clustering model was constructed, and new clusters called. Again,\ncluster purity and normalized mutual information were used to evaluate the clustering results.\nIn total, using the full set of available signatures, 363 new cluster models were constructed, and across clusters (C1-C6) we found\nthat as new replacement signatures have greater correlation with the original signatures, the NMI gradually increases. Starting\nfrom/C240.4 for single replacements and /C240.35 for double replacements. As the replacement signature correlation increases past\n0.95, we saw NMIs of 0.7 to 0.8 which indicate between 8%\u201315% of cluster labels changing. Using cluster purity we found a similareffect where increasing levels of correlation with the replacement signatures produced higher levels of purity. There are several\nexceptions. The C5 cluster is very robust regardless of the replacement signature with purity levels above 90%. The C6 cluster is\n(as above) very noisy with purity levels around 50%\u201360%. Among the remainder of the clusters (C1-C4), the C3 cluster shows thelowest levels of purity with an average of 0.80 when the signature correlation is greater than 0.95. When the correlation drops to\n0.9, the purity level for C3 drops to 70%.", "start_char_idx": 0, "end_char_idx": 4383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcffa9f3-fbcb-4f28-8724-1558f033a9e6": {"__data__": {"id_": "dcffa9f3-fbcb-4f28-8724-1558f033a9e6", "embedding": null, "metadata": {"page_label": "836", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9ccbc34e-dd32-411e-88ea-a70ab8c24cf9", "node_type": "4", "metadata": {"page_label": "836", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "78e52fbc1c95481a4f58c1b02b82fa3e89b989a35d4878b0695d1f9108835449", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "359c8fc0-a342-467f-8ab1-faf2afa24070", "node_type": "1", "metadata": {"page_label": "836", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "fe198801302bcb429440bd2906b73f1c5b0c6d29cc955a8d6e2ab6a5f13cc78f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56802194-142b-4fbd-bfc8-5d8c73906620", "node_type": "1", "metadata": {}, "hash": "5585bd56a56c354c2ced898e50c76832e3480a37df77ceacf78fe9516d83bdb0", "class_name": "RelatedNodeInfo"}}, "text": "As the replacement signature correlation increases past\n0.95, we saw NMIs of 0.7 to 0.8 which indicate between 8%\u201315% of cluster labels changing. Using cluster purity we found a similareffect where increasing levels of correlation with the replacement signatures produced higher levels of purity. There are several\nexceptions. The C5 cluster is very robust regardless of the replacement signature with purity levels above 90%. The C6 cluster is\n(as above) very noisy with purity levels around 50%\u201360%. Among the remainder of the clusters (C1-C4), the C3 cluster shows thelowest levels of purity with an average of 0.80 when the signature correlation is greater than 0.95. When the correlation drops to\n0.9, the purity level for C3 drops to 70%. Overall, while the purity levels gradual increase with signature correlation, the exception\nis C3 where the variance in purity values was relatively strong, indicating that the cluster was splitting. As the \ufb01eld moves forward,it is likely that we will see a more detailed classi\ufb01cation of samples found in C3.\nContributor: David L. Gibbs\nBiclustering of Immune-Expression SignaturesAs another measure of the robustness of the above model based sample clustering, we applied an entirely different clusteringmethod, iterative binary biclustering using iBBiG ( Gusenleitner et al., 2012 ). The iterative biclustering identi\ufb01es similarity blocks within\nthe matrix of signature scores, but with tumor sample groups (clusters) that are to allowed to overlap, unlike the model-based\nclustering. We analyzed the total 160 gene signature score sets using iBBiG, which yielded 15 biclusters. Model-based clusteringand biclustering have commonalities both in terms of shared tumor sample groupings and in the association of clusters to pheno-\ntypes, as evidenced by 13 signi\ufb01cant overlaps between the biclusters and the six immune subtypes according to a hypergeometric\ntest. Comparing functional annotations of these clusters, we found that overlap to be re\ufb02ected in the concordant distribution of meanscores of IFN- g, TGF- b, mutation load and overall leukocyte in\ufb01ltrate among the overlapping clusters.\nContributors: Aedin Culhane, Azfar Basunia\nLeukocyte and Stromal Fractions\nMethylation Analysis\nOverall leukocyte content in 10,817 TCGA tumor aliquots was assessed by identifying DNA methylation probes with the greatestdifferences between pure leukocyte cells and normal tissue, then estimating leukocyte content using a mixture model. From IlluminaIn\ufb01nium DNA methylation platform arrays HumanMethylation450, 2000 loci were identi\ufb01ed (200 for HumanMethylation27) that were\nthe most differentially methylated between leukocyte and normal tissues, 1000 in each direction. For each locus i, assuming two pop-\nulations ( j), for each sample we have\nImmunity 48, 812\u2013830.e1\u2013e14, April 17, 2018 e5", "start_char_idx": 3639, "end_char_idx": 6473, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56802194-142b-4fbd-bfc8-5d8c73906620": {"__data__": {"id_": "56802194-142b-4fbd-bfc8-5d8c73906620", "embedding": null, "metadata": {"page_label": "837", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "95b22f20-a73a-4e2e-b16c-294e8539016a", "node_type": "4", "metadata": {"page_label": "837", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "66275a84cda03a6d789e4468d16108ea035a7aefa288d810a8129350524fa919", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcffa9f3-fbcb-4f28-8724-1558f033a9e6", "node_type": "1", "metadata": {"page_label": "836", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "00f602c8cacc7c8e783ea9c05313a25b26e556f7da8aa26ff275d29c8566031e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7db29cb-aeb7-40b1-90fd-ff036b9d22e6", "node_type": "1", "metadata": {}, "hash": "2b7d2aa25c6ae95675d78004e7399014da656f2d79bc1c16c46057b7b4ccc467", "class_name": "RelatedNodeInfo"}}, "text": "bi=X2\nj=1bijpj\nUsing the tumor with the least evidence of leukocyte methylation as a surrogate for the beta value ( b) for each locus in the pure\ntumor, 2000 estimates were made, solving for p. We took the mode of 200 estimates to avoid loci that violate the assumptions. Using\nthe estimated pand the measured bfor tumor and leukocyte, with the same linear model, solved for b(deconvoluted value) extracting\nthe leukocyte fraction (LF). Estimates for DLBC (lymphoid neoplasm diffuse large B cell lymphoma), THYM (thymoma), LAML (acute\nmyeloid leukemia) were masked as their tissues of origin are expected to be related to leukocytes, and therefore there were not\nenough tissue-speci\ufb01c DNA methylation loci to distinguish the two.\nStromal fraction (SF) was de\ufb01ned as the total non-tumor cellular component, obtained by subtracting tumor purity from unity, with\nthe leukocyte proportion of stromal content R = LF/SF. Tumor purity was generated using ABSOLUTE ( Carter et al., 2012; Taylor\net al., 2018 ). R was estimated by the Pearson correlation coef\ufb01cient between SF and LF, r, assessed for individual sample groups\n(TCGA tumor types, subtypes, and immune subtypes).\nContributors: Hui Shen, Vesteinn Thorsson\nWhole-Slide Image Analysis\nCharacterization of tumor-in\ufb01ltrating lymphocytes (TILs) from TCGA H&E images was carried out using deep learning-basedlymphocyte classi\ufb01cation with Convolutional Neural Networks (CNNs) ( Saltz et al., 2018 ). TIL in\ufb01ltrated regions are presented\nas heatmaps overlaying H&E diagnostic images, allowing path ologists to curate those heatmaps to create \ufb01nal lymphocyte dis-\ntribution maps. The tool was trained by experts to delineate lymphocyte-in\ufb01ltrated tumor regions for each slide. In a whole slideimage, a given small region of 50x50 microns is considered lymphocyte in\ufb01ltrated if and only if 1) the predicted probability of\nlymphocyte in\ufb01ltration is above a threshold and 2) the patch is not classi\ufb01ed as necrotic tissue. The associated software pro-\nvides a visual interface for threshold selection but due to the large number of whole slide images, we developed the followingsemi-automatic method for setting thresholds. We select ten patches for each whole slide image strati\ufb01ed by predicted prob-ability. The whole slide images are then grouped into a small number of categories (seven) based on the agreement between\npredicted probabilities and pathologist labels. We sample eight slides per category and select thresholds visually based on\nthe heatmap overlaying images. The averaged threshold is used for all slides in the same category. TCGA tumor types analyzedwere LUAD, BRCA, PAAD, COAD, LUSC, PRAD, UCEC, READ, BLCA, STAD, CESC, SKCM and UVM. We began with gener-\nating 48K labeled patches to train our model for LUAD and incrementally added additional patches as necessary to train the\nmodel for BRCA, PAAD, COAD, LUSC, PRAD, UCED, READ, BLCA, STAD, CESC (in that order). For each new cancer type,we \ufb01rst applied the trained deep learning model. Pathologists then reviewed the results on a set of sample whole slide images.\nIf the pathologists judged that the lymphocyte classi\ufb01cation was inadequate, we retrained the model with additional training\npatches extracted from the new given cancer type, repeating this process until adequate accuracy was obtained. The deeplearning model for the two melanoma types \u2013 SKCM and UVM was trained separately. The TIL regional fraction was estimatedobtained as the number of TIL positive 50x50 micron regions over the total number of those 50x50 micron regions on the tis-\nsue image.\nContributors: Joel Saltz, Arvind UK Rao, Alexander J. Lazar, Ashish Sharma\nImmune Cellular Fraction Estimates\nThe relative fraction of 22 immune cell types within the leukocyte compartment were estimated using CIBERSORT ( Newman et al.,\n2015 ). These proportions were multiplied by LF to yield corresponding estimates in terms of overall fraction in tissue. Further, values\nwere aggregated in various combinations to yield abundance of more comprehensive cellular classes, such as lymphocytes, mac-\nrophages and CD4 T cells.", "start_char_idx": 0, "end_char_idx": 4102, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7db29cb-aeb7-40b1-90fd-ff036b9d22e6": {"__data__": {"id_": "d7db29cb-aeb7-40b1-90fd-ff036b9d22e6", "embedding": null, "metadata": {"page_label": "837", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "95b22f20-a73a-4e2e-b16c-294e8539016a", "node_type": "4", "metadata": {"page_label": "837", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "66275a84cda03a6d789e4468d16108ea035a7aefa288d810a8129350524fa919", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56802194-142b-4fbd-bfc8-5d8c73906620", "node_type": "1", "metadata": {"page_label": "837", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "a3c4d3ad216808ced68d60188e735ae5eea0c608b397bdb1d47250e633fd1ad3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28ae66e6-1c10-4582-83b5-daee0fe3c450", "node_type": "1", "metadata": {}, "hash": "bb08aa5ca11462e41acd64acbec01943fae9f35d14ff77623edd90a6775a79c6", "class_name": "RelatedNodeInfo"}}, "text": "The deeplearning model for the two melanoma types \u2013 SKCM and UVM was trained separately. The TIL regional fraction was estimatedobtained as the number of TIL positive 50x50 micron regions over the total number of those 50x50 micron regions on the tis-\nsue image.\nContributors: Joel Saltz, Arvind UK Rao, Alexander J. Lazar, Ashish Sharma\nImmune Cellular Fraction Estimates\nThe relative fraction of 22 immune cell types within the leukocyte compartment were estimated using CIBERSORT ( Newman et al.,\n2015 ). These proportions were multiplied by LF to yield corresponding estimates in terms of overall fraction in tissue. Further, values\nwere aggregated in various combinations to yield abundance of more comprehensive cellular classes, such as lymphocytes, mac-\nrophages and CD4 T cells. More speci\ufb01cally, we applied CIBERSORT to TCGA RNASeq data. CIBERSORT (cell-type identi\ufb01cation byestimating relative subsets of RNA transcripts) uses a set of 22 immune cell reference pro\ufb01les to derive a base (signature) matrix\nwhich can be applied to mixed samples to determine relative proportions of immune cells. As several key immune genes used in\nthe signatures are absent from TCGA GAF (Generic Annotation File) Version 3.0, we applied CIBERSORT to a re-quanti\ufb01cation ofthe TCGA data using Kallisto ( Bray et al., 2016 ) and the Gencode GTF ( Harrow et al., 2012 )(available from https://www.\ngencodegenes.org/ ), which includes the missing genes. A version of the entire TCGA RNA-seq data normalized to Gencode with\nKallisto was computed on the ISB Cancer Genomics Cloud by Steve Piccolo\u2019s group at BYU ( https://osf.io/gqrz9/wiki/home/ )(Tatlow\nand Piccolo, 2016 ).\nIn order to relate to results to other estimates in this study, three aggregation schemes were de\ufb01ned as follows\nAggregate 1\n(6 classes; Used in Figure 2 A, e.g.) Lymphocytes = B.cells.naive+B.cells.memory+T.cells.CD4.naive+T.cells.CD4.memory.\nresting+T.cells.CD4.memory.activated+T.cells.follicular.helper+T.cells.regulatory..Tregs+T.cells.gamma.delta+T.cells.CD8+NK.\ncells.resting+NK.cells.activated+Plasma.cells,\nMacrophages = Monocytes + Macrophages.M0 + Macrophages.M1 + Macrophages.M2Dendritic.cells = Dendritic.cells.resting + Dendritic.cells.activated,Mast.cells = Mast.cells.resting + Mast.cells.activated,\ne6Immunity 48, 812\u2013830.e1\u2013e14, April 17, 2018", "start_char_idx": 3315, "end_char_idx": 5639, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28ae66e6-1c10-4582-83b5-daee0fe3c450": {"__data__": {"id_": "28ae66e6-1c10-4582-83b5-daee0fe3c450", "embedding": null, "metadata": {"page_label": "838", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "36910835-2005-4969-a81c-7d9e3943368e", "node_type": "4", "metadata": {"page_label": "838", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "f68e9bf008ccbf1997585b0285296ec1e4ec311e4f8ed7bcaa0696a04a911f0d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7db29cb-aeb7-40b1-90fd-ff036b9d22e6", "node_type": "1", "metadata": {"page_label": "837", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "9cee11c9b540b0842149c28bb50475de887922b7e3154a9b55ec8d8fe928d87a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "835a638d-1256-4e5d-87ee-d9dada6163dd", "node_type": "1", "metadata": {}, "hash": "466c1814457372fba63c26a7b98f496788c1c63b11290dfb10c5435f823e672b", "class_name": "RelatedNodeInfo"}}, "text": "Neutrophils = Neutrophils,\nEosinophils = Eosinophils,\nAggregate 2\n(9 classes; used for cytokine network, including Figure 7 A,B,C)\nT.cells.CD8 = T.cells.CD8,T.cells.CD4 = T.cells.CD4.naive+T.cells.CD4.memory.resting+T.cells.CD4.memory.activated,\nB.cells = B.cells.naive + B.cells.memory,\nNK.cells = NK.cells.resting+NK.cells.activated,Macrophage = Macrophages.M0 + Macrophages.M1 + Macrophages.M2,\nDendritic.cells = Dendritic.cells.resting + Dendritic.cells.activated,\nMast.cells = Mast.cells.resting + Mast.cells.activated,Neutrophils = Neutrophils,Eosinophils = Eosinophils\nAggregate 3\n(11 classes)T.cells.CD8 = T.cells.CD8,T.cells.CD4 = T.cells.CD4.naive+T.cells.CD4.memory.resting+T.cells.CD4.memory.activated+T.cells.follicular.helper+T.cells.\nregulatory..Tregs,\nT.cells.gamma.delta = T.cells.gamma.delta,B.cells = B.cells.naive + B.cells.memory,\nNK.cells = NK.cells.resting+NK.cells.activated,\nPlasma.cells = Plasma.cells,Macrophage = Monocytes + Macrophages.M0 + Macrophages.M1 + Macrophages.M2, Dendritic.cells = Dendritic.cells.resting +\nDendritic.cells.activated,\nMast.cells = Mast.cells.resting + Mast.cells.activated,Neutrophils = Neutrophils,\nEosinophils = Eosinophils\nContributors: Andrew Gentles, Vesteinn Thorsson, Alexander J. Lazar, David L. Gibbs\nPrognostic Correlations of Immune Phenotypes\nUnivariate Analysis\nWe \ufb01rst estimated the prognostic impact of immune subtypes on OS and PFI using Kaplan-Meier analysis and computed hazardratios for each immune subtype relative to C1 in unadjusted models and in CoxPH models adjusted for tumor type.\nTo further dissect the prognostic impact of individual gene expression signatures or immune cell types within immune subtypes\nand tumor types, we used the concordance index (CI) ( Pencina and D\u2019Agostino, 2004 ) to correlate the immune signatures and the\ncellular fractions with the outcomes (OS and PFI). The concordance index is de\ufb01ned by the relative frequency of accurate pairwisepredictions of survival over all pairs of patients for which such a meaningful determination can be achieved. Samples with missing\nvalues in the features of interest or the outcomes were excluded from the analysis. Heatmaps were generated in R using the\nheatmap.2 function from the gplots package.\nContributors: Tai-Hsien Ou Yang, Dimitris Anastassiou\nMultivariate Analysis\nElastic net regression was performed on primary tumor data to predict overall survival using glmnet in R ( Friedman et al., 2010 ).\nFeatures tested included subtype scores, CIBERSORT data, immune gene signatures, TCR/BCR richness, neoantigen counts (Indeland SNV), lymphocyte fraction and average cancer testis antigen expression. Data were divided into discovery and validation sets\n(2/3 and 1/3 of the samples, respectively), which were balanced for survival events. The discovery set was further divided into test and\ntraining sets over 50 cross validation cycles across 20 alpha values to select optimal alpha and lambda values for the \ufb01nal model.Optimal parameters (alpha = 0.0022, lambda = 0.0066) were selected on model performance by taking the combination that\nproduced the highest average C-Index. LOESS \ufb01t of the actual outcomes was plotted against the model predictions. The span\nfor the LOESS \ufb01t was optimized by k-fold cross validation, using randomized training sets to \ufb01t the LOESS and testing the rootmean square (RMS) of the residual in a test set. The LOESS span producing the smallest RMS was selected for the \ufb01nal \ufb01t. Con\ufb01-\ndence intervals were generated using bootstrapping with replacement using the optimized span.\nFor each immune subtype, Cox Proportional Hazards (CoxPH) modeling was done to determine whether belonging to that subtype\npredicts patient survival. These data were divided according to cancer tissue type. Bars were colored according to whether there was\na negative or positive association with survival (blue or red outlines, respectively).", "start_char_idx": 0, "end_char_idx": 3901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "835a638d-1256-4e5d-87ee-d9dada6163dd": {"__data__": {"id_": "835a638d-1256-4e5d-87ee-d9dada6163dd", "embedding": null, "metadata": {"page_label": "838", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "36910835-2005-4969-a81c-7d9e3943368e", "node_type": "4", "metadata": {"page_label": "838", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "f68e9bf008ccbf1997585b0285296ec1e4ec311e4f8ed7bcaa0696a04a911f0d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28ae66e6-1c10-4582-83b5-daee0fe3c450", "node_type": "1", "metadata": {"page_label": "838", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "5c2e6fccdf45984973d56eda8f397a7bd420d89aeba67a3dde84f6ae13b0fdf8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f56e5171-9c4b-4b16-b1cd-3e6b7cbfa092", "node_type": "1", "metadata": {}, "hash": "21f9adf939df8e37d8db0afe058a3ff90ffc2d47ce52133eaee2f680aa58f92b", "class_name": "RelatedNodeInfo"}}, "text": "LOESS \ufb01t of the actual outcomes was plotted against the model predictions. The span\nfor the LOESS \ufb01t was optimized by k-fold cross validation, using randomized training sets to \ufb01t the LOESS and testing the rootmean square (RMS) of the residual in a test set. The LOESS span producing the smallest RMS was selected for the \ufb01nal \ufb01t. Con\ufb01-\ndence intervals were generated using bootstrapping with replacement using the optimized span.\nFor each immune subtype, Cox Proportional Hazards (CoxPH) modeling was done to determine whether belonging to that subtype\npredicts patient survival. These data were divided according to cancer tissue type. Bars were colored according to whether there was\na negative or positive association with survival (blue or red outlines, respectively). A False Discovery Rate (FDR) correction using the\nImmunity 48, 812\u2013830.e1\u2013e14, April 17, 2018 e7", "start_char_idx": 3128, "end_char_idx": 3998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f56e5171-9c4b-4b16-b1cd-3e6b7cbfa092": {"__data__": {"id_": "f56e5171-9c4b-4b16-b1cd-3e6b7cbfa092", "embedding": null, "metadata": {"page_label": "839", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "07c5de27-f8a8-4550-8aad-b9b941d9f002", "node_type": "4", "metadata": {"page_label": "839", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "b43a61b4cb30f88df7aa6948285f27a0510d6e6b4f3a452994922812ba3252e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "835a638d-1256-4e5d-87ee-d9dada6163dd", "node_type": "1", "metadata": {"page_label": "838", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "d5b38d0621d715aa3e2420a3f7d1b676705178b175eb6d3c6f967ca0992e8011", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33a7f957-e8dd-4888-a937-84d2680792b1", "node_type": "1", "metadata": {}, "hash": "f32b4c2083b8971dd3546f49e25498821b9d1d9ab57cf76ce46ec035c33e507f", "class_name": "RelatedNodeInfo"}}, "text": "BH method was applied to p values for the addition of stars. If data were signi\ufb01cant after FDR correction red stars were added to show\nsigni\ufb01cance with 1, 2 and 3 stars indicating FDR corrected values below 0.05, 0.01 and 0.001, respectively. Black stars indicate data\nthat were only signi\ufb01cant prior to FDR correction.\nContributors: Dante Bortone, Benjamin Vincent\nCopy Number and DNA Damage Scores\nAll purity, ploidy, LOH and CNV calls used to generate the DNA damage scores used in this study and summarized below weregenerated by the TCGA Aneuploidy AWG using ABSOLUTE ( Carter et al., 2012; Taylor et al., 2018 ). In brief, ABSOLUTE was run,\nusing default parameters, on segmentation data generated from Affymetrix genome-wide human SNP6.0 arrays by hapseg and\non SNV and indel calls from the MC3 variant \ufb01le. All clonality calls for quantifying intratumoral heterogeneity (ITH) were also deter-\nmined by ABSOLUTE, which models tumor copy number alterations and mutations as mixtures of subclonal and clonal componentsof varying ploidy. Speci\ufb01cally, for these analyses, ITH score was de\ufb01ned as the subclonal genome fraction (which measures the frac-\ntion of tumor genome that is not part of the \u2018\u2018plurality\u2019\u2019 clone), as determined from ABSOLUTE.\nScores for copy number burden, aneuploidy, loss of heterozygosity, and homologous recombination de\ufb01ciency (HRD) were\nderived ( Knijnenburg et al., 2018 ). Copy number burden scores frac_altered and n_segs (\u2018\u2018fraction altered,\u2019\u2019 and \u2018\u2018number of seg-\nments,\u2019\u2019 respectively) represent the fraction of bases deviating from baseline ploidy (de\ufb01ned as above 0.1 or below /C00.1 in log2\nrelative copy number (CN) space), and the total number of segments in each sample\u2019s copy number pro\ufb01le, respectively. LOH_n_segand LOH_frac_altered are the number of segments with LOH events and fraction of bases with LOH events, respectively. HRD scoreis a measure quantifying defects in homologous recombination that sums 3 separate metrics of genomic scarring: large (> 15 Mb)\nnon-arm-level regions with LOH, large-scale state transitions (breaks between adjacent segments of > 10 Mb), and subtelomeric re-\ngions with allelic imbalance.\nAneuploidy scores were calculated as the sum total of ampli\ufb01ed or deleted (collectively \u2018\u2018altered\u2019\u2019) arms ( Taylor et al., 2018 ). To call\narm alterations, sample chromosome arms were \ufb01rst strati\ufb01ed by sample tumor type, type of alteration being tested (ampli\ufb01cation or\ndeletion), and chromosome arm (1p, 1q, etc.). The samples are then clustered using an n-component Gaussian Mixture Model \ufb01tted\non that particular arm\u2019s start coordinate, end coordinate, and percentage length of longest joined segment in that arm for each\nsample (segments were joined until the joined segment either encompassed the entire chromosome or achieved > 20% contamina-\ntion by segments not of that alteration type) for each sample. For each clustering, number of clusters nwas chosen from 2-9 based on\nlowest Bayesian Information Criterion. Arms were designated as as altered if they belonged to a cluster of arms with mean fraction\naltered > = 80%. Each segment was designated ampli\ufb01ed, deleted, or neutral based on its copy number relative to the sample\u2019s\nrounded ploidy.\nContributors: Galen F. Gao, Andrew Cherniack\nGenomic Correlations with Immune Phenotypes\nDNA Damage ScoresFor each TCGA subtype containing at least 10 tumors, Spearman correlations were calculated between leukocyte fraction and\nmeasures of DNA alteration. Cohort-averaged correlation between DNA damage scores and leukocyte fraction was computed as\nthe arithmetic mean of the Spearman correlation coef\ufb01cients for each TCGA disease type considered individually.", "start_char_idx": 0, "end_char_idx": 3685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33a7f957-e8dd-4888-a937-84d2680792b1": {"__data__": {"id_": "33a7f957-e8dd-4888-a937-84d2680792b1", "embedding": null, "metadata": {"page_label": "839", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "07c5de27-f8a8-4550-8aad-b9b941d9f002", "node_type": "4", "metadata": {"page_label": "839", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "b43a61b4cb30f88df7aa6948285f27a0510d6e6b4f3a452994922812ba3252e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f56e5171-9c4b-4b16-b1cd-3e6b7cbfa092", "node_type": "1", "metadata": {"page_label": "839", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "b1023e85c3feeee1b7f8fd2cc2da8749106ca9b4e77081597054f8ec26aba6b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64223be2-293b-4c35-8f1b-eb12fc178bed", "node_type": "1", "metadata": {}, "hash": "1f76ab134b776cab76f1d202320fa6a26992ff53adfd88d967ddbb23b94c8cff", "class_name": "RelatedNodeInfo"}}, "text": "For each clustering, number of clusters nwas chosen from 2-9 based on\nlowest Bayesian Information Criterion. Arms were designated as as altered if they belonged to a cluster of arms with mean fraction\naltered > = 80%. Each segment was designated ampli\ufb01ed, deleted, or neutral based on its copy number relative to the sample\u2019s\nrounded ploidy.\nContributors: Galen F. Gao, Andrew Cherniack\nGenomic Correlations with Immune Phenotypes\nDNA Damage ScoresFor each TCGA subtype containing at least 10 tumors, Spearman correlations were calculated between leukocyte fraction and\nmeasures of DNA alteration. Cohort-averaged correlation between DNA damage scores and leukocyte fraction was computed as\nthe arithmetic mean of the Spearman correlation coef\ufb01cients for each TCGA disease type considered individually.\nContributors: Galen F. Gao, Vesteinn Thorsson\nCopy Number Variation\nAmpli\ufb01cation and deletion were de\ufb01ned as follows using a PanCan GISTIC2.0 run on the samples after performing In silico\nAdmixture Removal (ISAR) ( Zack et al., 2013 ) on the relative copy number values using the ABSOLUTE-estimated purity and\nploidy values of each sample ( Mermel et al., 2011 ). For each tumor sample, the median copy-ratio for each chromosome arm is\ncalculated. For each locus, a sample is called deep ampli\ufb01cation if the value is +2 (i.e., higher than the maximum of these arm values),\nwhile a /C02 (deep deletion) is a value less than the minimum of these values. Shallow (+/ /C01) ampli\ufb01cations and deletions correspond\nto alterations between 0.1 relative copy number and the thresholds for deep alterations.\nTo determine correlations between gene ampli\ufb01cation (GISTIC2.0 CN = 1 or CN = 2 as described above) and LF, expected mean\nleukocyte fraction for each gene was computed as the average of the mean leukocyte fractions for each individual TCGA disease typeweighted by the number of \u2018\u2018ampli\ufb01ed\u2019\u2019 samples present in each disease type. One-sample t tests were then used with BH multiple\nhypothesis correction to assess the signi\ufb01cance of the difference between the observed mean LF among \u2018\u2018ampli\ufb01ed\u2019\u2019 samples and\nthis expected mean LF. We report both this difference and its signi\ufb01cance. This analysis was then repeated for \u2018\u2018deleted\u2019\u2019 genes(GISTIC2.0 CN = /C01o rC N= /C02 as described above). Furthermore, for each gene, we similarly computed signi\ufb01cances of differences\nof CIBERSORT-estimated relative immune cell subtype levels from their expected levels \ufb01rst in \u2018\u2018ampli\ufb01ed\u2019\u2019 and then in \u2018\u2018deleted\u2019\u2019\nsamples in order to identify the effects of copy number ampli\ufb01cation and deletion respectively on immune in\ufb01ltrate compositionwhile controlling for cancer disease type. Genes localized on the X chromosome were disregarded for all analyses.\nContributors: Galen F. Gao, Andrew Cherniack\nDriver Gene Mutations\nWe focused our analysis on genes identi\ufb01ed as drivers by the TCGA PanCancer Atlas Driver Mutation Working Group (the CGATlist; TCGA Research Network, \u2018\u2018Comprehensive Discovery and Characterization of Driver Genes and Mutations in Human Cancers,\u2019\u2019\nunpublished data) that were identi\ufb01ed as 1) having 10 or more mutations overall and 2) mutated in two or more tissues. For each gene\ne8Immunity 48, 812\u2013830.e1\u2013e14, April 17, 2018", "start_char_idx": 2883, "end_char_idx": 6113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64223be2-293b-4c35-8f1b-eb12fc178bed": {"__data__": {"id_": "64223be2-293b-4c35-8f1b-eb12fc178bed", "embedding": null, "metadata": {"page_label": "840", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8cb669f5-65e6-49d2-8778-066c0becf55d", "node_type": "4", "metadata": {"page_label": "840", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "72da08ba58f3b5aa18073fe4a9dcbe7e5f941cf834d48d1f80ff9ff12381618f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33a7f957-e8dd-4888-a937-84d2680792b1", "node_type": "1", "metadata": {"page_label": "839", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "73ef9d132817a5c639c76a54342ffc0ccea7e2ba044ad5415b85ec5fde1e8b46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a9f58b3-c71e-4352-94d4-151f16b8a630", "node_type": "1", "metadata": {}, "hash": "f4918a94c19985b24d57fb1d72ef326b7844c074d116347f9d2a5465ba10063a", "class_name": "RelatedNodeInfo"}}, "text": "that \ufb01t these criteria, we created a three-dimensional matrix contingency table using the mutation status of each sample, its immune\nsubtype and its cancer type. We next used the Cochran-Mantel-Haenszel Chi-square test function from the R statistical package to\ntest whether the immune subtype and the genotype are independent. We kept all the associations that had a FDR below 0.1 after BH\ncorrection. Finally, we used Fisher\u2019s test to \ufb01nd which pairs of driver mutations and immune subtypes were statistically signi\ufb01cant andtheir associated odds ratio. We repeated the analysis using only the subset of mutations in each driver gene that are predicted to be\noncogenic according to the above source to ensure that we would not miss associations that might be weaker due to the presence of\npassenger mutations in driver genes.\nWe used domainXplorer to identify driver genes and mutations that correlate with the leukocyte fraction of the tumor sample. The\nalgorithm uses a linear model that takes into account potential biases caused by differences in the immune responses between the\ntissues of origin of the tumors, the gender of the patient, the total number of missense mutations in the sample or the patient\u2019s age as\ncovariates. The model is:\nLF=b\n0+b1T+b2N+b3D\nwhere LFis the leukocyte fraction of each sample, Tis the tissue of origin, Nthe total number of immunogenic mutations in the\nsample and Dis a binary variable showing whether the sample has a mutation in the driver gene. To correct for multiple testing,\nthe BH method is applied to p values of the Dfactor from the ANOVA test of each driver event. We repeated the analysis using\nonly the subset of mutations in each driver gene that are predicted to be oncogenic according to the TCGA Driver Genes Analysis\nWorking Group to ensure that we would not miss associations that might be weaker due to the presence of passenger mutationsin driver genes.\nContributors: Eduard Porta-Pardo and Adam Godzik\nGenomic Alterations in Signaling PathwaysTo study correlation of pathway aberrations with the leukocyte fraction and other immune composition scores, we used membership\nof the eight signaling pathways curated by the TCGA PanCancer Atlas Pathway subgroup ( Sanchez-Vega et al., 2018 ). The eight\npathways are PI3K signaling, RTK/RAS signaling, WNT signaling, TGF- bsignaling, NOTCH signaling, HIPPO signaling, MYC\nsignaling, and Mismatch Repair machinery (MMR). For each pathway, samples from each of 30 tumor types were divided intotwo groups of altered and intact cases based on acquisition of non-silent or frameshift mutations, heterozygous or homozygous\ndeletions, or ampli\ufb01cations, in at least one member of the pathway. The association of the genomically-altered pathways in each\ntumor type or patients subgroup with each CIBERSORT immune estimated score was calculated by a two-sided Student t-Test,\nassuming unequal variances (Welch\u2019s t test). Associations were assumed signi\ufb01cant if their BH p-value, adjusted for multiple com-\nparisons, were below 0.05. Tumor types with less than 5 samples in each of the comparison arms were excluded from association\nstudies. To ascertain whether the observed associations are derived by speci\ufb01c molecular subtypes, we repeated this analysis usingthe molecular subtypes previously identi\ufb01ed by the TCGA tumor-speci\ufb01c studies instead of tumor tissue of origin. The same\napproach was used to discover the association of tumor types or immune subgroups with 6 aggregated CIBERSORT estimates\n(using Aggregate 1 above).\nContributor: Farshad Farshidfar\nGenetic Ancestry\nPrincipal Components AnalysisWe evaluated the relationship between genetic ancestry and immune signatures in 9003 samples from which genome wide array\ngenotype data from normal blood and immune phenotypes were available. To infer genetic ancestry, we used the germline genetic\ndata (Affymetrix 6.0 normal). We downloaded the cel \ufb01les from the TCGA datasets and used Affymetrix software to make genotypecalls. Genotype calls were made to human genome Build37, forward strand. We used EIGENSOFT ( Price et al., 2006 ) to perform\nprincipal components analysis on the genotype data. We inferred how the principal components related to continental ancestry\nby comparing self report of race/ethnicity to the principal components.", "start_char_idx": 0, "end_char_idx": 4296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a9f58b3-c71e-4352-94d4-151f16b8a630": {"__data__": {"id_": "6a9f58b3-c71e-4352-94d4-151f16b8a630", "embedding": null, "metadata": {"page_label": "840", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8cb669f5-65e6-49d2-8778-066c0becf55d", "node_type": "4", "metadata": {"page_label": "840", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "72da08ba58f3b5aa18073fe4a9dcbe7e5f941cf834d48d1f80ff9ff12381618f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64223be2-293b-4c35-8f1b-eb12fc178bed", "node_type": "1", "metadata": {"page_label": "840", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "5c7719918196faaf5b982dc014f1d64ddb2349dacbb0d94a45a002f1d6032c3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5117bc10-bc5f-4d7b-bd02-58e517f2da48", "node_type": "1", "metadata": {}, "hash": "d6bd993299b16c74c8899b3c3d96c3da8b7fd335435ad2f43c0082d95733e7f6", "class_name": "RelatedNodeInfo"}}, "text": "Contributor: Farshad Farshidfar\nGenetic Ancestry\nPrincipal Components AnalysisWe evaluated the relationship between genetic ancestry and immune signatures in 9003 samples from which genome wide array\ngenotype data from normal blood and immune phenotypes were available. To infer genetic ancestry, we used the germline genetic\ndata (Affymetrix 6.0 normal). We downloaded the cel \ufb01les from the TCGA datasets and used Affymetrix software to make genotypecalls. Genotype calls were made to human genome Build37, forward strand. We used EIGENSOFT ( Price et al., 2006 ) to perform\nprincipal components analysis on the genotype data. We inferred how the principal components related to continental ancestry\nby comparing self report of race/ethnicity to the principal components. High values of principal component 1 (PC1) were foundamong African Americans, high values of PC2 were found among Asians, high values of PC3 were found among Hispanics and Native\nAmericans, and low values for PC1, PC2 and PC3 were found among Whites. We clustered genetic ancestry into 4 ancestry clusters\n(AC1-AC4) by performing K means clustering on genotype principal components PC1, PC2 and PC3.Correlation with Immune PhenotypesWe then tested the association between PC1, PC2 and PC3 and phenotypes: Leukocyte Fraction, log transformed PD-L1\nexpression, and CIBERSORT immune cell proportions by combined using Aggregate1 (see \u2018\u2018Immune cellular fraction estimates\u2019\u2019\nabove) using linear regression models. In models which included all cancers, we adjusted for cancer type as a categorical model\nin the regression model.\nCorrelation with SNPs\nTo perform association analyses with single nucleotide polymorphisms (SNPs) at the PDL1 locus, we imputed the genotype data\nusing the Haplotype Reference Consortium as a reference ( McCarthy et al., 2016 ). We de\ufb01ned the region in cisas 1 megabase\n(500 kilobases upstream and 500 kilobases downstream) around the transcriptional start side of PDL1 . We tested the association\nof all SNPs that had imputation quality R2>0.5 and allele frequency > 0.01 using linear regression. Each SNP was tested using an\nadditive model and we adjusted for genetic ancestry using PC1-PC10 and also adjusted for cancer subtype as a categorical variable\nImmunity 48, 812\u2013830.e1\u2013e14, April 17, 2018 e9", "start_char_idx": 3524, "end_char_idx": 5823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5117bc10-bc5f-4d7b-bd02-58e517f2da48": {"__data__": {"id_": "5117bc10-bc5f-4d7b-bd02-58e517f2da48", "embedding": null, "metadata": {"page_label": "841", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e3e4d821-4c75-4461-aa00-8c4540288cdf", "node_type": "4", "metadata": {"page_label": "841", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "36696a27ec51b33f1fa89342cf62294aacf50c70127f6da569269fd3bebdca95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a9f58b3-c71e-4352-94d4-151f16b8a630", "node_type": "1", "metadata": {"page_label": "840", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "99e3f2f4be658982774dc7eb9666a7d6a8822ce8036760b96c8d61c1fde751ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d7e58c2-790c-4cff-a9a8-caeefe9662a1", "node_type": "1", "metadata": {}, "hash": "379eb3728fe12031e8870aa61839bcf5c08cb013dd3f3c6cb58255b7a8e5a22c", "class_name": "RelatedNodeInfo"}}, "text": "in the model. To determine signi\ufb01cance level for SNP associations we used a method which calculated the effective number of in-\ndependent SNPs at the locus ( Li et al., 2012 ) and derived a threshold of 9.3x10/C05.\nContributors: Elad Ziv, Donglei Hu, Karen Wong\nIdenti\ufb01cation of Neoantigens\nHLA typing with OptiType\nHLA class I typing of samples (raw RNA-Seq from 8872 samples and aligned reads from 715 samples) was performed on the SevenBridges Cancer Genomics Cloud using a Common Work\ufb02ow Language (CWL) description of the OptiType tool (version 1.2) ( Szolek\net al., 2014 ). The aligned RNA-Seq samples were \ufb01rst converted to raw sequences using a CWL description of the Picard SamtoFastq\ntool (version 1.140). The reads from each raw RNA-Seq sample were \ufb01rst aligned to the HLA class I database using a CWL description\nof the yara aligner (version 0.9.9) ( Siragusa et al., 2013 ) with its error rate parameter set to 3%. Next, the CWL description of OptiType\nwas used to compute the HLA class I types for the sample. OptiType was run under its default parameters for RNA sequencing data\nusing the GLPK linear programming solver and the CBC linear programming solver in samples where the GLPK solver failed. In order\nto validate the typing results from OptiType, we compared the HLA class I four-digit types obtained from the software PolySolver onTCGA Whole Exome Sequencing data samples ( Shukla et al., 2015 ). For the 5222 patient cases shared by the two studies,\napproximately 90% of the typing calls were completely concordant for all HLA-A, HLA-B or HLA-C alleles, whereas completely\ndiscordant calls were found in less than 1.5% of cases for each of the genes. The HLA typing results are available at https://\nportal.gdc.cancer.gov/ .\nContributors: Raunaq Malhotra, Alexander Krasnitz\nNeoantigen Prediction from SNVs\nPotential neoantigenic peptides were identi\ufb01ed using NetMHCpan v3.0 ( Nielsen and Andreatta, 2016 ), based on HLA types derived\nfrom RNA-seq using OptiType as above. In brief, using the HLA calls from OptiType, for each sample, all pairs of MHC and minimal\nmutant peptide were input into NetMHCpan v3.0 using default settings. NetMHCpan will automatically extract all 8-11-mer peptides\nfrom a minimal peptide sequence and predict binding for each peptide-MHC pair. After computation, the results were parsed to onlyretain peptides which included the mutated position. Peptides containing amino acid mutations were identi\ufb01ed as potential antigens\non the basis of a predicted binding to autologous MHC (IC\n50< 500 nM) and detectable gene expression meeting an empirically\ndetermined threshold of 1.6 transcripts-per-million (TPM). This threshold was selected in order to divide the bimodal distributionin the expression data.\nSpeci\ufb01cally, somatic nonsynonymous coding single nucleotide variants were extracted from the MC3 variant \ufb01le\n(mc3.v0.2.8.CONTROLLED.maf) with the following \ufb01lters: FILTER in \u2018\u2018PASS,\u2019\u2019 \u2018\u2018wga,\u2019\u2019 \u2018\u2018native_wga_mix\u2019\u2019; NCALLERS > 1; barcodein whitelist where do_not_use = False; Variant_Classi\ufb01cation = \u2018\u2018Missense_Mutation\u2019\u2019; and Variant_Type = \u2018\u2018SNP.\u2019\u2019 For each SNV,the Ensembl protein reference sequence was obtained, and the minimal peptide encompassing the mutation site plus 10 amino acids\nup and downstream of the mutation site was extracted (21 aa long peptide). If the mutation occurred within 10 amino acids of the N- or\nC-terminal end of the protein, all available sequence between the mutation and start/end of the protein was taken, resulting in aminimal peptide shorter than 21 aa. The variant position within the minimal peptide was recorded, and the mutation was applied\nto the minimal peptide, resulting in a mutant minimal peptide.", "start_char_idx": 0, "end_char_idx": 3696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d7e58c2-790c-4cff-a9a8-caeefe9662a1": {"__data__": {"id_": "7d7e58c2-790c-4cff-a9a8-caeefe9662a1", "embedding": null, "metadata": {"page_label": "841", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e3e4d821-4c75-4461-aa00-8c4540288cdf", "node_type": "4", "metadata": {"page_label": "841", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "36696a27ec51b33f1fa89342cf62294aacf50c70127f6da569269fd3bebdca95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5117bc10-bc5f-4d7b-bd02-58e517f2da48", "node_type": "1", "metadata": {"page_label": "841", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "8a9e6f8b3c54b9e527770e2dd3e29fb9740751220667da5b05365a74ad6987e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e779041b-5988-4813-b94e-0d12a91b5cc9", "node_type": "1", "metadata": {}, "hash": "b6c3e6903e3d9cf1ebd0e14d6e4917a04f985077ade17ee1e012ea8f34d3d7fd", "class_name": "RelatedNodeInfo"}}, "text": "If the mutation occurred within 10 amino acids of the N- or\nC-terminal end of the protein, all available sequence between the mutation and start/end of the protein was taken, resulting in aminimal peptide shorter than 21 aa. The variant position within the minimal peptide was recorded, and the mutation was applied\nto the minimal peptide, resulting in a mutant minimal peptide. Variation in sequencing coverage and tumor purity require careful\nconsideration in order to mitigate the risk of impacting mutation calls and on pMHC, and prior to pMHC calling, sequencing datawas subjected to rigorous harmonization efforts, performed by the PanCancer MC3 Consortium( Ellrott et al., 2018 ).\nContributors: Scott D. Brown, Robert A. Holt\nNeoantigen Prediction from IndelsSomatic indel variants were extracted from the MC3 variant \ufb01le (mc3.v0.2.8.CONTROLLED.maf) with the following \ufb01lters: FILTERin \u2018\u2018PASS,\u2019\u2019 \u2018\u2018wga,\u2019\u2019 \u2018\u2018native_wga_mix\u2019\u2019 (with no combination with other tags); NCALLERS > 1; barcode in whitelist where do_not_use =\nFalse; Variant_Classi\ufb01cation = \u2018\u2018Frame_Shift_Ins,\u2019\u2019 \u2018\u2018Frame_Shift_Del,\u2019\u2019 \u2018\u2018In_Frame_Ins,\u2019\u2019 \u2018\u2018In_Frame_Del,\u2019\u2019 \u2018\u2018Missense_Mutation,\u2019\u2019\n\u2018\u2018Nonsense_Mutation\u2019\u2019; and Variant_Type = \u2018\u2018INS,\u2019\u2019 \u2018\u2018DEL.\u2019\u2019 For each Indel, the downstream protein sequence was obtained usingVEP v87 (Ensembl Variant Effect Predictor) ( McLaren et al., 2016 ) using default settings.\nUsing 9-mer peptides extracted from VEP downstream protein sequences and the HLA calls from OptiType, for each sample,\nbinding for each pair of mutant peptide-MHC were predicted using pVAC-Seq v4.0.8 pipeline ( Hundal et al., 2016 ) with NetMHCpan\nv3.0 using default settings, of which an IC\n50binding score threshold 500 nM was used to report the predicted binding epitopes as\nneoantigens.\nContributors: Nam Sy Vo, Ken Chen\nPrognostic Associations\nCox models with predicted neoantigen number (including SNV and indel neoantigens) binned into high and low groups across all\npossible neoantigen count thresholds and including as covariates patient age, gender, leukocyte fraction, and tumor type (ifapplicable) were used to evaluate PFI for each tumor type or immune subtype, and HR for each predicted neoantigen count thresholdcalculated.\nContributor: Scott D. Brown\ne10 Immunity 48, 812\u2013830.e1\u2013e14, April 17, 2018", "start_char_idx": 3318, "end_char_idx": 5606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e779041b-5988-4813-b94e-0d12a91b5cc9": {"__data__": {"id_": "e779041b-5988-4813-b94e-0d12a91b5cc9", "embedding": null, "metadata": {"page_label": "842", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fad20180-fd1e-4982-b95e-9f6797450289", "node_type": "4", "metadata": {"page_label": "842", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "b7928573e93cc353afc3fd4018a632b6582d2c78741daf8b5f525ee4010109e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d7e58c2-790c-4cff-a9a8-caeefe9662a1", "node_type": "1", "metadata": {"page_label": "841", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "0700c1d42514372f6108150fe7c5b94e83117596c97229d2e8f8a33325f9a551", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14007e47-4b81-4439-b2ab-b1dd8fda12c5", "node_type": "1", "metadata": {}, "hash": "062bc02a3ffd3d08a033efc9e16593531fa8b57a3d9fab671afdde401a2448b1", "class_name": "RelatedNodeInfo"}}, "text": "Genomic Viral Content Analysis\nViral Read Counts\nViral sequence libraries (\ufb01lter sets) were constructed for known tumor viruses EBV, HBV, and HPV. Scans were performed using\nBioBloom Tools ( Chu et al., 2014 ) on the ISB Cancer Genomics Cloud, reporting the number of hits and misses per \ufb01lter set as\nwell as shared and unique reads. For each virus and each sample, a score of normalized reads per million (NRPM) was de\ufb01ned\nas 106times the number of hits over the total reads in the sample. NRPM Thresholds HPV: 10, EBV: 5, HBV; 5. The NRPM values\nare provided in Table S1 .\nCorrelation with Immune ResponseViral read counts were correlated with expression signatures see (\u2018\u2018Immune-Expression Signatures\n\u2019\u2019),CIBERSORT fractions (both\noriginal and aggregated), expression of key immunotherapy targets (PD-L1,CTLA4,PD-1), Th1/Th2/Th17 signatures, DNA damage\nscores (AS,LOH), ITH, TCR/BCR diversity, stromal fraction and LF. Regression of read counts with these immune characterizationswas performed, using immune subtype as a covariate, and resulting p values were corrected for multiple testing using the BH\nmethod. For HPV, tumor types STAD, ESCA, LAML, and OV were excluded, due to evidence of possible false positives.\nContributors: Sheila M. Reynolds, Varsha Dhankani, Margaret Gulley, Reanne Bowlby, Yusanne Ma, Payal Sipahimalani, Karen\nMungall, Chandra Sekhar Pedamallu, Susan Bullman, Akinyemi I. Ojesina, Denise Wolf, Vesteinn Thorsson\nT- and B- Cell Receptor Analysis\nTCR Inference from Tumor RNA-Seq DataIdenti\ufb01cation of TCR CDR3 sequences from T cells present in the sequenced tumor sections was performed using MiTCR v1.0.3\n(Bolotin et al., 2013 ), and previously described parameters to optimize extraction from RNA-seq datasets ( Brown et al., 2015 ). Brie\ufb02y,\npaired-end fastq \ufb01les were concatenated into a single \ufb01le and run through MiTCR using the appropriate parameter set for thesequence read length as described in Brown et al. Runs were performed on the ISB Cancer Genomics Cloud. TCR diversity scores\n(Shannon Entropy, Evenness, and Richness) are provided in Table S1 .\nContributors: Scott D. Brown, Sheila M. Reynolds\nPrognostic Impact of TCR Diversity Scores\nCox models for TCR diversity within each TCGA tumor type were generated with Shannon entropy scores binned into high and low\ngroups across all possible thresholds and including as covariates patient age, gender, leukocyte fraction, and used to evaluate PFI foreach tumor type, and HR for each predicted neoantigen count threshold calculated. Due to the effect of read length on TCR\nextraction, 76 bp datasets were used for each TCGA tumor type or immune subtype if available, otherwise 50 bp datasets were used.\nContributor: Scott D. Brown\nBCR Inference from Tumor RNA-Seq DataWe used the VDJer tool ( Mose et al., 2016 ), running on the ISB Cancer Genomics Cloud, to reconstruct the immunoglobulin heavy\nchain for all tumor samples. Paired end mRNASeq FASTQ data were aligned to human reference genome hg38 using STAR version\n2.4.2a ( Dobin et al., 2013 ). FASTQ \ufb01les containing more than one read length were truncated to the shorter length. STAR was con\ufb01g-\nured to emit unmapped reads within the output BAM \ufb01les and samtools was used to generate BAM indices. An estimated insert size\nfor each sample was calculated by using bwa version 0.7.12 ( Li and Durbin, 2009 ) to align the \ufb01rst 1,000,000 read pairs of each\nsample to a reference human transcriptome and identifying the median bwa computed insert length. BCR heavy chain contigsand read alignments were generated using V\u2019DJer version 0.12 run in standard mode. RSEM version 1.2.21 ( Li and Dewey, 2011 )\nwas then used to quantify the BCR contigs.", "start_char_idx": 0, "end_char_idx": 3687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14007e47-4b81-4439-b2ab-b1dd8fda12c5": {"__data__": {"id_": "14007e47-4b81-4439-b2ab-b1dd8fda12c5", "embedding": null, "metadata": {"page_label": "842", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fad20180-fd1e-4982-b95e-9f6797450289", "node_type": "4", "metadata": {"page_label": "842", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "b7928573e93cc353afc3fd4018a632b6582d2c78741daf8b5f525ee4010109e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e779041b-5988-4813-b94e-0d12a91b5cc9", "node_type": "1", "metadata": {"page_label": "842", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "a71d623805710a16e8730968866dd1c3bbcf36a8c7ea9791c1a9ad1dd4cb7061", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3445ce62-8f52-4027-b311-6f6b3a1eb30e", "node_type": "1", "metadata": {}, "hash": "dcc59e618a56183f14becd162a40852b47721a84e59de56190dc7719a2b3942c", "class_name": "RelatedNodeInfo"}}, "text": "FASTQ \ufb01les containing more than one read length were truncated to the shorter length. STAR was con\ufb01g-\nured to emit unmapped reads within the output BAM \ufb01les and samtools was used to generate BAM indices. An estimated insert size\nfor each sample was calculated by using bwa version 0.7.12 ( Li and Durbin, 2009 ) to align the \ufb01rst 1,000,000 read pairs of each\nsample to a reference human transcriptome and identifying the median bwa computed insert length. BCR heavy chain contigsand read alignments were generated using V\u2019DJer version 0.12 run in standard mode. RSEM version 1.2.21 ( Li and Dewey, 2011 )\nwas then used to quantify the BCR contigs. The RSEM reference was generated by running rsem-prepare-reference against the\nBCR contig fasta \ufb01le and quanti\ufb01cation was performed using rsem-calculate-expression. Expression counts were normalized tothe total mRNASeq count for each sample. Isotypes for each contig were identi\ufb01ed by mapping the trailing 48 bases to the hg38reference and using the resultant alignment coordinates to call the isotype. IMGT/HighV-Quest ( Lefranc et al., 2009 )(http://www.\nimgt.org/IMGTindex/IMGTHighV-QUEST.php)was used to identify V and J gene segments, CDR3 sequence and V region identity\nfor each contig. IgH diversity scores (Shannon Entropy, Evenness, and Richness) are provided in Table S1 .\nContributors: Joel Parker, Lisle E. Mose, Sheila M. Reynolds, Benjamin Vincent\nImmunomodulator Identi\ufb01cation and Analysis\nImmunomodulator Compilation\nA list of immunomodulatory genes (Table S6) was curated from a literature review performed by immuno-oncology experts within the\nTCGA immune response working group, who reviewed each entry and con\ufb01rmed the immunomodulatory function of each gene,resulting in a list of 78 immunomodulators (IMs).\nIM Gene Expression\nCorresponding mRNA expression was unavailable for 3 of these IMs (HLA-DRB3, HLA-DRB4, KIR2DL2), which were excluded fromsubsequent analysis. Median expression levels (used to summarize expression in each subtype) were computed only using sampleswith non-missing values.\nPrior to differential expression and miRNA correlation analysis for IMs, any genes with missing expression values in at least one\nsample were removed; any samples for which LF or subtype designation were unavailable were also excluded. The resultingexpression data included 67 genes and 9,058 samples. PCA of all normalized expression values (log10(expression + 1)) was per-\nformed to check for batch or confounding effects.\nImmunity 48, 812\u2013830.e1\u2013e14, April 17, 2018 e11", "start_char_idx": 3040, "end_char_idx": 5577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3445ce62-8f52-4027-b311-6f6b3a1eb30e": {"__data__": {"id_": "3445ce62-8f52-4027-b311-6f6b3a1eb30e", "embedding": null, "metadata": {"page_label": "843", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "39b1baff-bd7a-4f97-881e-0efa18ec67de", "node_type": "4", "metadata": {"page_label": "843", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "4f09124cc93ffa21f3b80bc922c064e147d15d0883cf1bf2623f621c2cc8d4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14007e47-4b81-4439-b2ab-b1dd8fda12c5", "node_type": "1", "metadata": {"page_label": "842", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "64856653b6e13885f81c15aa0ca43731d9a7b0e6d4d62bd8a524ae5aaedaee41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39177dbc-01da-4022-8155-dbfd35a56c6b", "node_type": "1", "metadata": {}, "hash": "880e4755aae7e283a3aea97ada37328528f06ab005f456132bf381a0046374ec", "class_name": "RelatedNodeInfo"}}, "text": "To examine differences in IM expression across subtypes, we performed a Kruskal-Wallis test for each gene expression level with\nrespect to subtype; p values were adjusted for for multiple testing based on the BH method. Based on the observation from PCA that\nIM gene expression is correlated with LF within subtypes, we controlled for differences in LF by calculating residuals for expression\nwith respect to LF. We recomputed Kruskal-Wallis results for expression residuals and found all genes to remain signi\ufb01cant.Expression Correlation with DNA Methylation\nTo study the relationship between gene expression and DNA methylation of immunomodulators, we mapped DNA\nmethylation probes to genes using bioconductor packages IlluminaHumanMethylation450kanno.ilmn12.hg19 and IlluminaHuman\nMethylation27kanno.ilmn12.hg19 , containing manifests and annotation for Illumina\u2019s 450k and 27k arrays. For a given IM\ngene, Spearman correlation between gene expression and each corresponding gene-associated probe was evaluated, within\neach immune subtype. Results were then \ufb01ltered to retain sets of probes with similarly signed correlations, to reduce noise and in-\ncrease robustness of signal. The \ufb01lter produces probe-clusters, where probes are uniquely assigned a cluster, are within 10KB andhave the same correlation sign. Single correlation values per probe-cluster were found by averaging probes. In cases where multiple\nprobe clusters were associated with a single gene, the corresponding correlation value were averaged to yield the single correlation\nvalue reported in Figure 6 A.\nIM Copy Number\nUsing output from a PanCan GISTIC2.0 run on ISAR-corrected Affymetrix genome-wide human SNP6.0 array data, deep\nampli\ufb01cations, shallow ampli\ufb01cations, non-alterations, shallow deletions, and deep deletions of each immunomodulator genewere called as described in \u2018\u2018Genomic Correlations with Immune Phenotype\n\u2019\u2019 above for 8461 tumors that both were immune sub-\ntyped and had ABSOLUTE purity and ploidy calls. Proportions of samples with each type of copy number alteration were then\ncompared across immune subtypes. We also report the difference between observed and expected frequencies of ampli\ufb01cation\nfor each immunomodulator gene in each immune subtype, where the expected frequency is the overall frequency of ampli\ufb01cationamong all 8461 tumors. This difference calculation was then repeated for immunomodulator deletions.\nIM Gene Expression Correlation with miRNA\nWe examined the association of microRNA (miRNA) expression with immune populations and signatures across all immune sub-types. The normalized, batch corrected expression levels of 743 miRNA genes were tested for signi\ufb01cant correlation (Spearman,\nBH corrected p value < 0.05) within each subtype against mRNA expression of IM genes. Predicted binding targets for miRNA genes\nwere obtained from version 5.0 of the miRDB database ( http://www.mirdb.org/ ) and mapped to IMs based on HGNC gene symbol.\nImmune Phenotype Correlation with miRNA & IMs\nWe examined the association of microRNA (miRNA) expression with immune populations and signatures across all tumor types. The\nnormalized, batch corrected expression levels of 743 miRNA genes were tested for signi\ufb01cant correlation (Spearman, BH correctedp value < 0.05) within each tumor group against 95 different features from several other working group datasets and observations:total leukocyte fraction (based on DNA methylation assays); immune in\ufb01ltrate subpopulations estimated by CIBERSORT (9 adaptive\nimmune cell types, 13 innate immune cell types); and mRNA expression of immune-related genes (22 checkpoint stimulator genes,\n34 checkpoint inhibitor genes, 5 MHC class I genes, 9 MHC class II genes, and 2 cytolytic markers). Hematologic (LAML, THYM) andlymphatic (LAML) cancers were excluded from all correlations.\nContributors: Christopher Plaisier, Benjamin Vincent, Galen F. Gao, David L. Gibbs, Vesteinn Thorsson, James A. Eddy\nThe Cell-to-Cell Communication Network\nA network of documented ligand-receptor, cell-receptor, and cell-ligand pairs ( Ramilowski et al., 2015 ) was retrieved from the\nFANTOM5 resource at ( http://fantom.gsc.riken.jp/5/suppl/Ramilowski_et_al_2015/ ).", "start_char_idx": 0, "end_char_idx": 4195, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39177dbc-01da-4022-8155-dbfd35a56c6b": {"__data__": {"id_": "39177dbc-01da-4022-8155-dbfd35a56c6b", "embedding": null, "metadata": {"page_label": "843", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "39b1baff-bd7a-4f97-881e-0efa18ec67de", "node_type": "4", "metadata": {"page_label": "843", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "4f09124cc93ffa21f3b80bc922c064e147d15d0883cf1bf2623f621c2cc8d4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3445ce62-8f52-4027-b311-6f6b3a1eb30e", "node_type": "1", "metadata": {"page_label": "843", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "51a07cb70e22982415e9cfc165d996006a4a603e76bfe8874eb532428c67aec9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f72a469-7c1a-4904-93f9-ee7c7409d029", "node_type": "1", "metadata": {}, "hash": "5d8fc0682795732a2bdbf7dd67f1054a1c3651677095687f38a24b49d76b9db2", "class_name": "RelatedNodeInfo"}}, "text": "Hematologic (LAML, THYM) andlymphatic (LAML) cancers were excluded from all correlations.\nContributors: Christopher Plaisier, Benjamin Vincent, Galen F. Gao, David L. Gibbs, Vesteinn Thorsson, James A. Eddy\nThe Cell-to-Cell Communication Network\nA network of documented ligand-receptor, cell-receptor, and cell-ligand pairs ( Ramilowski et al., 2015 ) was retrieved from the\nFANTOM5 resource at ( http://fantom.gsc.riken.jp/5/suppl/Ramilowski_et_al_2015/ ).\nCIBERSORT cell types are more granular than the immune cells in FANTOM5 and were therefore summed to yield estimates for\nFANTOM5 immune cell abundances, as de\ufb01ned above in \u2018\u2018Immune cellular fraction estimates\n\u2019\u2019 Aggregate 2. For example, FANTOM5\nCD19 B cell estimates are the combination of CIBERSORT naive and memory B cells. This network was augmented with additional\nknown interactions of immumodulators, and only ligand-receptor edges that contained at least one cell or one immune modulatorwere retained, yielding a \u2018scaffold\u2019 of possible interactions.\nFrom the scaffold of possible interactions, interactions were identi\ufb01ed that could be playing a role within the TME in each subtype\nas follows. Cellular fractions were binned into tertiles (low, medium, high), as were gene expression values for ligands and receptors,yielding ternary values for all \u2018nodes\u2019 in the network. The binning was performed over all TCGA samples. In subsequent processing,\nnodes and edges were treated uniformly in processing, without regard to type (cell,ligand,receptor). From the scaffold, interactions\npredicted to take place in the TME were identi\ufb01ed \ufb01rst by a criterion for the nodes to be included (\u2018present\u2019 in the network), then by acriterion for inclusion of edges, potential interactions. For nodes, if at least 66% of samples within a subtype map to mid or high value\nbins, the node is entered into the subtype-network. An edge present in the scaffold network between any two nodes is then evaluated\nfor inclusion. A contingency table is populated for the ternary values of the two nodes, over all samples in the subtype, and aconcordance versus discordance ratio (\u2018\u2018concordance score\u2019\u2019) is calculated for the edge in terms of the values of ((high,high)+(low,low))/((low,high)+(high,low)). Edges were retained with concordance score > 2.9, set based on evaluation of quantile\ndistributions.\nContributors: David L. Gibbs, Vesteinn Thorsson, Ilya Shmulevich\ne12 Immunity 48, 812\u2013830.e1\u2013e14, April 17, 2018", "start_char_idx": 3738, "end_char_idx": 6194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f72a469-7c1a-4904-93f9-ee7c7409d029": {"__data__": {"id_": "1f72a469-7c1a-4904-93f9-ee7c7409d029", "embedding": null, "metadata": {"page_label": "844", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3303ff81-498c-471b-9453-c65f30d41ce2", "node_type": "4", "metadata": {"page_label": "844", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "146a8109ddcc04b1d4f8bd6397e07b143ebaf38356cbc1c5cdc4642732c7832a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39177dbc-01da-4022-8155-dbfd35a56c6b", "node_type": "1", "metadata": {"page_label": "843", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "6daf58966a6674b9657d313bf14d94f9afee9f0ae3bbd780a624ed321b987ff5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbedaa9b-af8a-42c0-90ad-c5d00173dc63", "node_type": "1", "metadata": {}, "hash": "37357b1fdd16c7171a5a61924368449ef0ca539f8d067f6a2eef35cd8269d54a", "class_name": "RelatedNodeInfo"}}, "text": "Master Regulators of Immune Genes\nThe Master Regulators (MRs) are identi\ufb01ed by \ufb01rst inferring protein activity of candidate MRs as transcriptional in\ufb02uence on groups of\nco-expressed genes using the VIPER algorithm ( Alvarez et al., 2016 ), then using the DIGGIT algorithm ( Chen et al., 2014 ) to \ufb01nd\nsomatically altered proteins signi\ufb01cantly associated with the MRs, and \ufb01nally linking the two through a method called TieDIE ( Drake\net al., 2016; Paull et al., 2013 ), which \ufb01nds connecting \u2018\u2018paths\u2019\u2019 through a network of known and predicted interactions. MRs that\ncorrelate with leukocyte fraction (LF) are prioritized, as are somatic alterations seen by domainXplorer.\nWe applied the VIPER algorithm ( Alvarez et al., 2016 ) across all samples, using tissue-matched ARACNE ( Margolin et al., 2006 )\ninteractomes, to infer protein-activity for 2506 potential transcription factor and co-factor candidate \u2018\u2018master regulators\u2019\u2019 (cMRs)from the expression of their downstream targets. Pearson correlation of the inferred protein activity with LF was calculated. Samples\nwere clustered into an optimal number of 67 clusters based on inferred cMR activity, using a modi\ufb01ed silhouette score based on the\nnative distance metric de\ufb01ned by VIPER. We then integrated the p-values of the mean activity in each cluster to rank overall cMR\nactivity across the PanCancer dataset.\nSimilarly, we used the DIGGIT algorithm ( Chen et al., 2014 ) to \ufb01nd mutation and copy-number events signi\ufb01cantly associated with\neach cMR. Brie\ufb02y: for each tumor type, we computed the aREA ( Alvarez et al., 2016 ) enrichment of the sample set with non-silent\ncoding mutations in a given gene, against the ranked protein-activity signature inferred by VIPER for a given MR. This was performed\nfor each cMR / mutated gene pair with at least 4 samples with a non-silent alteration. Similarly SNP6 copy number pro\ufb01les were\ndownloaded from the Broad Institute and thresholded at a value of 0.5. We then ranked the cMRs by combining the p values ofall signi\ufb01cant DIGGIT interactions (p < 0.05; uncorrected) across all tumor types using Stouffer\u2019s method. Similarly, we overlappedpredicted protein-protein interactions taken from the PrePPI 1.2.0 database ( Zhang et al., 2012 )(https://bhapp.c2b2.columbia.edu/\nPrePPI/ ) with DIGGIT interactions generated in the previous step to generate a second ranking of cMRs based on structural data.\nThese (2) separate rankings were integrated in a Bayesian context with the ranks derived from VIPER clustering to produce a singlePanCancer ranking of cMR activity. In the top decile, we found 32 candidate MRs that also had a positive correlation of 0.5 or greater\nwith LF.\nMutation or copy-number events identi\ufb01ed by the domainXplorer algorithm were tested for statistical association with the 32 cMRs\nidenti\ufb01ed, using the DIGGIT algorithm (above), and retained if associated with one or more of the 32 cMRs in at least one tumor-\nspeci\ufb01c context. In addition we considered genomic events with broad statistical association with leukocyte fraction across the\nPanCancer dataset that were not identi\ufb01ed by domainXplorer (< 0.15 FDR; BH correction), resulting in 44 total genomic eventssigni\ufb01cantly associated with both the phenotype and the cMRs identi\ufb01ed in the \ufb01rst step.\nTo elucidate functional and molecular relationships between these genomic events and the 32 cMRs, we applied the TieDIE\nalgorithm ( Drake et al., 2016; Paull et al., 2013 ) with a database consisting of literature-based regulatory and signaling interactions\nas well as high-con\ufb01dence predicted protein-protein interactions ( Khurana et al., 2013 ).", "start_char_idx": 0, "end_char_idx": 3623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbedaa9b-af8a-42c0-90ad-c5d00173dc63": {"__data__": {"id_": "bbedaa9b-af8a-42c0-90ad-c5d00173dc63", "embedding": null, "metadata": {"page_label": "844", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3303ff81-498c-471b-9453-c65f30d41ce2", "node_type": "4", "metadata": {"page_label": "844", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "146a8109ddcc04b1d4f8bd6397e07b143ebaf38356cbc1c5cdc4642732c7832a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f72a469-7c1a-4904-93f9-ee7c7409d029", "node_type": "1", "metadata": {"page_label": "844", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "12ca31ce566162302cc3505c4d572a2b244972a129a2250293fb228bbec040db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19722332-929f-4b1a-8e55-f227cf4e8002", "node_type": "1", "metadata": {}, "hash": "56bcddc1f6f29cf9b1a8ba564b27158a8dc3cf0969146e074a2f0e2093518b59", "class_name": "RelatedNodeInfo"}}, "text": "In addition we considered genomic events with broad statistical association with leukocyte fraction across the\nPanCancer dataset that were not identi\ufb01ed by domainXplorer (< 0.15 FDR; BH correction), resulting in 44 total genomic eventssigni\ufb01cantly associated with both the phenotype and the cMRs identi\ufb01ed in the \ufb01rst step.\nTo elucidate functional and molecular relationships between these genomic events and the 32 cMRs, we applied the TieDIE\nalgorithm ( Drake et al., 2016; Paull et al., 2013 ) with a database consisting of literature-based regulatory and signaling interactions\nas well as high-con\ufb01dence predicted protein-protein interactions ( Khurana et al., 2013 ). TieDIE found the 44 genomic events\nwere signi\ufb01cantly \u2018\u2018close\u2019\u2019 to the 32 MRs in pathway space (p value < 0.021) and identi\ufb01ed a network MR-PanImmune connecting\n15 of these altered genes to 26 MRs across 222 database interaction containing 60 transcriptional regulatory, 8 signaling, 3 phos-\nphorylation and 151 protein-protein interactions.\nContributors: Evan O. Paull, Mariano Alvarez, Federico Giorgi, Jing He and Andrea Califano\nSYstems Genetics Network AnaLysis\nThe SYstems Genetics Network AnaLysis (SYGNAL) pipeline is composed of 4 steps ( Plaisier et al., 2016 ). Command line parameters\nfor all programs in SYGNAL pipeline can be found in Plaisier et al., 2016 ( Plaisier et al., 2016 ). Each tumor type was run separately\nthrough the pipeline to reduce the confounding from tissue of origin differences. Highly expressed genes were discovered for eachtumor type by requiring that genes have greater than or equal to the median expression of all genes across all conditions in R50% of\npatients ( Plaisier et al., 2016 ). These gene sets were then used as input to SYGNAL.\nMechanistic Regulatory Network Inference\nIn the \ufb01rst step, the cMonkey\n2biclustering algorithm ( Reiss et al., 2015 ) was used to reduce the genes expression pro\ufb01les from each\ntumor type into co-regulated biclusters. The number of biclusters was determined using two times the number of genes divided by\nthe expectation of 30 genes on average per cluster. The training con\ufb01guration for cMonkey 2included co-expression, GeneMania\ngene-gene interaction network, and enrichment of either TF or miRNA target genes using the set-enrichment module ( Reiss et al.,\n2015 ). In total, cMonkey 2was run three times for each tumor type and we discovered 43,000 biclusters. The \ufb01rst run used the TF-tar-\nget gene interaction database as input to the set-enrichment module to discover TF mediated regulation. The second and third\nruns used PITA ( Kertesz et al., 2007 ) and TargetScan ( Agarwal et al., 2015 ) as input to the set-enrichment module to discover miRNA\nmediated regulation.\nPost-Processing and Filtering of Biclusters\nBiclusters were considered signi\ufb01cantly co-expressed if the variance explained by \ufb01rst principal component was greater thanor equal to 0.3 and was signi\ufb01cantly larger than random samples (empirical p-value%0.05). Each of the 43,000 cMonkey\n2\nbiclusters were then post-processed to discover: (i) co-expression quality via variance explained by \ufb01rst principal component\n(empirical p-value < 0.05 and variance explained R0.3), (ii) putative TF regulators via de novo motif detection with MEME or WEEDER\n(Bailey et al., 2009; Pavesi and Pesole, 2006 ) and comparison of motif to known DNA recognition motifs (TOMTOM q-value%0.05),\nand enrichment of TF target genes (Bonferroni corrected p-value%0.05 and percent target genes R10%); (iii) TF family expansion\nusing the TFClass database ( Wingender et al., 2013 ); (iv) putative miRNA regulators via the FIRM pipeline ( Plaisier et al., 2012 ),\nImmunity 48, 812\u2013830.e1\u2013e14, April 17, 2018 e13", "start_char_idx": 2951, "end_char_idx": 6659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19722332-929f-4b1a-8e55-f227cf4e8002": {"__data__": {"id_": "19722332-929f-4b1a-8e55-f227cf4e8002", "embedding": null, "metadata": {"page_label": "845", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "750ecb05-ce93-4c55-b516-5dee9433b779", "node_type": "4", "metadata": {"page_label": "845", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "969b0fabe95d9d0833694e1ce1aefb23bb8ee85f3bf21c605f6b8c2d38a5cfd3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbedaa9b-af8a-42c0-90ad-c5d00173dc63", "node_type": "1", "metadata": {"page_label": "844", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "574c85740f1d690fcfb2ee71b7c802177af75578cf04116b96e602a9e3442c74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ead72480-90e7-4caf-8d2d-4bf4726ce808", "node_type": "1", "metadata": {}, "hash": "88f699935d8e63f2496af757e1438bdc9858f32353887c617082e8646f37e630", "class_name": "RelatedNodeInfo"}}, "text": "(v) correlation of TF and miRNA regulators with bicluster eigengenes ( Langfelder and Horvath, 2007 )(TFs: RR0.3 or%/C00.3 and\np-value%0.05; miRNAs: R %/C00.3 and p-value%0.05); (vi) enrichment of IM genes ( p-value%0.05); (vii) association of total\nleukocyte fraction bicluster eigengenes ( p-value%0.05); (viii) functional enrichment with GO biological process terms (BH-corrected\np-value%0.05) ( Plaisier et al., 2012 ); and (ix) association with hallmarks of cancer (Jiang-Conrath Semantic Similarity Score R0.8,\npermuted p-value%5.1310/C04)(Hanahan and Weinberg, 2011; Plaisier et al., 2012 ). The biclusters were \ufb01ltered by validating\nco-expression and ensuring disease relevance. A bicluster was considered signi\ufb01cantly co-expressed if the variance explained\nby \ufb01rst principal component was greater than or equal to 0.3 and was signi\ufb01cantly larger than random samples (empirical p-value%\n0.05). A bicluster was considered immune-related if the genes were signi\ufb01cantly enriched with immunomodulators ( p-value%0.05)\nand conditional elevated and decreased regulation was signi\ufb01cantly associated with total leukocyte fraction ( p-value%0.05) or\nassociated with either evading immune detection or tumor promoting in\ufb02ammation (the two immune hallmarks of cancer ( Plaisier\net al., 2016 ).\nIn all 6,667 biclusters were signi\ufb01cantly associated with total leukocyte fraction ( p-value%0.05). Additionally, 197 biclusters were\nsigni\ufb01cantly enriched with a curated set of immunomodulatory genes (Bonferroni corrected p value %0.05) There was a signi\ufb01cant\noverlap of 171 biclusters (87%) that were enriched with immunomodulators and associated with total leukocyte in\ufb01ltration (p value =1.4310\n/C0110).\nCausal regulatory network inference\nIn the third step of the SYGNAL pipeline, the single.marker.analysis function from the network edge orienting (NEO) package in R(Aten et al., 2008; Plaisier et al., 2009; Plaisier et al., 2016 ) was applied to infer causal \ufb02ows of information anchored on a somatically\nmutated gene or pathway to expression of a TF or miRNA to a bicluster eigengenes. The single.marker.analysis function compares\n\ufb01ve different causal graphical models to test for signi\ufb01cant evidence of causal \ufb02ow across the variables tested. The model of interest\nfor these studies was the causal graph anchored on a somatically mutated gene or pathway (M) which affects the expression of a TFor miRNA (R) that in turn alters the expression of a bicluster eigengene (B), i.e., the causal graph M /R/B. The \ufb01t of this model was\nassessed using the local structural equation modeling (SEM) based, edge orienting, next best single marker (LEO.NB. SingleMarker )\nscore, which is the log\n10probability of this model divided by the log 10probability of the next best \ufb01tting alternative model ( Aten et al.,\n2008 ). A causal \ufb02ow was inferred when the LEO.NB. SingleMarker score was positive and three times more likely than the next\nbest alternative model (LEO.NB.SingleMarker score R0.5)(Plaisier et al., 2009 ). For miRNAs, we imposed the additional\nrequirement that the regulation of the miRNA on the bicluster eigengene must be repressive (ZPathAB < 0). Thus any LEO.NB.SingleMarker score greater than or equal to 0.5 was considered suf\ufb01cient evidence to infer causal \ufb02ow through the causal graph\nM/R/B. To reduce the overall number of tests, only TFs and miRNAs that were signi\ufb01cantly associated with a somatic mutation\nwere evaluated (Student\u2019s t test p-value%0.05 and FC R1.25).", "start_char_idx": 0, "end_char_idx": 3479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ead72480-90e7-4caf-8d2d-4bf4726ce808": {"__data__": {"id_": "ead72480-90e7-4caf-8d2d-4bf4726ce808", "embedding": null, "metadata": {"page_label": "845", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "750ecb05-ce93-4c55-b516-5dee9433b779", "node_type": "4", "metadata": {"page_label": "845", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "969b0fabe95d9d0833694e1ce1aefb23bb8ee85f3bf21c605f6b8c2d38a5cfd3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19722332-929f-4b1a-8e55-f227cf4e8002", "node_type": "1", "metadata": {"page_label": "845", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "921854c317d4ef7307eb7179ab7e3bf5e5368c75d900c8538bb0ed322d348b12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e86e60e1-6417-4169-9a8a-51afea16bb97", "node_type": "1", "metadata": {}, "hash": "f5b30f6b8507d05daa224025f58f07dc88702c4378f8361bce9052b542636014", "class_name": "RelatedNodeInfo"}}, "text": "A causal \ufb02ow was inferred when the LEO.NB. SingleMarker score was positive and three times more likely than the next\nbest alternative model (LEO.NB.SingleMarker score R0.5)(Plaisier et al., 2009 ). For miRNAs, we imposed the additional\nrequirement that the regulation of the miRNA on the bicluster eigengene must be repressive (ZPathAB < 0). Thus any LEO.NB.SingleMarker score greater than or equal to 0.5 was considered suf\ufb01cient evidence to infer causal \ufb02ow through the causal graph\nM/R/B. To reduce the overall number of tests, only TFs and miRNAs that were signi\ufb01cantly associated with a somatic mutation\nwere evaluated (Student\u2019s t test p-value%0.05 and FC R1.25).\nIntegration of Mechanistic & Causal NetworksIn the fourth and \ufb01nal step of the SYGNAL pipeline we integrate the regulatory in\ufb02uences by either taking the intersection for\ntranscription factors and union for miRNAs. For the intersection of TF mediated regulation it was also required that the causal and\nmechanistic predictions must be for regulation of the same bicluster.\nContributor: Christopher Plaisier\nQUANTIFICATION AND STATISTICAL ANALYSISThe statistical details of all experiments are reported in the text, \ufb01gure legends and \ufb01gures, including statistical analysis performed,\nstatistical signi\ufb01cance and counts.\nSOFTWARE AND DATA AVAILABILITY\nThe raw data, processed data and clinical data can be found at the legacy archive of the GDC ( https://portal.gdc.cancer.gov/legacy-\narchive/search/f ) and the Pancancer Atlas publication page ( https://gdc.cancer.gov/about-data/publications/pancanatlas ). The\nmutation data can be found at https://gdc.cancer.gov/about-data/publications/mc3-2017 . Details for software availability are in\nthe Key Resources Table. Additional data resources for this manuscript are at https://gdc.cancer.gov/about-data/publications/\npanimmune . Interactive exploration and visualization of data and results in this manuscript is available at the CRI iAtlas portal\n(http://www.cri-iatlas.org ).\nSoftware used for the analyses for each of the data platforms and integrated analyses are described and referenced in the\nindividual Method Details subsections and are listed in the Key Resources Table.\ne14 Immunity 48, 812\u2013830.e1\u2013e14, April 17, 2018", "start_char_idx": 2810, "end_char_idx": 5057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e86e60e1-6417-4169-9a8a-51afea16bb97": {"__data__": {"id_": "e86e60e1-6417-4169-9a8a-51afea16bb97", "embedding": null, "metadata": {"page_label": "846", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2a96318f-77c2-48c3-833f-cd4bad0f1fca", "node_type": "4", "metadata": {"page_label": "846", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "96b925ad652c6506ea80e21538dccbbccc5a56e99db8c6bc88337e47797e078d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ead72480-90e7-4caf-8d2d-4bf4726ce808", "node_type": "1", "metadata": {"page_label": "845", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "3eb49aa67b3e7a8be6de6619108ceaec6a3338c192c607c95b3a30490c669fbb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9dc2dc99-b10b-4f4f-8313-fe8423bf82c0", "node_type": "1", "metadata": {}, "hash": "4900fe3624e50c101cd0ae83baa878a4d54fc8fe885df48259029a6fbed87936", "class_name": "RelatedNodeInfo"}}, "text": "Update\nImmunity\nVolume 51, Issue 2, 20 August 2019, Page 411\u2013412\n https://doi.org/10.1016/j.immuni.2019.08.004DOI:", "start_char_idx": 0, "end_char_idx": 114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9dc2dc99-b10b-4f4f-8313-fe8423bf82c0": {"__data__": {"id_": "9dc2dc99-b10b-4f4f-8313-fe8423bf82c0", "embedding": null, "metadata": {"page_label": "847", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7f46c743-42a4-4295-984f-c07a2c5453a1", "node_type": "4", "metadata": {"page_label": "847", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "67a7ab5eb53ab8fc35c0de13e7f1093a8f2af989fcfdf3ece94a33c8d929c925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e86e60e1-6417-4169-9a8a-51afea16bb97", "node_type": "1", "metadata": {"page_label": "846", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "96b925ad652c6506ea80e21538dccbbccc5a56e99db8c6bc88337e47797e078d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfe40769-c5ea-46cd-b8f7-7e8993559d3d", "node_type": "1", "metadata": {}, "hash": "58c295bdc979d82535d4168d56fdfa879fd900a1ad5ffcf2bd44ca6a3c455848", "class_name": "RelatedNodeInfo"}}, "text": "Immunity\nCorrection\nThe Immune Landscape of Cancer\nVe\u00b4steinn Thorsson,1,37,*David L. Gibbs,1,36Scott D. Brown,2Denise Wolf,3Dante S. Bortone,4Tai-Hsien Ou Yang,5\nEduard Porta-Pardo,6,7Galen F. Gao,8Christopher L. Plaisier,1,9James A. Eddy,10Elad Ziv,11Aedin C. Culhane,12\nEvan O. Paull,13I.K. Ashok Sivakumar,14Andrew J. Gentles,15Raunaq Malhotra,16Farshad Farshidfar,17\nAntonio Colaprico,18Joel S. Parker,4Lisle E. Mose,4Nam Sy Vo,19Jianfang Liu,20Yuexin Liu,19Janet Rader,21\nVarsha Dhankani,1Sheila M. Reynolds,1Reanne Bowlby,2Andrea Califano,13Andrew D. Cherniack,8\nDimitris Anastassiou,5Davide Bedognetti,22Younes Mokrab,22Aaron M. Newman,35Arvind Rao,19Ken Chen,19\nAlexander Krasnitz,23Hai Hu,20Tathiane M. Malta,24,25Houtan Noushmehr,24,25Chandra Sekhar Pedamallu,26\nSusan Bullman,26Akinyemi I. Ojesina,27Andrew Lamb,10Wanding Zhou,28Hui Shen,28Toni K. Choueiri,26\nJohn N. Weinstein,19Justin Guinney,10Joel Saltz,29Robert A. Holt,2Charles S. Rabkin,30\nThe Cancer Genome Atlas Research Network, Alexander J. Lazar,31Jonathan S. Serody,32Elizabeth G. Demicco,33,36\nMary L. Disis,34,36Benjamin G. Vincent,4,*and Ilya Shmulevich1,*\n1Institute for Systems Biology, 401 Terry Ave N, Seattle, WA 98109, USA\n2Canada\u2019s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC V5Z 4S6, Canada\n3University of California, San Francisco, Box 0808, 2340 Sutter Street, S433, San Francisco, CA 94115, USA\n4Lineberger Comprehensive Cancer Center, Curriculum in Bioinformatics and Computational Biology, University of North Carolina, 125\nMason Farm Road, Chapel Hill, NC 27599-7295, USA\n5Department of Systems Biology and Department of Electrical Engineering, Columbia University, New York, NY 10027, USA\n6Barcelona Supercomputing Centre, c/Jordi Girona, 29, 08034 Barcelona, Spain\n7SBP Medical Discovery Institute, La Jolla, CA 92037, USA\n8The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA\n9School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ 85281, USA\n10Sage Bionetworks, 2901 Third Ave, Suite 330, Seattle, WA 98121, USA\n11Department of Medicine, Institute for Human Genetics, Helen Diller Family Comprehensive Cancer Center, University of California, San\nFrancisco, 1450 3rd St, San Francisco, CA 94143, USA\n12Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA\n13Irving Cancer Research Center, Room 913,1130 St.", "start_char_idx": 0, "end_char_idx": 2489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfe40769-c5ea-46cd-b8f7-7e8993559d3d": {"__data__": {"id_": "cfe40769-c5ea-46cd-b8f7-7e8993559d3d", "embedding": null, "metadata": {"page_label": "847", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7f46c743-42a4-4295-984f-c07a2c5453a1", "node_type": "4", "metadata": {"page_label": "847", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "67a7ab5eb53ab8fc35c0de13e7f1093a8f2af989fcfdf3ece94a33c8d929c925", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9dc2dc99-b10b-4f4f-8313-fe8423bf82c0", "node_type": "1", "metadata": {"page_label": "847", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "12b69c302de56a54ba9235eaef7ea9edcb980d601fc8942f5330237cb745a5b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdcd1b76-d431-4094-a5c2-3e11c8e1a2e8", "node_type": "1", "metadata": {}, "hash": "5144494caa5eb5b40bd9d4f3331a0c75a4d6eb82e33243a0e594bab504d03461", "class_name": "RelatedNodeInfo"}}, "text": "Nicholas Avenue, New York, NY 10032, USA\n14Department of Computer Science, Institute for Computational Medicine; Johns Hopkins University, Baltimore, MD 21218, USA\n15Departments of Medicine and Biomedical Data Science, Stanford University, Stanford, CA 94305, USA\n16Seven Bridges Genomics, Cambridge, MA 02142, USA\n17Department of Oncology, University of Calgary, Calgary, AB T2N 4N1, Canada\n18Universite libre de Bruxelles (ULB), Computer Science Department, Faculty of Sciences, Boulevard du Triomphe - CP212, 1050 Bruxelles,\nBelgium\n19Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA\n20Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA 15963, USA\n21Medical College of Wisconsin, 9200 Wisconsin Avenue, Milwaukee, WI 53226 USA\n22Division of Translational Medicine, Research Branch, Sidra Medical and Research Center, PO Box 26999, Doha, Qatar\n23Simons Center for Quantitative Biology, Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724, USA\n24Department of Neurosurgery, Henry Ford Hospital, Detroit, MI 48202, USA\n25Department of Genetics, Ribeirao Preto Medical School, University of Sa \u02dco Paulo, Sa \u02dco Paulo, Brazil\n26Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA\n27University of Alabama at Birmingham, Birmingham, AL 35294, USA\n28Center for Epigenetics, Van Andel Research Institute, Grand Rapids, MI 49503, USA\n29Department of Biomedical Informatics, Stony Brook Medicine, 100 Nicolls Rd, Stony Brook, NY 11794, USA\n30Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Dr., Bethesda, MD 20892, USA\n31Departments of Pathology, Genomics Medicine and Translational Molecular Pathology, The University of Texas MD Anderson Cancer\nCenter, 1515 Holcombe Blvd-Unit 85, Houston, TX 77030, USA\n32Department of Medicine and Microbiology and Lineberger Comprehensive Cancer Center, 125 Mason Farm Road, Chapel Hill, NC\n27599-7295, USA\n33Mount Sinai Hospital, Department of Pathology and Laboratory Medicine, 600 University Ave., Toronto, ON M5G 1X5, Canada\n34UW Medicine Cancer Vaccine Institute, 850 Republican Street, Brotman Building, 2nd Floor, Room 221, Box 358050, University of\nWashington, Seattle, WA 98109-4714, USA\n35Institute for Stem Cell Biology and Regenerative Medicine and Department of Biomedical Data Science, Stanford University, Stanford, CA\n94305, USA\n36These authors contributed equally\n37Lead Author\n*Correspondence: vesteinn.thorsson@systemsbiology.org (V.T.), benjamin.vincent@unchealth.unc.edu (B.G.V.), ilya.shmulevich@\nsystemsbiology.org (I.S.)\nhttps://doi.org/10.1016/j.immuni.2019.08.004\n(Immunity 48, 812\u2013830.e1\u2013e14; April 17, 2018)\nImmunity 51, 411\u2013412, August 20, 2019 \u00aa2019 The Author(s). Published by Elsevier Inc. 411\nThis is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).", "start_char_idx": 2490, "end_char_idx": 5465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdcd1b76-d431-4094-a5c2-3e11c8e1a2e8": {"__data__": {"id_": "fdcd1b76-d431-4094-a5c2-3e11c8e1a2e8", "embedding": null, "metadata": {"page_label": "848", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f756ad64-f0d3-4093-b9ef-8499b3cf1904", "node_type": "4", "metadata": {"page_label": "848", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "5e342b8b1c83bb85610b63e037f39994465bda7a4c05643f02895a13937722f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfe40769-c5ea-46cd-b8f7-7e8993559d3d", "node_type": "1", "metadata": {"page_label": "847", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "9b534c62c3ad19a9b9425406ef0ac0095af54a8365fda9c3d7031866b7f0d017", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b44cdc30-f355-4d61-8285-2c60c232d0cc", "node_type": "1", "metadata": {}, "hash": "24aa2305d8ef9f2888f8ffa3b0c4e87494a665bc8efb1cb89d03b1572d76ae52", "class_name": "RelatedNodeInfo"}}, "text": "In the originally published version of this article, the authors neglected to include Younes Mokrab and Aaron M. Newman as co-\nauthors and misspelled the names of authors Charles S. Rabkin and Ilya Shmulevich. The author names have been corrected\nhere and online.\nIn addition, the concluding sentence of the subsection \u2018\u2018Immune Signature Compilation\u2019\u2019 in the Method Details in the original pub-\nlished article was deemed unclear because it did not specify differences among the gene set scoring methods. The concluding sen-\ntences now reads \u2018\u2018Gene sets from Bindea et al., Senbabaoglu et al., and the MSigDB C7 collection were scored using single-samplegene set enrichment (ssGSEA) analysis (Barbie et al., 2009), as implemented in the GSVA R package (H \u20acanzelmann et al., 2013). All\nother signatures were scored using methods found in the associated citations.\u2019\u2019\n412 Immunity 51, 411\u2013412, August 20, 2019", "start_char_idx": 0, "end_char_idx": 905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b44cdc30-f355-4d61-8285-2c60c232d0cc": {"__data__": {"id_": "b44cdc30-f355-4d61-8285-2c60c232d0cc", "embedding": null, "metadata": {"page_label": "137", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f69d1a74-5d69-4f94-807a-cefb2c59c1f9", "node_type": "4", "metadata": {"page_label": "137", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "6feff49a12a47759ce2bb651f53d823b7a91269c164f4d7f1b8e6f97395f318b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdcd1b76-d431-4094-a5c2-3e11c8e1a2e8", "node_type": "1", "metadata": {"page_label": "848", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}, "hash": "5e342b8b1c83bb85610b63e037f39994465bda7a4c05643f02895a13937722f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05429d5f-26ba-4e97-9e5f-16dec6dcac91", "node_type": "1", "metadata": {}, "hash": "5b3a3a00e24473b7e9e72479f3c6bb411a8c581f7f3b148ee19df234ebcd1891", "class_name": "RelatedNodeInfo"}}, "text": "Immunity, Vol. 21, 137\u2013148, August, 2004, Copyright \uf8e92004 by Cell Press\nReview The Immunobiology\nof Cancer Immunosurveillanceand Immunoediting\ntective versus tumor-sculpting actions of the immune\nsystem in cancer (Shankaran et al., 2001; Dunn et al.,2002, 2004). Herein, we summarize recent work on thecancer immunosurveillance and immunoediting pro-cesses\u2014underscoring a new optimism that an enhancedGavin P. Dunn,\n1Lloyd J. Old,2\nand Robert D. Schreiber1,*\n1Department of Pathology and Immunology\nCenter for ImmunologyWashington University School of Medicine660 South Euclid Avenue understanding of naturally occurring immune system/\ntumor interactions will lead to the development of more Box 8118\nSt. Louis, Missouri 63110 effective immunologically based cancer therapies.\n2Ludwig Institute for Cancer Research\nNew York Branch at Memorial Sloan-Kettering From Cancer Immunosurveillance\nCancer Center to Cancer Immunoediting\n1275 York Avenue In 1909, Paul Ehrlich predicted that the immune system\nNew York, New York 10021 repressed the growth of carcinomas that he envisaged\nwould otherwise occur with great frequency (Ehrlich,1909), thus initiating a century of contentious debateover immunologic control of neoplasia. Fifty years later,\nThe last fifteen years have seen a reemergence of as immunologists gained an enhanced understanding\ninterest in cancer immunosurveillance and a broaden- of transplantation and tumor immunobiology and immu-\ning of this concept into one termed cancer immuno- nogenetics, F. Macfarlane Burnet and Lewis Thomas\nediting. The latter, supported by strong experimental revisited the topic of natural immune protection against\ndata derived from murine tumor models and provoca- cancer. Burnet\u2019s thinking was shaped by a consideration\ntive correlative data obtained by studying human can- of immune tolerance; he believed that tumor cell-spe-\ncer, holds that the immune system not only protects cific neo-antigens could provoke an effective immuno-\nthe host against development of primary nonviral can- logic reaction that would eliminate developing cancers\ncers but also sculpts tumor immunogenicity. Cancer (Burnet, 1957, 1964, 1971). Alternatively, Thomas\u2019s early\nimmunoediting is a process consisting of three phases: view was evolutionary in nature; he theorized that com-\nelimination (i.e., cancer immunosurveillance), equilib- plex long-lived organisms must possess mechanisms\nrium, and escape. Herein, we summarize the data sup- to protect against neoplastic disease similar to those\nporting the existence of each of the three cancer im- mediating homograft rejection (Thomas, 1959). With the\nmunoediting phases. The full understanding of the functional demonstration of mouse tumor-specific anti-\nimmunobiology of cancer immunosurveillance and im- gens supporting the ideas of Ehrlich, Burnet, and\nmunoediting will hopefully stimulate development of Thomas (Old and Boyse, 1964), the cancer immunosur-\nmore effective immunotherapeutic approaches to veillance hypothesis, which stated that sentinel thymus-\ncontrol and/or eliminate human cancers. dependent cells of the body constantly surveyed host\ntissues for nascently transformed cells (Burnet, 1970),gained recognition. Despite subsequent challenges to\nComments made decades ago by the architects of the this hypothesis over the next several decades (Stutman,\ncancer immunosurveillance hypothesis, Burnet and 1974, 1979), new studies in the 1990s\u2014fueled by tech-\nThomas, that \u201cthere is little ground for optimism about nologic advances in mouse genetics and monoclonal\ncancer\u201d (Burnet, 1957) and \u201cthe greatest trouble with the antibody (mAb) production\u2014reinvigorated and ulti-\nidea of immunosurveillance is that it cannot be shown to mately validated the cancer immunosurveillance con-\nexist in experimental animals\u201d (Thomas, 1982), reflect cept (Smyth et al., 2001b; Dunn et al., 2002, 2004) and\nthe problems that, until recently, fomented intense de- expanded it to incorporate the contributions of both\nbate over whether natural immune defense mechanisms innate and adaptive immunity.\ncan protect the host against the development of can- However, there has been a growing recognition that\ncers of nonviral origin.", "start_char_idx": 0, "end_char_idx": 4211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05429d5f-26ba-4e97-9e5f-16dec6dcac91": {"__data__": {"id_": "05429d5f-26ba-4e97-9e5f-16dec6dcac91", "embedding": null, "metadata": {"page_label": "137", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f69d1a74-5d69-4f94-807a-cefb2c59c1f9", "node_type": "4", "metadata": {"page_label": "137", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "6feff49a12a47759ce2bb651f53d823b7a91269c164f4d7f1b8e6f97395f318b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b44cdc30-f355-4d61-8285-2c60c232d0cc", "node_type": "1", "metadata": {"page_label": "137", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "bea7920f89138122b51e24db63a8d851b7576bd000c639cff48acb24ff4c3c01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef3b6c2b-647e-4ac2-8ec6-85397b35cd0c", "node_type": "1", "metadata": {}, "hash": "7a40eb9058542c90549418430df935773b5a1e1ac3a5767bb6c4dcb95a6714be", "class_name": "RelatedNodeInfo"}}, "text": "can protect the host against the development of can- However, there has been a growing recognition that\ncers of nonviral origin. The difficulty was clear: if im- immunosurveillance represents only one dimension of\nmunosurveillance of developing tumors in immunocom- the complex relationship between the immune system\npetent hosts was indeed successful, then how could and cancer (Dunn et al., 2002, 2004; Schreiber et al.,\nsuch an apparently invisible process be experimentally 2004). Recent work has shown that the immune system\nrevealed? With the development of mouse tumor models may also promote the emergence of primary tumors with\nusing inbred mice with molecularly defined immunodefi- reduced immunogenicity that are capable of escaping\nciencies, it has become possible to demonstrate the immune recognition and destruction (Shankaran et al.,\nexistence of a cancer immunosurveillance process that 2001). These findings prompted the development of the\ncan prevent primary tumor growth. Moreover, there is an cancer immunoediting hypothesis to more broadly en-\nemerging recognition that cancer immunosurveillance compass the potential host-protective and tumor-sculpt-\nrepresents only one step of a broader process, termed ing functions of the immune system throughout tumor\ncancer immunoediting, that stresses the dual host-pro- development (Dunn et al., 2002, 2004). Cancer immuno-\nediting is a dynamic process composed of three phases:elimination, equilibrium, and escape (Figure 1). Elimina-\n*Correspondence: schreiber@immunology.wustl.edu", "start_char_idx": 4083, "end_char_idx": 5631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef3b6c2b-647e-4ac2-8ec6-85397b35cd0c": {"__data__": {"id_": "ef3b6c2b-647e-4ac2-8ec6-85397b35cd0c", "embedding": null, "metadata": {"page_label": "138", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1d95806f-bb56-4341-a077-d50b281119f3", "node_type": "4", "metadata": {"page_label": "138", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "fd3ae78462d686a09024edd45213701a2be717362e797a20fbed49457a5881a9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05429d5f-26ba-4e97-9e5f-16dec6dcac91", "node_type": "1", "metadata": {"page_label": "137", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "d81647fe070f4469149df126b67d96c7c4e2182fdd8e88702d8c39114b67051b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ae3427e-259b-4ad6-acfb-23368ccb295e", "node_type": "1", "metadata": {}, "hash": "37f115871a39ec411fa845a7237c283cf38c878aa4743ddc722fe47ea246e3dc", "class_name": "RelatedNodeInfo"}}, "text": "Immunity\n138\nFigure 1. The Three Phases of the Cancer Immunoediting Process\nNormal cells (gray) subject to common oncogenic stimuli ultimately undergo transformation and become tumor cells (red) (top). Even at early\nstages of tumorigenesis, these cells may express distinct tumor-specific markers and generate proinflammatory \u201cdanger\u201d signals that initiatethe cancer immunoediting process (bottom). In the first phase of elimination, cells and molecules of innate and adaptive immunity, whichcomprise the cancer immunosurveillance network, may eradicate the developing tumor and protect the host from tumor formation. However,if this process is not successful, the tumor cells may enter the equilibrium phase where they may be either maintained chronically orimmunologically sculpted by immune \u201ceditors\u201d to produce new populations of tumor variants. These variants may eventually evade the immunesystem by a variety of mechanisms and become clinically detectable in the escape phase.\ntion represents the classical concept of cancer immuno- sor and protects the immunocompetent host from the\ndevelopment of neoplasia. In this section, we discuss surveillance, equilibrium is the period of immune-medi-\nated latency after incomplete tumor destruction in the current work on the elimination phase of the cancer\nimmunoediting process that specifically addresses the elimination phase, and escape refers to the final out-\ngrowth of tumors that have outstripped immunological following three central questions. (1) What cells protect\nthe host from tumor development? (2) What are the criti- restraints of the equilibrium phase.\ncal effector functions of the immune system in cancerimmunosurveillance? (3) How does the immune systemThe Elimination Phase: Assembling the Cancerdistinguish between a transformed cell and its normalImmunosurveillance Networkprogenitor?Pivotal studies on IFN- /H9253(Dighe et al., 1994; Kaplan et\nal., 1998; Shankaran et al., 2001; Street et al., 2001, 2002)and perforin (van den Broek et al., 1996; Smyth et al., Adaptive and Innate Immune Cells Play Critical\nRoles in Cancer Immunosurveillance 2000a, 2000b; Street et al., 2001, 2002) have shown that\ndeficiencies in key immunologic molecules enhanced Rapidly accumulating data have begun to elucidate the\ncellular basis of cancer immunosurveillance and demon- host susceptibility to both chemically induced and spon-\ntaneous tumors, demonstrating for the first time a critical strate that lymphocytes of both the adaptive and innate\nimmune compartments prevent tumor development. prediction of the prescient, but previously unsubstanti-\nated, cancer immunosurveillance hypothesis. Further- One of the most definitive studies performed to date\nemployed gene-targeted mice lacking the recombinase more, other compelling data suggest that immunosur-\nveillance is not restricted to mouse models but also activating gene (RAG)-2 (Shankaran et al., 2001) and\ndemonstrated that lymphocytes expressing rearranged exists in humans (Dunn et al., 2002, 2004). Thus, today\nthe question is not if\u2014but, rather, how\u2014cancer immu- antigen receptors play critical roles in the cancer im-\nmunosurveillance process. Mice lacking RAG-2 (or its nosurveillance functions as an extrinsic tumor suppres-", "start_char_idx": 0, "end_char_idx": 3254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ae3427e-259b-4ad6-acfb-23368ccb295e": {"__data__": {"id_": "2ae3427e-259b-4ad6-acfb-23368ccb295e", "embedding": null, "metadata": {"page_label": "139", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "575eaf74-47b0-47d0-8d55-0bea36c35712", "node_type": "4", "metadata": {"page_label": "139", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "7d03b98c36436ed8962e3ea7bb65eceb15b52b4c9a8e14604b7ac2055390cb27", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef3b6c2b-647e-4ac2-8ec6-85397b35cd0c", "node_type": "1", "metadata": {"page_label": "138", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "fd3ae78462d686a09024edd45213701a2be717362e797a20fbed49457a5881a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72c760c5-0411-4bc1-8611-779a563049dc", "node_type": "1", "metadata": {}, "hash": "31b0bb14e7abda745c04abcf3da5b944ef94c6b3fa3c98fbc85881979c366638", "class_name": "RelatedNodeInfo"}}, "text": "Review\n139\nobligate partner RAG-1) cannot somatically rearrange gression of developing papillomas to more aggressive\nlymphocyte antigen receptors and therefore cannot pro- carcinomas. Together, these results reveal that /H9251/H9252and\nduce peripheral /H9251/H9252T cells, B cells, NKT cells, or /H9253/H9254 /H9253/H9254T cell subsets make critical, but distinct, contributions\nT cells (Shinkai et al., 1992). Since RAG-2 expression is to host antitumor defense mechanisms.\nlimited to cells of the lymphoid system, RAG-2/H11002//H11002mice NK and NKT cells also participate in cancer immuno-\nprovided an appropriate model to exclusively study the surveillance. C57BL/6 mice, depleted of both NK and\neffects of host lymphocyte deficiency on tumor develop- NKT cells by using the anti-NK1.1 mAb, were two to\nment. Unlike other genetic models of immunodeficiency three times more susceptible to MCA-induced tumori-\n(such as SCID mice), the absence of RAG-2 does not genesis than wild-type controls (Smyth et al., 2001a). A\naffect DNA damage repair pathways in nonimmune cells similar effect was observed in C57BL/6 mice treated\nundergoing transformation. Following subcutaneous in- with anti-asialo-GM1, which selectively depletes NK but\njection of the chemical carcinogen 3 /H11032-methylcholan- not NKT cells. Although anti-asialo-GM1 can also de-\nthrene (MCA), 129/SvEv RAG-2/H11002//H11002mice developed sar- plete activated macrophages, the latter observation\ncomas at the injection site faster and with greater nevertheless supports the involvement of innate immune\nfrequency than strain-matched wild-type controls cells in blocking primary tumor development. NKT cells\n(Shankaran et al., 2001). After 160 days, 30/52 RAG-2/H11002//H11002were also implicated in immunosurveillance by two\nmice formed tumors, compared with 11/57 wild-type additional observations. First, J /H9251281/H11002//H11002mice, lacking\nmice (p /H110210.0001). Similar findings were obtained in V/H925114J/H9251281-expressing invariant NKT cells, developed\nC57BL/6 RAG-1/H11002//H11002mice treated with MCA (Smyth et MCA-induced sarcomas at a higher frequency than wild-\nal., 2001a). type controls (Smyth et al., 2000a). Second, mice treated\nIn addition, Helicobacter -negative RAG-2/H11002//H11002129/ with the NKT cell-activating ligand /H9251-galactosylceramide\nSvEv mice aged in a specific pathogen-free mouse facil- (/H9251-GalCer) throughout MCA-induced tumorigenesis ex-\nity and maintained on broad-spectrum antibiotics ad- hibited a reduced incidence of tumors and displayed a\nministered every other month developed significantly longer latency period to tumor formation than control\nmore spontaneous epithelial tumors than did wild-type mice (Hayakawa et al., 2003).\ncounterparts (Shankaran et al., 2001; A.T. Bruce and A recent provocative study by Cui et al. (Cui et al.,\nR.D.S., unpublished data). Specifically, 31/32 RAG-2/H11002//H110022003) provides further evidence that innate immune cells\nmice (13\u201328 months old) developed spontaneous neo-comprise an important arm of the immunosurveillance\nplasia, predominantly of the intestine. Eight had prema-network. A single BALB/c mouse was serendipitously\nlignant intestinal adenomas, 22 had intestinal adenocar-found that failed to form ascites when injected intraperi-\ncinomas, and one had an intestinal adenoma and a lungtoneally with the extremely aggressive S180 sarcoma\nadenocarcinoma. In contrast, 21/33 wild-type mice re-cell line. Subsequent breeding revealed that the ob-\nmained neoplasia free to the end of their lives.", "start_char_idx": 0, "end_char_idx": 3567, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72c760c5-0411-4bc1-8611-779a563049dc": {"__data__": {"id_": "72c760c5-0411-4bc1-8611-779a563049dc", "embedding": null, "metadata": {"page_label": "139", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "575eaf74-47b0-47d0-8d55-0bea36c35712", "node_type": "4", "metadata": {"page_label": "139", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "7d03b98c36436ed8962e3ea7bb65eceb15b52b4c9a8e14604b7ac2055390cb27", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ae3427e-259b-4ad6-acfb-23368ccb295e", "node_type": "1", "metadata": {"page_label": "139", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "4e7f6c699eee779ac4f24352714653ba7e064d9d2e8a094ae74977f13af4c28d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bedc3d7a-801e-4c30-a72c-6db929a0a8ce", "node_type": "1", "metadata": {}, "hash": "bc54271a5035c99bcc349bfa0b27d8ab854831139d9694911d84175e3de2ad1e", "class_name": "RelatedNodeInfo"}}, "text": "(Cui et al.,\nR.D.S., unpublished data). Specifically, 31/32 RAG-2/H11002//H110022003) provides further evidence that innate immune cells\nmice (13\u201328 months old) developed spontaneous neo-comprise an important arm of the immunosurveillance\nplasia, predominantly of the intestine. Eight had prema-network. A single BALB/c mouse was serendipitously\nlignant intestinal adenomas, 22 had intestinal adenocar-found that failed to form ascites when injected intraperi-\ncinomas, and one had an intestinal adenoma and a lungtoneally with the extremely aggressive S180 sarcoma\nadenocarcinoma. In contrast, 21/33 wild-type mice re-cell line. Subsequent breeding revealed that the ob-\nmained neoplasia free to the end of their lives. Of theserved cancer resistance trait was germline transmissi-\nwild-type mice that developed neoplastic disease, six hadble and was likely controlled by a single autosomal domi-\nadenomas of the Harderian gland, lung, intestine, stom-nant locus. In addition, the resulting \u201cspontaneous\nach, or liver, while six others developed unrelated can-regression/complete remission\u201d (SR/CR) mice were able\ncers that predominantly appeared late in life. Thus, lym-to kill a range of both syngeneic and allogeneic tumorphocytes protect mice against both chemically-inducedcells derived from multiple tissue sites. Despite theirand spontaneous tumor formation.avid antitumor resistance, SR/CR mice did not exhibitSubsequent studies have extended these findings byautoimmune pathology or shortened lifespan. Interest-identifying which of the possible RAG-dependent lym-ingly, resistance to S180 was also observed when thephocyte subsets contribute to host antitumor defense.SR/CR trait was bred onto a nude genetic background,This work highlighted roles for /H9253/H9254T cells, /H9251/H9252T cells,suggesting that the SR/CR phenotype is predominantlyand NKT cells in the immunosurveillance process. Micemediated by innate immune cells. Characterization oflacking either /H9251/H9252T cells (TCR /H9252/H11002//H11002mice) or /H9253/H9254T cellsthe locus controlling the SR/CR phenotype should pro-(TCR /H9254/H11002//H11002mice) are more susceptible to MCA-inducedvide new insights into innate immune control of tumortumor formation than wild-type mice (on either an FVBgrowth.or C57BL/6 genetic background) (Girardi et al., 2001;Taken together, these data not only highlight roles forGao et al., 2003). In contrast, using a carcinogenesisboth innate and adaptive immune components in themodel involving initiation with 7, 12-dimethylbenzelimination phase of cancer immunoediting but also[a]anthracene (DMBA) and promotion with 12-O-tetra-underline the complexity of the host\u2019s immune responsedecanoylphorbol 13-acetate (TPA), host protection\nto developing tumors. Specifically, cancer immunosur-against tumor formation was found to be more depen-\nveillance appears to be a multivariable process in whichdent on the action of /H9253/H9254T cells than /H9251/H9252T cells. Whereas\nimmunologic responses are influenced by a tumor\u2019s cel-FVB strain TCR /H9254/H11002//H11002mice formed significantly more\nlular origin, mode of transformation, anatomic location, DMBA/TPA tumors than wild-type FVB controls, FVB\nstromal response, cytokine production profile, and in- strain TCR /H9252/H11002//H11002did not (Girardi et al., 2001, 2003). How-\nherent immunogenicity.", "start_char_idx": 2847, "end_char_idx": 6212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bedc3d7a-801e-4c30-a72c-6db929a0a8ce": {"__data__": {"id_": "bedc3d7a-801e-4c30-a72c-6db929a0a8ce", "embedding": null, "metadata": {"page_label": "139", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "575eaf74-47b0-47d0-8d55-0bea36c35712", "node_type": "4", "metadata": {"page_label": "139", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "7d03b98c36436ed8962e3ea7bb65eceb15b52b4c9a8e14604b7ac2055390cb27", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72c760c5-0411-4bc1-8611-779a563049dc", "node_type": "1", "metadata": {"page_label": "139", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "4b41a0509f9ece3595c8b6ba5d62d4ad1f5956eb63c74d6e5ceac3b67881cf59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9f18101-8be1-477f-8308-578eeee46688", "node_type": "1", "metadata": {}, "hash": "e4f57577fe2ca414c902a47cf54d8ef4eafb86cf9aecd0d58f0981095db4fdaf", "class_name": "RelatedNodeInfo"}}, "text": "Specifically, cancer immunosur-against tumor formation was found to be more depen-\nveillance appears to be a multivariable process in whichdent on the action of /H9253/H9254T cells than /H9251/H9252T cells. Whereas\nimmunologic responses are influenced by a tumor\u2019s cel-FVB strain TCR /H9254/H11002//H11002mice formed significantly more\nlular origin, mode of transformation, anatomic location, DMBA/TPA tumors than wild-type FVB controls, FVB\nstromal response, cytokine production profile, and in- strain TCR /H9252/H11002//H11002did not (Girardi et al., 2001, 2003). How-\nherent immunogenicity. Thus, it remains critical to ever, TCR /H9252/H11002//H11002/H11003/H9254/H11002//H11002mice were significantly more sus-\nassess the effects of a wide range of immunologic ceptible to DMBA/TPA carcinogenesis than singly-defi-\ncomponents on tumor development in many different cient TCR /H9254/H11002//H11002mice (Girardi et al., 2003), revealing a\nmodels\u2014both chemically induced and spontaneous\u2014 host-protective role for /H9251/H9252T cells in the setting of /H9253/H9254\nto determine whether the immunosurveillance of all T cell deficiency. Interestingly, in the same study TCR\ncancer-susceptible tissues of the body is globally similar /H9254/H11002//H11002mice exhibited the highest ratio of carcinomas to\npapillomas, suggesting that /H9253/H9254T cells regulate the pro- or locally distinct.", "start_char_idx": 5618, "end_char_idx": 7008, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9f18101-8be1-477f-8308-578eeee46688": {"__data__": {"id_": "f9f18101-8be1-477f-8308-578eeee46688", "embedding": null, "metadata": {"page_label": "140", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e4ee745d-241c-4117-94d0-f29138fb9121", "node_type": "4", "metadata": {"page_label": "140", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "684fe31337ca4ca10bd5e59912a79290bab35c089bfb8fc8dc3719b6239acfa8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bedc3d7a-801e-4c30-a72c-6db929a0a8ce", "node_type": "1", "metadata": {"page_label": "139", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "3005463214d42ab546b2163c9e48d7fff1d2720c82895be43495f791db78a821", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe21853b-2bfe-407b-af49-d68ff1dd0e56", "node_type": "1", "metadata": {}, "hash": "a64e387ac927572dbfa2cc3093a328002ccc8d6252cb4f8ad55f06f7d8e23274", "class_name": "RelatedNodeInfo"}}, "text": "Immunity\n140\nEffector Functions Underlying Immunosurveillance: IFN-/H9253/H11001//H11001and TCR /H9254/H11002//H11002IFN-/H9253/H11001//H11001mice, whereas the exper-\nimental group consisted of lethally irradiated IFN- /H9253/H11002//H11002IFN/H9253Production and Cytotoxicity\nIFN/H9253Production mice reconstituted with a mixture of bone marrow from\nTCR/H9252/H11002//H11002/H11003IFN-/H9253/H11002//H11002and TCR /H9254/H11002//H11002IFN-/H9253/H11001//H11001mice. Thus, The studies that identified physiologically relevant cellu-\nlar effectors of immunosurveillance have been comple- the only deficiency in the reconstituted experimental\ngroup was that mature /H9253/H9254T cells could not produce mented by studies that defined two of the critical tasks\nthese immune cells must effect to eradicate developing IFN- /H9253. When challenged with MCA, the control bone\nmarrow chimera group displayed a susceptibility to tu- tumors: the production of IFN- /H9253and the ability to kill.\nEndogenously produced interferon- /H9253(IFN-/H9253) was shown mor formation similar to that of wild-type mice. In con-\ntrast, chimeric mice with /H9253/H9254T cells that could not to protect the host against the growth of transplanted\ntumors and also the formation of primary chemically produce IFN- /H9253were significantly more susceptible to\nMCA-induced tumor formation than wild-type counter- induced and spontaneous tumors (Dighe et al., 1994;\nKaplan et al., 1998; Shankaran et al., 2001; Street et al., parts and displayed an increased MCA susceptibility,\nindistinguishable from that of IFN- /H9253/H11002//H11002mice. Thus, /H9253/H9254 2001, 2002). Injection of neutralizing mAbs for IFN- /H9253into\nmice bearing transplanted, established Meth A tumors T cells are one physiologically relevant source of IFN- /H9253\nin the cancer immunosurveillance process. Additional blocked LPS-induced tumor rejection (Dighe et al.,\n1994). In addition, transplanted fibrosarcomas grew work is required to identify if there are other cellular\nsources of IFN- /H9253during tumor development and to de- faster and more efficiently in mice treated with IFN- /H9253-\nspecific mAbs. In models of primary tumor formation, termine whether other IFN- /H9253-producing cells participate\nin responses to different types of tumors. IFN-/H9253-insensitive 129/SvEv mice lacking either the\nIFNGR1 ligand binding subunit of the IFN- /H9253receptor or More is known about the physiologically relevant tar-\ngets of IFN- /H9253\u2019s actions. Host cells are important targets STAT1, the transcription factor that mediates much of\nIFN-/H9253\u2019s biologic effects on cells (Bach et al., 1997), were of IFN- /H9253during development of protective antitumor\nimmune responses. STAT1/H11002//H11002mice with generalized found to be 10\u201320 times more sensitive than wild-type\nmice to MCA tumor induction (Kaplan et al., 1998). These IFN- /H9253/IFN- /H9251/H9252insensitivity are more sensitive to MCA\nprimary tumor induction (Kaplan et al., 1998) and also mice developed more tumors, more rapidly, and at lower\ncarcinogen doses than did wild-type controls. Similar cannot reject highly immunogenic transplanted IFN- /H9253-\nsensitive tumor cells (Fallarino and Gajewski, 1999; V. results were obtained in independent experiments by\nusing C57BL/6 mice lacking the gene encoding IFN- /H9253 Shankaran and R.D.S., unpublished data). At least in\npart, these results are explained by a requirement for (Street et al., 2001).", "start_char_idx": 0, "end_char_idx": 3470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe21853b-2bfe-407b-af49-d68ff1dd0e56": {"__data__": {"id_": "fe21853b-2bfe-407b-af49-d68ff1dd0e56", "embedding": null, "metadata": {"page_label": "140", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e4ee745d-241c-4117-94d0-f29138fb9121", "node_type": "4", "metadata": {"page_label": "140", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "684fe31337ca4ca10bd5e59912a79290bab35c089bfb8fc8dc3719b6239acfa8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9f18101-8be1-477f-8308-578eeee46688", "node_type": "1", "metadata": {"page_label": "140", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "a962d0e1010f4539910ce70d55edb0fc4fa85a998eb0931c9182a23c62a5da26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "678d3b30-b33d-4992-b394-2c9c3e55eccb", "node_type": "1", "metadata": {}, "hash": "6d49c84cf5fe25a6826e1555a1c3e34bccf97ab138440fb430abb55a26c2cceb", "class_name": "RelatedNodeInfo"}}, "text": "These IFN- /H9253/IFN- /H9251/H9252insensitivity are more sensitive to MCA\nprimary tumor induction (Kaplan et al., 1998) and also mice developed more tumors, more rapidly, and at lower\ncarcinogen doses than did wild-type controls. Similar cannot reject highly immunogenic transplanted IFN- /H9253-\nsensitive tumor cells (Fallarino and Gajewski, 1999; V. results were obtained in independent experiments by\nusing C57BL/6 mice lacking the gene encoding IFN- /H9253 Shankaran and R.D.S., unpublished data). At least in\npart, these results are explained by a requirement for (Street et al., 2001). In models of genetically driven tu-\nmorigenesis, mice lacking both the p53 tumor suppres- IFN- /H9253sensitivity at the level of the host immune compart-\nment. Through its capacity to promote the generation sor gene and either IFNGR1 or STAT1 formed a wider\ntumor spectrum compared to IFN- /H9253-sensitive mice lack- of tumor-specific CD4/H11001Th1 T cells and cytolytic T cells\n(CTL) and to activate cytocidal activity in macrophages, ing p53 only (Kaplan et al., 1998). In another study, 16/\n32 of IFN- /H9253/H11002//H11002C57BL/6 mice developed disseminated IFN- /H9253facilitates development of powerful anti-tumor ef-\nfector functions mediated by both adaptive and innate lymphomas compared to 0/39 wild-type C57BL/6 mice\n(Street et al., 2002). immunity (Bach et al., 1997). However, the tumor cells\nthemselves have also been shown to represent a critical The overlap between the IFN- /H9253- and lymphocyte-\ndependent tumor suppressor pathways was revealed cellular target of IFN- /H9253. Highly immunogenic MCA-in-\nduced tumor cells derived from IFN- /H9253sensitive RAG- by comparing tumor formation in 129/SvEv mice lacking\nIFN-/H9253responsiveness (IFNGR1/H11002//H11002or STAT1/H11002//H11002mice), 2/H11002//H11002mice are rejected when injected into naive synge-\nneic immunocompetent recipients (Shankaran et al., lymphocytes (RAG-2/H11002//H11002mice), or both (RAG-2/H11002//H11002x\nSTAT1/H11002//H11002) (RkSk mice) (Shankaran et al., 2001). Each 2001; G.P.D., C.M. Koebel, and R.D.S., unpublished\ndata). However, when the IFN- /H9253sensitivity of these cells group of mice formed three times more chemically in-\nduced tumors than syngeneic wild-type mice when in- is ablated by overexpression of a dominant-negative\nIFNGR1 mutant, they become poorly immunogenic and jected with 100 /H9262g of MCA. Since no significant differ-\nences were detected between any of the gene-targeted form aggressively growing tumors in wild-type mice\n(Dighe et al., 1994; G.P.D., C.M. Koebel, and R.D.S., mice, it was concluded that the IFN- /H9253/STAT1- and lym-\nphocyte-dependent tumor suppressor mechanisms were unpublished data). Conversely, poorly immunogenic\nMCA-sarcoma cells derived from IFNGR1/H11002//H11002mice be- largely overlapping. However, RkSk mice developed\nspontaneous breast tumors that were not observed in come highly immunogenic cells and are rejected in im-\nmunocompetent mice after ectopic expression of wild- wild-type or RAG-2/H11002//H11002mice, therefore demonstrating\nthat the overlap between the two pathways was incom- type IFNGR1 and restoration of IFN- /H9253sensitivity (Kaplan\net al., 1998). IFNGR1/H11002//H11002tumor cells are also rendered plete.", "start_char_idx": 2877, "end_char_idx": 6157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "678d3b30-b33d-4992-b394-2c9c3e55eccb": {"__data__": {"id_": "678d3b30-b33d-4992-b394-2c9c3e55eccb", "embedding": null, "metadata": {"page_label": "140", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e4ee745d-241c-4117-94d0-f29138fb9121", "node_type": "4", "metadata": {"page_label": "140", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "684fe31337ca4ca10bd5e59912a79290bab35c089bfb8fc8dc3719b6239acfa8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe21853b-2bfe-407b-af49-d68ff1dd0e56", "node_type": "1", "metadata": {"page_label": "140", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "2880b481a748b3d3b513fe0735539d589b8782ba5287773efc9baad764c0e9f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1f7ca74-2bf2-4004-8640-3c996aba31fc", "node_type": "1", "metadata": {}, "hash": "10d7375a4f4b80aaf5c0ea8c5b547e2550f92f799b65ec70354f564cf581b6fd", "class_name": "RelatedNodeInfo"}}, "text": "Koebel, and R.D.S., mice, it was concluded that the IFN- /H9253/STAT1- and lym-\nphocyte-dependent tumor suppressor mechanisms were unpublished data). Conversely, poorly immunogenic\nMCA-sarcoma cells derived from IFNGR1/H11002//H11002mice be- largely overlapping. However, RkSk mice developed\nspontaneous breast tumors that were not observed in come highly immunogenic cells and are rejected in im-\nmunocompetent mice after ectopic expression of wild- wild-type or RAG-2/H11002//H11002mice, therefore demonstrating\nthat the overlap between the two pathways was incom- type IFNGR1 and restoration of IFN- /H9253sensitivity (Kaplan\net al., 1998). IFNGR1/H11002//H11002tumor cells are also rendered plete.\nAdditional work has begun to identify the relevant highly immunogenic by ectopic expression of IFN- /H9253-\ninducible components of the MHC class I antigen pro- cellular sources and targets of IFN- /H9253in immunosurveil-\nlance. Recent work suggests that /H9253/H9254T cells are an impor- cessing and presentation pathway (Shankaran et al.,\n2001; A.T. Bruce and R.D.S., unpublished data), thus tant source of IFN- /H9253during the development of protec-\ntive antitumor responses (Gao et al., 2003). To directly revealing that IFN- /H9253\u2019s ability to upregulate tumor immu-\nnogenicity is sufficient to explain the effects on tumor test if /H9253/H9254T cells were a physiologically important source\nof IFN- /H9253in blocking primary tumor formation, two sets detection and elimination in immunocompetent hosts.\nOne key remaining question is whether type I interfer- of bone marrow chimeras were generated. In the control\ngroup, IFN- /H9253/H11002//H11002mice were lethally irradiated and recon- ons (IFN- /H9251//H9252) also participate in cancer immunosurveil-\nlance. Longstanding work from Gresser and colleagues stituted with a mixture of bone marrow from TCR /H9252/H11002//H11002", "start_char_idx": 5456, "end_char_idx": 7342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1f7ca74-2bf2-4004-8640-3c996aba31fc": {"__data__": {"id_": "e1f7ca74-2bf2-4004-8640-3c996aba31fc", "embedding": null, "metadata": {"page_label": "141", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f826b24e-a8f1-4488-a76d-d87018b9107e", "node_type": "4", "metadata": {"page_label": "141", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "b2d9ebad5c11f5b465af34d94d337cbf83353aa75d832cc2b0d41dc9e96b31bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "678d3b30-b33d-4992-b394-2c9c3e55eccb", "node_type": "1", "metadata": {"page_label": "140", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "3e078ec48f94883d023ca719cf2b0dee0a7f111818e09b4d95278a7998de7808", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0f5ddbf-3206-4b92-a60b-2cf534a23db3", "node_type": "1", "metadata": {}, "hash": "c629645ebf4783d9cd4c1dbc6314c348a95ae4e2bfaf778d173a576b6b81eb22", "class_name": "RelatedNodeInfo"}}, "text": "Review\n141\nhas shown that in vivo neutralization of endogenously and CD8/H11001/H9251/H9252T cells recognize tumor antigens in the\ncontext of MHC class II and class I proteins, respec- produced IFN- /H9251//H9252enhances growth of transplanted tu-\ntively. Since the first human tumor antigen was identified mors in wild-type mice (Gresser and Belardelli, 2002).\nin 1991 (van der Bruggen et al., 1991), many tumor anti- Moreover, administration of IFN- /H9251//H9252has positive thera-\ngens have been cloned and can be segregated into five peutic actions on certain types of murine and human\ncategories: (1) differentiation antigens, e.g., melanocyte cancers (Belardelli et al., 2002). More recent in vitro\ndifferentiation antigens, Melan-A/MART-1, tyrosinase, work has pointed to a role for IFN- /H9251//H9252in preventing\nand gp-100; (2) mutational antigens, e.g., abnormal cellular transformation through mechanisms involving\nforms of p53; (3) overexpressed/amplified antigens, e.g., enhanced cellular expression of the p53 tumor suppres-\nHER-2/neu; (4) cancer-testis (CT) antigens, e.g., MAGE sor gene in cells exposed to type I IFN (Takaoka et\nand NY-ESO-1; and (5) viral antigens, e.g., EBV and HPV al., 2003). Further work is needed to define the precise\n(Boon and van der Bruggen, 1996; Rosenberg, 1999; cellular targets of IFN- /H9251//H9252in the cancer immunosur-\nOld, 2003). The molecular definition of tumor antigens veillance process and to determine whether IFN- /H9251//H9252\nhas revolutionized the field of tumor immunology by functions in a manner that is identical to or distinct\nproviding a firm basis for how the adaptive immune from IFN- /H9253.\nsystem discriminates between normal and neoplastic Cytolytic Capacity\ncells. The second critical effector function of cancer immuno-\nIn addition to tumor antigens presented on MHC mole- surveillance is the immune system\u2019s ability to kill tumor\ncules, transformed cells may overexpress other mole- cells. Early studies identified perforin (pfp) as a critical\ncular signposts that can function as recognition targets cytolytic molecule in the primary host antitumor re-\nin the immunosurveillance process. Several studies sponse. After challenge with MCA, pfp/H11002//H11002mice formed\nhave pointed to the NKG2D-activating receptor, ex- two to three times more tumors than wild-type mice (van\npressed on NK cells, /H9253/H9254T cells, and CD8 /H9251/H9252T cells den Broek et al., 1996; Smyth et al., 2000a, 2000b; Street\n(Bauer et al., 1999; reviewed in Raulet, 2003), as one et al., 2001). In addition, 50% (10/20) of aging pfp/H11002//H11002\nimportant component that is used by both adaptive and C57BL/6 mice developed spontaneous disseminated\ninnate immune cells to distinguish cancer cells from lymphomas as compared to 1/16 wild-type mice (Smyth\nnormal cells. Functional NKG2D receptors complexeset al., 2000b). The kinetics of lymphoma development\nconsist of the NKG2D ligand binding polypeptide andwere accelerated in pfp/H11002//H11002mice also lacking p53 (Smyth\neither the DAP10 or DAP12 signaling polypeptide (Gilfil-et al., 2000b) or /H92522 microglobulin (Street et al., 2004).\nlan et al., 2002).", "start_char_idx": 0, "end_char_idx": 3174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0f5ddbf-3206-4b92-a60b-2cf534a23db3": {"__data__": {"id_": "e0f5ddbf-3206-4b92-a60b-2cf534a23db3", "embedding": null, "metadata": {"page_label": "141", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f826b24e-a8f1-4488-a76d-d87018b9107e", "node_type": "4", "metadata": {"page_label": "141", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "b2d9ebad5c11f5b465af34d94d337cbf83353aa75d832cc2b0d41dc9e96b31bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1f7ca74-2bf2-4004-8640-3c996aba31fc", "node_type": "1", "metadata": {"page_label": "141", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "269dcfb45eaa2366d8df6c5f762580d90f7e833f096259a0b2dbbd0f08d646f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf0a70bc-64a5-4675-abd4-20e0738f3175", "node_type": "1", "metadata": {}, "hash": "6736fe855c6d95d93855c945f752a42018dc1298762f391d86532e8a65174304", "class_name": "RelatedNodeInfo"}}, "text": "In addition, 50% (10/20) of aging pfp/H11002//H11002\nimportant component that is used by both adaptive and C57BL/6 mice developed spontaneous disseminated\ninnate immune cells to distinguish cancer cells from lymphomas as compared to 1/16 wild-type mice (Smyth\nnormal cells. Functional NKG2D receptors complexeset al., 2000b). The kinetics of lymphoma development\nconsist of the NKG2D ligand binding polypeptide andwere accelerated in pfp/H11002//H11002mice also lacking p53 (Smyth\neither the DAP10 or DAP12 signaling polypeptide (Gilfil-et al., 2000b) or /H92522 microglobulin (Street et al., 2004).\nlan et al., 2002). In humans, NKG2D binds to the MHCSubsequent studies revealed an important role for the\nclass I chain-related proteins A and B (MICA/B), as wellTNF-related apoptosis-inducing ligand (TRAIL) and have\nas the UL16 binding proteins (ULBPs) (Cosman et al.,underscored the importance of cytotoxicity manifest by\n2001; Pende et al., 2002) and the recently discoveredinnate immunity in immunosurveillance. A member of\nlymphocyte effector cell toxicity-activating ligand (Letal)the TNF superfamily that induces apoptosis through en-\n(Conejo-Garcia et al., 2003) (first reported as RAET1Egagement of the TRAIL-R2 (DR5) receptor in mice, TRAIL\n[Radosavljevic et al., 2002] and also termed ULBP4is expressed constitutively on a subset of liver NK cells\n[Chalupny et al., 2003]). The MICA/B proteins are highlyand is induced by either IFN- /H9253or IFN- /H9251//H9252in monocytes,polymorphic, nonclassical MHC cell surface glycopro-NK cells, and dendritic cells (Smyth et al., 2003). Whenteins that do not associate with /H92522m or require TAP1injected with low doses of MCA, C57BL/6 mice treatedfor expression (Groh et al., 1996; Bahram, 2000). Inter-with neutralizing antibodies to TRAIL (Takeda et al.,estingly, while MIC expression in normal tissues has only2002) or lacking the TRAIL gene (Cretney et al., 2002)been documented on the gastrointestinal epithelium ofdeveloped fibrosarcomas at a higher incidence thanthe stomach and large intestines, MICA/B proteins arewild-type controls. Moreover, p53/H11001//H11002C57BL/6 miceoften expressed in primary carcinomas of the lung, kid-treated with the neutralizing TRAIL-specific antibody de-ney, prostate, ovary, colon (Groh et al., 1999) and liverveloped more spontaneous sarcomas and disseminated(Jinushi et al., 2003b), as well as in melanomas (Vetterlymphomas over a two-year period than control IgG-et al., 2002). In addition, ULBPs (Pende et al., 2002) andtreated mice (Takeda et al., 2002). Further study is re-Letal (Conejo-Garcia et al., 2003) are also frequentlyquired to identify the specific innate cell subsets thatexpressed on tumor cells. In mice, NKG2D binds to themanifest the TRAIL-dependent antitumor effects. Con-retinoic acid early transcript 1 (Rae-1) family proteinssidering that the TRAIL-R2 receptor is upregulated byRae-1 /H9251-/H9280, the minor histocompatibility antigen H60 (Die-p53 in response to DNA damage (Wu et al., 1997, 1999),fenbach et al., 2000; Cerwenka et al., 2001), and mouseTRAIL killing may be a critical link between target cellUL16 binding protein-like transcript (MULT-1) (Carayan-\ngenotoxic distress and immune-mediated destruction.nopoulos et al., 2002; Diefenbach et al., 2003).", "start_char_idx": 2556, "end_char_idx": 5844, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf0a70bc-64a5-4675-abd4-20e0738f3175": {"__data__": {"id_": "bf0a70bc-64a5-4675-abd4-20e0738f3175", "embedding": null, "metadata": {"page_label": "141", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f826b24e-a8f1-4488-a76d-d87018b9107e", "node_type": "4", "metadata": {"page_label": "141", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "b2d9ebad5c11f5b465af34d94d337cbf83353aa75d832cc2b0d41dc9e96b31bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0f5ddbf-3206-4b92-a60b-2cf534a23db3", "node_type": "1", "metadata": {"page_label": "141", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "7af1193fb46911facde681e5a80c51ce2d3cdf20fe320e7f773fed5d2660a499", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c861258-b0c4-488c-9bb4-60d1bb865dd6", "node_type": "1", "metadata": {}, "hash": "99cbff8d4a4262954ab73d1033fdfb0600138720d4b7db8bcbf5bee32265d037", "class_name": "RelatedNodeInfo"}}, "text": "In mice, NKG2D binds to themanifest the TRAIL-dependent antitumor effects. Con-retinoic acid early transcript 1 (Rae-1) family proteinssidering that the TRAIL-R2 receptor is upregulated byRae-1 /H9251-/H9280, the minor histocompatibility antigen H60 (Die-p53 in response to DNA damage (Wu et al., 1997, 1999),fenbach et al., 2000; Cerwenka et al., 2001), and mouseTRAIL killing may be a critical link between target cellUL16 binding protein-like transcript (MULT-1) (Carayan-\ngenotoxic distress and immune-mediated destruction.nopoulos et al., 2002; Diefenbach et al., 2003). NKG2D\nligand expression has been observed on a wide range\nPatrolling Transformation: Mechanisms that Adaptive of murine tumors (Diefenbach et al., 2000), and ectopic\nversus Innate Immunity Use to Distinguish Tumor expression of Rae-1, H60, or MULT-1 was sufficient to\nCells from Normal Cells induce the rejection of several progressively growing,\nThe third central question concerns how cells of the transplantable tumors (Cerwenka et al., 2001; Diefen-\nimmunosurveillance network distinguish nascent trans- bach et al., 2001, 2003).\nformed or established tumor cells from normal cells. It will be important to characterize the regulation of\nWork over the last decade has begun to reveal the mo- NKG2D ligand expression in both human and murine\nlecular basis of this crucial distinction particularly within cells. These molecules are often described as \u201cstress\nmolecules,\u201d but to date no cancer-relevant signaling the adaptive immune compartment. Specifically, CD4/H11001", "start_char_idx": 5269, "end_char_idx": 6816, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c861258-b0c4-488c-9bb4-60d1bb865dd6": {"__data__": {"id_": "0c861258-b0c4-488c-9bb4-60d1bb865dd6", "embedding": null, "metadata": {"page_label": "142", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c460400d-e882-48d3-b8e0-d254fd17abd8", "node_type": "4", "metadata": {"page_label": "142", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "a94d6103232d063670fc5e8b56979731f585dc868eb9b2ba8a83e8ea356d5153", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf0a70bc-64a5-4675-abd4-20e0738f3175", "node_type": "1", "metadata": {"page_label": "141", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "80d08fab29c0a2b05f6022e6dbf967cbf23fc58ac002cbec6484c172fd4b0422", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f90d074-930c-4ffd-b1f2-56a48b194329", "node_type": "1", "metadata": {}, "hash": "3c4384e1b16aff03b5a158e94dab5cd37a8b59a943cd4074d7f50db81ab82891", "class_name": "RelatedNodeInfo"}}, "text": "Immunity\n142\npathways have been causally linked to their expression. (Burnet, 1970). Moreover, the surveillance functions of\nthe immune system were thought to be executed only In human cells, MICA/B gene expression has been in-\nduced in several nontransformed human cell lines by at the earliest stages of tumorigenesis. However, recent\nstudies have started to explain what happens when tu- heat shock at 42 /H11034C (Groh et al., 1999), infection with\nhuman cytomegalovirus (Groh et al., 2001), or exposure mors develop in immunocompetent hosts, as they do\nin individuals with cancer, and what has emerged from toE. coli (Tieng et al., 2002), although in dendritic cells\nMICA/B is upregulated by type I interferon (Jinushi et this is the realization that even when immunosurveil-\nlance fails, the relationship between immunity and can- al., 2003a) or M. tuberculosis infection (Das et al., 2001).\nHowever, it remains unclear how these conditions over- cer is far from over.\nAn appreciation of the complexity of the immune sys- lap the molecular cascades that underlie neoplastic\ntransformation (Hahn and Weinberg, 2002a; Hahn and tem/tumor interaction is based on work that compared\nthe immunogenicities of tumors derived from immuno- Weinberg, 2002b). In mice, Rae-1 is upregulated by reti-\nnoic acid in F9 cells (Nomura et al., 1994) and is also compromised versus immunocompetent mice. In one\nstudy, 17/17 tumors derived from wild-type 129/SvEv expressed early in development (Raulet, 2003). In addi-\ntion, one study assessed the expression of the NKG2D mice and 20/20 tumors derived from immunodeficient\nRAG-2/H11002//H11002mice grew progressively when transplanted ligands H60 and Rae-1 after topical application of DMBA\nand TPA (Girardi et al., 2001). While no expression of into RAG-2/H11002//H11002hosts (Shankaran et al., 2001). Further-\nmore, all 17 wild-type tumors grew progressively when these molecules was observed by RT-PCR in normal\nskin, Rae-1 and H60 expression became detectable 24 transplanted into immunocompetent recipients. How-\never, 8/20 tumors from RAG-2/H11002//H11002mice were rejected hr after carcinogen treatment. Strikingly, expression of\nboth molecules was significantly increased in papillo- when transplanted into wild-type mice. These findings\nshowed that tumors formed in an immunodeficient envi- mas and carcinomas generated by DMBA/TPA treat-\nment. It is possible that the transformation process itself ronment are, as a group, more immunogenic than tu-\nmors that develop in immunocompetent hosts. Similarly, induces molecules such as the NKG2D ligands so that\nthe genomic upheaval of tumorigenesis is directly trans- MCA-induced sarcomas derived from nude (Svane et\nal., 1996) or SCID mice (Engel et al., 1996) were rejected lated into enhanced immune recognition. Further study\non the immunology of transformation will be necessary more frequently than similar tumors derived from wild-\ntype mice when transplanted into wild-type hosts. More- to detail when\u2014and how\u2014in the course of tumorigene-\nsis a cancer cell becomes immunogenic. over, sarcomas from J /H9251281/H11002//H11002mice grew progressively\nwhen transplanted into J /H9251281/H11002//H11002recipients, but their One aspect of the cancer immunosurveillance pro-\ncess that has been the subject of much controversy is growth was significantly impaired when transplanted\ninto wild-type mice (Smyth et al., 2000a). In addition, whether the unmanipulated immune system can detect a\ndeveloping tumor, even one that may express distinctive lymphomas from pfp/H11002//H11002mice grew avidly when trans-\nplanted into pfp/H11002//H11002recipients, but most were rejected recognition molecules on its surface or contain tumor-\nspecific antigens. In the past, it was argued that cellular when transplanted into wild-type mice (Street et al.,\n2002).", "start_char_idx": 0, "end_char_idx": 3841, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f90d074-930c-4ffd-b1f2-56a48b194329": {"__data__": {"id_": "8f90d074-930c-4ffd-b1f2-56a48b194329", "embedding": null, "metadata": {"page_label": "142", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c460400d-e882-48d3-b8e0-d254fd17abd8", "node_type": "4", "metadata": {"page_label": "142", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "a94d6103232d063670fc5e8b56979731f585dc868eb9b2ba8a83e8ea356d5153", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c861258-b0c4-488c-9bb4-60d1bb865dd6", "node_type": "1", "metadata": {"page_label": "142", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "07e884785258c2022f69056ac75955fdaa48a17afda0acbcaddc0b899198d2d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bcc1590-3bbd-4f58-9769-bd1308b18a3c", "node_type": "1", "metadata": {}, "hash": "6e563cd73edd9d270dab8166e20b0b7d56b889db57ad62c70894121179114218", "class_name": "RelatedNodeInfo"}}, "text": "over, sarcomas from J /H9251281/H11002//H11002mice grew progressively\nwhen transplanted into J /H9251281/H11002//H11002recipients, but their One aspect of the cancer immunosurveillance pro-\ncess that has been the subject of much controversy is growth was significantly impaired when transplanted\ninto wild-type mice (Smyth et al., 2000a). In addition, whether the unmanipulated immune system can detect a\ndeveloping tumor, even one that may express distinctive lymphomas from pfp/H11002//H11002mice grew avidly when trans-\nplanted into pfp/H11002//H11002recipients, but most were rejected recognition molecules on its surface or contain tumor-\nspecific antigens. In the past, it was argued that cellular when transplanted into wild-type mice (Street et al.,\n2002). transformation did not provide a sufficient proinflamma-\ntory or \u201cdanger\u201d signal to alert the immune system to Together, the functional demonstration that immunity\nshapes tumor immunogenicity has laid the foundation the presence of a developing tumor (Matzinger, 1994;\nPardoll, 2003). However, it was recently realized that (1) for the development of the cancer immunoediting hy-\npothesis. This concept not only incorporates the original danger signals, such as uric acid (Shi et al., 2003), may\narise from the inherent biology of the tumor itself (Seong no tion of cancer immunosurveillance but also recognizes\nthat even after escaping immunosurveillance, a tumor\u2019s and Matzinger, 2004) and (2) induction of proinflamma-\ntory responses through the generation of potential Toll- im munogenic phenotype is continuously shaped by the\nimmunological forces in its environment. In trying to like receptor ligands, such as heat shock proteins\n(Ohashi et al., 2000; Asea et al., 2002; Srivastava, 2002), understand how tumors may ultimately be sculpted by\nimmunity, we propose that a tumor that has breached or extracellular matrix derivatives, such as hyaluronic\nacid (Termeer et al., 2002) or heparan sulfates (John- the elimination phase of the immunoediting process may\nexperience two subsequent phases in its interactions son et al., 2002), may share similarities to the events\nthat underlie activation of innate immune responses to with the host\u2019s immune system: equilibrium, followed\nby escape (Dunn et al., 2002, 2004). microbial pathogens (Janeway, 1989). Importantly,\nwhereas locally controlled inflammation may be involvedin initiating responses to tumors, excessive inflamma- The Equilibrium Phase of Cancer Immunoediting\ntion may facilitate the transformation process (Balkwill Based on the experimental systems described above,\nand Mantovani, 2001; Coussens and Werb, 2002; Dra- cancer immunosurveillance\u2014i.e., the elimination phase\nnoff, 2004). It is therefore important to better define how of the cancer immunoediting process\u2014can eradicate a\ninflammation inhibits or promotes tumor development significant percentage of transformed cells. However,\nin vivo. some tumor cells may withstand the formidable pres-\nsure exerted by cancer immunosurveillance\u2019s arsenal.Therefore, we envision that there exists a period of la- Immunologic Sculpting of Cancer: When\nTumors Escape Immunosurveillance tency extending from the end of the elimination phase\nto the beginning of the escape phase and the emergence Originally, cancer immunosurveillance was envisaged\nas a binary process: the immune system either protected of clinically detectable malignant disease. This poten-\ntially protracted period in the course of the immune the host from the development or cancer, or it did not", "start_char_idx": 3077, "end_char_idx": 6621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bcc1590-3bbd-4f58-9769-bd1308b18a3c": {"__data__": {"id_": "5bcc1590-3bbd-4f58-9769-bd1308b18a3c", "embedding": null, "metadata": {"page_label": "143", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b5714203-bd3b-4d38-81e3-f958daee6998", "node_type": "4", "metadata": {"page_label": "143", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "93ceecf766479675b0cd68f98fcf662a0c8a86d3bb13325d3f42aafc8522d43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f90d074-930c-4ffd-b1f2-56a48b194329", "node_type": "1", "metadata": {"page_label": "142", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "840de22278a1406d83b425884f4eb019dd81058fa88664a957b1a1c957f5f4a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "effccb3f-b112-4274-9896-e7ae58f09586", "node_type": "1", "metadata": {}, "hash": "a3be9bfb15cf16e1a648e407ded19c1c00e6a122369e0d3e9a2ff147eadaf5b8", "class_name": "RelatedNodeInfo"}}, "text": "Review\n143\nsystem/tumor interaction that probably occurs prior to Likewise, we envision three possible outcomes for a\nthe detection of clinically apparent tumors constitutes tumor that has entered the latent period of equilibrium:\nthe equilibrium phase. The events that occur in the equi- (1) eventual elimination by the immune system, (2) per-\nlibrium phase of cancer immunoediting are likely quite manent maintenance in the equilibrium phase by the\nsimilar to those previously envisaged to occur in a pro- cellular and molecular controls of immunity, or (3) es-\ncess termed tumor dormancy (Wheelock et al., 1981; cape from immune pressure and transit to the final es-\nUhr et al., 1991). In both cases, while the immune system cape phase of the immunoediting process. Importantly,\ninitially constrains the growth of heterogeneous tumors the first two phases of the cancer immunoediting pro-\ncomposed of unstable and rapidly mutating cells, it may cess represent potential goals for immunotherapy: tu-\napproach an asymptote that Darwin could have pre- mor elimination or the durable control of cancer in equi-\ndicted; although many of the original tumor cells are librium. Currently, the equilibrium phase is the most\ndestroyed, new variants arise carrying more mutations hypothetical of the three phases, and more data are\nthat provide them with increased resistance to immune needed to prove its existence. Thus, it is critical to estab-\nattack. Ultimately, the dynamic interaction between im- lish new tumor models that will stringently test for the\nmunity and cancer in the equilibrium phase produces existence of the equilibrium phase during primary tumor\nnew populations of tumor cells vetted for survival in the development and subsequently define the effects of ex-\nimmunocompetent host. perimentally controlled variable periods of equilibrium\nThe tumor substrate on which immune cells continu- on the immunogenicities of established cancers in im-\nously act can contain cancer cells that harbor thousands munocompetent hosts.\nof mutations (Loeb, 1991; Loeb et al., 2003). The enor-\nmous plasticity of the cancer cell genome is thought toThe Escape Phase of Cancer Immunoediting\narise from several types of genetic instability, includingEdited tumor cells surviving the equilibrium phase of\nnucleotide-excision repair instability, microsatellite in-the cancer immunoediting process enter the escapestability, and chromosomal instability (Lengauer et al.,phase where tumor growth proceeds unrestrained by1998), the latter of which may induce gains or losses ofimmune pressure. To become clinically detectable in thewhole chromosomes. Thus, the tumor cell\u2019s constantimmunocompetent host, cancer cells must circumventgenomic metamorphosis may eventually give rise to newboth innate and adaptive immunologic defenses. Thephenotypes that display reduced immunogenicity. Im-degree to which a tumor\u2019s immunogenicity is shapedportantly, while the genesis of variation in tumor cellby its interaction with the host immune system mayimmunogenicity may be stochastic, the tumor that ulti-be determined by the identities of the immune editorsmately emerges from the equilibrium phase is instruc-operative during the equilibrium phase. It is possibletively shaped by the repertoire of immune \u201ceditors\u201d inthat tumor escape from each different tissue site ofits local environment and is thus conditioned to progressorigin may be mechanistically distinct. It therefore fol-into the escape phase of the immunoediting process.lows that metastatic lesions may experience the mostA clinical scenario that likely demonstrates the exis-significant immunologic sculpting\u2014hewn by immunetence of the equilibrium phase in humans is the transmis-pressure from both primary tissue sites of origin as wellsion of cancer from organ transplant donors to recipi-as distant sites of manifestation.ents. In these situations, transplanted organs appearMany studies have documented that tumor escapegrossly cancer free at harvest. While some organ donorscan be a direct consequence of alterations occurring inare subsequently found to harbor disease in other ana-edited tumor targets themselves. For example, sometomic sites, other transplant donors either have no clini-tumor cells develop direct or indirect lesions in antigencal history of cancer or have been in durable remissionprocessing and presentation pathways that facilitatefrom cancer prior to transplantation. One recent studyevasion from adaptive immune recognition. Analysis ofreported the occurrence of metastatic melanoma 1\u20132human tumor specimens has shown that many displayyears posttransplant in two allograft recipients who hadlosses of HLA class I proteins (Algarra et al., 2000; Marin-each received kidneys from the same donor (MacKie et\ncola et al., 2000). In addition, other components of thisal., 2003).", "start_char_idx": 0, "end_char_idx": 4850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "effccb3f-b112-4274-9896-e7ae58f09586": {"__data__": {"id_": "effccb3f-b112-4274-9896-e7ae58f09586", "embedding": null, "metadata": {"page_label": "143", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b5714203-bd3b-4d38-81e3-f958daee6998", "node_type": "4", "metadata": {"page_label": "143", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "93ceecf766479675b0cd68f98fcf662a0c8a86d3bb13325d3f42aafc8522d43c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bcc1590-3bbd-4f58-9769-bd1308b18a3c", "node_type": "1", "metadata": {"page_label": "143", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "e95e34e82dd9b11671cc6474df80e142586d50a2359100d4750568d9ca6e99f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f02f8199-8c9a-4151-8165-f7bd02754e86", "node_type": "1", "metadata": {}, "hash": "02e6b0b64aa04df1c655e0bdfaac3d229d324acdc9239187bf1e60cebaa19ece", "class_name": "RelatedNodeInfo"}}, "text": "While some organ donorscan be a direct consequence of alterations occurring inare subsequently found to harbor disease in other ana-edited tumor targets themselves. For example, sometomic sites, other transplant donors either have no clini-tumor cells develop direct or indirect lesions in antigencal history of cancer or have been in durable remissionprocessing and presentation pathways that facilitatefrom cancer prior to transplantation. One recent studyevasion from adaptive immune recognition. Analysis ofreported the occurrence of metastatic melanoma 1\u20132human tumor specimens has shown that many displayyears posttransplant in two allograft recipients who hadlosses of HLA class I proteins (Algarra et al., 2000; Marin-each received kidneys from the same donor (MacKie et\ncola et al., 2000). In addition, other components of thisal., 2003). Upon subsequent investigation, it was found\npathway, including TAP1 and the immunoproteasomethat the donor had been treated for primary melanoma\nsubunits LMP2 and LMP7, are frequently deficient in16 years before her death, but was considered tumor\nhuman tumors (Seliger et al., 2000). Moreover, otherfree at the time of organ donation. This study, together\nlesions were identified that indirectly lead to antigenwith others in the literature (Penn, 1991, 1996; Elder et\nprocessing or presentation defects. In one study, 4/17 al., 1997; Suranyi et al., 1998), suggests that the pharma-\n(25%) human lung adenocarcinoma cell lines were found cologic suppression of the immune systems of these\nto be unresponsive to IFN- /H9253due to the absence or ab- transplant recipients facilitated the rapid and progres-\nnormal function of components of the IFN- /H9253receptor sive outgrowth of occult tumors that were maintained\nsignaling pathway (Kaplan et al., 1998). Tumor cells ex- in the equilibrium phase by the donor\u2019s intact immune\npressing these lesions failed to upregulate MHC class I system.\npathway activity when exposed to IFN- /H9253. Similar lesions We stress here that the cancer immunoediting pro-\nwere found in other studies that reported deficiencies of cess may not always represent the linear progression\nIFN receptor signaling pathway components in prostate of a tumor from the elimination phase through the equi-\ncancer (G.P.D. and R.D.S., unpublished data) and mela- librium phase and into the final escape phase of clinical\nnoma (Wong et al., 1997). detection. Indeed, this process may be terminated in\nTumor escape has also been observed as one out- the elimination phase if the cancer immunosurveillance\nprocess is successful at destroying a developing tumor. come of specific immunotherapeutic approaches. In one", "start_char_idx": 4003, "end_char_idx": 6679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f02f8199-8c9a-4151-8165-f7bd02754e86": {"__data__": {"id_": "f02f8199-8c9a-4151-8165-f7bd02754e86", "embedding": null, "metadata": {"page_label": "144", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "02b6a1d8-b496-4ac9-ab89-d339d0f7f743", "node_type": "4", "metadata": {"page_label": "144", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "3444e7f1652242f11f93012db09c1fb3a43bef181ecccff55982c9eef05ecb54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "effccb3f-b112-4274-9896-e7ae58f09586", "node_type": "1", "metadata": {"page_label": "143", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "7db3b583646d9b025437e49d24284582031cdd3a71fadc353df45ab6dc758f6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1455d3f0-9b2a-4285-8698-7aee6f5183f3", "node_type": "1", "metadata": {}, "hash": "1d3cdafd0a9a710219019a5311d8122c5ce63d97efad63b1f5f1e39b8e3f4214", "class_name": "RelatedNodeInfo"}}, "text": "Immunity\n144\nstudy, ten patients harboring metastatic melanoma re- mice to reject tumors that grew progressively in con-\nceived adoptively transferred T cells specific to the tu- trol mice.\nmor antigens MART-1/MelanA or gp100 with adjuvant These observations have stimulated interest in defin-\nIL-2 therapy (Yee et al., 2002). Although 8/10 patients ing the tumor antigens recognized by Tregs and in de-\nexperienced stable, minor, or mixed clinical responses, termining whether an inhibitory T cell subset operates\n3/5 patients studied exhibited specific loss of the tumor similarly in human cancer patients. By using SEREX\nantigen that was targeted during treatment. Similar find- analysis (Sahin et al., 1995), an expression cloning tech-\nings were made in two other melanoma vaccine trials nique wherein IgG class antibodies present in the sera\nin which multiple tumors from individual patients under- of tumor bearing hosts are used to identify tumor anti-\ngoing vaccination with peptides from gp-100, MART-1, gens, a set of normal, nonmutated proteins, including\nand tyrosinase lost expression of either the targeted Dna J-like 2, were identified as tumor antigens. When\nmelanoma antigens or all HLA molecules on which the challenged intravenously with fibrosarcoma cells, naive\nantigens were presented (Jager et al., 1997; Khong et mice preimmunized with a subset of these SEREX-\nal., 2004). These studies clearly show that tumors may defined antigens displayed a remarkable enhancement\nevade both naturally occurring or therapeutically in- of pulmonary metastases compared to control mice\nduced immune responses and suggest that at least (Nishikawa et al., 2003). This effect was inhibited if Dna\nsome of the dynamics underlying the cancer immuno- J-like 2-immunized mice were first depleted of CD25/H11001\nediting process in the unmanipulated host are also at cells. Moreover, permissiveness for tumor growth could\nwork when the three phases of cancer immunoediting be transferred to naive mice by passive transfer of\nare initiated therapeutically. CD4/H11001CD25/H11001T cells derived from Dna J-like 2-immu-\nOther work has shown that inhibition of the protective nized hosts. More striking were the subsequent obser-\nfunctions of the immune system may also facilitate tu- vations that (1) Dna J-like 2-immunized mice developed\nmor escape. In this scenario, immunologically sculpted MCA-induced primary tumors more rapidly and with\ntumor cell variants may overproduce immunosuppres- greater frequency compared to control mice and (2) this\nsive cytokines, such as TGF- /H9252or IL-10 (Khong and effect was abrogated if the immunized mice were pre-\nRestifo, 2002), or inhibit immune responses through treated with a depleting CD25-specific mAb (H. Nishi-\nother mechanisms. One study documented that solublekawa, T. Kato, L.J.O., and H. Shiku, unpublished data).\nforms of the MIC NKG2D ligands, secreted by certainTogether, these results suggest that CD4/H11001CD25/H11001Tregs\nhuman tumors, downregulated the NKG2D receptor onplay an important role in suppressing protective immune\nimmune effector cells and attenuated lymphocyte-medi-responses against both primary and transplanted tumors.\nated cytotoxicity (Groh et al., 2002). Other studies dem-Recent studies have suggested that Tregs can also\nonstrated that some tumor cells overproduce inhibitorsbe detected in a variety of human cancers. Specifically,\nof T cell responses, such as galectin-1 (Rubinstein etindividuals with nonsmall cell lung cancer or cancers of\nal., 2004) and indoleamine 2,3-dioxygenase (IDO) (Uytten-the ovary (Woo et al., 2001), breast, or pancreas (Liya-\nhove et al., 2003). Finally, other developing tumors sup-nage et al., 2002) all displayed elevated levels of\npress induction of proinflammatory danger signalsCD4/H11001CD25/H11001Tregs.", "start_char_idx": 0, "end_char_idx": 3826, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1455d3f0-9b2a-4285-8698-7aee6f5183f3": {"__data__": {"id_": "1455d3f0-9b2a-4285-8698-7aee6f5183f3", "embedding": null, "metadata": {"page_label": "144", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "02b6a1d8-b496-4ac9-ab89-d339d0f7f743", "node_type": "4", "metadata": {"page_label": "144", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "3444e7f1652242f11f93012db09c1fb3a43bef181ecccff55982c9eef05ecb54", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f02f8199-8c9a-4151-8165-f7bd02754e86", "node_type": "1", "metadata": {"page_label": "144", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "6056c9544d70394381f5eeec98736784664d083085e899905e3550c4bfc9a0bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a348906-ec20-44fc-a355-cdba0a470d7d", "node_type": "1", "metadata": {}, "hash": "fb63e4a01c05cca7eb5585bae062cbfd13cea86c13215bdd93a7a11dd6478b41", "class_name": "RelatedNodeInfo"}}, "text": "ated cytotoxicity (Groh et al., 2002). Other studies dem-Recent studies have suggested that Tregs can also\nonstrated that some tumor cells overproduce inhibitorsbe detected in a variety of human cancers. Specifically,\nof T cell responses, such as galectin-1 (Rubinstein etindividuals with nonsmall cell lung cancer or cancers of\nal., 2004) and indoleamine 2,3-dioxygenase (IDO) (Uytten-the ovary (Woo et al., 2001), breast, or pancreas (Liya-\nhove et al., 2003). Finally, other developing tumors sup-nage et al., 2002) all displayed elevated levels of\npress induction of proinflammatory danger signalsCD4/H11001CD25/H11001Tregs. Moreover, another study has identi-\nthrough mechanisms involving activated STAT3, leadingfied the CT antigen LAGE-1 as the first human tumorto impaired dendritic cell maturation that, in turn, pro-antigen specifically recognized by Tregs (Wang et al.,vides the developing tumor with a potential mechanism2004). These studies not only complement those in ani-to escape immune detection (Wang et al., 2003). Thus,mal models but also point to the probable clinical rele-a tumor may directly inhibit antitumor immune re-vance of regulatory T cell activity in human cancer. Fur-sponses by multiple mechanisms.ther studies will be necessary to characterize theSignificant interest has recently focused on thephenotypes of Tregs, elucidate the molecular basis ofpremise that tumors may also facilitate the generation,their suppressive functions and identify more fully theiractivation, or function of immunosuppressive T cell pop-physiologic ligands.ulations (Terabe and Berzofsky, 2004), such as IL-13-\nproducing NKT cells (Terabe et al., 2000) or CD4/H11001CD25/H11001\nConclusionregulatory T cells (T regs). The latter have attracted con-\nIn his writings about cancer immunosurveillance, Lewissiderable attention due to their involvement in control-\nThomas reflected that, \u201cIt seemed to me then, and stillling both pathologic and protective immune responses.\ndoes, that some such built-in immunologic mechanismOriginally identified as a CD4/H11001T cell subset (comprising\nought to exist for natural defense against cancer\u201d 5%\u201310% of all peripheral T cells) constitutively express-\n(Thomas, 1982). In this review, we have summarized ing CD25 that controls the behavior of autoreactive\nthe functional evidence showing that such immunologic T cells in vivo and suppresses T cell responses in vitro\ndefenses do, in fact, exist in the immunocompetent host (Sakaguchi et al., 1995; Read et al., 1998; Thornton and\nand have discussed the nature of the known cellular and Shevach, 1998), CD4/H11001CD25/H11001Tregs were subsequently\nmolecular components that inhibit tumor development. suggested to play important roles in inhibiting naturally\nFurthermore, we have pointed out several remaining occurring and therapeutically induced protective im-\ncritical questions whose answers will ultimately frame mune responses against tumors. Two studies showed\na full understanding of the host-protective cancer immu- that CD4/H11001CD25/H11001Tregs are often responsible for the\nnosurveillance network. We have also discussed the failure of naive murine hosts to eliminate transplanted\nstudies demonstrating that cancer immunosurveillance tumors (Onizuka et al., 1999; Shimizu et al., 1999). Col-\nis not the whole story, thus prompting the development lectively, these studies documented that depletion of\nCD4/H11001CD25/H11001Tregs by using an anti-CD25 mAb enabled of the cancer immunoediting hypothesis\u2014i.e., the ac-", "start_char_idx": 3198, "end_char_idx": 6727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a348906-ec20-44fc-a355-cdba0a470d7d": {"__data__": {"id_": "6a348906-ec20-44fc-a355-cdba0a470d7d", "embedding": null, "metadata": {"page_label": "145", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f2557d05-79aa-4670-b627-97d3e7d55973", "node_type": "4", "metadata": {"page_label": "145", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "0c0e828c5c4421eef258e493c968d8e7679af9d8d3d68a3d750030f1ac7fed79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1455d3f0-9b2a-4285-8698-7aee6f5183f3", "node_type": "1", "metadata": {"page_label": "144", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "f762312f68f0dbee5ef60dc6bc1f9ed13d11dde618b8ed63a093835129db3c10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c919b4d9-d475-4a60-acf9-8e8de0353489", "node_type": "1", "metadata": {}, "hash": "7bd5496793623e0f23f838f496ac8d98c5c810af89c85e183b7dd2d061468814", "class_name": "RelatedNodeInfo"}}, "text": "Review\n145\nCerwenka, A., Baron, J.L., and Lanier, L.L. (2001). Ectopic expres- knowledgment that immunity\u2019s powers to protect the\nsion of retinoic acid early inducible-1 gene (RAE-1) permits naturalhost from cancer may also drive the generation of tu-\nkiller cell-mediated rejection of a MHC class I-bearing tumor in vivo.mors better suited to survive in an immunologically in-Proc. Natl. Acad. Sci. USA 98, 11521\u201311526.tact environment. The most significant clinical implica-Chalupny, J.N., Sutherland, C.L., Lawrence, W.A., Rein-Weston, A.,tion of this hypothesis is that most, if not all, tumors thatand Cosman, D. (2003). ULBP4 is a novel ligand for human NKG2D.develop in humans may have undergone immunologicBiochem. Biophys. Res. Commun. 305, 129\u2013135.\nsculpting as a result of a cancer immunoediting process,Conejo-Garcia, J.R., Benencia, F., Courreges, M.C., Khang, E.,\nwith the most dramatic consequences of the process Zhang, L., Mohamed-Hadley, A., Vinocur, J.M., Buckanovich, R.J.,\nprobably occurring before the tumor is clinically detect- Thompson, C.B., Levine, B., and Coukos, G. (2003). Letal, A tumor-\nassociated NKG2D immunoreceptor ligand, induces activation and able. Ultimately, if the cancer immunoediting process\nexpansion of effector immune cells. Cancer Biol. Ther. 2, 446\u2013451. indeed emerges as one of the leitmotifs of cancer pro-\nCosman, D., Mullberg, J., Sutherland, C.L., Chin, W., Armitage, R., gression, then an improved understanding of the immu-\nFanslow, W., Kubin, M., and Chalupny, N.J. (2001). ULBPs, novelnobiology of cancer immunoediting and a molecular\nMHC class I-related molecules, bind to CMV glycoprotein UL16 anddefinition of how tumors are shaped by this processstimulate NK cytotoxicity through the NKG2D receptor. Immunitywill undoubtedly bring us closer to tumor immunology\u2019s14, 123\u2013133.\ncapstone: the use of immunotherapy to control and/orCoussens, L.M., and Werb, Z. (2002). Inflammation and cancer.eradicate neoplastic disease in the human cancer pa-Nature 420, 860\u2013867.\ntient.Cretney, E., Takeda, K., Yagita, H., Glaccum, M., Peschon, J.J., and\nSmyth, M.J. (2002). Increased susceptibility to tumor initiation and\nAcknowledgments metastasis in TNF-related apoptosis-inducing ligand-deficient mice.\nJ. Immunol. 168, 1356\u20131361.\nThe authors are grateful to Drs. Ravindra Uppaluri and Jack Bui ofCui, Z., Willingham, M.C., Hicks, A.M., Alexander-Miller, M.A., How-Washington University School of Medicine for helpful commentsard, T.D., Hawkins, G.A., Miller, M.S., Weir, H.M., Du, W., andduring the preparation of this manuscript. Work in the authors\u2019 labo-DeLong, C.J. (2003). Spontaneous regression of advanced cancer:ratories quoted in this review was supported by grants from theidentification of a unique genetically determined, age-dependentNational Cancer Institute, the Ludwig Institute for Cancer Researchtrait in mice. Proc. Natl. Acad. Sci. USA 100, 6682\u20136687.and the Cancer Research Institute.\nDas, H., Groh, V., Kuijl, C., Sugita, M., Morita, C.T., Spies, T., and\nBukowski, J.F. (2001). MICA engagement by human V /H92532V/H92542 T cellsReceived: July 20, 2004enhances their antigen-dependent effector function.", "start_char_idx": 0, "end_char_idx": 3173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c919b4d9-d475-4a60-acf9-8e8de0353489": {"__data__": {"id_": "c919b4d9-d475-4a60-acf9-8e8de0353489", "embedding": null, "metadata": {"page_label": "145", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f2557d05-79aa-4670-b627-97d3e7d55973", "node_type": "4", "metadata": {"page_label": "145", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "0c0e828c5c4421eef258e493c968d8e7679af9d8d3d68a3d750030f1ac7fed79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a348906-ec20-44fc-a355-cdba0a470d7d", "node_type": "1", "metadata": {"page_label": "145", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "7eae0c01dfb39e39e34d1df76a58e5077f7c6e19ceec1ce42804668f8eceb7bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4443bd53-5015-40bc-97a3-e5abcdf72531", "node_type": "1", "metadata": {}, "hash": "4aa8349ead511e22133d1b46d1588c1f502a991ac250526a709a98ea0278f1a3", "class_name": "RelatedNodeInfo"}}, "text": "Work in the authors\u2019 labo-DeLong, C.J. (2003). Spontaneous regression of advanced cancer:ratories quoted in this review was supported by grants from theidentification of a unique genetically determined, age-dependentNational Cancer Institute, the Ludwig Institute for Cancer Researchtrait in mice. Proc. Natl. Acad. Sci. USA 100, 6682\u20136687.and the Cancer Research Institute.\nDas, H., Groh, V., Kuijl, C., Sugita, M., Morita, C.T., Spies, T., and\nBukowski, J.F. (2001). MICA engagement by human V /H92532V/H92542 T cellsReceived: July 20, 2004enhances their antigen-dependent effector function. Immunity 15,Revised: July 27, 200483\u201393.Accepted: July 28, 2004\nDiefenbach, A., Jamieson, A.M., Liu, S.D., Shastri, N., and Raulet, Published: August 17, 2004\nD.H. (2000). Ligands for the murine NKG2D receptor: expression\nby tumor cells and activation of NK cells and macrophages. Nat.References\nImmunol. 1, 119\u2013126.\nDiefenbach, A., Jensen, E.R., Jamieson, A.M., and Raulet, D.H. Algarra, I., Cabrera, T., and Garrido, F. (2000). The HLA crossroad\n(2001). Rae1 and H60 ligands of the NKG2D receptor stimulate tu- in tumor immunology. Hum. Immunol. 61, 65\u201373.\nmour immunity. Nature 413, 165\u2013171.Asea, A., Rehli, M., Kabingu, E., Boch, J.A., Bare, O., Auron, P.E.,\nDiefenbach, A., Hsia, J.K., Hsiung, M.Y., and Raulet, D.H. (2003). A Stevenson, M.A., and Calderwood, S.K. (2002). Novel signal trans-\nnovel ligand for the NKG2D receptor activates NK cells and macro- duction pathway utilized by extracellular HSP70: role of toll-like\nphages and induces tumor immunity. Eur. J. Immunol. 33, 381\u2013391. receptor (TLR) 2 and TLR4. J. Biol. Chem. 277, 15028\u201315034.\nBach, E.A., Aguet, M., and Schreiber, R.D. (1997). The IFN /H9253receptor: Dighe, A.S., Richards, E., Old, L.J., and Schreiber, R.D. (1994). En-\na paradigm for cytokine receptor signaling. Annu. Rev. Immunol. hanced in vivo growth and resistance to rejection of tumor cells\n15, 563\u2013591. expressing dominant negative IFN /H9253receptors. Immunity 1, 447\u2013456.\nBahram, S. (2000). MIC genes: from genetics to biology. Adv. Immu- Dunn, G.P., Old, L.J., and Schreiber, R.D. (2004). The Three Es of\nnol.76, 1\u201360. Cancer Immunoediting. Annu. Rev. Immunol. 22, 329\u2013360.\nBalkwill, F., and Mantovani, A. (2001). Inflammation and cancer: Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., and Schreiber, R.D.\nback to Virchow? Lancet 357539\u2013545. (2002). Cancer immunoediting: from immunosurveillance to tumor\nescape. Nat. Immunol. 3, 991\u2013998. Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J.H., Lanier, L.L.,\nand Spies, T. (1999). Activation of NK cells and T cells by NKG2D, Dranoff, G. (2004).", "start_char_idx": 2580, "end_char_idx": 5214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4443bd53-5015-40bc-97a3-e5abcdf72531": {"__data__": {"id_": "4443bd53-5015-40bc-97a3-e5abcdf72531", "embedding": null, "metadata": {"page_label": "145", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f2557d05-79aa-4670-b627-97d3e7d55973", "node_type": "4", "metadata": {"page_label": "145", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "0c0e828c5c4421eef258e493c968d8e7679af9d8d3d68a3d750030f1ac7fed79", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c919b4d9-d475-4a60-acf9-8e8de0353489", "node_type": "1", "metadata": {"page_label": "145", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "54f3ee8c3906e2571474aaf2ef66afc26ed7e9d46c586ec88d2dffae68f82e1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d0d5aac-8548-46c8-867e-a408192887b4", "node_type": "1", "metadata": {}, "hash": "fc39052442c4cf8e6d8f65d6308a6e3e34c85f5030920b5f4ec1991de67229cf", "class_name": "RelatedNodeInfo"}}, "text": "Annu. Rev. Immunol. 22, 329\u2013360.\nBalkwill, F., and Mantovani, A. (2001). Inflammation and cancer: Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., and Schreiber, R.D.\nback to Virchow? Lancet 357539\u2013545. (2002). Cancer immunoediting: from immunosurveillance to tumor\nescape. Nat. Immunol. 3, 991\u2013998. Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J.H., Lanier, L.L.,\nand Spies, T. (1999). Activation of NK cells and T cells by NKG2D, Dranoff, G. (2004). Cytokines in cancer pathogenesis and cancer\na receptor for stress-inducible MICA. Science 285, 727\u2013729. therapy. Nat. Rev. Cancer 4, 11\u201322.\nBelardelli, F., Ferrantini, M., Proietti, E., and Kirkwood, J.M. (2002). Ehrlich, P. (1909). Ueber den jetzigen Stand der Karzinomforschung.\nInterferon-alpha in tumor immunity and immunotherapy. Cytokine Ned. Tijdschr. Geneeskd. 5, 273\u2013290.\nGrowth Factor Rev. 13, 119\u2013134.Elder, G.J., Hersey, P., and Branley, P. (1997). Remission of trans-\nBoon, T., and van der Bruggen, P. (1996). Human tumor antigens planted melanoma\u2013clinical course and tumour cell characterisation.\nrecognized by T lymphocytes. J. Exp. Med. 183, 725\u2013729. Clin. Transplant. 11, 565\u2013568.\nBurnet, F.M. (1957). Cancer\u2014a Biological Approach. BMJ 1, 841\u2013847. Engel, A.M., Svane, I.M., Mouritsen, S., Rygaard, J., Clausen, J., and\nWerdelin, O. (1996). Methylcholanthrene-induced sarcomas in nude Burnet, F.M. (1964). Immunological factors in the process of carcino-\nmice have short induction times and relatively low levels of surface genesis. Br. Med. Bull. 20, 154\u2013158.\nMHC class I expression. APMIS 104, 629\u2013639.Burnet, F.M. (1970). The concept of immunological surveillance.\nFallarino, F., and Gajewski, T.F. (1999). Cutting edge: differentiation Prog. Exp. Tumor Res. 13, 1\u201327.\nof antitumor CTL in vivo requires host expression of Stat1. J. Immu-Burnet, F.M. (1971). Immunological surveillance in neoplasia. Trans-\nnol.163, 4109\u20134113.plant. Rev. 7, 3\u201325.\nGao, Y., Yang, W., Pan, M., Scully, E., Girardi, M., Augenlicht, L.H.,Carayannopoulos, L.N., Naidenko, O.V., Fremont, D.H., and Yoko-\nCraft, J., and Yin, Z. (2003). /H9253/H9254T cells provide an early source ofyama, W.M. (2002). Cutting edge: murine UL16-binding protein-like\ninterferon /H9253in tumor immunity. J. Exp. Med. 198, 433\u2013442.transcript 1: a newly described transcript encoding a high-affinity\nligand for murine NKG2D. J. Immunol. 169, 4079\u20134083. Gilfillan, S., Ho, E.L., Cella, M., Yokoyama, W.M., and Colonna, M.", "start_char_idx": 4758, "end_char_idx": 7207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d0d5aac-8548-46c8-867e-a408192887b4": {"__data__": {"id_": "4d0d5aac-8548-46c8-867e-a408192887b4", "embedding": null, "metadata": {"page_label": "146", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cff20283-f30e-44d8-8d99-aa3a6662fb19", "node_type": "4", "metadata": {"page_label": "146", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "52a2767cce9c4cb48db5dc16711ee54aeee09ac7c72521a2f0eed4d8da8d0d4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4443bd53-5015-40bc-97a3-e5abcdf72531", "node_type": "1", "metadata": {"page_label": "145", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "4db1ee933dbd0b23eee1838ee59166a634ab7f9c0618f5f55b6f72896bdbb7b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "daceba57-bd3c-46d0-9ff9-e76352e88a4c", "node_type": "1", "metadata": {}, "hash": "59a5cc2cc98204c1b8a4dce0c9fbfbea0612b053aaf50c15c4a4b4d5d7e8293f", "class_name": "RelatedNodeInfo"}}, "text": "Immunity\n146\n(2002). NKG2D recruits two distinct adapters to trigger NK cell acti- Lengauer, C., Kinzler, K.W., and Vogelstein, B. (1998). Genetic insta-\nbilities in human cancers. Nature 396, 643\u2013649. vation and costimulation. Nat. Immunol. 3, 1150\u20131155.\nLiyanage, U.K., Moore, T.T., Joo, H.G., Tanaka, Y., Herrmann, V., Girardi, M., Glusac, E., Filler, R.B., Roberts, S.J., Propperova, I.,\nDoherty, G., Drebin, J.A., Strasberg, S.M., Eberlein, T.J., Goedege- Lewis, J., Tigelaar, R.E., and Hayday, A.C. (2003). The distinct contri-\nbuure, P.S., and Linehan, D.C. (2002). Prevalence of regulatory butions of murine T cell receptor (TCR) /H9253/H9254/H11001and TCR /H9251/H9252/H11001T cells to\nT cells is increased in peripheral blood and tumor microenvironment different stages of chemically induced skin cancer. J. Exp. Med.\nof patients with pancreas or breast adenocarcinoma. J. Immunol. 198, 747\u2013755.\n169, 2756\u20132761.Girardi, M., Oppenheim, D.E., Steele, C.R., Lewis, J.M., Glusac, E.,\nLoeb, L.A. (1991). Mutator phenotype may be required for multistage Filler, R., Hobby, P., Sutton, B., Tigelaar, R.E., and Hayday, A.C.\ncarcinogenesis. Cancer Res. 51, 3075\u20133079. (2001). Regulation of cutaneous malignancy by /H9253/H9254T cells. Science\n294, 605\u2013609. Loeb, L.A., Loeb, K.R., and Anderson, J.P. (2003). Multiple mutations\nand cancer. Proc. Natl. Acad. Sci. USA 100, 776\u2013781.Gresser, I., and Belardelli, F. (2002). Endogenous type I interferons as\nMacKie, R.M., Reid, R., and Junor, B. (2003). Fatal melanoma trans- a defense against tumors. Cytokine Growth Factor Rev. 13, 111\u2013118.\nferred in a donated kidney 16 years after melanoma surgery. N.Groh, V., Bahram, S., Bauer, S., Herman, A., Beauchamp, M., and\nEngl. J. Med. 348, 567\u2013568.Spies, T. (1996). Cell stress-regulated human major histocompatibil-\nMarincola, F.M., Jaffee, E.M., Hicklin, D.J., and Ferrone, S. (2000). ity complex class I gene expressed in gastrointestinal epithelium.\nEscape of human solid tumors from T-cell recognition: molecular Proc. Natl. Acad. Sci. USA 93, 12445\u201312450.\nmechanisms and functional significance. Adv. Immunol. 74,Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K.H., and181\u2013273.Spies, T. (1999). Broad tumor-associated expression and recogni-\nMatzinger, P. (1994). Tolerance, danger, and the extended family. tion by tumor-derived /H9253/H9254T cells of MICA and MICB. Proc. Natl.\nAnnu. Rev. Immunol. 12, 991\u20131045. Acad. Sci. USA 96, 6879\u20136884.", "start_char_idx": 0, "end_char_idx": 2455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "daceba57-bd3c-46d0-9ff9-e76352e88a4c": {"__data__": {"id_": "daceba57-bd3c-46d0-9ff9-e76352e88a4c", "embedding": null, "metadata": {"page_label": "146", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cff20283-f30e-44d8-8d99-aa3a6662fb19", "node_type": "4", "metadata": {"page_label": "146", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "52a2767cce9c4cb48db5dc16711ee54aeee09ac7c72521a2f0eed4d8da8d0d4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d0d5aac-8548-46c8-867e-a408192887b4", "node_type": "1", "metadata": {"page_label": "146", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "fb5e45dba57ec13b5d09054d8db33898ea7c675a93d75517fc2297617d697aab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cec4ed2-bed3-47e2-9fb2-f63345acbcfd", "node_type": "1", "metadata": {}, "hash": "6c6c89532aa9a77fec810f7818948c3da26863f9dadf0db48cba740a39da26e4", "class_name": "RelatedNodeInfo"}}, "text": "Escape of human solid tumors from T-cell recognition: molecular Proc. Natl. Acad. Sci. USA 93, 12445\u201312450.\nmechanisms and functional significance. Adv. Immunol. 74,Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K.H., and181\u2013273.Spies, T. (1999). Broad tumor-associated expression and recogni-\nMatzinger, P. (1994). Tolerance, danger, and the extended family. tion by tumor-derived /H9253/H9254T cells of MICA and MICB. Proc. Natl.\nAnnu. Rev. Immunol. 12, 991\u20131045. Acad. Sci. USA 96, 6879\u20136884.\nNishikawa, H., Kato, T., Tanida, K., Hiasa, A., Tawara, I., Ikeda, H.,Groh, V., Rhinehart, R., Randolph-Habecker, J., Topp, M.S., Riddell,\nIkarashi, Y., Wakasugi, H., Kronenberg, M., Nakayama, T., et al.S.R., and Spies, T. (2001). Costimulation of CD8 /H9251/H9252T cells by NKG2D\n(2003). CD4/H11001CD25/H11001T cells responding to serologically definedvia engagement by MIC induced on virus-infected cells. Nat. Immu-\nautoantigens suppress antitumor immune responses. Proc. Natl.nol.2, 255\u2013260.\nAcad. Sci. USA 100, 10902\u201310906.\nGroh, V., Wu, J., Yee, C., and Spies, T. (2002). Tumour-derived solu-Nomura, M., Takihara, Y., and Shimada, K. (1994). Isolation andble MIC ligands impair expression of NKG2D and T-cell activation.characterization of retinoic acid-inducible cDNA clones in F9 cells:Nature 419, 734\u2013738.one of the early inducible clones encodes a novel protein sharing\nHahn, W.C., and Weinberg, R.A. (2002a). Modelling the molecularseveral highly homologous regions with a Drosophila polyhomeotic\ncircuitry of cancer. Nat. Rev. Cancer 2, 331\u2013341.protein. Differentiation 57, 39\u201350.\nHahn, W.C., and Weinberg, R.A. (2002b). Rules for making human Ohashi, K., Burkart, V., Flohe, S., and Kolb, H. (2000). Cutting edge:\ntumor cells. N. Engl. J. Med. 347, 1593\u20131603. heat shock protein 60 is a putative endogenous ligand of the toll-\nlike receptor-4 complex. J. Immunol. 164, 558\u2013561. Hayakawa, Y., Rovero, S., Forni, G., and Smyth, M.J. (2003).\n/H9251-Galactosylceramide (KRN7000) suppression of chemical- and Old, L.J. (2003). Cancer vaccines 2003: opening address. Cancer\noncogene-dependent carcinogenesis. Proc. Natl. Acad. Sci. USA Immun. 3(Suppl 2), 1.\n100, 9464\u20139469.Old, L.J., and Boyse, E.A. (1964). Immunology of Experimental Tu-\nJager, E., Ringhoffer, M., Altmannsberger, M., Arand, M., Karbach, mors. Annu. Rev. Med. 15, 167\u2013186.\nJ., Jager, D., Oesch, F., and Knuth, A. (1997). ImmunoselectionOnizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., and\nin vivo: independent loss of MHC class I and melanocyte differentia-Nakayama, E. (1999).", "start_char_idx": 1947, "end_char_idx": 4524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cec4ed2-bed3-47e2-9fb2-f63345acbcfd": {"__data__": {"id_": "5cec4ed2-bed3-47e2-9fb2-f63345acbcfd", "embedding": null, "metadata": {"page_label": "146", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cff20283-f30e-44d8-8d99-aa3a6662fb19", "node_type": "4", "metadata": {"page_label": "146", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "52a2767cce9c4cb48db5dc16711ee54aeee09ac7c72521a2f0eed4d8da8d0d4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "daceba57-bd3c-46d0-9ff9-e76352e88a4c", "node_type": "1", "metadata": {"page_label": "146", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "3f873c7a1e1c7d85ca5d2cba8802ffb7b0506150709e210aa282c2ef189b5471", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88759eb9-e1c6-4b40-8258-0a003c283fd9", "node_type": "1", "metadata": {}, "hash": "3a849e63e277f7dd5eba14a6552d7506ac0bfe369b7f3f5eed70d7765a7d0778", "class_name": "RelatedNodeInfo"}}, "text": "Proc. Natl. Acad. Sci. USA Immun. 3(Suppl 2), 1.\n100, 9464\u20139469.Old, L.J., and Boyse, E.A. (1964). Immunology of Experimental Tu-\nJager, E., Ringhoffer, M., Altmannsberger, M., Arand, M., Karbach, mors. Annu. Rev. Med. 15, 167\u2013186.\nJ., Jager, D., Oesch, F., and Knuth, A. (1997). ImmunoselectionOnizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., and\nin vivo: independent loss of MHC class I and melanocyte differentia-Nakayama, E. (1999). Tumor rejection by in vivo administration of\ntion antigen expression in metastatic melanoma. Int. J. Canceranti-CD25 (interleukin-2 receptor /H9251) monoclonal antibody. Cancer\n71, 142\u2013147.Res. 59, 3128\u20133133.\nJaneway, C.A., Jr. (1989). Approaching the asymptote? Evolution Pardoll, D. (2003). Does the immune system see tumors as foreign\nand revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. or self? Annu. Rev. Immunol. 21, 807\u2013839.\n54, 1\u201313.Pende, D., Rivera, P., Marcenaro, S., Chang, C.C., Biassoni, R.,\nJinushi, M., Takehara, T., Kanto, T., Tatsumi, T., Groh, V., Spies, T., Conte, R., Kubin, M., Cosman, D., Ferrone, S., Moretta, L., and\nMiyagi, T., Suzuki, T., Sasaki, Y., and Hayashi, N. (2003a). Critical Moretta, A. (2002). Major histocompatibility complex class I-related\nrole of MHC class I-related chain A and B expression on chain A and UL16-binding protein expression on tumor cell lines\nIFN-/H9251-stimulated dendritic cells in NK cell activation: impairment in of different histotypes: analysis of tumor susceptibility to NKG2D-\nchronic hepatitis C virus infection. J. Immunol. 170, 1249\u20131256. dependent natural killer cell cytotoxicity. Cancer Res. 62, 6178\u2013\n6186.Jinushi, M., Takehara, T., Tatsumi, T., Kanto, T., Groh, V., Spies, T.,\nPenn, I. (1991). Donor transmitted disease: cancer. Transplant. Proc. Kimura, R., Miyagi, T., Mochizuki, K., Sasaki, Y., and Hayashi, N.\n23, 2629\u20132631. (2003b). Expression and role of MICA and MICB in human hepatocel-\nlular carcinomas and their regulation by retinoic acid. Int. J. Cancer Penn, I. (1996). Malignant melanoma in organ allograft recipients.\n104, 354\u2013361. Transplantation 61, 274\u2013278.\nJohnson, G.B., Brunn, G.J., Kodaira, Y., and Platt, J.L. (2002). Recep- Radosavljevic, M., Cuillerier, B., Wilson, M.J., Clement, O., Wicker,\ntor-mediated monitoring of tissue well-being via detection of soluble S., Gilfillan, S., Beck, S., Trowsdale, J., and Bahram, S. (2002). A\nheparan sulfate by Toll-like receptor 4. J. Immunol. 168, 5233\u20135239. cluster of ten novel MHC class I related genes on human chromo-\nsome 6q24.2-q25.3. Genomics 79, 114\u2013123.Kaplan, D.H., Shankaran, V., Dighe, A.S., Stockert, E., Aguet, M.,\nRaulet, D.H. (2003).", "start_char_idx": 4072, "end_char_idx": 6732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88759eb9-e1c6-4b40-8258-0a003c283fd9": {"__data__": {"id_": "88759eb9-e1c6-4b40-8258-0a003c283fd9", "embedding": null, "metadata": {"page_label": "146", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cff20283-f30e-44d8-8d99-aa3a6662fb19", "node_type": "4", "metadata": {"page_label": "146", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "52a2767cce9c4cb48db5dc16711ee54aeee09ac7c72521a2f0eed4d8da8d0d4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cec4ed2-bed3-47e2-9fb2-f63345acbcfd", "node_type": "1", "metadata": {"page_label": "146", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "da4fbc71b9d5667a925ce50482f6ed3a13aadfc47e6f171b9c7fbd6f76d4929e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1655e39f-e135-48be-83f8-1e60b712ef87", "node_type": "1", "metadata": {}, "hash": "d6e17926da5a49e6f3f0a99ba509d10ef151c15a992849c2a075c3702b4e0339", "class_name": "RelatedNodeInfo"}}, "text": "(2002). Recep- Radosavljevic, M., Cuillerier, B., Wilson, M.J., Clement, O., Wicker,\ntor-mediated monitoring of tissue well-being via detection of soluble S., Gilfillan, S., Beck, S., Trowsdale, J., and Bahram, S. (2002). A\nheparan sulfate by Toll-like receptor 4. J. Immunol. 168, 5233\u20135239. cluster of ten novel MHC class I related genes on human chromo-\nsome 6q24.2-q25.3. Genomics 79, 114\u2013123.Kaplan, D.H., Shankaran, V., Dighe, A.S., Stockert, E., Aguet, M.,\nRaulet, D.H. (2003). Roles of the NKG2D immunoreceptor and its Old, L.J., and Schreiber, R.D. (1998). Demonstration of an interferon\nligands. Nat. Rev. Immunol. 3, 781\u2013790. /H9253-dependent tumor surveillance system in immunocompetent mice.\nProc. Natl. Acad. Sci. USA 95, 7556\u20137561. Read, S., Mauze, S., Asseman, C., Bean, A., Coffman, R., and Powrie,\nF. (1998). CD38/H11001CD45RBlowCD4/H11001T cells: a population of T cells with Khong, H.T., and Restifo, N.P. (2002). Natural selection of tumor\nimmune regulatory activities in vitro. Eur. J. Immunol. 28, 3435\u20133447. variants in the generation of \u201ctumor escape\u201d phenotypes. Nat. Immu-\nnol.3, 999\u20131005. Rosenberg, S.A. (1999). A new era for cancer immunotherapy based\non the genes that encode cancer antigens. Immunity 10, 281\u2013287. Khong, H.T., Wang, Q.J., and Rosenberg, S.A. (2004). Identification\nof multiple antigens recognized by tumor-infiltrating lymphocytes Rubinstein, N., Alvarez, M., Zwirner, N.W., Toscano, M.A., Ilarregui,\nJ.M., Bravo, A., Mordoh, J., Fainboim, L., Podhajcer, O.L., and Rabi- from a single patient: tumor escape by antigen loss and loss of\nMHC expression. J. Immunother. 27, 184\u2013190. novich, G.A. (2004). Targeted inhibition of galectin-1 gene expres-", "start_char_idx": 6248, "end_char_idx": 7943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1655e39f-e135-48be-83f8-1e60b712ef87": {"__data__": {"id_": "1655e39f-e135-48be-83f8-1e60b712ef87", "embedding": null, "metadata": {"page_label": "147", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4ebec4af-53d0-48f9-9c9f-6ccce56aad51", "node_type": "4", "metadata": {"page_label": "147", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "8b60eaf59762a2e20215bdd28b0e9dde9e19846c7da50bd533e92be3af50e056", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88759eb9-e1c6-4b40-8258-0a003c283fd9", "node_type": "1", "metadata": {"page_label": "146", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "f0c622d81960f301d8eb10d0e8dc37da97327960bdeb63f85c7a40e73025b30f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "884f0274-61fe-4505-9d80-bc4328a0edfd", "node_type": "1", "metadata": {}, "hash": "751d9bf1b7d99316308a5e867189d159fc43075375bee57e6d9f50570a551bc0", "class_name": "RelatedNodeInfo"}}, "text": "Review\n147\nsion in tumor cells results in heightened T cell-mediated rejection; in immunologically deficient athymic-nude mice. Science 183,\n534\u2013536. A potential mechanism of tumor-immune privilege. Cancer Cell 5,\n241\u2013251.Stutman, O. (1979). Chemical carcinogenesis in nude mice: compari-\nSahin, U., Tureci, O., Schmitt, H., Cochlovius, B., Johannes, T., son between nude mice from homozygous and heterzygous matings\nSchmits, R., Stenner, F., Luo, G., Schobert, I., and Pfreundschuh, and effect of age and carcinogen dose. J. Natl. Cancer Inst. 2,\nM. (1995). Human neoplasms elicit multiple specific immune re- 353\u2013358.\nsponses in the autologous host. Proc. Natl. Acad. Sci. USA 92,Suranyi, M.G., Hogan, P.G., Falk, M.C., Axelsen, R.A., Rigby, R.,\n11810\u201311813.Hawley, C., and Petrie, J. (1998). Advanced donor-origin melanoma\nSakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., and Toda, M. in a renal transplant recipient: immunotherapy, cure, and retrans-\n(1995). Immunologic self-tolerance maintained by activated T cells plantation. Transplantation 66, 655\u2013661.\nexpressing IL-2 receptor /H9251-chains (CD25). Breakdown of a singleSvane, I.M., Engel, A.M., Nielsen, M.B., Ljunggren, H.G., Rygaard,\nmechanism of self-tolerance causes various autoimmune diseases.J., and Werdelin, O. (1996). Chemically induced sarcomas from nude\nJ. Immunol. 155, 1151\u20131164.mice are more immunogenic than similar sarcomas from congenic\nSchreiber, R.D., Old, L.J., Hayday, A.C., and Smyth, M.J. (2004). normal mice. Eur. J. Immunol. 26, 1844\u20131850.\nResponse to \u2018A cancer immunosurveillance controversy\u2019. Nat. Im-Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Ki-\nmunol. 5, 4\u20135.kuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., and Taniguchi,\nSeliger, B., Maeurer, M.J., and Ferrone, S. (2000). Antigen-pro- T. (2003). Integration of interferon- /H9251//H9252signaling to p53 responses\ncessing machinery breakdown and tumor growth. Immunol. Today in tumour suppression and antiviral defence. Nature 424, 516\u2013523.\n21, 455\u2013464.Takeda, K., Smyth, M.J., Cretney, E., Hayakawa, Y., Kayagaki, N.,\nSeong, S.Y., and Matzinger, P. (2004). Hydrophobicity: an ancient Yagita, H., and Okumura, K. (2002). Critical role for tumor necrosis\ndamage-associated molecular pattern that initiates innate immune factor-related apoptosis-inducing ligand in immune surveillance\nresponses. Nat. Rev. Immunol. 4, 469\u2013478. against tumor development. J. Exp. Med. 195, 161\u2013169.\nShankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Terabe, M., and Berzofsky, J.A. (2004). Immunoregulatory T cells in\nOld, L.J., and Schreiber, R.D. (2001). IFN /H9253and lymphocytes prevent tumor immunity. Curr. Opin. Immunol. 16, 157\u2013162.", "start_char_idx": 0, "end_char_idx": 2711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "884f0274-61fe-4505-9d80-bc4328a0edfd": {"__data__": {"id_": "884f0274-61fe-4505-9d80-bc4328a0edfd", "embedding": null, "metadata": {"page_label": "147", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4ebec4af-53d0-48f9-9c9f-6ccce56aad51", "node_type": "4", "metadata": {"page_label": "147", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "8b60eaf59762a2e20215bdd28b0e9dde9e19846c7da50bd533e92be3af50e056", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1655e39f-e135-48be-83f8-1e60b712ef87", "node_type": "1", "metadata": {"page_label": "147", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "94b0498330840da454ff7f8cdb55103489fa586161d81fabd0239265d7eb0185", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86e1fe65-887c-45bd-a7ab-e9f4093f1c0c", "node_type": "1", "metadata": {}, "hash": "81e0a14ba620ccc9357219625925aa082157b1f0885fcc57481dcd489ba8c44d", "class_name": "RelatedNodeInfo"}}, "text": "(2002). Critical role for tumor necrosis\ndamage-associated molecular pattern that initiates innate immune factor-related apoptosis-inducing ligand in immune surveillance\nresponses. Nat. Rev. Immunol. 4, 469\u2013478. against tumor development. J. Exp. Med. 195, 161\u2013169.\nShankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Terabe, M., and Berzofsky, J.A. (2004). Immunoregulatory T cells in\nOld, L.J., and Schreiber, R.D. (2001). IFN /H9253and lymphocytes prevent tumor immunity. Curr. Opin. Immunol. 16, 157\u2013162.\nprimary tumour development and shape tumour immunogenicity.Terabe, M., Matsui, S., Noben-Trauth, N., Chen, H., Watson, C.,\nNature 410, 1107\u20131111.Donaldson, D.D., Carbone, D.P., Paul, W.E., and Berzofsky, J.A.\nShi, Y., Evans, J.E., and Rock, K.L. (2003). Molecular identification (2000). NKT cell-mediated repression of tumor immunosurveillance\nof a danger signal that alerts the immune system to dying cells. by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1, 515\u2013520.\nNature 425, 516\u2013521.Termeer, C., Benedix, F., Sleeman, J., Fieber, C., Voith, U., Ahrens,\nShimizu, J., Yamazaki, S., and Sakaguchi, S. (1999). Induction of T., Miyake, K., Freudenberg, M., Galanos, C., and Simon, J.C. (2002).\ntumor immunity by removing CD25/H11001CD4/H11001T cells: a common basis Oligosaccharides of Hyaluronan activate dendritic cells via toll-like\nbetween tumor immunity and autoimmunity. J. Immunol. 163, 5211\u2013 receptor 4. J. Exp. Med. 195, 99\u2013111.\n5218.Thomas, L. (1959). Discussion. In Cellular and Humoral Aspects of\nShinkai, Y., Rathbun, G., Lam, K.P., Oltz, E.M., Stewart, V., Mendel- the Hypersensitive States, H.S. Lawrence, ed. (New York: Hoeber-\nsohn, M., Charron, J., Datta, M., Young, F., Stall, A.M., and Alt, F.W. Harper), pp. 529\u2013532.\n(1992). RAG-2-deficient mice lack mature lymphocytes owing toThomas, L. (1982). On immunosurveillance in human cancer. Yale\ninability to initiate V(D)J rearrangement. Cell 68, 855\u2013867.J. Biol. Med. 55, 329\u2013333.\nSmyth, M.J., Crowe, N.Y., and Godfrey, D.I. (2001a). NK cells andThornton, A.M., and Shevach, E.M. (1998). CD4/H11001CD25/H11001immunoreg-\nNKT cells collaborate in host protection from methylcholanthrene-ulatory T cells suppress polyclonal T cell activation in vitro by inhib-\ninduced fibrosarcoma. Int. Immunol. 13, 459\u2013463.iting interleukin 2 production. J. Exp. Med. 188, 287\u2013296.\nSmyth, M.J., Godfrey, D.I., and Trapani, J.A. (2001b). A fresh lookTieng, V., Le Bouguenec, C., du Merle, L., Bertheau, P., Desreumaux,\nat tumor immunosurveillance and immunotherapy. Nat. Immunol.P., Janin, A., Charron, D., and Toubert, A. (2002).", "start_char_idx": 2188, "end_char_idx": 4797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86e1fe65-887c-45bd-a7ab-e9f4093f1c0c": {"__data__": {"id_": "86e1fe65-887c-45bd-a7ab-e9f4093f1c0c", "embedding": null, "metadata": {"page_label": "147", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4ebec4af-53d0-48f9-9c9f-6ccce56aad51", "node_type": "4", "metadata": {"page_label": "147", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "8b60eaf59762a2e20215bdd28b0e9dde9e19846c7da50bd533e92be3af50e056", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "884f0274-61fe-4505-9d80-bc4328a0edfd", "node_type": "1", "metadata": {"page_label": "147", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "fb369cc67ff5f31e012eb4657f40f06ce5bb7e24c727133a327d5f13592e6f61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07f3087e-050e-4d26-a071-7b65c556750a", "node_type": "1", "metadata": {}, "hash": "2c803aa3532a120245280d04ddbcc9ef4df3c705e77de9b1d8f71de9ff780094", "class_name": "RelatedNodeInfo"}}, "text": "(1998). CD4/H11001CD25/H11001immunoreg-\nNKT cells collaborate in host protection from methylcholanthrene-ulatory T cells suppress polyclonal T cell activation in vitro by inhib-\ninduced fibrosarcoma. Int. Immunol. 13, 459\u2013463.iting interleukin 2 production. J. Exp. Med. 188, 287\u2013296.\nSmyth, M.J., Godfrey, D.I., and Trapani, J.A. (2001b). A fresh lookTieng, V., Le Bouguenec, C., du Merle, L., Bertheau, P., Desreumaux,\nat tumor immunosurveillance and immunotherapy. Nat. Immunol.P., Janin, A., Charron, D., and Toubert, A. (2002). Binding of Esche-\n2, 293\u2013299.richia coli adhesin AfaE to CD55 triggers cell-surface expression of\nSmyth, M.J., Takeda, K., Hayakawa, Y., Peschon, J.J., van den Brink, the MHC class I-related molecule MICA. Proc. Natl. Acad. Sci. USA\nM.R., and Yagita, H. (2003). Nature\u2019s TRAIL\u2013on a path to cancer 99, 2977\u20132982.\nimmunotherapy. Immunity 18, 1\u20136.Uhr, J.W., Tucker, T., May, R.D., Siu, H., and Vitetta, E.S. (1991).\nSmyth, M.J., Thia, K.Y., Street, S.E., Cretney, E., Trapani, J.A., Tani- Cancer dormancy: studies of the murine BCL1 lymphoma. Cancer\nguchi, M., Kawano, T., Pelikan, S.B., Crowe, N.Y., and Godfrey, D.I. Res. 51, 5045s\u20135053s.\n(2000a). Differential tumor surveillance by natural killer (NK) and NKTUyttenhove, C., Pilotte, L., Theate, I., Stroobant, V., Colau, D., Par-cells. J. Exp. Med. 191, 661\u2013668.mentier, N., Boon, T., and Van den Eynde, B.J. (2003). Evidence\nSmyth, M.J., Thia, K.Y., Street, S.E., MacGregor, D., Godfrey, D.I., for a tumoral immune resistance mechanism based on tryptophan\nand Trapani, J.A. (2000b). Perforin-mediated cytotoxicity is critical degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269\u2013\nfor surveillance of spontaneous lymphoma. J. Exp. Med. 192, 1274.\n755\u2013760.van den Broek, M.F., Kagi, D., Ossendorp, F., Toes, R., Vamvakas,\nSrivastava, P. (2002). Interaction of heat shock proteins with pep- S., Lutza, W.K., Melief, C.J.M., Zinkernagel, R.M., and Hengartner,\ntides and antigen presenting cells: chaperoning of the innate and H. (1996). Decreased tumor surveillance in perforin-deficient mice.\nadaptive immune responses. Annu. Rev. Immunol. 20, 395\u2013425. J. Exp. Med. 184, 1781\u20131790.\nStreet, S.E., Cretney, E., and Smyth, M.J. (2001). Perforin and inter- van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De\nferon- /H9253activities independently control tumor initiation, growth, and Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T. (1991). A gene\nmetastasis. Blood 97, 192\u2013197. encoding an antigen recognized by cytolytic T lymphocytes on a\nhuman melanoma. Science 254, 1643\u20131647.", "start_char_idx": 4265, "end_char_idx": 6852, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07f3087e-050e-4d26-a071-7b65c556750a": {"__data__": {"id_": "07f3087e-050e-4d26-a071-7b65c556750a", "embedding": null, "metadata": {"page_label": "147", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4ebec4af-53d0-48f9-9c9f-6ccce56aad51", "node_type": "4", "metadata": {"page_label": "147", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "8b60eaf59762a2e20215bdd28b0e9dde9e19846c7da50bd533e92be3af50e056", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86e1fe65-887c-45bd-a7ab-e9f4093f1c0c", "node_type": "1", "metadata": {"page_label": "147", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "ad63144cce5e2423e4d5290b6285fb413f0f2c4de9a4cd76dbc81e4cfb8db44d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e445081a-5dd1-4611-88c7-005ef0543d58", "node_type": "1", "metadata": {}, "hash": "dc08b9953a35a0329cdf08408c58df0f704587cfc7961554fdc11d69b8b80d0e", "class_name": "RelatedNodeInfo"}}, "text": "adaptive immune responses. Annu. Rev. Immunol. 20, 395\u2013425. J. Exp. Med. 184, 1781\u20131790.\nStreet, S.E., Cretney, E., and Smyth, M.J. (2001). Perforin and inter- van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De\nferon- /H9253activities independently control tumor initiation, growth, and Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T. (1991). A gene\nmetastasis. Blood 97, 192\u2013197. encoding an antigen recognized by cytolytic T lymphocytes on a\nhuman melanoma. Science 254, 1643\u20131647. Street, S.E., Trapani, J.A., MacGregor, D., and Smyth, M.J. (2002).\nSuppression of lymphoma and epithelial malignancies effected byVetter, C.S., Groh, V., thor Straten, P., Spies, T., Brocker, E.B., and\ninterferon /H9253. J. Exp. Med. 196, 129\u2013134.Becker, J.C. (2002). Expression of stress-induced MHC class I re-\nlated chain molecules on human melanoma. J. Invest. Dermatol. Street, S.E., Hayakawa, Y., Zhan, Y., Lew, A.M., MacGregor, D.,\n118, 600\u2013605. Jamieson, A.M., Diefenbach, A., Yagita, H., Godfrey, D.I., and Smyth,\nM.J. (2004). Innate immune surveillance of spontaneous B cell lym-Wang, H.Y., Lee, D.A., Peng, G., Guo, Z., Li, Y., Kiniwa, Y., Shevach,\nphomas by natural killer cells and /H9253/H9254T cells. J. Exp. Med. 199,E.M., and Wang, R.F. (2004). Tumor-specific human CD4/H11001regulatory\n879\u2013884.T cells and their ligands: implications for immunotherapy. Immunity\n20, 107\u2013118. Stutman, O. (1974). Tumor development after 3-methylcholanthrene", "start_char_idx": 6349, "end_char_idx": 7811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e445081a-5dd1-4611-88c7-005ef0543d58": {"__data__": {"id_": "e445081a-5dd1-4611-88c7-005ef0543d58", "embedding": null, "metadata": {"page_label": "148", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "46711fc8-6987-43ef-bdca-0be10f58dc73", "node_type": "4", "metadata": {"page_label": "148", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "24d6c5669e981209a3b68892a6effa071738dca3924202262dc993ef25c1f9ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07f3087e-050e-4d26-a071-7b65c556750a", "node_type": "1", "metadata": {"page_label": "147", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}, "hash": "0e45e2c55a04186e59fd2586e9523247ba40c9694f1c3810c13f16cacdf43e13", "class_name": "RelatedNodeInfo"}}, "text": "Immunity\n148\nWang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang,\nS., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., et al.(2003). Regulation of the innate and adaptive immune responses byStat-3 signaling in tumor cells. Nat. Med. 10, 48\u201354.\nWheelock, E.F., Weinhold, K.J., and Levich, J. (1981). The tumor\ndormant state. Adv. Cancer Res. 34, 107\u2013140.\nWong, L.H., Krauer, K.G., Hatzinisiriou, I., Estcourt, M.J., Hersey,\nP., Tam, N.D., Edmondson, S., Devenish, R.J., and Ralph, S.J. (1997).Interferon-resistant human melanoma cells are deficient in ISGF3components, STAT1, STAT2, and p48-ISGF3 /H9253. J. Biol. Chem. 272,\n28779\u201328785.\nWoo, E.Y., Chu, C.S., Goletz, T.J., Schlienger, K., Yeh, H., Coukos,\nG., Rubin, S.C., Kaiser, L.R., and June, C.H. (2001). RegulatoryCD4\n/H11001CD25/H11001T cells in tumors from patients with early-stage non-\nsmall cell lung cancer and late-stage ovarian cancer. Cancer Res.61, 4766\u20134772.\nWu, G.S., Burns, T.F., McDonald, E.R., 3rd, Jiang, W., Meng, R.,\nKrantz, I.D., Kao, G., Gan, D.D., Zhou, J.Y., Muschel, R., et al. (1997).KILLER/DR5 is a DNA damage-inducible p53-regulated death re-ceptor gene. Nat. Genet. 17, 141\u2013143.\nWu, G.S., Burns, T.F., Zhan, Y., Alnemri, E.S., and El-Deiry, W.S.\n(1999). Molecular cloning and functional analysis of the mousehomologue of the KILLER/DR5 tumor necrosis factor-related apo-ptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 59,\n2770\u20132775.\nYee, C., Thompson, J.A., Byrd, D., Riddell, S.R., Roche, P., Celis, E.,\nand Greenberg, P.D. (2002). Adoptive T cell therapy using antigen-specific CD8\n/H11001T cell clones for the treatment of patients with meta-\nstatic melanoma: in vivo persistence, migration, and antitumor effectof transferred T cells. Proc. Natl. Acad. Sci. USA 99, 16168\u201316173.", "start_char_idx": 0, "end_char_idx": 1802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/ref_doc_info": {"e8367158-985b-429e-a5c8-e8ab2e069226": {"node_ids": ["be5bce79-eb27-4d8a-95bc-7b0f3aadb33c"], "metadata": {"page_label": "812", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "fbc7b43c-64d6-4628-8f48-f6bdd57f9126": {"node_ids": ["77f477f9-acc8-4d5b-86e1-52d88b3d883c", "a5613f3c-bd79-4559-b9d7-5fa741e489c6"], "metadata": {"page_label": "813", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "e8c6d2a2-0adb-4cf9-ae00-3cc3d3748f38": {"node_ids": ["440cea16-129a-48ab-b1dc-0eb994e05aa9", "e367707b-7065-418b-8892-9d462cf4e40d"], "metadata": {"page_label": "814", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "179fea6b-a621-4ca2-bc32-2f58591dc0a3": {"node_ids": ["b80d98ae-8507-4a50-9f3a-454b781f73f1", "fa999e05-7f52-4821-8c6c-18dbb9eda2d1", "8d32498e-a8d9-4e72-854f-494352eedbd5"], "metadata": {"page_label": "815", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "828116ce-92d6-4423-96f3-0627d28d4fa6": {"node_ids": ["7d886c06-e2b7-4dbf-9d6b-722f83cefdd3"], "metadata": {"page_label": "816", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "60ca1e0c-4a43-4c6d-b606-ba4f3c37a057": {"node_ids": ["407595dc-9fd0-4d16-b81a-ba9505f8c735"], "metadata": {"page_label": "817", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "ec61d254-153e-4310-926b-f98d96d2ac84": {"node_ids": ["34ab9799-60bd-46a0-94f4-8f583fe96cbf", "a7f11ea8-7379-40e0-8847-b466446f8cfb"], "metadata": {"page_label": "818", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "e6885415-de4d-40e1-a0a2-095ddde91d24": {"node_ids": ["5ff4b21a-ed02-4e7d-91ac-81e8f68f886f"], "metadata": {"page_label": "819", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "0b416d6f-9590-4f69-95ce-4b9373c5b1be": {"node_ids": ["5120c0d5-2ab3-41e6-a192-a42056abbd7d", "8ed60e2c-2ed2-414c-8b80-85e6fd60e891", "08203a68-55a7-4557-8fd1-3c11d7243920"], "metadata": {"page_label": "820", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "cfbc779e-1774-4513-8728-83aa3e098f80": {"node_ids": ["79d1e961-1570-40df-b300-d1740e97f430"], "metadata": {"page_label": "821", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "4d7bdc16-de54-452a-835d-765c70565c00": {"node_ids": ["aabdd5a0-f667-444c-a944-43473cf1af7c", "208768f7-5921-49bc-9786-d158f4c33ff3", "2c655528-e28f-4472-9ca8-d4bcbcc584eb"], "metadata": {"page_label": "822", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "d909c016-22b6-4f23-bfa8-ca12ca21c02f": {"node_ids": ["24b7101e-cbc4-404d-9837-5f38cf5197d5"], "metadata": {"page_label": "823", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "d80c027b-d513-4b32-bc73-dd8fcf4d152f": {"node_ids": ["6e75b99d-7f6b-4be8-a8b0-af2689c142ff"], "metadata": {"page_label": "824", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "39facf3d-c35f-4301-8e54-c92941485bb6": {"node_ids": ["3a3a8fb4-509a-42ac-a18f-dbe63b54a782", "79413c02-507c-40db-ad28-2abfa2733d6e"], "metadata": {"page_label": "825", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "52ba0a41-116e-4925-b6dd-035394193eba": {"node_ids": ["9a0c095a-1054-4c85-b40e-3aff2286fc5b", "fe81a5fd-0f01-44c3-9470-8edfc9347ac1", "939d8416-be1a-4862-bf53-f8586b920a77"], "metadata": {"page_label": "826", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "33e9d596-74a3-4bd5-bdca-245e5237612e": {"node_ids": ["bb265177-6182-451b-adab-d5bc91004bdb", "bc2b06be-8e87-4274-b56f-24d0156bc624"], "metadata": {"page_label": "827", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "c3d89a56-4b22-43e5-8c22-e710f1fdff3f": {"node_ids": ["89591778-7fdb-4196-8712-a5aaf4ff8377", "4067330b-497b-404d-a51d-1459e38829d8", "c9c92c30-a621-4840-a1fb-6c0a6e6ca7ca", "0ff980a9-ea75-4c8e-83da-35234a8307d4"], "metadata": {"page_label": "828", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "8c68f38c-d94a-4ba3-a644-6ffc84869e2f": {"node_ids": ["f4529daf-160a-4783-9e6a-d483b23c65c6", "241fa311-b5ff-4f54-b854-9b6655690f3b", "540ed3df-e85b-4a29-8cae-53ec560c99bf", "4d1deb53-b2c9-4676-8c7c-90555d41b910"], "metadata": {"page_label": "829", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "b2b1dd3d-5ec3-4335-a5eb-bbabbabceb8a": {"node_ids": ["108948e1-c9b3-4ecb-b438-4cad50941c4a", "0b7832d7-8d9e-433f-bd1b-31eb3aacc380", "18828972-2bba-4fb8-afd3-e1a2a4cdddca", "e9c34073-59d5-4c24-bea4-c343710eb374"], "metadata": {"page_label": "830", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "62affe7e-6ea2-4c56-babc-22aaa7e11d8f": {"node_ids": ["3ab5b55f-aa72-4335-855e-a916f109c160"], "metadata": {"page_label": "831", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "c0b6ecab-08db-4692-933c-8af2a53e82e9": {"node_ids": ["6e77fdf8-83f9-41dd-9750-5c71a7b177f4"], "metadata": {"page_label": "832", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "c6c9d8b2-2236-4692-8975-0343a2614cf3": {"node_ids": ["dee44469-9b53-4909-a7b5-ba501654f9ce"], "metadata": {"page_label": "833", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "d89b1f18-9ad1-4ab1-8e8c-9b3913387db7": {"node_ids": ["8a5fbe2f-2c32-40f3-bfc3-9c955425261a", "9d8199a8-124d-4097-9388-79e046b848d8"], "metadata": {"page_label": "834", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "98f038f5-6726-480f-abf4-c950e88e7a8b": {"node_ids": ["19f9ba9e-0a35-41f5-af09-823ca29c720e", "be9e326d-47e8-436d-a198-8b9bf4f96b79"], "metadata": {"page_label": "835", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "9ccbc34e-dd32-411e-88ea-a70ab8c24cf9": {"node_ids": ["359c8fc0-a342-467f-8ab1-faf2afa24070", "dcffa9f3-fbcb-4f28-8724-1558f033a9e6"], "metadata": {"page_label": "836", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "95b22f20-a73a-4e2e-b16c-294e8539016a": {"node_ids": ["56802194-142b-4fbd-bfc8-5d8c73906620", "d7db29cb-aeb7-40b1-90fd-ff036b9d22e6"], "metadata": {"page_label": "837", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "36910835-2005-4969-a81c-7d9e3943368e": {"node_ids": ["28ae66e6-1c10-4582-83b5-daee0fe3c450", "835a638d-1256-4e5d-87ee-d9dada6163dd"], "metadata": {"page_label": "838", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "07c5de27-f8a8-4550-8aad-b9b941d9f002": {"node_ids": ["f56e5171-9c4b-4b16-b1cd-3e6b7cbfa092", "33a7f957-e8dd-4888-a937-84d2680792b1"], "metadata": {"page_label": "839", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "8cb669f5-65e6-49d2-8778-066c0becf55d": {"node_ids": ["64223be2-293b-4c35-8f1b-eb12fc178bed", "6a9f58b3-c71e-4352-94d4-151f16b8a630"], "metadata": {"page_label": "840", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "e3e4d821-4c75-4461-aa00-8c4540288cdf": {"node_ids": ["5117bc10-bc5f-4d7b-bd02-58e517f2da48", "7d7e58c2-790c-4cff-a9a8-caeefe9662a1"], "metadata": {"page_label": "841", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "fad20180-fd1e-4982-b95e-9f6797450289": {"node_ids": ["e779041b-5988-4813-b94e-0d12a91b5cc9", "14007e47-4b81-4439-b2ab-b1dd8fda12c5"], "metadata": {"page_label": "842", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "39b1baff-bd7a-4f97-881e-0efa18ec67de": {"node_ids": ["3445ce62-8f52-4027-b311-6f6b3a1eb30e", "39177dbc-01da-4022-8155-dbfd35a56c6b"], "metadata": {"page_label": "843", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "3303ff81-498c-471b-9453-c65f30d41ce2": {"node_ids": ["1f72a469-7c1a-4904-93f9-ee7c7409d029", "bbedaa9b-af8a-42c0-90ad-c5d00173dc63"], "metadata": {"page_label": "844", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "750ecb05-ce93-4c55-b516-5dee9433b779": {"node_ids": ["19722332-929f-4b1a-8e55-f227cf4e8002", "ead72480-90e7-4caf-8d2d-4bf4726ce808"], "metadata": {"page_label": "845", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "2a96318f-77c2-48c3-833f-cd4bad0f1fca": {"node_ids": ["e86e60e1-6417-4169-9a8a-51afea16bb97"], "metadata": {"page_label": "846", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "7f46c743-42a4-4295-984f-c07a2c5453a1": {"node_ids": ["9dc2dc99-b10b-4f4f-8313-fe8423bf82c0", "cfe40769-c5ea-46cd-b8f7-7e8993559d3d"], "metadata": {"page_label": "847", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "f756ad64-f0d3-4093-b9ef-8499b3cf1904": {"node_ids": ["fdcd1b76-d431-4094-a5c2-3e11c8e1a2e8"], "metadata": {"page_label": "848", "file_name": "cancer_paper.pdf", "file_path": "data\\cancer_paper.pdf", "file_type": "application/pdf", "file_size": 10343419, "creation_date": "2024-03-05", "last_modified_date": "2024-03-05", "last_accessed_date": "2024-03-19"}}, "f69d1a74-5d69-4f94-807a-cefb2c59c1f9": {"node_ids": ["b44cdc30-f355-4d61-8285-2c60c232d0cc", "05429d5f-26ba-4e97-9e5f-16dec6dcac91"], "metadata": {"page_label": "137", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}}, "1d95806f-bb56-4341-a077-d50b281119f3": {"node_ids": ["ef3b6c2b-647e-4ac2-8ec6-85397b35cd0c"], "metadata": {"page_label": "138", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}}, "575eaf74-47b0-47d0-8d55-0bea36c35712": {"node_ids": ["2ae3427e-259b-4ad6-acfb-23368ccb295e", "72c760c5-0411-4bc1-8611-779a563049dc", "bedc3d7a-801e-4c30-a72c-6db929a0a8ce"], "metadata": {"page_label": "139", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}}, "e4ee745d-241c-4117-94d0-f29138fb9121": {"node_ids": ["f9f18101-8be1-477f-8308-578eeee46688", "fe21853b-2bfe-407b-af49-d68ff1dd0e56", "678d3b30-b33d-4992-b394-2c9c3e55eccb"], "metadata": {"page_label": "140", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}}, "f826b24e-a8f1-4488-a76d-d87018b9107e": {"node_ids": ["e1f7ca74-2bf2-4004-8640-3c996aba31fc", "e0f5ddbf-3206-4b92-a60b-2cf534a23db3", "bf0a70bc-64a5-4675-abd4-20e0738f3175"], "metadata": {"page_label": "141", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}}, "c460400d-e882-48d3-b8e0-d254fd17abd8": {"node_ids": ["0c861258-b0c4-488c-9bb4-60d1bb865dd6", "8f90d074-930c-4ffd-b1f2-56a48b194329"], "metadata": {"page_label": "142", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}}, "b5714203-bd3b-4d38-81e3-f958daee6998": {"node_ids": ["5bcc1590-3bbd-4f58-9769-bd1308b18a3c", "effccb3f-b112-4274-9896-e7ae58f09586"], "metadata": {"page_label": "143", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}}, "02b6a1d8-b496-4ac9-ab89-d339d0f7f743": {"node_ids": ["f02f8199-8c9a-4151-8165-f7bd02754e86", "1455d3f0-9b2a-4285-8698-7aee6f5183f3"], "metadata": {"page_label": "144", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}}, "f2557d05-79aa-4670-b627-97d3e7d55973": {"node_ids": ["6a348906-ec20-44fc-a355-cdba0a470d7d", "c919b4d9-d475-4a60-acf9-8e8de0353489", "4443bd53-5015-40bc-97a3-e5abcdf72531"], "metadata": {"page_label": "145", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}}, "cff20283-f30e-44d8-8d99-aa3a6662fb19": {"node_ids": ["4d0d5aac-8548-46c8-867e-a408192887b4", "daceba57-bd3c-46d0-9ff9-e76352e88a4c", "5cec4ed2-bed3-47e2-9fb2-f63345acbcfd", "88759eb9-e1c6-4b40-8258-0a003c283fd9"], "metadata": {"page_label": "146", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}}, "4ebec4af-53d0-48f9-9c9f-6ccce56aad51": {"node_ids": ["1655e39f-e135-48be-83f8-1e60b712ef87", "884f0274-61fe-4505-9d80-bc4328a0edfd", "86e1fe65-887c-45bd-a7ab-e9f4093f1c0c", "07f3087e-050e-4d26-a071-7b65c556750a"], "metadata": {"page_label": "147", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}}, "46711fc8-6987-43ef-bdca-0be10f58dc73": {"node_ids": ["e445081a-5dd1-4611-88c7-005ef0543d58"], "metadata": {"page_label": "148", "file_name": "cancer_paper_2.pdf", "file_path": "data\\cancer_paper_2.pdf", "file_type": "application/pdf", "file_size": 269754, "creation_date": "2024-03-18", "last_modified_date": "2024-03-18", "last_accessed_date": "2024-03-19"}}}}